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The total synthesis of FR901464 was accomplished in at total of 29 steps, which is the shortest 
synthesis to date. Degradation studies were performed on the fully functionalized right fragment 
of FR901464 and this insight was used to rationally design a more stable analog, which led to the 
rational development of meayamycin, an FR901464 analog with enhanced biological properties. 
Additional analogs were synthesized examining the A-ring, C4’ position, and the C3 position of 
the B-ring. These analogs demonstrated that the A-ring of FR901464 is optimal, the C4’ acetate 
should remain intact for higher potency, and the spiroepoxide is required for antiproliferative 
properties. The low potency of the desepoxy analogs indicate that FR901464 covalently modifies 
is target(s) via its epoxide, which led to the synthesis of cold iodide-containing analog, which 
could be used for target identification experiments.  
Due to the concern of non-specific reactions of epoxides with endogenous thiols, a 
method was developed to study the consumption of epoxides with thiols. Experiments of 
common epoxide motifs showed that these reactions were negligible under biologically relevant 
conditions. Moreover, a model system for the amide chain of FR901464 demonstrated that its Z-
enamide will not react non-specifically with endogenous thiols. 
There was a need for a general method for the alkynyl addition to epoxides to give 
propargylic alcohols as products. Towards this end, the Ag/Zr-promoted alkynyl addition 
methodology discovered in the Koide laboratories was successfully applied. These studies began 
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with the preparation of 11 silver acetylides and examining their safety as reagents for organic 
synthesis. Subsequently, these silver acetylides were shown to add to epoxides via 1,2-shifts to 
give propargylic alcohols in the presence of Cp2ZrCl2 and AgOTf. The scope and limitations of 
both the epoxide and alkyne were realized and was demonstrated in over 20 successful reactions. 
Moreover, the 11 new silver acetylides used in the epoxide alkynyl addition methodology should 
be readily applicable to the aldehyde alkynyl addition methodology. Finally, mechanistic studies 
were undertaken and were crucial in understanding the roles of all additives necessary for this 
alkynyl addition reaction to be successful, culminating in the generation of a proposed 
mechanism.  
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1.0  CHEMICAL AND BIOLOGICAL STUDIES OF FR901464 
1.1 CANCER BACKGROUND AND CURRENT THERAPEUTIC REGIMENS 
Cancer historically has been and remains the leading disease-related cause of death in the human 
population, responsible for 7 million deaths in 2005.1,2 In 2005, the National Cancer Institute 
(NCI) made public their Cancer Trends Progress Report available online, which shows that the 
rate of cancer incidence has remained nearly constant from 1978 to 1998 at 500 incidences per 
100,000 people (1/200 people) per year. Moreover, the death rate for individuals with cancer in 
2002 was 200 out of 100,000 per year, which showed no improvement from 1978, but was a 
slight improvement over the 215 out of 100,000 per year death rate in 1991. In China, which 
accounts for approximately 1/5 of the world population, deaths due to cancer in 2000 were 
estimated to be 1.4 million people, and projected to increase to 1.8 and 2.4 million deaths in 
2010 and 2020, respectively.3 Moreover, the incidence of cancer in China was estimated to 
increase by 14.6% from 2000−2005.4 These trends also extend to Europe where cancer incidence 
increased by 300,000, a 10% increase, from 2004−2006, and the mortality from cancer was 
rising.5 These expected increases in cancer incidence and mortalities are alarming, and reflect 
cancer being a pandemic disease.  
Tumors may develop when controlled cellular processes such as signal transduction and 
gene expression become irregular.1 There are more than 200 molecular mechanisms postulated 
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for tumorigenesis, each with many variants.6 Few chemotherapeutic regimens have yielded 
remission of cancer for extended periods of time, partly because of the numerous cancer types. 
Currently available drugs are limited to targeting DNA, nuclear hormone receptors, a tyrosine 
kinase, the proteasome, and microtubules. More recently, inhibitors of histone deacetylase 
(HDAC) have also demonstrated promising results in clinical trials.7  
Modern-day chemotherapy has its origins in World War I, when mustard gas was used in 
battlefields. Military doctors noticed that deceased soldiers that were exposed to mustard gas 
died due to bone marrow aplasia. This observation led to the discovery that nitrogen mustard 
operates by inducing DNA damage, and in 1942 a hospital in the United States used these 
compounds to treat patients with lymphoma, albeit with little success.  
Platinum-based DNA damaging agents, cisplatin and carboplatin (Figure 1), remain the 
backbone of cancer chemotherapy.8 Their modes of action involve the cross-linking of DNA 
strands inhibiting DNA replication to cause tumor cell death. These heavy-metal agents have 
dose-dependent toxicities and require careful dosing in patients. Additional DNA-damaging 
agents are mitomycin C, tirapazamine, and bleomycin (Figure 1).9,10 Mitomycin C causes DNA 
alkylation and subsequent crosslinking by two discrete mechanisms; the first mechanism 
involves aziridine opening in an acidic environment to form a carbocation, and in the second 
mitomycin C acts as a prodrug in a reducing enviroments, where its quinone is reduced and 
subsequently opens its aziridine ring via a quinone methide.11 Tirapazamine is reduced to a 
radical under hypoxic conditions, and subsequently abstracts a hydrogen atom from DNA 
causing strand breaks, wheras bleomycin may be activated by O2 and Fe
II complexes to produce 
a bleomycin radical and O2
•−, which cause DNA and RNA damage. An alternative to these DNA 
damaging agents is the supplementation of nucleoside analogs such as 5-fluorouracil and 
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gemcitabine (Gemzar®), which act by being incorporated into DNA during DNA synthesis and 
subsequently terminating chain elongation.10 
Toposisomerases have critical function in DNA replication and chromosome 
condensation and segregation, and thus the inhibition of topoisomerases I and II is commonly 
used strategy in treating many cancers. Topoisomerase I is responsible for creating single strand 
DNA breaks, and topoisomerase II is responsible for creating double strand DNA breaks. 
CamptothecinTM (Figure 1) is an inhibitor of topoisomerase I and generates a cytotoxic poison by 
stabilizing this enzyme in its catalytic form.18,19 Etoposide (Figure 1), a semisynthetic derivative 
of podophyllotoxin, is a clinically prescribed inhibitor of topoisomerase II that does not 
intercalate DNA or have the cardiotoxicity seen with anthracyclines such as adriamycin (Figure 
1).12  
Estradiol (structure not shown), the most potent endogenous estrogen, has been 
implicated in both the initiation and promoters of carcinogenesis.13 Many human breast cancer 
cell lines require estrogen for proliferation in vitro and in vivo; thus, targeting the estrogen 
receptor (ER) has been a common method to treat breast cancer. This proliferation can be 
blocked by administration of ligands that compete with estrogen for the ER binding site. 
tamoxifen (Figure 1) is a partial antagonist of the ER in humans and is an effective drug for 
treating breast cancer, but a tamoxifen regimen loses efficacy over time, and >80% of tumors 
will develop resistance.1,13  
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder, 
accounting for 15−20% of all cases of leukemia. Juxtaposition of the breakpoint cluster region 
on chromosome 22 and the c-abl oncogene on chromosome 9 is present in 95% of patients with 
CML; the resulting protein functions as a constitutively activated tyrosine kinase. GleevecTM  
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Figure 1. Structures of anticancer drugs/agents 
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(Figure 1) specifically inhibits the proliferation of cell lines containing the protein from this 
juxtaposition, demonstrating the potential of very specific targeting of molecular pathogenic 
events in cancer.14 
Lactacystin (Figure 1) is a natural product that was shown to induce neuritogenesis,15,16 
and later to inhibit cancer cell proliferation by proteasome inhibition.17 Due to the importance of 
the latter pathway, bortezomib (Velcade®) was subsequently developed as a reversible inhibitor 
(Ki 0.6 nM) of the 20S catalytic core of the 26S proteosome.
18,19 As a result, apoptosis occurs, 
which is presumably a direct result of the stabilization of pro- and antiapoptotic proteins and the 
inhibition of NF-κB.18,19 
Compounds such as the vinca alkaloids and paclitaxel (Figure 1) have utility in the 
treatment of cancer by their perturbing activities against microtubules.20,21 During eukaryotic cell 
division, microtubules form the mitotic spindle, the key machinery for mediating segregation of 
chromosomes to the two new daughter cells. Perturbing the mitotic spindle may cause arrest of 
the cell cycle in the mitotic phase, eventually leading to apoptosis.  
Histone deacetylases (HDAC) remove the acetyl groups from lysine residues of proteins, 
and their substrates are involved in transcription, cell proliferation, and cell death.22,23 HDAC 
inhibitors selectively activate gene transcription by remodeling of the DNA-histone complex. 
Inhibition of these enzymes causes hyper-acetylation of the histone lysine residues, thereby 
neutralizing the positive charges that attract the negatively charged DNA and making the DNA 
more accessible. Other targets of HDACs are E2F, p53, and the cyclin dependent kinase (cdk) 
inhibitors p21WAF1/Cip1 and p27Kip1; this could account for the antiproliferative activity associated 
with HDAC inhibitors. Trichostatin A (Figure 1), the first reversible inhibitor of HDAC 
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identified, functions by inducing apoptosis and inhibiting angiogenesis in a plethora of 
carcinoma cell lines in vitro. FR901228 (aka FK228, shown in Figure 1), a natural product, also 
functions by inhibition of HDAC and has progressed to phase II clinical trials.24-28 
Few of these chemotherapeutic regimens have yielded remission of cancer for extended 
periods of time, and their lack of differentiation between cancer and normal cells leads to high 
toxicity.1,29 Moreover, there is concern amongst oncologists that a plateau has been reached with 
existing cancer therapies.10 
Discoveries of anticancer agents with novel modes of action continue to be of paramount 
importance for cancer chemotherapy.1,29-32 Wall and Wani developed a new paradigm to guide 
the isolation of natural products, such as camptothecin and paclitaxel, by using the bioactivity of 
crude extracts.33-35 This bioactivity-directed fractionation method is now commonly used for 
discovering compounds with novel modes of action. This approach can be extended to target 
identification and validation, development of new screening methods, and the development of 
new agents based on their novel mode of action (Scheme 1). The use of natural products for this 
method specifically directed towards cancer therapy was brought to great fruition from the 
research on Taxus brevifolia research, which allowed for the validation of the microtubule as a 
druggable target.35-37 This discovery led to the development of microtubule screening methods, 
and the discoveries of discodermolide and the epothilones as perturbers of microtubules.38,39 
Moreover, research into the unique mode of action of camptothecin led to the discovery of 
topoisomerase I as a drug target, the development of drugs such as irinotecan and topotecan, and 
the isolation of the natural products lamellarin D, kalihinol F and wakayin.12 More recently, the 
elucidation of the novel biological mechanism induced by lactacystin has demonstrated the 
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proteosome as a target for cancer therapy.17 Since this discovery, omuralide and bortezomib have 
been discovered using this novel target.16-18  
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Scheme 1. Paradigm for development of novel biological modes of action 
1.2 ISOLATION AND CHARACTERIZATION OF FR901464 AND BIOLOGICALLY 
RELATED COMPOUNDS 
1.2.1 Discovery of FR901464 
As part of a drug discovery program, the Nakajima group at Fujisawa Pharmaceutical Co., Ltd. 
(now Astellas Pharma, Inc.) employed a reporter assay in human breast adenocarcinoma cells 
using the stably transfected simian virus 40 (SV40) promoter and chloroamphenicol 
acetyltransferase (CAT) reporter gene (pSV2-CAT) in their search for natural products with 
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novel modes of action. They isolated the structurally unique compounds FR901463, FR901464, 
and FR901465 from the culture broth of a bacterium Pseudomonas sp. No. 2663 based on their 
ability to activate transcription in cancer cells (structures shown in Figure 2).40 These compounds 
were also reported as WB2663A, B, and C, respectively, in a European patent by the same 
group.41 The culture broth (400 L) of this bacterium yielded FR901463 (512 mg), FR901464 
(819 mg), and FR901465 (70 mg), after purification by silica gel and reverse phase 
chromatographies. Of these compounds, FR901464 was shown to be the most potent in vitro and 
in vivo. The IC50 of FR901464 was shown to be 1.0−3.4 nM in MCF-7 (human breast), A549 
(human lung), HCT116 (human colon), SW480 (human leukemia), and P388 (murine leukemia) 
tumor cell lines.40 FR901464 displayed a dose-dependent, prominent effect at 0.1−0.56 mg/kg 
against A549, colon 38, and Meth A fibrosarcoma xenografts implanted in mice, thereby 
showing its clinical potential.42 The structures of FR901463, FR901464, and FR901465 were 
shown to be quite similar, differing only in their B-rings. Specifically, these compounds differed 
at C2 and C18. The relative stereochemistry of FR901464 was assigned by the Fujisawa group, 
and the absolute stereochemistry was subsequently shown by the Jacobsen group after their total 
synthesis.41,43 
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Figure 2. Structures of FR901463, FR901464, and FR901465 
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The biological activity of FR901464 was shown to be distinct from agents with other 
known modes of action. Transcriptional activation of tumor cells was observed in FR901464-
treated (20 nM) MCF-7 cells transfected with a plasmid containing the SV40 promoter via 
increased activity of the downstream CAT reporter gene.40 CAT induction became significant at 
6 h after treatment with FR901464 and increased linearly to 24 h when the observations were 
halted. In the absence of FR901464, no activity was observed although no positive control was 
used for these experiments. The RNA transcript levels of inducible genes were measured by 
extraction from the cells, RT-PCR amplification (25 cycles), and subsequent resolution by 
electrophoresis with comparison to the endogenous levels. Human c-myc (oncogene), E2F-1 
(transcription factor), p53 (tumor suppressor gene), and p21WAF1/Cip1 (cyclin dependent kinase 
inhibitor) were compared to non-inducible genes, G3PDH (glyceraldehyde-3-phosphate 
dehydrogenase) and β-actin. The authors claimed that the amounts of c-myc, E2F-1, p53, and 
p21WAF1/Cip1 were all lowered, while the amount of G3PDH and β-actin remained the same.42 
However, after inspection of the published gels, c-myc is much lower in FR901464-treated cells, 
p53 appears to be slightly lower, and E2F-1 and p21WAF1/Cip1 transcript levels may be lower, but 
the small quantities do not give definitive data. Examination of the cell cycle distribution of 
FR901464-treated MCF-7 cells indicated G1 and G2/M phase arrest. Internucleosomal 
degradation of genomic DNA was observed with the same kinetics as the transcriptional 
activation. Comparison of FR901464 to other anticancer agents with known modes of action 
revealed the unique mode of action of this natural product, since FR901464 produced phenotypes 
distinctly different from paclitaxel, adriamycin, camptothecin, trichostatin A, and, later, 
FR901228.24,42  
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1.2.2 Isolation of herboxidiene (GEX1), TMC-205, and the pladienolides 
Microorganisms may produce potent phytotoxic natural products that could be used as herbicides 
towards weeds or other unwanted vegetation. In 1992, Monsanto Agricultural Co. was screening 
for potent herbicides from natural sources and reported the isolation of herboxidiene (Figure 3) 
from Streptomyces sp. A7847.44,45 The absolute stereochemistry of this natural product was later 
determined by Edmunds and Oppolzer.46 Later, herboxidiene was isolated by Yoshida and 
coworkers at Kyowa Hakko Kogyo Co. while screening natural products based on their ability to 
affect transcription using an SV40 promoter.47,48 Yoshida found this compound, renamed 
GEX1A, to act as an antiproliferative agent against human tumor cell lines in vitro with IC50 
values of 3.7−7.6 nM and its efficacy in xenograft models, causing G1 and G2/M phase arrest in 
the cell cycle.48 Moreover, GEX1A did not enhance the expression of endogenous genes 
involved in the cell cycle, proliferation, or apoptosis, but shorter sized transcripts of cdc25A and 
cdc2 genes were observed as well as their normal sized ones.47 GEX1A is toxic in vivo as low as 
0.13 mg/kg, causing a decrease in white blood cells, platelets, and body weight.48 Yoshida 
concluded that GEX1A appears to function by a novel biological mode of action. 
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Figure 3. Structures of herboxidiene, TMC-205, and pladienolide B 
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  In 2001, the Sakuarai group at Tanabe Seiyaku Co., Ltd. reported on the transcriptional 
activation in HeLa cells using an SV40 promoter with TMC-205 (Figure 3).49 The culture broth 
of a fungus (7 L) yielded only 3.3 mg of this compound.49 The transcriptional activation was 
shown to be concentration-dependent and increased linearly from 6−24 h.49 Removal of the 
SV40 enhancer element disabled the transcriptional perturbing activity of TMC-205, suggesting 
that its mechanism of action involves the binding of transcriptional factors to the SV40 enhancer 
element. This light-sensitive agent also was cytotoxic against various human and murine tumor 
cell lines in vitro, with effective concentrations against 13 cell lines ranging from 64−203 µM.49 
Many types of tumors are severely hypoxic and have a series of signaling pathways to 
adapt to this environment. Accordingly, these signaling pathways could be a potent target for 
antitumor agents. The Sakai group at Eisai Co., Ltd. used a reporter gene under the control of the 
VEGF promoter to screen for natural products that increase transcription in cancer cells. From 
this screen, they isolated seven structurally-related compounds named the pladienolides from the 
culture broth of the bacterium Streptomyces platensis Mer-11107.50,51 The most potent of these 
was pladienolide B, which had IC50 values of 0.4−8.9 nM in 45 cancer cell lines including six 
drug-resistant cell lines (Figure 3).52 This compound was also effective in a xenograft model at 
2.5 mg/kg/day. In 2007, a research group at Eisai Co., Ltd. demonstrated that the target of 
pladienolide B is the SF3b splicing factor using 3H-labeled, fluorescent reporter-tagged, and 
photoaffinity/biotin tagged pladienolide probes. This target was subsequently validated by small 
interfering RNA (siRNA), and unequivocally implicated the splicing machinery as the target of 
pladienolide; however, FR901464 was the first compound discovered that alters this novel 
antitumor drug target.53 
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FR901464, herboxidiene (GEX1A), TMC-205, and the pladienolides were all isolated 
using screening methods that monitor transcriptional activity in cancer cells. Although no 
rationale is given for this screening method, it was subsequently validated with the development 
of E7107, an analog of pladienolide B currently in phase I clinical trials.54,55 
1.3 PREVIOUS TOTAL SYNTHESES OF FR901464 
The impressive biological activity and novel structure of FR901464 caught the attention of many 
synthetic organic chemists. Since its reported activity, this compound has been synthesized by 
the Jacobsen, Kitahara, and finally the Koide group.43,56-58 The Funk group also undertook 
studies on FR901464 but have yet to report a successful synthetic route. 
1.3.1 Synthesis by the Jacobsen group 
The first total synthesis of FR901464 was accomplished by the Jacobsen group in 2000 as 
depicted in Scheme 2.43,56 Acid fragment 2 was efficiently prepared in five steps from ynone 1 
utilizing Noyori’s asymmetric reduction to install the C4’ stereocenter.59 Their A-ring 
preparation commenced with 4-penyn-1-ol and its conversion to aldehyde 4 according to the 
literature.60 Although not described, TES-enol ether 5 was presumably prepared from 
commercially available ketone 3 in one step. The key step for the A-ring preparation involved 
the enantioselective hetero-Diels-Alder reaction of these two fragments using a chromium 
catalyst developed in the Jacobsen group.61 This powerful reaction correctly installed the C11, 
C12, and C15 stereocenters. To arrive at vinyl iodide 6, nine additional steps were required, 
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including a Rubottom oxidation, alkynye inward isomerization, and hydrozirconation. The 
preparation of the B-ring fragment began with the three step conversion of aldehyde 7 to TES-
enol ether 8. The subsequent step involved another hetero-Diels-Alder reaction with 
(tbutyldimethylsiloxy)acetaldehyde using their chromium catalyst that correctly installed the C1 
and C5 stereocenters. To arrive at alkyne 9, nine additional steps were required, including a 
Rubottom oxidation and directed epoxidation. The endgame of the Jacobsen synthesis involved 
the Negishi coupling of vinyl iodide 6 and alkyne 9, and four additional steps to complete the 
total synthesis. It should be mentioned that installation of the spiroepoxide with VO(acac)2 after 
the union of advanced intermediates was not regioselective and therefore the epoxide was 
installed prior to the Negishi coupling. This synthesis was accomplished in 37 total steps, with 
19 steps in the longest linear sequence.56,62 Considering the complexity and instability of the 
target compound, this is an efficient and concise synthesis of FR901464. Moreover, this work 
unambiguously established the stereochemistry of the natural product from extensive analog 
synthesis as well as established the equilibrium of FR901464 and its B-ring opened form, 
FR901464-open.56  
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Scheme 2. Jacobsen’s total synthesis of FR901464 
 
1.3.2 Synthesis by the Kitahara group 
The Kitahara group unveiled their first generation total synthesis of FR901464 in 2001 using the 
chiral pool as the source of their starting materials.57 Due to several problems in the late stages of 
their synthesis, they devised a second generation total synthesis in 2006 which will be 
discussed.58 Acid 10 was prepared by the four step conversion of ethyl (S)-(−)-lactate that 
already contained the C4’ stereocenter (Scheme 3). Preparation of the A-ring fragment began 
from L-threonine, which contains the C14 and C15 stereocenters of FR901464. Sulfone 11 was 
prepared from L-threonine in 18 linear steps including a substrate controlled stereoselective 
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hydrogenation, which established the C11 and C12 stereocenters in high selectivity, and three 
Wittig reactions. The preparation of the A-ring began from commercially available 2-deoxy-D-
glucose. The synthesis of aldehyde 12 was accomplished in 15 linear steps involving standard 
carbohydrate chemistry. Completion of the Kitahara synthesis involved the coupling of acid 10 
and amine of sulfone 11, a remarkable modified Julia coupling of a sulfone to aldehyde 12, and 
four additional steps were required to accomplish the total synthesis of FR901464. The Kitahara 
group also found epoxide installation to be low yielding (22%) after union of advanced 
interemediates.57 This total synthesis was accomplished in 41 total steps, with 22 steps in the 
longest linear sequence.58,62 
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Scheme 3. Kitahara’s total synthesis of FR901464 
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1.4 STUDIES ON STRUCTURE ACTIVITY RELATIONSHIP AND ON THE MODE 
OF ACTION OF FR901464 
1.4.1 Synthesis of analogs of FR901464 
The unprecedented biological profile of FR901464 has resulted in the preparation of various 
analogs. The Jacobsen group was the first group to undertake analog studies upon completion of 
their total synthesis.56 The amide sidechain of FR901464 was the first fragment examined. 
Acetamide 13 gave an IC50 of 1700 nM as compared to 2.0 nM for FR901464 in Tag Jurkat cells, 
thereby showing the importance of the α,β-unsaturated amide moiety in the side chain.56 The 
C4’ stereocenter was shown to exert a small effect on the antiproliferative activity with 14, 
having a 15-fold lower activity than the natural product.56 Takahashi demonstrated the C4’ ester 
is amenable to modification since 15 only gave a 40-fold decrease as compared to FR901464 in 
activity in EL4 murine lymphoma cells.63 Next, the B-ring fragment was probed. Takahashi 
established that ester 16 had an IC50 of 500 nM, a 250-fold decrease in activity as compared to 
the natural product, demonstrating the sensitivity of the C4-OH moiety.63 The importance of the 
oxygen atom of the spiroepoxide was demonstrated by the Jacobsen and Kitahara groups. 
Cyclopropane 17 was inactive at 4000 nM, and alkene 18 was less effective than FR901464 at 
stimulating the cytomegalovirus (CMV) promoter-driven transcription by a factor, as the authors 
termed it, of “+++.”56,64 It was not explained why CMV was employed to drive the 
transcriptional activity induced by FR901464 or the magnitude of their ± scale. Finally, the C1 
position was modified by the Jacobsen and Kitahara groups to give enhanced biological results. 
Tetrahydropyran 19 had an IC50 of 1.6 nM and methyl glycoside 20 (later named spliceostatin A) 
promoted transcription slightly better than FR901464 by a factor of “+.”56,64,65 Therefore, further 
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analog studies could be directed at the amide chain, the unstudied A-ring, and the B-ring at 
positions C1 but not C4-OH. 
While derivatizing FR901464 position C1 under acidic conditions, in unknown solvents, 
the Kitahara group noticed significant decomposition. The decomposition products claimed by 
Kitahara were aldehyde 21 and presumably 22, although it may give 23, but no experimental 
data to support either product were reported (Scheme 4).64  
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Scheme 4. Kitahara’s proposed decomposition of FR901464 under acidic conditions 
1.4.2 Studies on the novel mode of action of FR901464 
Eukaryotic tumor cells evolve adaptive responses to environmental stresses for survival, many of 
these responses are redox dependent.66 The human form of the enzyme thioredoxin (Trx) is 
involved in the reversible redox reactions in many thiol-dependent cellular functions, including 
gene expression, signal transduction, and proliferation.67 Trx typically has a CGPC active site 
sequence, but there is some variability within the thioredoxin suprafamily.67 Transmembrane 
thioredoxin-related protein (TMX) is a member of the thioredoxin family that has a unique 
CPAC sequence in its active site. TMX is primarily localized in the endoplasmic reticulum (ER), 
and also inhibits the ER stress-induced apoptosis by caused by brefeldin A.68,69  In December of 
2005, a patent was disclosed implicating TMX as a target of FR901464, which was validated by 
siRNA experiments.70 Moreover, this patent describes a method for screening anticancer agents 
using this protein. TMX remains an exciting target for chemotherapy, but has not garnered 
attention in oncology since its discovery in 2001. However, thioredoxin has been targeted for 
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chemotherapy, and PX-12 (1-methylhydroxypropyl 2-imidazoloyl disulfide), an inhibitor of Trx, 
is currently in clinical development.71,72 
 It has been approximated that 15% of all human genetic diseases are due to deviations in 
pre-mRNA splicing.73 Yet, how and why these deviations occur is unknown, and studying the 
mechanisms of the spliceosome had been limited to using small polypeptide inhibitors for known 
splicing proteins.74 In 2007, 20 (spliceostatin A) was also shown to target the SF3b RNA splicing 
factor.65 To gain insight into the mechanism in which FR901464 arrests the cell cycle, the 
expression of cdks were monitored for their implication in cell cycle progression. There was no 
change in the level of cdk expression, whereas the cdk inhibitors, p16 and p27, were upregulated. 
Moreover, a truncated form of p27 was produced in FR901464-treated cells. This truncated 
protein was named p27*, and was shown not to be a product of the proteosome. The production 
of p27* was also observed by treatment of cells with spliceostatin A in concentrations as low as 
5.8 nM. Biotinylated probe 24 (Figure 4) was chemically synthesized and shown to cause the 
production of p27* at 500 nM. HeLa cell extracts were mixed with 24 and purified on a 
streptavidin column. The binding proteins were removed from the column by washing with 
buffer and purified by electrophoresis to identify SAP155, SAP145, and SAP130 as targets of 
24. A competition experiment showed spliceostatin was able to inhibit these proteins from 
binding to 24. The ease of removal of these proteins from the streptavidin column demonstrated 
non-covalent binding between these proteins and 24. Treatment of HeLa cells with siRNA for 
SAP155, SAP145, and SAP130 all caused the formation of p27*. However, the siRNA for 
SAP155 or SAP130 knocked down the levels of both p27 and p27*. Finally, endogenous cdk2 
was inhibited in cells expressing p27*, implicating this as the antiproliferative mode of action for 
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FR901464. Therefore, it appears that the spliceosome, which had not been thought of as a 
chemotherapeutic target previously, is a target of FR901464. 
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Figure 4. Structure of biotinylated analog 24 
 
1.5 PREVIOUS TOTAL SYNTHETIC EFFORTS TOWARD FR901464 IN THE 
KOIDE GROUP 
The long term goals for this project were the elucidation of the unique mode of action of this 
natural product and to impact medicine by developing agents that could be used for cancer 
treatment. Toward these ends, a concise, flexible total synthesis was required for access of this 
natural product and the rapid development of analogs. 
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1.5.1 Experiments on the stability of FR901464 
Lessons learned from the two previous syntheses are that the epoxide should be installed prior to 
union of advanced intermediates and a minimum of transformations should take place after the 
union of these intermediates for maximum yield and convergency.62 The following stability 
studies conducted in the Koide laboratories gave valuable information to influence the endgame 
of the synthesis including the choice of protecting groups. The Jacobsen and Kitahara syntheses 
demonstrated the acid lability of FR901464 via both the instability on silica gel and the low-
yielding hydrolysis of the C1 methyl glycosidic bond of 20.43,56-58 However, the stability of 
FR901464 towards a range of acids and bases was unknown. To address these concerns, the 
stability of small (~0.1 mg) samples of the natural product (a gift from Fujisawa Pharmaceutical 
Co., Ltd) was examined under the conditions shown in Table 2. Exposure of FR901464 to EtOH 
in toluene, even in the presence of SiO2, gave no reaction (entries 1 and 2). However, subjection 
of FR901464 to EtOH in the presence of AcOH or PPTS led to decomposition of the natural 
product (entries 3 and 4). The isolation of FR901464 precluded the use of MeOH due to the 
observation of a methanol-containing artifact of the natural product, presumably 20.41 Treatment 
of FR901464 with MeOH in toluene gave no reaction (entry 5), but upon addition of SiO2 a less 
polar compound (as judged by TLC, entry 6) was generated, presumably 20. Exposure of 
FR901464 to excess pyridine in THF/CH2Cl2 gave no reaction at 0 °C, but slow decomposition 
upon warming to 23 °C (entry 7). Finally, treatment of FR901464 with HF•py in THF/CH2Cl2 
gave no reaction at 0 °C, but upon addition of pH 7 buffer some decomposition occurred (entry 
8). From these studies, the lability of FR901464 towards weak acid (entries 3 and 4), weak base 
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(entry 7), and even buffers (entry 8) was realized. These studies proved valuable in the total 
synthesis of FR901464, especially in the late stages of the synthesis.  
 
Table 2. Acid and base lability studies of FR901464 
entry additive(s) solvent temp (°C) result
a 
1 EtOH toluene 23 no reaction 
2 EtOH, SiO2 toluene 23 no reaction 
3 EtOH, AcOH toluene 23 decomposition 
4 EtOH, PPTS toluene 23 decomposition 
5 MeOH toluene 23 no reaction 
6 MeOH, SiO2 toluene 23 non-polar byproduct 
formation 
7 py (10 equiv) THF/CH2Cl2 0 to 23 decomposition 
8 HF•py THF/CH2Cl2 0 no reaction
b 
a Determined by TLC analysis; b Decomposition upon addition of pH 7 buffer 
1.5.2 First generation retrosynthetic analysis 
Due to the instability of FR901464 towards weak acids and bases, a coupling strategy 
utilizing advanced intermediates with a minimum number of labile protecting groups was 
desirable. Therefore, a mild coupling reaction was necessary to unite functionalized fragments, 
and a Nozaki-Hiyama-Kishi (NHK) reaction of 25 and 26 was envisioned as the final coupling to 
form the C5−C6 bond (Scheme 5). 75,76 NHK reaction conditions are mild and generally proceed 
in accordance with Felkin selectivity for additions into α-chiral aldehydes.77 Another obvious 
disconnection of FR901464 would be at the amide bond to give acid 2, vinyl iodide 35, and 
ketoaldehyde 27 as the three fragments. Acid 2 could be derived from ynal 27 by oxidation of the 
aldehyde and partial hydrogenation of the alkyne. This ynal could be prepared from alcohol 30 
by an ozonolysis and acetylation of the hydroxyl group. This alcohol could be prepared by an 
asymmetric alkynylation reaction of acetaldehyde and enyne 33. Vinyl iodide 25 could be 
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formed from tetrahydropyran 28 by a cross-olefin metathesis reaction to generate the C8−C9 
alkene. This tetrahyropyran could be formed through an allylation−reduction sequence of 31. 
Lactone 31 could be derived from the commercially available L-threonine-derivative 34 that 
contains the C14 and C15 stereocenters. The ketoaldehyde fragment could arise from diene 29  
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Scheme 5. First generation retrosynthetic approach toward FR901464 
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by oxidative cleavage reactions of both alkenes. This diene could be generated from 
epoxyaldehyde 32 by a vinyl addition reaction and subsequent protection of the hydroxy group. 
Finally, this epoxyaldehyde could be prepared by the condensation of commercially available 
propargyl alcohol and methallyl bromide and successive oxidation reactions. 
 This synthetic endeavor commenced with the concise preparation of acid 2 by Dr. Naka 
(Scheme 6). A styryl unit was chosen to mask an aldehyde that would effectively suppress the 
volatility and water solubility of otherwise low molecular weight intermediates. Homologation of 
commercially available cinnamaldehyde with TMSCHN2 and LDA gave enyne 33 in 84% 
yield.78 The Corey-Fuchs method was less efficient in forming 33,79 and the Seyforth-Ohira-
Bestman method gave 1-(1-methoxybut-3-ynyl)benzene as the major product.80,81 Subsequent 
Carreira asymmetric alkynyl addition to acetaldehyde gave alcohol 30 in 41% yield with a 6.1:1 
er.82 This transformation was explored in more detail (Table 3). The catalytic version of this 
reaction was unsuccessful.83 Subsequent acetylation of alcohol 30 was accomplished in 
quantitative yield to afford 35. This ester was then subjected to ozonolysis conditions and after 
reductive workup aldehyde 27 was obtained in 89% yield. Finally, oxidation of this aldehyde and 
subsequent partial hydrogenation of the ynoic acid gave 2 in 75% two step yield. Therefore, acid 
2 could be prepared in six linear steps from cinnamaldehyde.7  
 
 25 
Ph
OHC
Ph
Ph
HO
Ph
AcO
CHO
AcO
LDA, 81%
TMSCHN2
CH3CHO, Zn(OTf)2
(−)-N-methylephedrine
41%, er = 6.1:1
Ac2O
pyr
quant.
89%75% (2 steps)
1. NaClO2, NaH2PO4
2. H2, Lindlar's cat. O3; Me2S
27
30
35
33
OH
AcO
O
2  
Scheme 6. Preparation of acid 2 
 
The synthesis of the A-ring, performed by Dr. Naka and Dr. Sivaramakrishan, began 
from commericailly available L-thereonine derivative 34 which was derivatized into its 
acetonide in quantitative yield (Scheme 7). This acetonide was partially reduced with DIBALH 
to give Garner’s aldehyde,84 and subsequently transformed to 36 by a Horner-Emmons-
Wadsworth reaction in 84% yield over two steps. The subsequent hydrogenation of this 
unsaturated ester gave a 2:1 mixture of diastereomers that was realized after acetonide removal 
and lactonization to give 31 and 12-epi-31 as an inseparable mixture. Since poor substrate 
control was obtained in a linear system, a more rigid, cyclic substrate was desired. Towards this 
end, acetonide 36 was reduced with DIBALH and subsequently homologated by a Wittig 
reaction to give 38 in 74% over two steps. This material was deprotected with CSA/MeOH to 
give 39 in 95% yield. This alcohol was transformed into ether 40 in 86% yield by the action of 
Ag2O and methallyl bromide. This ether was transformed to dihydropyran 41 by a ring-closing 
metathesis using Grubbs’ II catalyst85 in quantitative yield. It was later shown that the ruthenium 
catalyst developed by Hoveyda was similarly effective in this transformation, but could not be 
recovered.86 This substrate was then regioselectively oxidized with PDC to give lactone 42 in 
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72% yield. Alternatively, this regioselective oxidation could be accomplished with PCC to give 
unsaturated lactone 42 in 67% yield. This unsaturated lactone was hydrogenated by the action of 
PtO2 in EtOH to give 31 in quantitative yield and a 10:1 dr. This lactone was allylated with allyl  
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Scheme 7. Preparation of tetrahydropyran 28 
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magnesium chloride to give 43 in 85% yield. Subsequent reduction of this hemiketal with 
BF3•OEt2 and Et3SiH gave 28 in 20−34% yields and a 10:1 dr along with the stereoselective 
production of pyrrolidine 44 in 21% yield (this strategy is further discussed in section 1.6.2). 
 The examination of the Nozaki-Hiyama-Kishi (NHK) coupling is shown in Scheme 8. 
Cross-olefin metathesis of tetrahydropyran 28 and methacrolein gave 45 stereoselectively in 65% 
yield. Treatment of aldehyde 45 to Takai olefination conditions gave vinyl iodide 25 in 63% 
yield.87 Deprotection of the Boc-carbamate of 25 with TFA and subsequent coupling with acid 2 
by the action of HATU gave 46 in 70% yield. Subjection of vinyl iodide 46 and ketoaldehyde 26 
(synthesis shown in Scheme 19) to NHK coupling conditions gave protodeiodination of 46 to 
give 47 and decomposition of 26. This strategy is further discussed below. 
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Scheme 8. Examination of the NHK coupling strategy 
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1.5.3 Second generation retrosynthetic analysis 
The second generation retrosynthesic analysis featured a modified Julia-Kocienski coupling to 
form the C6−C7 alkene and amide bond formation from acid 2, aldehyde 45, and sulfone 48 
(Scheme 9). Julia olefinations are typically highly E-selective and functional group compatible 
and therefore could serve as an ideal strategy.88-90 Acid 2 and aldehyde 45 were already prepared. 
However, B-ring fragment 48 would require new methodology to prepare this type of 
intermediate from enone 49. Unfortunately, sulfone 48 could not be prepared (see section 1.6.4), 
and this strategy was abandoned.  
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Scheme 9. Second generation retrosynthetic approach toward FR901464 
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1.5.4 Third generation retrosynthetic analysis 
With the troubles encountered in the late stages of the synthesis, a new, bolder approach to unite 
two fully functionalized fragments was envisioned (Scheme 10a). This retrosynthetic analysis 
involved formation of the C6−C7 alkene again for the final coupling of diene 47 and monoene 50 
by a cross-olefin metathesis reaction. Metatheses using ruthenium-based catalysts are tolerant of 
functional groups and have enjoyed application in complex molecule synthesis.91,92 At the onset 
of this endeavor 1,3-diene−ene cross-metatheses were relatively unexplored transformations and 
had not been utilized in natural product synthesis (Scheme 10b).93 This was thought to be a 
viable approach because: (1) a ruthenium catalyst (Ru=) would preferentially react with 55 to 
form ruthenium alkylidene 56 rather than the conjugated olefins of diene 54; (2) the resulting 
alkylidene 56 would preferentially reversibly react with 55 to form 52, but could be minimized 
by slow addition of 55 to the reaction mixture; (3) eventually, alkylidene 56 would reversibly 
react with the sterically more accessible olefin of diene 54 to form the thermodynamically 
favored 57; and (4) if ruthenium alkylidene 53 is generated from the ruthenium catalyst and 
diene 54, this species will react faster with 55 than with diene 54 to form 57 faster than the 
thermodynamically favored 51. This strategy was later substantiated in 2005 by the Crimmins 
group during their total synthesis of apoptolidinone.94 A potential disadvantage of this strategy 
would be the contamination of 57 (or FR901464) by highly toxic ruthenium byproducts. 
However, there are many convenient methods for ruthenium removal of metatheses reactions 
including the addition of P(CH2OH)3,
95 activated charcoal,96 DMSO,97 Ph3P=O,
97 mesopourous 
silicates,98 or Pb(OAc)4.
99  
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Scheme 10. Third generation retrosynthetic approach toward FR901464 
 
 With this coupling strategy in mind, a method to form diene 47 was pursued (Scheme 
11). Initially, previously prepared aldehyde 45 was transformed to diene 58 by a Wittig 
homologation in 80% yield (Scheme 10a). The Boc group of this diene was removed by the 
action of TFA, and subsequently coupled to acid 2 to give adduct 47 as a mixture of stereo- and 
geometrical isomers. To avoid the acid-sensitivity of the diene, Boc removal was performed 
prior to installation of the diene. Treatment of 28 with TFA and subsequent amide formation 
with 2 gave 59 in 86% yield. This allowed for the selective cross-olefin metathesis of 59 and 
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methacrolein in the presence of the Grela catalyst (structure, Scheme 7)100,101 to give an 
unsaturated aldehyde in 57% yield. Wittig homologation of this aldehyde gave diene 47 in 86% 
yield, thereby completing the synthesis of the left fragment coupling partner.7,102 The preparation 
of the right fragment and successful conclusion of this strategy is discussed below.  
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Scheme 11. Preparation of diene 47 
1.6 CONTRIBUTION TO THE TOTAL SYNTHESIS OF FR901464 BY BRIAN J. 
ALBERT 
1.6.1 Acid chain studies 
With a successful strategy for the preparation of acid 2 in hand, efforts were directed towards 
improving the enantioselectivity of forming Carreira asymmetric alkynylation adduct 30 (Table 
3). Using only 2.0−2.5 equiv of CH3CHO and Et3N as the base led to formation of 30 in an 
improved 45% yield, but surprisingly decreased the er to 3.3:1 (entry 1). In 2003 Carreira, based 
on Noyori’s diethyl zinc model,103 proposed transition state 60 where the X−group could be the 
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base chosen for the reaction (Figure 5).104 Therefore, different bases were examined in this 
alkynyl addition reaction. When DBU was employed as the base, a higher yield of 30 was 
obtained but in a lower (2.3:1) er (entry 2). A smaller base, Me2NEt gave 30 in 45% yield and a 
modest 2.5:1 er (entry 3). Using a larger base, iPr2NEt, gave adduct 30 in 59% yield and 3.5:1 er 
(entry 4). Lowering of the temperature for these reaction conditions gave 30 in 36% yield and 
4.7:1 er (entry 5). Finally, executing this reaction from 0 to 23 °C gave 30 in 33% and 3.8:1 er 
(entry 6). Therefore, there appears to be an effect of the base on the observed enantioselectivity 
of this reaction. It should be mentioned that slow addition of acetaldehyde, which is unstable, 
was crucial in suppressing aldol condensation. Without an excess of acetaldehyde in the reaction 
mixture, the enantioselectivity was significantly lower. Later, it was discovered that the er of 30 
could be improved to 98:2 by one recrystallization in Et2O/hexanes at −20 °C. 
 
Table 3. Base effects in the preparation of 30 
Ph
Ph
HO
CH3CHO (2−2.5 equiv)
Zn(OTf)2 (1.5 equiv)
(−)-N-methylephedrine (1.6 equiv)
base (1.6 equiv), toluene
41%, 86:14 er 3033
entry base temp (oC) er
1 23 3.3:1b
2.3:1a
2.5:1b
3.5:1a
aDetermined by chiral HPLC, (S,S) Whelk column, 25 cm, 5%
iPrOH/hexanes, 1 mL/min. b Detemined by optical rotation of 35
2
3
4
5
6
Et3N
DBU
Me2NEt
iPr2NEt
iPr2NEt
iPr2NEt 0 to 23
0
23
23
yield (%)
45
2351
59
36
33
4.7:1a
3.8:1a
45
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Figure 5. Carreira’s proposed asymmetric alkynylation transition state 
 
Although 30 could be produced in high er, the overall yield was quite low (10−20%). 
Therefore, alternative methods were envisioned to prepare 30 similarly. In 2005, the Shibasaki 
group developed an alkynyl addition reaction utilizing InBr3 and BINOL.
105 However, when 
applied to enyne 33 and acetaldehyde, no desired product was generated (Scheme 12a). 
Therefore, this strategy was slightly modified, and enyne 33 was added to acetaldehyde 
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Scheme 12. Alternative method for the preparation of 30 
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by the action of nBuLi to give rac-30 in 93% (Scheme 12b). This alcohol was then oxidized using 
Parikh-Doering conditions to give unsaturated ketone 61 in 94% yield. The transfer 
hydrogenation reaction of this ketone with Noyori’s (S,S) catalyst 62 gave the desired 
propargylic alcohol 30 in 26% yield and >20:1 er.59 Unfortunately, the turnover number for this 
catalyst was 5.2 and therefore this method was abandoned. Alternatively, reduction of this 
material with catalyst 67 (structure, Scheme 12) and catechol borane gave 30 in quantitative 
yield but only in 2.5:1 er. 
 With the preparation of acid 2 requiring a respectable 6 linear steps, shortening the 
sequence was desired if it did not jeopardize the scalability of the sequence. Toward this end, the 
two-step oxidation of 35 to ynoic acid 63 was targeted for improvement. Treatment of 35 with 
less than 1 mol % of OsO4 and Oxone
® gave ynoic acid 63 and benzoic acid in nearly 
quantitative yields as an inseparable mixture (Scheme 13).106  After partial hydrogenation of this 
mixture, acid 2 was generated in a 60% two step yield free of impurities from benzoic acid. 
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Scheme 13. Alternative method enveiled for the preparation of acid 2 
 
 Developing a more scalable route to acid 2 was desired due to the cost and safety issues 
of using TMSCHN2 in large scale, and the low yielding approach for the preparation of 
propargylic alcohol 30. Coupling of N-acetylmorpholine and tetrahydro-2-(2-propynoxy)-2H-
pyran by the action of nBuLi gave ynone 63 in 78−93% yields (Scheme 14).107 Reduction of this 
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ynone with a substoichiometric amount of commercially available 67 and catechol borane in 
EtNO2 gave 64 in near quantitative yield, and acetylation of this material gave 65 in 97% yield 
over two steps.108,109  Subsequent THP-removal and concomitant oxidation of the putative 
alcohol to ynoic acid 66 was accomplished in 74% yield and revealed that the er was 5.1:1. 
Finally, partial hydrogenation gave acid 2 in a total of five steps. Alternatively, the THP-group of 
65 could be removed via methanolysis under acidic conditions in 82% yield. Subsequent 
successive oxidations with Dess-Martin periodinane and NaClO2 gave 66 in 84% also in a 5.1:1 
er, indicating that no epimerization occurs in the formation of 66 from 65.110  
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Scheme 14. Alternate preparation of acid 2 
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1.6.2 A-Ring studies 
With established schemes to fully functionalized A-ring fragments, methods were desired to 
make the routes shorter and/or more efficient. The first synthetic step that was improved was the 
preparation of 38 (Scheme 15). Partial reduction of ester 36 with DIBALH, addition of 
Ph3P=CH2 at −78 °C, and subsequent mild heating gave 38 in 77% yield in one pot without 
epimerization.111 This procedure was executed on 30 g scale several times without mishap, 
thereby demonstrating the utility of this procedure. Moreover, this one-pot procedure avoided 
tedious aqueous workups of the Garner aldehyde. The DIBALH purchased from Aldrich gave 
superior results to that purchased from other vendors.  
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Scheme 15. One-pot procedure for the preparation of 38 
 
 Although two procedures were established to prepare the preparation of unsaturated 
lactone 42, the efficiencies were of concern for large-scale preparation of A-ring fragments. In 
scale-up efforts, the use of 2.0 equiv of PCC and 4.1 equiv of aq. tBuOOH gave 42 in 49% yield 
(entry 1, Table 4). Increasing the amount of PCC to 2.5 or 3.0 equiv gave 42 in lower yield, 
demonstrating the adverse effect of using more PCC (entries 2 and 3). The use 10 equiv of 
CrO3/3,5-dimethylpyrazole generated 42 in 67% yield (entry 4).
112,113 However, concerned with 
the amount of chromium waste generated, the amount was reduced to 8.0 equiv of CrO3, which 
gave 42 in 70% yield (entry 5). Further reduction of reagents to 6.0 equiv gave 42 in only 53% 
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yield (entry 6), indicating that 8 equivalents was optimal. With an improved method to prepare 
unsaturated lactone 42 from dihydropyran 41, the amount of toxic waste generated was still of 
concern. Therefore, a rhodium catalyst developed by Doyle was used to oxidize dihydropyran 41 
to 42, but in only 42% yield (entry 7).114  
 
Table 4. Preparations of dihydropyran 42 
O
BocHN
O
BocHN
O
entry reagents (equiv) temp (oC) yield (%)
1
PCC (2.0)
tBuOOHa (4.1)
23 49
67
4241
PCC (2.5)
tBuOOHa (4.0)
Rh2(cap)4 (0.007)
tBuOOHa (2.0), K2CO3 (0.5)
CrO3 (10.0)
tBuOOHa (10.0)
0 to 23 42
2
4
7
4723
-30 to 0
conditions
a 70% wt/wt in H2O
PCC (3.0)
tBuOOHa (3.0)
3 3223
70CrO3 (8.0)
tBuOOHa (8.0)
5 -30 to 0
53CrO3 (6.0)
tBuOOHa (6.0)
6 -30 to 23
CH2Cl2
 
 
 Tetrahydropyran 28 could be prepared from lactone 31 by an allylation/reduction 
sequence (Scheme 16a), but a reduction/allylation sequence could give the same product, and 
possibly in higher yield (Scheme 16b). To help decide between these pathways, the reactions of 
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similar substrates were consulted. Bartlett and Holmes treated 69 with BF3•OEt2 and 
allyltrimethylsilane to generate putative oxocarbenium ion 70, which subsequently gave 1,5-
trans-71 in >10:1 dr (Scheme 17a).115 Therefore, nucleophiles prefer to add in trans-fashion to 5-
substituted oxocarbenium ions. Woerpel and coworkers performed other nucleophilic additions 
to putative oxocarbenium ions probing the C2 and C4 positions, which would be relevant to the 
preparation of 28.116,117 Electronegative substituents at position C4 of 72 prefer pseudoaxial 
positioning in 73, and therefore give rise to 1,4-trans-74 in a 7−100:1 dr (Scheme 17b). 
However, no nitrogen-based C4-substituents, found in 31 and 28, were examined by Woerpel in 
this study. Exposure of 75 to these reaction conditions generated oxocarbenium ion 76, which 
Woerpel postulates has a steric interaction with the incoming nucleophile, and therefore 
produced 77 non-selectively (Scheme 17c). From these results, pathway a (Scheme 16) should 
be chosen for the synthesis of 28. The C15-methyl group and C14-carbamate moiety should 
reinforce nucleophilic addition from the α-face, but the C12-methyl group may prove detrimental 
to the addition.  
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Scheme 16. Two pathways to synthesize tetrahydropyran 28 from 31 
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 The allylation/reduction sequence of lactone 31 to form tetrahydropyran 28 was 
examined due to its low yield (typically 20−25%). Treatment of lactone 31 with allylmagnesium 
chloride at −78 °C gave hemiketal 43 in 96% yield (Table 5). The key to this 11% improvement 
was to add the Grignard reagent down the flask sides in order to avoid bis-addition to lactone 31. 
Reduction of this hemiketal with a 10:4:8 ratio of Et3SiH/BF3•OEt2/CF3CH2OH in CH2Cl2 at −78 
°C reproducibly gave tetrahydropyran 28 in 39% yield and pyrrolidine 44 in 20% yield (entry 1). 
Using this reagent combination in CH2Cl2 at −42 °C produced tetrahydropyran 28 in only 29% 
yield (entry 2). Therefore, low temperature was beneficial in forming tetrahydropyran 28. To 
examine if such a large excess of reagents were necessary, a 5:2:4 ratio of 
Et3SiH/BF3•OEt2/CF3CH2OH in CH2Cl2 at −78 °C, was found to give tetrahydropyran 28 and 
pyrrolidine 44 in 30% and 33% yields, respectively (entry 3). Finally, using MeCN as the solvent 
led to almost exclusive formation of pyrrolidine 44 and tetrahydropyran 28 in only 5% yield. 
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Thus, this sequence was improved, affording tetrahydropyran 28 in greater yields during large-
scale A-ring fragment preparations.  
 
Table 5. Optimization of the allylation/reduction sequence of lactone 31 
O
BocHN
OH O
BocHN
N
BocHO
11
43 44
dr = 10:1
28
dr = 10:1
+
entry
Et3SiH/BF3 OEt2/CF3CH2OH
(equiv) temp (
oC)
yield (%) of 28
(yield (%) of 44)
1
2
3
4
10:4:8
10:4:8
5:2:4
10:4:8
-78
-42
-78
-42
Et3SiH
CF3CH2OH
BF3 OEt2
solvent
solvent
CH2Cl2
CH2Cl2
CH2Cl2
MeCN
38 (39)
29 (20)
30 (33)
5 (35)
11
1131
MgCl
96%
 
 
1.6.3 Forward synthesis of the first retrosynthetic analysis 
Preparation of the B-ring fragment was envisioned with installation of the epoxide early on in the 
synthetic sequence. Although this could have proven detrimental to the completion of the total 
synthesis, in the end, the payoff was immense. Utilizing a known protocol,118 propargyl alcohol 
and methallyl bromide were coupled by the action of zinc dust to give skipped diene 78 in 93% 
yield (Scheme 18). This reaction proved to be quite reproducible and scalable, routinely 
performed on 80 g scale. The subsequent regioselective Sharpless asymmetric epoxidation of 78 
gave epoxyalcohol 79 in 90% yield and excellent enantioselectivity (er = 98:2).119 This reaction 
reproducibly gave 79 in >80% yield on 30 g scale, allowing for facile scale-up of this 
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intermediate. Oxidation of this epoxyalcohol with the Dess-Martin periodinane gave 32 in 81% 
yield.110 Alternatively, a Parikh-Doering oxidation could be used to prepare 32 in 65−70% yields 
in larger scale preparations. Obtaining high levels of substrate control for the vinyl addition to 
this epoxyaldehyde proved quite difficult (Table 6). Simple addition of vinylmagnesium bromide 
to 32 gave allylic alcohols 80 and 81 in 53% combined yield in a 1.0:1 ratio, respectively. The 
elucidation of the stereochemistry of the C4 position of these allylic alcohols is described 
Scheme 23. The addition of 1.0 equiv of ZnCl2 gave a 0.3:1 ratio of 80:81, but the addition of 2.0 
or 4.0 equiv of ZnCl2 afforded these alcohols without selectivity (entries 2−4). Therefore, the 
generation of the desired diastereomer, 80, as the major product remained elusive. Addition of 
hexanes, to precipitate some of the inorganic salts, and 2.0 equiv of ZnCl2 to the reaction mixture 
produced allylic alcohols 80 and 81 in 54% combined yield in a 2.0:1 ratio, respectively (entry 
5). Treatment of vinylbromide with tBuLi, to generate vinyllithium in situ,120 and subsequent 
addition of epoxyaldehyde 32 afforded allylic alcohols in 46% yield non-selectively (entry 6). 
Finally, to overcome the poor selectivities using substrate control, reagent control was attempted. 
Addition of vinylmagnesium bromide, ZnCl2, and (−)-N-methylephedrine to 32 gave allylic 
alcohols 80 and 81 in 42% yield and a 1.0:1 ratio, respectively (entry 7). Although low 
selectivity was obtained in this transformation, the focus remained on moving the synthetic 
sequence forward. Towards this end, undesired C4 diastereomer 81 was subjected to Mitsunobu 
reaction conditions using p-nitrobenzoic acid as the latent nucleophile to invert the C4 
stereocenter, thereby generating 82. This ester was subsequently cleaved with basic methanol to 
produce 80 in 75% yield over two steps.  
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Scheme 18. Initial right fragment preparation studies 
 
Table 6. Preparation of allylic alcohols 80 and 81 
H
O O
OH
O
OH
8132 80
+
4 4
O
entry
(2 equiv) yield (%)
a
1 51
additive(s)
(equiv)
ZnCl2 (1.0)
---
ZnCl2 (4.0)
1.0:1b
1.0:1b
2
4
0.3:1b71
42
aCombined yield. bRatios determined from isolated products. cRatios
determined by crude 1HNMR analysis. d (−)-NME = (−)-N-methylephedrine.
ZnCl2 (2.0)3 1.0:1
b42
tBuLi (2.0) 1.0:1c6 46
-MgBr
-MgBr
-MgBr
-MgBr
-Br
M
THF, −78 oC
M
7 -MgBr
ZnCl2 (2.0), toluene
(−)-NMEd (2.0)
42
2.0:1c5 54-MgBr
ZnCl2 (2.0)
nhexane
1.0:1c
80:81
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 With a moderate quantity of allylic alcohol 80 produced, the preparation of ketoaldehyde 
26 was explored (Scheme 19). Protection of 80 as its TES-ether was accomplished in 
quantitative yield by the action of TESCl/imidazole to provide diene 83. Subsequent ozonolysis 
of this diene reproducibly afforded ketoaldehyde 26 in <10% yield. Sequential regioselective 
dihydroxylation of the 1,1-disubstituted olefin and subsequent oxidative cleavage gave enone 85 
in 58% yield over two steps. Ozonolysis of this enone followed by reductive workup using 
Me2S/
nBu3P of this enone afforded unsaturated ketone 86 in 15% yield. However, employing 
only Me2S in the reductive workup step successfully produced unstable ketoaldehyde in 54−82% 
yields. With a successful method to prepare ketoaldehyde 26 in hand, it became evident that the 
large-scale separation of allylic alcohols 80 and 81 was a major obstacle, and a better method to 
form the C4 stereocenter was desired.  
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Scheme 19. The first method to prepare ketoaldehyde 26 
 
Despite an established route towards ketoaldehyde 26, a better method to install the C4-
stereocenter was sought. Treatment of epoxyaldehyde 32 with either trimethylsilylacetylene or 2-
methyl-3-propyn-2-ol gave no desired product under Carreira’s conditions, and caused 
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decomposition of aldehyde 32 under mild heating (Scheme 20a).82 Alternatively, the 
alkynylation of 32 with ethynylmagnesium bromide gave 87 in 34% yield as a 2:1 mixture of 
diastereomers (Scheme 20b). Warming of this reaction gave 87 in higher yield but the desired 
compound was contaminated with Payne rearrangement products. To elucidate the 
stereoselectivity of this alkynyl addition reaction, propargylic alcohols 87 were subjected to 
partial hydrogenation conditions to afford allylic alcohols 80 and 81 in a 1.7:1 ratio, respectively. 
Finally, the Ag/Zr-promoted alkynyl addition of silver acetylide 88 to 32 produced ynoate 89 in 
84% yield and a 6:1 dr (Scheme 20 c).121 This exquisite transformation is further discussed in 
Chapter 2. Satisfied with the diastereoselectivity and yield from this alkynyl addition reaction, 
efforts were focused on preparing ketoaldehyde 32 from 89. The partial hydrogenations of this 
propargylic alcohol and its TES-ether, 90, failed to afford Z-enoates 91 or 92, respectively. 
Therefore, utilizing another methodology developed in the Koide laboratories,122 intramolecular 
hydride delivery was accomplished by treating 89 with Red-Al® to selectively give E-enoate 93 
in 81% yield. Protection of the hydroxy group of 93 was accomplished with TESCl/imidazole 
affording 94 in quantitative yield. Ozonolysis of this material and subsequent reductive workup 
with Me2S gave ketoaldehyde in quantitative yield as determined by 
1H NMR. Thus, access to 
ketoaldehyde 26 was now attainable in only seven steps and without the need for successive 
oxidative cleavage reactions. Therefore, all that remained was the coupling to form the C5−C6 
bond of FR901464. 
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Scheme 20. Alternative methods to install the C4-stereocenter 
 
 The first generation coupling strategy was examined using ketoaldehyde 26. It was 
previously discovered that subjection of vinyl iodide 46 and ketoaldehyde 26 under NHK 
reaction conditions gave proto-deiodination of 46 and decomposition of 26 (Scheme 8). 
Similarly, treatment of vinyl iodide 25 and ketoaldehyde 26 to NHK reaction conditions gave 58 
and decomposition of the ketoaldehyde (Scheme 21b). Therefore, a bolder strategy was 
envisioned involving lithium-halogen exchange where bond formation would be expected to 
occur rapidly, which could prevent the decomposition of 26. However, this reaction would be 
expected to be difficult in the presence of the N-H bond found in the carbamate moiety. 
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Nonetheless, treatment of vinyl iodide 25 with nBuLi in the presence of ketoaldehyde 26 
afforded 58 and decomposition of the ketoaldehyde (Scheme 21b). To examine if the carbamate 
was the cause of the failed couplings, treatment of (E)-1-iodo-3-methylbuta-1,3-diene with nBuLi 
in the presence of ketoaldehyde 26 again produced only decomposition products (Scheme 21c). 
With the realization of the ketoaldehyde instability and the difficulty in forming the C5−C6 bond 
in the late stages of the synthesis, alternative coupling strategies were explored.  
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Scheme 21. Further coupling attempts using the first retroynthetic strategy 
 
1.6.4 Forward synthesis of the second retrosynthetic analysis 
Since the highly-functionalized sulfone intermediate 48 was desired for use in the Julia coupling, 
it was recognized that previously prepared intermediates could allow for rapid preparation of 
such a sulfone. A bromolactolization was envisioned to provide such an intermediate (Scheme 
22d). This method would differ from other tactics often employed, involving the intramolecular 
attack of a hydroxy group onto a pendant aldehyde/ketone to give hemiacetal/hemiketal 
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products.123-129 One of the most common methods for electrophilic cyclizations involves the 
haloetherification or halolactonization of alcohols or carboxylic acids, 95, to electrophile-
activated alkenes to give 96 as products (Scheme 21a). Similarly, amides 97 may be utilized 
under comparable reaction conditions to form iminium ions 98 that are ultimately hydrolyzed to 
provide lactones 99 where the pendant sulfoxide induces stereoselectivity in the bond forming 
stereocenter (Scheme 22b).125 Treatment of o-alkynyl benzaldehyde derivatives 100 with 
bispyridine iodonium tetrafluoroborate is thought to generate oxocarbenium 101, which can be 
trapped intermolecularly by alcohols to form acetals 102 (Scheme 22c).124 Similarly, it was 
postulated that the activation of the alkene in an enolizable aliphatic enal/enone 103 with NBS or 
another electrophilic reagent could generate the pi-complex 104, which would allow for 
cyclization using the carbonyl oxygen and subsequent trapping with an alcohol or water (R’OH) 
to give hemiacetal/hemiketal 105 (Scheme 22d). However, enolization and subsequent C−C 
bond formation could occur to give carbocyclic products. This intramolecular cyclization would 
be expected to proceed via the pi-complex 104 rather than a bromonium or β-halocarbenium ions, 
since pi-complexes are known species123,130,131 and they match kinetic models where onium or β-
halocarbenium ions species would not.132 While the approach shown in Scheme 22d was an 
unknown tactic, the exciting possibility of exploring this reaction inspired the examination of the 
postulate.  
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Scheme 22. Electrophilic cyclization tactics 
 
 Treatment of enone 85 with NBS in THF/H2O (8:1) gave 106 as a single diastereomer in 
75% yield (Scheme 23). This hemiketal was in equilibrium with its open keto-alcohol conformer 
and thus, for unambiguous structural determination, methyl glycoside 107 was prepared in 40% 
yield by treating 106 with PPTS and MeOH. NMR analysis of methyl glycoside 107 revealed the 
NOE between the -OMe and C5-H, indicating the diaxial relationship. Moreover, the C4−C5 J-
value was 1.4 Hz, indicating the equatorial placement of the C4-OTES group. Disappointingly, 
107 had the incorrect C5-stereochemistry and could not be used in the preparation of 48. 
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Treatment of 85 with NBS in the presence of MeOH gave 107 again in 59% yield, thereby 
supporting the postulate that external nucleophiles could trap putative oxocarbenium ions.133 
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Scheme 23. Preparation of methyl glycoside 107 
 
 Although the NBS-promoted cyclization of enone 85 gave the incorrect stereochemistry 
at C5, the efficiency of this reaction was encouraging. It seemed reasonable that switching to its 
C4-epimer could reverse the observed stereoselectivity in the cyclization. Therefore, enone 110 
was prepared as shown in Scheme 24. Exposure of this enone to NBS in acetone/H2O (8:1) gave 
111 as a single diastereomer in 95% yield. Treatment of 111 with PPTS and methanol afforded 
methyl glycoside 112 in 75% yield. Alternatively, methyl glycoside 112 could be prepared from 
enone 110 in 47% yield by exposure to NBS in MeOH. The absolute stereochemistry of this 
material was confirmed by X-ray crystallographic analysis, also revealing the 
diastereoselectivities for the vinyl and alkynyl additions into epoxyaldehyde 32.  
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Scheme 24. Preparation of methyl glycoside 112 
 
 With the successful stereoselective preparations of 106 and 111, it was not clear whether 
H2O attacked a bromide ion-activated alkene 115 to generate bromohydrin 117 (R = H), which 
could spontaneously cyclize to lactol 106, or the carbonyl oxygen atom (or its hemiketal) 
intramolecularly reacted (Scheme 25b). In collaboration with Professor Kendall Houk, it was 
predicted that the reaction of acetone with bromonium ion 113 to 114 is exothermic by 40−50 
kcal/mol (quantum mechanical calculations using Gaussian 98 and Gaussian 03 using Hartree-
Fock at 3-21G level of theory with B3LYP functional & 6-31G basis sets; Scheme 25a). 
Although these numbers should be taken with caution, as they are unrefined and neglect the 
bromine counterion, they illustrate the distinct driving force for the intramolecular reaction. It 
was also observed that the reactions of 85 and 110 in the presence of methanol did not show any 
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generation of methyl ethers 117 by analysis of the crude reaction mixture. Therefore, treatment 
of enone 85 with NBS should rapidly generate oxocarbenium ion 118 that can react with MeOH 
to give glycoside 107.133  
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Scheme 25. Explanation for the observed reactions of 85 
  
 To explain the high stereoselectivity for these cyclization reactions, all four possible half-
chair transition states were analyzed (Scheme 26). Approach of the electrophilic bromide from 
the α-face of the C5−C6 alkene of 110 would give rise to the pi-complexes 119 and 120.123,134 
Half-chair 119 is destabilized by the pseudo-1,3-diaxial interaction of the spiroepoxide and the 
forming C6-methylene bromide. Transition state 120 places σ*C4−O nearly parallel to pi C5−C6, 
suffering from the inside alkoxy effect,135  and additionally may suffer steric repulsion from the 
bulky -OTES and forming C6-methylene bromide. Approach of the electrophilic bromide from 
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the β-face of the C5−C6 alkene would give rise to the pi-complexes 121 and 122. Transition state 
121 is electronically preferred stereoelectronically and sterically. Half-chair 122 places its σ*C4−O 
nearly parallel to pi C5−C6, destabilized by the inside alkoxy effect. Thus, transition state 121 is the 
most favorable, and is thought to lead to the experimentally observed products 111 and 112.133  
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Scheme 26. Model to explain the observed stereoselectivity for the cyclizations of 110 
 
With a method to prepare 112 containing the entire carbon skeleton of sulfone 48 in hand, 
further functionalizations towards 48 were examined. The first task was the installation of the 
C6-thioether (Scheme 27). Treatment of methyl glycoside 112 with 1-phenyl-1H-tetrazole-5-
thiol gave epoxide-opened product 125 in 60% yield. Moreover, addition of NaI or use of 
Cs2CO3 as the base gave similar results. To examine whether the bulky, axial C4-OTES group 
was blocking the C6 position from SN2 attack, 112 was deprotected by the action of TBAF to 
give 123 in 80% yield. Treatment of this material to 1-phenyl-1H-tetrazole-5-thiol and Et3N gave 
epoxide-opened product 126 in 74% yield. Since thiolate anions preferentially react with the 
spiroepoxide rather than the methylene bromide, conversion of the methylene bromide to a 
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hydroxy group could allow for a mild Mitsunobu reaction to introduce the thioether. Towards 
this end, treatment of 112 with KO2 and 18-crown-6 gave oxetane 127 in 64% yield with no 
evidence of desired product formation. With no success in the preparation of a C6-thioether, a 
Mitsunobu reaction of 123 was attempted to invert the C4-hydroxy group using p-nitrobenzoic 
acid as the nucleophile. After methanolysis, alcohol 123 was observed, not 124, presumably due 
to the crowded steric environment.136 Due to the difficulty in inverting the C4-hydroxy group 
and the sensitivity of the spiroepoxide towards thiols, the Julia-olefination synthetic strategy was 
abandoned. 
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Scheme 27. Unsuccessful preparations of a B-ring sulfone coupling partner 
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1.6.5 Forward synthesis of the third retrosynthetic analysis  
To pursue the cross-olefin metathesis strategy, the remaining task was to prepare a right 
fragment. With ketoaldehyde 26 in hand, a direct approach would be a chemoselective vinyl 
addition to this ketoaldehyde to afford a coupling partner (Table 7). Treatment of fragile 26 with 
vinylmagnesium bromide gave an inseparable mixture of 128 and 5-epi-128 in 40% yield with 
no diastereoselectivity (entry 1). Addition of HMPA or TMEDA slightly improved the desired 
Felkin selectivity and overall yield of 128 (entries 2 and 3). In situ generation of vinyllithium 
from vinyltributyltin and nBuLi, and subsequent addition of 26 gave 128 and 5-epi-128 in 33% 
yield with no diastereoselectivity (entry 4). Addition of HMPA gave these alcohols in better 
diastereoselectivity (dr = 2:1) but in only 16% yield (entry 5). Neither switching the solvent to 
CH2Cl2 or toluene, nor preparing the organocerium reagent from CeCl3 improved this difficult 
transformation (not shown).137,138 Moreover, alkynyl additions to ketoaldehyde 26 required 
higher temperatures (≥ −20 °C). However, enough materials were synthesized to examine the 
viability of the coupling strategy.102 
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Table 7. Preparation of right fragment coupling partners 128 and 5-epi-128 
OO
OTES
H
O
26
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THF
entry
(2 equiv) yield (%)
a
1 40
additive(s)
(equiv)
HMPA (2.5)
---
---
1.0:1
1.0:1
2
4
1.3:146
33
aCombined yield; bDetermined by 1H NMR analysis;
c Prepared from CH2=CHSnBu3 and
nBuLi
TMEDA (2.5)3 2.0:131
HMPA (2.5) 2.0:15 16
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OH
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OO
OTES
OH
OH
5
5
5
5
5
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+
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M
128:5-epi-128b
-MgBr
-MgBr
-MgBr
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-Lic
M
 
 
 With fully functionalized coupling fragments 47 and 128 in hand, the stage was set to test 
the cross-olefin metathesis coupling strategy. Treatment of 47 and the C6-epimeric mixture 128-
mixture gave inseparable metathesis adducts 129 in 22% yield (Scheme 28). Subsequent removal 
of the TES ethers of 129 was accomplished by the action of HF•py to furnish FR901464 and 
presumably its C5 epimer. The successful preparation of FR901464 was confirmed by HPLC 
analysis using an authentic sample of FR901464 showing the viability of this coupling strategy! 
However, it was clear that a method to prepare a diastereomerically pure right fragment was of 
paramount importance to avoid wasting precious materials and tedious purification. 
 
 56 
 
O
O
OH
TESO
O
N
H
OAcO
O
O
OH
TESO
O
N
H
AcO
O
Grubbs' II
+
6
7
6
7
THF, 22%
129128-mixture47
HF py
THF, 0 oC
O
N
H
OAcO
O
O
OH
HO
FR901464
 
Scheme 28. First synthesis of FR901464 in the Koide group 
 
 In order to prepare a right fragment more efficiently, formation of the C5 stereocenter 
required much to be improvement. The use of a TBS ether rather than the TES ether could favor 
Felkin addition to ketoaldehyde 133 by suppressing α-alkoxy group chelation. Towards this end, 
130 was prepared in 88% yield from allylic alcohol 80 by the action of TBSCl/imidazole 
(Scheme 29). Regioselective oxidative cleavage of the 1,1-disubstituted alkene of 130 was 
accomplished in 45% yield over the two steps to give enone 132 via diol 131. This enone was 
subjected to ozonolysis conditions and subsequent reductive workup afforded 133 in 89% yield. 
Disappointingly, subjection of this ketoaldehyde to vinyl or alkynyl additions only gave complex 
mixtures, apparently due to poor chemoselectivity of the aldehyde and ketone. 
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Scheme 29. Preparation and use of ketoaldehyde 133 
 
 To explain the poor yields for the additions to ketoaldehydes 26 and 133 and their 
temperature sensitivity during these reactions, the following mechanism is proposed (Scheme 
30). After chemoselective addition to the aldehyde of 134, alkoxide 135 will be formed. This 
alkoxide will presumably be in equilibrium with hemiketal alkoxide 136 which could protect it 
from further reactions to give 137 upon aqueous workup. However, alkoxide 135 could also 
reversibly deprotonate the C2 position thereby giving enolate 138. This enolate would be 
expected to undergo facile β-elimination affording enones 139 irreversibly and 140 upon 
aqueous workup. From the experimental results, C2-deprotonation presumably occurs rapidly at 
≥ −20 °C explaining why alkynyl addition reactions afforded no desired products and the low 
yields for the alkenyl addition reactions.  
 
 58 
OO
OSi
H
O
134
SiO
OO
135
O
O
O
Nu
SiO
136
H2O
O
O
OH
Nu
SiO
137
Nu-M
ONu
H
SiO
O
OHNu
O
H2O
SiO
OHNu
O
O
SiO
OHNu
O
HO
139 140138
2
Si = TES
or TBS
 
Scheme 30. Proposed explanation for the low yielding additions to 26 and 133 
 
 Because of the poor selectivity and yields for additions to ketoaldehydes, other methods 
were explored to develop a functionalized right fragment to use for the cross metathesis strategy. 
Several methods to simultaneously install the C4 and C5 stereoecenters were explored. The first 
method employed, developed by MacMillan, involved the use L-proline to mediate an aldol 
reaction of epoxyaldehyde 32 and 141 (Scheme 31a).139 However, aldol adduct 142 was obtained 
in only <5% yield as a C5-epimeric mixture, implying that the equilibrium lies strongly towards 
the starting materials. Since reagent control was unsuccessful in installing the C4 and C5 
stereocenters silmultaneously, substrate control was revisited. Propargyl addition reactions have 
been shown to be highly anti-selective and would contain all of the requisite carbons for 
128.140,141 The in situ formation of the allenyl-titatinium or zinc reagents and subsequent addition 
of epoxyaldehyde 32 afforded 144 in 66% and 86% yields and in 6:3:1:1 and 3:2:1:1 dr, 
respectively (Scheme 31b). Because of the low observed diastereoselectivities and the difficult 
task of proving the configuration of the diastereomers, this transformation was deemed not 
worthy of further investigation.  
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Scheme 31. Methods to introduce the C4 and C5 stereocenters simultaneously 
 
 Since the introduction of the C4 and C5 stereocenters could not be accomplished in high 
selectivity, previously prepared enoate 94 was revisited. Treatment of this enoate with 3.0 equiv 
of DIBALH in THF gave alcohol 145 in 95% yield (Scheme 32). The use of CH2Cl2 also gave 
145 but generated many products. At this point, both an asymmetric Sharpless epoxidation and a 
[2,3]-Mislow-Evans-like rearrangement strategy were envisaged to introduce the C5-
stereocenter. Despite no reported diastereoselective [2,3]-sigmatropic rearrangements using 
primary allylic alcohols, this strategy made for a bold approach but with potentially high payoff. 
With this in mind, selenide 146 was prepared in quantitative yield from alcohol 145. With little 
optimization of this [2,3]-sigmatropic rearrangement strategy for linear systems, this reaction 
was investigated thoroughly. Utilizing typical conditions, H2O2 and py, alcohols 148 and 5-epi-
148 were produced in a combined 94% yield and a 4.0:1 dr repectively (entry 1, Table 8). Since 
sulfoxides and their sulfenates in the Mislow-Evans reaction have been modeled to have 
hydrogen bonding capabilities in their transitions states,142 it is possible that a protic solvent 
could enhance the substrate control. Performing this reaction in EtOH gave 148 and its C5-
epimer in 87% combined yield in an unimproved 4.0:1 dr (entry 2). Similarly, the reaction in 
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acetone gave 148 and its C5-epimer in 96% combined yield but now in a 3.5:1 dr (entry 3), and 
in CH2Cl2 148 and 5-epi-148 were obtained in a 67% combined yield and a 3.5:1 dr (entry 4). 
Therefore, the only solvent effect observed was for the rate of the reaction and not the 
stereoselectivity; thus, the base employed in the reaction was examined.  
A bulkier base, 2,6-lutidine, was employed in this reaction and gave 148 and its C5-
epimer in a combined 73% yield and a 4.0:1 dr (entry 5). More nucleophilic bases such as 
DMAP and 4-pyrrolidinopyridine generated alcohol 148 and 5-epi-148 in a combined yield of 95 
and 84% yields and a 7.5:1 and 8.1:1 dr, respectively (entries 6 and 7). To test if these results 
were due to the strength of the bases employed, Et3N was utilized in the reaction and gave 148 
and 5-epi-148 in 80% combined yield and a 3.7:1 dr (entry 8). Thus, the nucleophilicity of the 
base employed appears to be the cause of the increased observed diastereoselectivity, with the 
slightly more nucleophilic base, 4-pyrrolodinopyridine, giving the highest diastereoselectivity. 
The amount of the more economical base, DMAP, was then optimized. Decreasing the amount 
of DMAP below 3.0 equiv proved to be detrimental to the stereoselectivity with 3.0, 1.5, and 0.5 
equiv of DMAP giving diastereomeric ratios of 7.8:1, 5.3:1, and 3.3:1, respectively (entries 9, 
10, and 11). Therefore, the amount of DMAP necessary for this reaction should be at least 3 
equivalents. Finally, to examine if the nitro-group on the phenyl ring had any role in the 
stereoselectivity of this reaction, phenyl selenide 147 was prepared, and subsequently used in 
this reaction to produce 148 and 5-epi-148 in 91% combined yield and a 7.0:1 dr (entry 12). 
Therefore, the nitro group has no major role in this reaction, other than suppressing the volatility 
of toxic selenium byproducts. It was later shown that alcohol 145 could be converted to 148 in 
one pot using the same strategy and 4.0 equiv of DMAP in the oxidation step to give 148 and 5-
epi-148 in a combined 91% yield and a 7.0:1 dr.  
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Alcohol 148 was then subjected to oxidative cleavage conditions that gave desired enone 
128 in 27% yield, but lacked regioselectivity. Therefore, 148 was protected as its bis-TES ether 
149 in 95% yield to crowd the steric environment around the monosubstituted alkene. Subjection 
of this material to dihydroxylation conditions and subsequent oxidative cleavage conditions gave 
enone 150 in 71% yield (86% based on recovered 149). It should be mentioned that the oxidative 
cleavage of the putative diol was accomplished with NaIO4 as well, but in only 39% yield (86% 
based on recovered 149), presumably due to the poor water solubility of the bis-TES protected 
diol. Alkene 150 was found to be unreactive under the cross metathesis conditions with 47, and 
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Scheme 32. Preparation of 50 
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therefore global deprotection was accomplished using 3:3:1 AcOH/THF/H2O to give 50 in 91% 
yield. More commonly employed reagents such as HF•py and TBAF/AcOH gave 50 in 43 and 
31% yields, respectively. These low yields were partly due to the water solubility of 50 as well 
as its acid and base lability (see below). Therefore, the synthesis of fully-functionalized B-ring 
fragment 50 was accomplished in 11 linear steps, but the viability of this material towards the 
cross metathesis coupling strategy was unknown. 
 
Table 8. Optimization of the [2,3]-sigmatropic rearrangement strategy 
O
OTES
Se
O
OTES
OH
5
5
148
H2O2 (9-10 equiv)
conditions
entry
1
2
4
aCombined yield. bDetermined by 1H NMR analysis.
3
5
R
R base (equiv) solvent temp (
oC) yield (%)a dr
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO26
7
9
8
10
11
12
NO2
NO2
py (5)
py (5)
py (5)
py (5)
2,6-lutidine (5)
DMAP (5)
4-pyrrolidino-py (5)
Et3N (5)
DMAP (3)
DMAP (1.5)
DMAP (0.5)NO2
H DMAP (5)
THF
EtOH
acetone
CH2Cl2
THF
THF
THF
THF
THF
THF
THF
THF
−20
−44 to −20
−20
0 to 20
−44 to 23
−44 to 23
−44 to 23
−44 to 23
−44 to 23
−44 to 23
−44 to 23
−44 to 23
4.0:1
7.8:1
7.5:1
3.7:1
4.0:1
3.5:1
4.0:1
3.5:1
8.1:1
5.3:1
3.3:1
7.0:1
94
87
96
67
73
95
84
80
80
87
34
91
146: R = NO2
145: R = H
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 To explain the high diastereoselectivity for the formation of 148 over its C5-epimer six 
Newman projections of the putative selenates were analyzed. Oxidation of selenide 146 or 145 
would give a mixture of water sensitive epimeric selenoxides.143 These selenoxides are in 
equilibrium with their epimeric selenates intermediates.143 The cleavage of the Se−O bond is rate 
determining in this reaction, and thus, the preceding reversible sigmatropic rearrangements and 
the epimerizable selenoxide stereochemistry will not be discussed.143 Of the six possible 
rotamers, three were easily omitted and thus not shown. Of the remaining three, the selenate 
shown in Scheme 33a sterically is accessible for the attack of a nucleophile on the selenium 
atom, explaining the formation of 148. The selenates shown in Scheme 33b and c give rise to 5-
epi-148 upon cleavage of the Se−O bond. The one shown in 33b should be destabilized by 
gauche interactions, but it places its oxygen atoms anti to each other that could stabilize the 
forming negative charge after Se−O bond cleavage. Finally, there are less severe gauche 
interactions in the selenate shown in 33c than in 33b, and the selenate sterically more accessible 
towards nucleophiles. A more nucleophilic base, such as DMAP, would lower the transition state 
energy to break the Se−O bond. The selenate shown in a would electronically be favored over c 
which could explain the higher observed diastereoselectivity observed under the reaction 
conditions that utilize more nucleophilic bases.  
With two fully functionalized fragments, the metathesis was again examined. Treatment 
of diene 47 with a slight excess of more reactive 50 with Grubbs’ II gave FR901464 in 12% 
yield (Table 9). The use of the Hoveyda catalyst gave FR901464 in 13% yield. However, the use 
of the Grela catalyst was much more efficient, affording FR901464 in 28% yield and after one 
recycling of starting materials gave this natural product in a combined 40% yield with only the 
E-C5−C6 isomer formed. This was a remarkable result since 50 was shown to form an unreactive 
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homodimer by its preparation and subjection to the metathesis conditions. Moreover, B-ring 
fragment 50 was shown to decompose in 1,2-dichloroethane at ≥47 °C, thereby limiting the 
temperature for the metathesis reaction. This completed the total synthesis of FR901464 in a 
total of 28 steps and 13 steps in the longest linear sequence. Thus, this represents the most 
concise synthesis to date by a total of nine steps, thereby accomplishing a goal of this work.62 
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Scheme 33. Selenate rotamers leading to 148 and 5-epi-148 
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Table 9. Optimization of the preparation of FR901464 
O
O
OH
HO
O
N
H
OAcO
O
O
OH
HO
O
N
H
AcO
O
catalyst
+
6
7
6
7
catalyst temperature yield (%)
50
(1.6−1.8 equiv)
Grubbs' II
Hoveyda
Grela
42
42
23
12
13
28 (40)a
aYield after one recycling of recovered starting materials
ClCH2CH2Cl
5−8.5 h
47 FR901464
 
1.7 CHEMICAL REACTIVITY OF FR901464 AND THE DEVELOPMENT OF 
MEAYAMYCIN 
1.7.1 Discovery of the source of the instability of FR901464 
The instability of FR901464 towards weak acids and bases in organic solvents was previously 
studied, which prompted the study of FR901464 under aqueous conditions. The total synthesis of 
FR901464 gave insight into the reactive moieties of this natural product, with the right fragment 
being the most chemically reactive fragment. Therefore, the decomposition of fully 
functionalized B-ring fragment 50 was studied in aqueous phosphate buffers at 37 °C to mimic 
more biologically relevant conditions (Table 10). The half-life of 50 in pH 6 buffer was 
estimated to be 12 h. In pH 7 buffer, the half-life of 50 was 8 h, and in pH 7.4 buffer, the half-life 
was estimated to be only 4 h.  
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Table 10. Instability of 50 at different pH values in aqueous buffers 
O
O
OH
HO
50
buffer
37 oC
decomposition products
pH t1/2 (h)
a
6
7
7.4
12
8
4
aEstimated by TLC analysis  
 
 As a consequence of the instability of 50 in buffers, this decomposition was further 
investigated mechanistically. Subjection of 50 to pH 7.4 buffer at 37 °C for 1 d produced ≥3 
products, as judged by TLC analysis. Purification and analysis of the major products formed in 
the decomposition of 50 in pH 7.4 buffer revealed the formation of 151, 152, and furan 157 
(Scheme 34a). Hemiketal 50 was observed to exist as its linear ketoalcohol form, 50-open, in 
CD2Cl2 or D2O in a 10:1 ratio in accordance with Jacobsen’s observation.
56 Therefore, 50-open 
could enolize and rapidly undergo β-elimination opening of the epoxide to form enones 151 and 
152 that were obtained in 39% combined yield. The E-enone could exist in equilibrium with its 
5-membered ring hemiketal 155, which could undergo dehydration to give furan 157 in 7% 
yield. Alternatively, Z-enone 151 could exist as its five and six-membered ring hemiketals 153 
and 154, respectively, but of the three compounds, 153 should be thermodynamically disfavored 
due to its ring strain. Therefore, furan 156 is not observed over the time course studied. In 
postulating the other pathways, Kitahara’s mechanism that would produce 23 and acrolein 
(Scheme 34b),64 and a Grob or retro-ene reaction would form acetate 159 (Scheme 34c).144,145 
Acrolein was carefully searched for by NMR and HPLC, but not even trace amounts were  
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Scheme 34. Decomposition pathways of 50 
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observed, and therefore, Kitahara’s decomposition pathway appears not to be relevant in aqueous 
conditions. However, a remote possibility it that acrolein could possibly evaporate before 
detection. A retro-ene pathway was considered plausible due to the instability of 50 in 
ClCH2CH2Cl ≥47 °C, but heating of this compound at 60 °C in C6D6 for 1 d gave only minor 
decomposition products (Scheme 34c). With no significant quantity of 159 generated via 158 in 
C6D6, a retro-ene pathway is unlikely, and the decomposition observed in ClCH2CH2Cl could be 
attributed to trace amounts of HCl. Acetate 159 was possibly observed by crude 1H NMR, 
specifically looking for the methyl group of the acetate moiety around 2 ppm. However, with the 
complex equilibria of enones 151 and 159 and the amount of products observed in the crude 1H 
NMR, this was clearly insuffient evidence. Since no chromophore exists in 159, HPLC analysis 
was of little help in proving the formation of this acetate. However, an IR spectra of the crude 
mixture showed a stretch around 1735 cm-1, indicative of an ester, presumably 159. Although, 
this acetate was not obtained in pure form, and thus its formation is only speculated upon. This 
study revealed that the opening of the hemiketal moiety in 50 leads to the major decomposition 
products, and preventing this opening could vastly improve the stability of the right fragment of 
FR901464.102 With is poor stability in buffers, FR901464 could be of little use as a biological 
probe or of therapeutic potential. 
1.7.2 Preparation of a more stable B-ring fragment 
As previsouly demonstrated by the Jacobsen and Kitahara groups, locking the right fragment of 
FR901464 in its closed form should prevent the major decomposition pathway, namely the 
enolization-β-elimination predicament. Initial efforts were focused on reducing the C1-position 
under acidic conditions. Addition of excess Et3SiH to 150 in 2.5:2.5:1 AcOH/THF/H2O was 
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attempted in the hopes of silyl ether removal and concomitant reduction of the C1 hemiketal, but 
only silyl ether hydrolysis was realized, affording 50 in 53% yield (Scheme 35). More acidic 
conditions were employed and 50 was treated with excess Et3SiH and BF3•OEt2 at −78 °C which 
resulted in decomposition. Therefore, reduction of the C1 position was deemed too difficult due 
to the lack of success of these experiments.  
 
 
OO
OTES
TESO
150
AcOH/THF/H2O
O
O
OH
HO
50
BF3 OEt2
Et3SiH
CH2Cl2, −78
oC
decomposition
Et3SiH
 
Scheme 35. Attempted reductions of 50 and 150 
 
With no success towards the reduction of C1, the preparation of a C1-thioglycoside could 
prove of utility without further functionalizations or allow for reduction of C1. Towards this end, 
the subjection of 50 to thiophenol under various acidic conditions was examined (Table 11). 
Treatment of 50 with 2.0 equiv of thiophenol in 3:3:1 AcOH/THF/H2O gave loss of the epoxide 
(entry 1). Therefore, stronger acids were utilized in the absence of competing nucleophiles. 
Treatment of 50 with thiophenol and a catalytic amount of PPTS in CH2Cl2 gave similar results 
(entry 2). The use of chloroacetic acid or CSA gave decomposition products with loss of the 
epoxide and no formation of 160 (entries 3 and 4). Therefore, functionalization at C1 from a 
hemiketal appears to be limited to oxygen nucleophiles, with thiols and hydride sources not 
producing the desired adducts.  
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Table 11. Failed thioglycoside formations 
O
O
OH
HO
1
50
O
O
SPh
HO
1
160
SH
conditions
entry
equiv
thiophenol
acid (equiv) solvent temp (oC) result
X
23
23
0
0
epoxide loss
epoxide loss
epoxide loss
epoxide loss
AcOHa THF/H2O
a
CH2Cl2
CH2Cl2
CH2Cl2
PPTS (0.10)
ClCH2CO2H (0.10)
CSA (0.10)
2.0
2.0
1.7
1.4
1
2
3
4
aAcOH/THF/H2O 3:3:1 v/v/v solvent system employed  
 
 With no success in adding a hydride or thiol to the C1 position of 50, incorporation of a 
methyl group at C1 was also envisioned to avoid the sensitive hemiketal moiety. A methyl 
analog should also be more stable than Kitahara’s methyl glycoside and would be similar in size 
to the hydroxy group of FR901464, whereas Jacobsen’s analog 19 is not.56,64 Therefore, 1,1-
dimethyl right fragment analog 161 was seemingly readily accessible from previously prepared 
diene 148 via its putative tertiary carbocation under acidic conditions (Table 12). However, 
treatment of 148 with a catalytic amount of PPTS gave no reaction (entry 1). CSA caused 
decomposition (entry 2). Treatment of 148 with Amberlyst® 15 acidic resin gave no reaction 
(entry 3). Therefore, protic catalysts were abandoned and Lewis acidic catalysts were examined. 
Using a catalytic amount of AgOTf gave decomposition when heated to 80 °C (entry 4).146 
Moreover, Widenhoefer’s conditions utilizing a platinum catalyst gave no formation of 161.147 
While tetrachloroethane was not employed as the solvent, Cl3CCH3, dioxane (also used 
successfully by Widenhoefer), benzene and chlorobenzene were all ineffective solvents.  
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Table 12. Failed etherification reactions of 148 
O
OTES
OH
5
148
O
O
TESO
entry
1
conditions (equiv)
no reaction
decomposition
2
4
decomposition
aDetermined by 1H NMR and or TLC. b Cl3CCH3, dioxane, and PhCl
were ineffective solvents in promoting this reaction.
3 no reaction
<5%5
conditions
PPTS (0.10)
CSA (0.10)
Et2O
CH2Cl2
resultatemp (oC)
23
23
AgOTf (0.10)
Amberlyst 15 CHCl3
ClCH2CH2Cl
−28 to 23
23 to 80
Pt2Cl2(CH2=CH2)2 (0.02)
(p-CF3Ph)3P (0.04)
benzeneb 75
solvent
161
5
 
 
 Typical iodoetherification conditions with NIS provided 162 in 27% yield with the major 
product being a tetrahydrofuran derivative with loss of the C4-OTES group, but the use of NaI 
and Pb(OAc)4 gave 162 in a much improved yield of 77% (Scheme 36).
148 Radical-promoted 
deiodination of 162 afforded tetrahydropyran 161 in 63% yield. Alternatively, treatment of 148 
with Hg(OAc)2 and subsequent reduction with NaBH4 and Et3B gave desired 161 in 77% 
yield.149 Deprotection of 161 was accomplished with HF•py, but unexpectedly gave pinacol-like 
rearranged product 163. Fortunately, treatment of 161 with TBAF cleanly produced desired 164 
in 97% yield. Subjection of this material to HF•py again generated ring-contracted aldehyde 163, 
implicating the possible acid lability of 164.  
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Scheme 36. Preparation of 164 
 
 With a right fragment in hand that should prevent the major decomposition pathway, the 
stability was tested in aqueous conditions (Table 13). The potential acid-lability was realized 
during the preparation of 164, and therefore this material was exposed to 0.1 N H2SO4 at 37 °C it 
had a half-life of 3.5 h, but yielded no ring-contracted aldehyde 163. The half-lives of 164 at pH 
3 and 4 were determined to be 24 and 40 h, repectively. Moreover, the pH 5 and 6 half-lives 
were determined to be 48 and 40 h, respectively. Finally, at pH 7 and 7.4 the half-lives of 164 
were found to be approximately 48 h. Therefore, the stability of 164 was much better than that of 
50, approximately 10-fold higher at pH 7 and 7.4 in aqueous buffers. With this improved 
stability, the next conquest undertaken was the preparation of an FR901464 analog with this 
right fragment.  
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Table 13. Instability of 164 at different pH values in aqueous buffers 
O
O
HO
164
buffer
37 oC
decomposition products
pH t1/2 (h)
a
3
4
5
6
7
7.4
3.5
24
40
48
40
48
48
aEstimated by TLC analysis
0.1 N H2SO4
 
 
1.7.3 Synthesis and initial biological testing of meayamycin 
The next step was to examine the cross metathesis of 164 with left fragment 47, and to test the 
biological properties of this FR901464 analog. Analog 165, later named meayamycin, was 
prepared by the cross metathesis strategy, which was accomplished by treating 47 with a slight 
excess of 164 and Grela’s catalyst to afford meayamycin in 59% yield after one recycling of 
recovered starting materials (Scheme 37). With the more stable right fragment, higher reaction 
temperatures could be used, and consequently the yield of this metathesis reaction was improved 
as compared to the synthesis of FR901464.  
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Scheme 37. Preparation of meayamycin 
 
 The stability of meayamycin in biological experimental conditions was of chief concern. 
The reported half-life of FR901464 was later reported to be 45 min in 10% FBS-containing 
culture media.65 HPLC was used to determine the half-lives of meayamycin in aqueous buffers at 
37 °C using benzoic acid as the internal standard (Figure 6), and then in human and mouse sera 
at 37 °C using rhodamine B as the internal standard (Figure 7). The half-lives of meayamycin 
were determined to be 125, 301, 139, and 82.6 h in pH 5, 6, 7, and 7.4 buffers, respectively. 
Therefore, meayamycin was shown to be mildly acid- and base-sensitive from the lower half-
lives at pH 5 and 7.4. In more biologically relevant experiments, the half-life of meayamycin was 
determined to be 2.2 h in mouse serum and 9.3 h in human serum. With many esterases, C4’-
desacetyl meayamycin, 170 (structure, Scheme 39), was also rapidly generated. From these 
experiments, meayamycin was shown to have significantly improved stability over FR901464, 
but the lability of its acetate may be of concern in a biological setting.  
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Figure 6. Half-life determination of 10 µM meayamycin in buffers 
 
Degradation of Meayamycin in Sera
[meayamycin] = 1.4174e
-0.0748x
R
2
 = 0.9513
[meayamycin] = 1.2634e
-0.3097x
R
2
 = 0.9966
0
0.5
1
1.5
0 5 10 15 20 25 30 35
time (h)
a
n
a
ly
te
/r
h
o
d
a
m
in
e
 B
 r
a
ti
o
170 in mouse
serum
170 in human
serum
 
Figure 7. Half-life determination of 10 µM meayamycin in human (■) and mouse sera (▲) 
 
With the preparation of meayamycin, the stage was set to test the hypothesis that the 
replacement of the C1-OH group with a methyl group will impact the biological profile. The 
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model cell line chosen to examine the antiproliferative effect of FR901464 and meayamycin was 
the MCF-7 breast cancer line. This cell line was chosen partially because it was used by 
Fujisawa to test the potency of FR901464.40 The MTS assay was chosen as the method to 
examine the cell viability and proliferation150 because of its simplicity, commercial availability, 
and reproducibility. The MTS tetrazolium salt and formazan product are water soluble, and 
therefore no detergents or ethanol are required (Scheme 38). The intracellular reduction of MTS 
to its formazan requires two electrons to reductively cleave the tetrazolium core of MTS, which 
can be monitored easily using a standard plate reader. This reaction progress and thus the amount 
of viable cells is measure by the change in absorbance because the formazan product at absorbs 
at 490 nm, where the MTS reagent does not. To judge the effectiveness of meayamycin, MCF-7 
cells were treated with this analog and FR901464 for 7 or 10 days, then analyzed after adding the 
MTS reagent. Antiproliferative assays were also performed for 5 days, but generally gave higher 
variability with the MTS assay. Growth inhibition was concentration-dependent for MCF-7 cells 
treated with FR901464 and meayamycin (Figure 8). FR901464 was shown to have an impressive 
GI50 of 1.1 nM in accordance with the literature value,
40 but surprisingly meayamycin displayed 
a 10 pM GI50 value!
102  Moreover, these results were reproducible, and confirmed by manual cell 
counting using visible microscopy and Trypan blue dye. As a positive control paclitaxel was 
employed and displayed a GI50 of 0.50 nM (Figure 9), similar to the reported value of 2.0 nM in 
the same cell line.151 Therefore, the more stable FR901464 analog, meayamycin, indeed gave 
enhanced biological properties in accordance with the hypothesis. 
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Scheme 38. Intracellular reduction of MTS to its formazan 
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Figure 8. Growth inhibition of MCF-7 cells by FR901464 (■) and meayamycin (●) 
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Figure 9. Growth inhibition of MCF-7 cells by paclitaxel 
1.8 OTHER ANALOG SYNTHESES AND ANTIPROLIFERATIVE ACTIVITIES 
1.8.1 Desired analogs 
While the potent antiproliferative activity of meayamycin was a major success, other moieties of 
FR901464 warranted exploration. The first moiety to be probed was the C12 methyl group, 
found in the A-ring of FR901464. The A-ring of FR901464 and meayamycin likely exists in a 
chair conformation placing the C12 methyl and C14 amide groups axial (Figure 9a). This 
placement creates an unfavorable steric interaction between these groups, but could be offset by 
H-bonding of the amide N-H and the pyran oxygen atom. The destabilization of the A-ring 
conformation FR901464 could populate conformer FR901464’, where the C11 aliphatic and C15 
methyl groups are placed axially (Figure 9b). FR901464’ is expected to be minor due to the 
larger diaxial interaction between the aliphatic and methyl groups with the smaller C11−O and 
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C15−O bonds. Therefore, removal of the C12 methyl group could stabilize conformer 166 by 
eliminating the destabilizing diaxial interaction, and the equilibrium of 166 and 166’ should lie 
well to the left.  
The epoxide moiety may be unnecessary for biological activity (Figure 9c). Jacobsen’s 
cyclopropyl analog 17 was not antiproliferative in TAG-Jurgat cells. However, analogs without 
the epoxide moiety but retaining the oxygen atom have not been prepared to date. Therefore, 
analogs 167, 168, and 169 should give a more definitive answer to the reversible/covalent 
modifier quandary for FR901464 and meayamycin.  
The acetate group was shown to be labile in the half-life studies of meayamycin in sera 
(Figure 9d). Therefore, meayamycin’s C4’-desacetyl analog, 170, should be prepared to 
understand the potency of this relevant metabolite. Finally, with previous problems preparing 
acid chain 2 in high yield and enantioselectivity, prepation of an achiral acid chain was desired 
(Figure 9e). Therefore, a C4’-primary acetate 171 or -tertiary acetate 172 could prove 
synthetically more accessible, but their effects on the biological properties could be similar to 
meayamycin, since Jacobsen’s C4’-epimer analog 14 gave only a 15-fold decrease in potency. 
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Figure 10. Rationale for the preparation of more analogs 
 
1.8.2 Preparation of desired analogs 
 With these many analogs in mind, efforts were focused on preparing the C4-desacetyl, 
C12-desmethyl, and a C11 acetal analogs, also without the C12-methyl group similar to 
Wender’s SAR studies of  bryostatin.152 Left fragment 47 was deacetylated by the action of 
K2CO3 and MeOH to give 173 in 82% yield (Scheme 39a). This material was treated with an 
excess of 164 and a catalytic amount of the Grela catalyst to generate desired adduct 170 in 55% 
yield after one recycling of recovered starting materials. Left fragments 174 and 175, prepared 
by Dr. Miaosheng Li, were coupled to 164 with the Grela catalyst to give 166 and 176 in 50% 
and 53% yields, respectively, after one recycling of recovered starting materials (Scheme 39b 
and c) 
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Scheme 39. Preparation of analogs 170, 166, and 176 
 
 To prepare 167, 168, and 169, previsouly synthesized materials were utilized for rapid 
preparation of the necessary right fragment coupling partners. Spiroepoxide 161 was reduced 
with LAH to give 177 in 80% yield with concomitant removal of the silyl ether (Figure 39a). 
This diol was protected as its p-methoxyphenyl acetal, 178, in 84% yield and a 1.5:1 dr. Right 
fragment 164 was treated with PMBCl and Ag2O to afford 179 in 74% yield (Scheme 40b). This 
material was exposed to KOH in warm DMSO to generate diol 180 in 77% yield. This diol was 
cleaved using NaIO4 to give an unstable ketone that was immediately reduced with Li
sBu3BH to 
afford 181 as a single diastereomer in 69% yield over two steps. This material was then oxidized 
with DDQ to give a mixture of esters and acetals, which was then methanolized using a catalytic 
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amount of CSA, and subsequent addition of KOH cleaved the esters to form diol 182 in 79% 
two-step yield. This diol was protected as its p-methoxyphenyl acetal, 183, in quantitative yield  
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Scheme 40. Preparation of right fragment analogs 
 
and a 1.5:1 dr. Alternatively, alcohol 181 was methylated by the action of NaH and MeI to give 
184 in 94% yield. PMB group removal was accomplished with DDQ to give alcohol 186 in 89% 
yield, which was protected as its THP ether, 186, in quantitative yield with CSA and 3,4-
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dihydro-2H-pyran. This completed the preparations of the three desired right fragments to 
examine whether the epoxide moiety is necessary for the activity of FR901464 and meayamycin. 
 The completion of the desired right fragment analogs is shown in Scheme 41. Treatment 
of 177 and left fragment 47 gave no reaction. Fortunately, treatment of 47 and 178 with the Grela 
catalyst gave desired adduct 187 in 41% yield after one recycling of starting materials (Scheme 
41a). Deprotection of this material was accomplished with 3:1:1 AcOH/THF/H2O to give desired 
analog 167 in 66% yield. Similarly, the cross-olefin metathesis reaction of diol 182 and 47 gave 
only decomposition of 182. However, metathesis of acetal 183 and left fragment 47 in the 
presence of the Grela catalyst furnished 188 in 48% yield after one recycling of recovered 
starting materials (Scheme 41b). This material was then subjected to 3:1:1 AcOH/THF/H2O to 
give 168 in 68% yield. Moreover, coupling of 185 and 47 was found to afford 169 in <5% yield, 
but 186 and 47 were successfully coupled in the presence of the Grela catalyst to give adduct 189 
in 40% yield after two recycling of recovered starting materials (Scheme 41c). Interestingly, the 
reactivity of 186 was lower than left fragment, and therefore 47 was used in excess to increase 
the coupling efficiency. Adduct 189 was deprotected with 3:1:1 AcOH/THF/H2O to afford 169 
in 63% yield. The non-reactivity and/or decomposition of these free alcohols could be explained 
by bidentate-chelation to the ruthenium catalyst and subsequent chloride displacement thereby 
blocking the coordination site trans to the N-heterocyclic carbene.153,154 Suppression of these 
phenomena was readily accomplished by protection of the C4-hydroxy group. For unknown 
reasons, 50 and 164 were devoid of such complications. 
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Scheme 41. Preparation of analogs 167, 168, and 169 
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 Removal of the C4’ stereocenter was investigated due to the preparations of acid 2 being 
hampered by low enantioselectivity and chemical yields. Removal of this stereocenter would 
increase the scalability of the preparation of an acid chain, but its impact on the biological 
activity was unknown. One acid chain analog would be devoid of the C4’ methyl group and its 
preparation began with the mono-acetylation of cis-butenediol in 56% yield (Scheme 42a). 
Oxidation of this mono-acetate with the Dess-Martin reagent110 afforded aldehyde 190. This 
aldehyde was further oxidized with NaClO2 to give desired acid 191 in 80% for the two-step 
oxidation sequence, and completed the synthesis in a total of three steps and in 45% total yield. 
Alternatively, removal of the C4’ stereocenter could be accomplished by the addition of another 
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Scheme 42. Preparation of C4’ acid chain analogs 
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methyl group at this position. Towards this end, the bisanion of 2-methyl-3-butyn-2-ol was 
generated by treatment with excess nBuLi, and through this solution was added CO2 which gave 
acid 192 in quantitative yield upon acidic workup (Scheme 42 b).  This ynoic acid was acetylated 
by the action of AcCl to give 193, and the resulting acetate was subjected to partial 
hydrogenation conditions to afford enoic acid 194 in 31% yield for the two steps. Therefore, the 
preparation of this acid chain analog was accomplished in three total steps and 31% overall yield. 
With acid chain analogs 191 and 194 in hand, the preparation of fully functionalized left 
fragments was undertaken. Deprotection of tetrahydropyran 28 was accomplished with TFA, and 
subsequent coupling with acid 191 generated amide 195 in 61% yield (Scheme 43a). Cross 
metathesis of 195 and methacrolein gave enal 196 in 23% yield. Wittig homologation of this enal 
gave desired diene 197 in 58% yield. Similarly, the preparation of amide 198 was accomplished 
by the deprotection of 28 with TFA and subsequent coupling to acid 194 in 61% yield (Scheme 
43b). Cross-olefin metathesis of this material with methacrolein gave 199 in 57% yield, and 
Wittig homologation of this aldehyde gave diene 200, but this diene appears to be a mixture as 
indicated by the 1H NMR. With Dr. Miaosheng Li’s improved method to form acid 2 by a 
Noyori reduction of 63,59 these left fragments were temporarily abandoned. Interestingly, the 
steric environments of the enamides appears to effect the yields of the cross metatheses with 
methacrolein. More substitution at C4’ give metathesis adducts in higher yields, and less 
substitution, as seen in 195, gives lower yields. 
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Scheme 43. Preparation of C4’ analogs 
 
1.8.3 Biological testing of these analogs 
With these analogs in hand, their antiproliferative activities were tested in MCF-7 cells. 
Antiproliferative experiments were again performed over 7 days. Concentration-dependent 
growth inhibition by A-ring analogs 166 and 177 was observed (Figure 10). The GI50 for 166 
was determined to be 0.16 nM, and the GI50 for 177 was determined to be 5.4 nM. The positive 
controls for this experiment were meayamycin that gave a GI50 of 65 pM in this experiment. 
 88 
Therefore, the removal of the C12-methyl group has a somewhat deleterious effect on the 
antiproliferative activity, but these analogs remained remarkably potent. NMR studies of these 
A-rings were performed in CD3OD to understand whether a conformational change or the loss of 
a hydrophobic interaction was responsible for the losses in activity. D2O would have been an 
ideal solvent for these NMR studies, but 47, 147, and 175 were found to be poorly soluble. 
Inspection of the J-values of these fully functionalized left fragements revealed only subtle 
differences (Figure 11). Therefore, the decrease in activity of 166 and 167 is presumably due to a 
loss in a hydrophobic interaction. Although 166 and 167 were synthetically easier to prepare, the 
removal of the C12-methyl group decreased the potency, yet 166 was still quite potent. 
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Figure 11. Relative growth inhibition of MCF-7 cells by 166 (■) and 167 (▲) 
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Figure 12. J-Values for left fragment analogs 
 
No growth inhibitory effects were observed for desepoxy analogs 167, 168, and 169 in 
MCF-7 cells (data not shown). As positive controls, meayamycin and 5-fluorouracil displayed 
antiproliferative potential (data not shown). These results clearly demonstrate that the epoxide 
moiety is needed for growth inhibition of MCF-7 cells, suggesting covalent modification of its 
target(s).  
The concentration-dependent growth inhibition of MCF-7 cells by C4’-desacetyl analog 
174 is shown in Figure 12. The GI50 for 174 was determined to be a respectable 0.60 nM, but this 
was a 60-fold decrease in activity, and therefore the acetate group should be retained for potency.  
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Figure 13. Relative growth inhibition of MCF-7 cells by 174 
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1.8.4 Biological probe development for target identification 
It was assumed that FR901464 and meayamycin act by covalent modification of intracellular 
protein(s), and this hypothesis was later supported by the finding that the removal of the 
spiroepoxide is detrimental to the growth inhibition of MCF-7 cells. However, examination of 
meayamycin-treated cells based on their abilities to recover from short exposures to meayamycin 
would give further support to this hypothesis. For noncovalent modification of an intracellular 
target of meayamycin, the majority of the meayamycin would be removed upon removal of the 
media. Upon addition of fresh, meayamycin-free media, diffusion could occur, thereby removing 
most of this compound from within the cell and allowing for cell proliferation. However, for the 
scenario of covalent modification, a nucleophilic residue would open the epoxide to generate an 
alcohol. Upon removing the meayamycin-containing media and adding fresh media, most of the 
unbound molecules would be removed, but the covalently bound meayamycin would silence the 
cell proliferation.   
To investigate this hypothesis cultures of MCF-7 cells were treated with meayamycin for 
4, 8, 24, 48, and 72 h, and after 72 total h cell numbers were determined by the MTS method. In 
parallel, MCF-7 cells were treated with 0.1 and 1.0 nM meayamycin for the indicated period of 
time, the media was removed, replaced with fresh media, and allowed to incubate for 72 total 
hours (Figure 13). This experiment was repeated for 7 days, and gave nearly identical results (not 
shown). After 4 h of exposure to meayamycin (0.1 or 1.0 nM), there wass 65−70% growth 
inhibition, but after exposure from 8−72 h there was almost 100% growth inhibition. From these 
results, it appears that the binding of meayamycin is covalent. Moreover, 8 h of exposure to 
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meayamycin is required to exhibit its full antiproliferative potential. However, without 
spectrometric experiments the covalent binding of meayamycin to its target(s) can only be 
speculated upon. 
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Figure 14. Time dependent growth inhibition of MCF-7 cells by meayamcin; 0.1 nM (red) and 1.0 nM (blue) 
 
The discovery of SF3b as a target of FR901464 was predicated on reversible binding, 
which is in direct opposition to the data presented here. Moreover, their identification experiment 
involved the mixing of 24 and cell extracts at 4 °C for 6 h.65 Therefore, the RIKEN group could 
have missed covalently bound proteins responsible for the antiproliferative activity, including 
TMX, which they previously reported as an FR901464 target. Based on meayamycin covalently 
modifying its intracellular target(s), the preparation of a radiolabeled meayamycin analog was 
desired for target identification experiments. It was previously found that incorporation of an 
iodine atom, in the preparation of 162, was possible, and thus incorporation of a 125I atom into an 
FR901464 analog would seemingly be facile. The high sensitivity of detection of 125I makes it an 
ideal isotope for the discovery of potentially small quantities of protein adducts. One concern 
was the susceptibility of an alkyl iodide towards substitution reactions, but the epoxide was 
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found to be more reactive towards a variety of nucleophiles in 162 and 201, consistent with the 
non-reactivity of related neopentyl iodides. Moreover, 162 and 201 are stable towards homolytic 
cleavage of the C−I bond under ambient light at 23 °C for several days in benzene. Towards this 
end, 162 was deprotected with TBAF to give 201 in nearly quantitative yield (Scheme 44). 
Cross-olefin metathesis of this alkene with diene 47 gave 202 in 52% yield (dr = 1.5:1) after one 
recycling of recovered of starting materials. 
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Scheme 44. Preparation of iodides 202 
 
The antiproliferative activity of 202 was examined, and the GI50 was determined to be 1.4 
nM (Figure 14). However, MCF-7 cells are not typically used for target identification, 
presumably due to the difficulty and time required to grow a sufficient number of such cells, but 
HeLa cells are easy to grow and are often used. Thus, the antiproliferative activity of 202 was 
tested in this cell line, and the GI50s for meayamycin and 202 were shown to be 0.10 nM and 
0.75 nM, respectively. Therefore, less than a 10-fold decrease in activity was observed (Figure 
15), indicating that 202 is a suitable probe for target identification experiments.  
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Figure 15. Relative growth inhibition of MCF-7 cells by 202 
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Figure 16. Relative growth inhibition of HeLa cells by meayamycin (■) and 202 (▲) 
 
 Although iodides 202 were easily prepared on a semi-preparative scale, their preparation 
on a much smaller scale would be required for target identification experiments, and thus the 
viability of a microscale preparation of 202 was investigated. Typically, Na125I is purchased in an 
aqueous solution, but H2O was expected to have a deleterious effect on the iodoetherification 
reaction. This assumption was later confirmed by Professor Chet Mathis and Dr. Scott Mason at 
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the PET facility in the University of Pittsburgh Medical School. However, the removal of H2O 
was accomplished by azeotroping with dry MeCN to afford a dry sample of NaI, which was 
employed in the iodoetherification reaction conditions with diene 148 to generate 162 in 
quantitative yield, based on NaI as determined by crude 1H NMR (Scheme 45). A larger sample 
(10 µmol of 162 and 148 combined) of this mixture was then deprotected with excess TBAF to 
give 201 and presumably 203. Finally, 3 µmol of 201 was subjected to the cross-olefin 
metathesis conditions to generate 202. This result was confirmed by TLC and HPLC using 
authentic materials as references. The first two reactions of this three step sequence were 
validated by Dr. Mason using carrier added Na125I, showing the desired incorporation of 125I in 
the products. Moreover, the purification of these radioactive mixtures only require filtrations 
through Celite 545® and Florisil for the iodoetherification and deprotection reactions, 
respectively, making this a simple task. Therefore, the microscale preparation of 202 was shown 
to be viable and could be used for target identification experiments for FR901464.  
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Scheme 45. Microscale procedure to prepare iodide 202 
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1.9 REACTIVITY OF ELECTROPHILIC MOIETIES OF FR901464 WITH THIOLS 
FR901464 contains two electrophiles, namely a spiroepoxide and an α,β-unsaturated 
enamide, which could react with its target protein(s) or non-specifically with small molecules or 
proteins. An understanding of the reactivity of these moieties towards thiols or other 
nucleophiles would be crucial in understanding the reactivity of FR901464 for biological 
experiments. Despite the importance of reactions of epoxides and α,β-unsaturated enamides 
towards biologically relevant thiols, presumably the most abundant and powerful nucleophile in 
a biological setting, kinetic data for these transformations are quite limited.  
1.9.1 Reactions of epoxides with thiols 
Epoxides are common features of many biologically active natural products and drugs (Figure 
17). For example, FR901464 and meayamycin display encouraging results in cancer cells by 
unknown mechanisms. The following small molecules form a covalent bond with their target 
proteins via epoxide opening reactions. Trapoxin B binds to histone deacetylases,155 and its 
analogs are currently in clinical trials for cancer therapy. Epoxomicin is a specific electrophile 
for the 20S proteosome.156 Fumagillin binds to methionine aminopeptidase 2,157 and its analog 
TNP-470 is now in phase III trials for cancer therapy.158 However, epoxides do not necessarily 
form covalent bonds with their biological targets. The epothilones are a class of natural products 
that non-covalently modify their biological target, microtubules. Triptolide is an ingredient in 
traditional Chinese herbal therapy lei gong teng, used to treat inflammatory disorders, and also 
does not form covalent bonds with its target proteins, in spite of its three epoxides.159,160 Finally, 
scopolamine is a clinically prescribed for motion sickness. Despite the importance of these 
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molecules, and their proven efficacy in cell and organism based experiments, there remains 
concern about toxicity, presumably arising from non-specific reactions in a biological setting, 
which has been seen in environmental legislation.161 Non-specific reactions of epoxides with 
extra- and intracellular components would be expected to come from powerful nucleophiles, 
such as thiols found in abundant thiol-containing proteins, and small molecules such as 
glutathione, which could greatly decrease the concentration of epoxide-containing probe. 
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Figure 17. Structures of epoxide containing natural products and biological probes 
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 While interested in the biology of spiroepoxide containing compounds FR901464 and 
meayamycin, it was not clear if their epoxides would react non-specifically with thiols before 
reaching their intended targets.162 Quantitative analyses of epoxide opening by thiols has been 
limited to arene oxides and ethylene oxide at 30 and 20 °C, respectively, and α,α’-bisepoxy 
cyclohexanones at 22 °C in 4:1 THF/H2O.
163,164 Many common epoxide motifs found in Figure 
17 were not examined, and therefore presented an opportunity to study this significant reaction. 
Moreover, these studies could help to understand the biological results obtained using FR901464 
and its analogs. However, in designing experiments to address this question, one must consider 
that the local concentrations of thiols and epoxides may vary in vivo, thiols may be activated 
enzymatically under certain biological conditions (e.g., glutathione transferases),165 and that 
epoxide hydrolases can cause enzymatic depletion of epoxides.  
 To address the unanswered concern if nonenzymatic covalent bonding of epoxides was of 
major biological consequence, a model system was required. The model system initially chosen 
was condensation of epoxyalcohol 79 and N-acetylcysteamine to give 204, due to the water 
solubility and accessibility of these substrates (Scheme 46).133 Moreover, the pKa of the 
mercapto group of N-acetylcysteamine (9.92) is close to that of glutathione (9.42 ± 0.17) and 
other biologically relevant thiols like cysteine (pKa = 10.2). Glutathione was avoided because 
undesirable kinetic resolutions could complicate data obtained from condensation reactions with 
chiral epoxides, and the characterization of complex products would not be trivial. To obtain 
kinetic data, the reaction of 79 and N-acetylcysteamine in buffered D2O was monitored in an 
NMR tube at 37 °C (method A). This method gave 204 as the major, expected SN2 product, 
verified by its preparation in organic solvent. However, this method was not general due to 
overlap of signals in the NMR spectra when using other epoxides. Consequently, epoxides were 
 98 
extracted from an aqueous reaction mixture using CDCl3, and their consumption was quantified 
by comparison to an internal standard by 1H NMR spectroscopy (method B). The internal 
standard chosen was benzyl alcohol due to its favorable solubility properties and non-reactivity 
in the assay conditions. The accuracy of this method was validated by comparing the results for 
the consumption of 79 by methods A and B (not shown). Figure 18 displays the experimental 
data for the consumption of 79 in pH 6, 7, and 8 buffers. Consumption of 79 (20 mM) by N-
acetylcysteamine (100 mM) in pH 6 phosphate buffer gave a half-life of 70 h.166 In pH 7 and 8 
buffer, 79 had half-lives of 7.0 and 1.7 h, respectively. To verify this was an SN2 process, the 
concentration of N-acetylcysteamine was lowered to 40 mM in pH 7 buffer, and as expected for 
a bimolecular reaction, the half-life of 79 was 17.9 h under these conditions (Figure 17). 
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Scheme 46. Reaction of epoxyalcohol 79 and N-acetylcysteamine 
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Figure 18. Consumption of 79 by N-acetylcysteamine in aqueous buffers at 37 °C 
 
 With an established method to determine the half-lives of epoxides in the presence of N-
acetylcysteamine, other common epoxide motifs were explored. The half-lives for spiroepoxide 
205 (20 mM) in the presence of N-acetylcysteamine (100 mM) in pH 7 and 8 phosphate buffers 
were determined to be 3.7 and 0.85 h, respectively (Figure 18). A monosubstituted epoxide, 1,2-
epoxy-5-hexene, displayed half-lives of 2.1 and 0.59 h at pH 7 and pH 8, repectively (Figure 19). 
Cyclohexene oxide gave half-lives of 9.3 and 2.1 h under the same conditions, respectively 
(Figure 20). Finally, α,β-unsaturated ketone, 2-cyclohexen-1-one oxide, was too reactive under 
the typical reaction conditions, and therefore the conditions were modified. To successfully 
measure the half-lives of 2-cyclohexen-1-one oxide with N-acetylcysteamine, the concentrations 
were lowered to 1 and 2 mM, respectively, giving half-lives of 1.8 and 0.22 h at pH 7 and 8, 
respectively (Figure 21).166 This result was not a complete surprise, since the Wipf group has 
documented the high reactivity of these substrates, presumably through attack of the more 
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electrophilic carbonyl by the thiol and subsequent  opening of the epoxide with the putative 
thioether, rather than simple SN2 reactions.
164 
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Figure 19. Consumption of epoxide 205 at 37 °C in phosphate buffers 
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Figure 20. Consumption of 1,2-epoxy-5-hexene by N-acetylcysteamine in buffers at 37 °C 
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Figure 21. Consumption of cyclohexene oxide by N-acetylcysteamine in buffers at 37 °C 
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Figure 22. Consumption of 2-cyclohexen-1-one by N-acetylcysteamine in buffers at 37 °C 
 
 Unlike these cell-free experiments, the concentrations of biological thiols should be nearly 
constant due to the homeostatic environment, and in a large excess relative to epoxides. Thus, to 
gauge the reaction rates of these epoxides under biological conditions, the experimentally 
determined half-lives (summarized in Table 14) were converted to pseudo-first order by 
determining the initial rate (these half-lives not shown). Next, the psuedo-first order half-lives were 
adjusted to biologically relevant conditions using lower concentrations of thiols and epoxides. 
Intra- and extracellular concentrations of total thiols are approximately 12 mM and 0.3 mM, 
respectively,167,168 indicating the intracellular environment as the major concern for the epoxide 
opening. Small molecule agents are typically used below 10 µM, and typically around 1 µM. Thus, 
the following biological half-lives (t1/2
biol) were calculated for the epoxide motifs using 1 µM as the 
concentration of epoxide and 12 µM for the concentration of thiols at pH 7 and 8 (Table 14). As 
seen for epoxyalcohol 79, spiroepoxide 205, 1,2-epoxy-5-hexene, and cyclohexene oxide, the half-
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lives were 8.2−130 y! Considering the high concentration of epoxide, these reactions are clearly 
inconsequential in biological experiments. One exception is the reactive 2-cyclohexen-1-one oxide, 
which has biological half-lives of 220 and 27 h at pH 7 and 8, respectively (Table 14).166 This 
could explain the non-specific covalent binding of trapoxin B.155  
 
Table 14. Half-lives of epoxides at 37 °C in pH 7/pH 8 phosphate buffers 
O
O
O
O
O
HO
O
t1/2
exp
t1/2
biol a
7.0 h/1.7 h
97 y/23 y
3.7 h/0.85 h
51 y/12 y
2.1 h/0.59 h
29 y/8.2 y
9.3 h/2.9 h
130 y/40 y
7.0 h/1.7 h
220 h/27 h
a half-lives under biologically relevant conditions: [epoxide] = 1 µM, [thiols] = 12 mM.
79 205
 
 
 While the opening of epoxides with small molecule thiols appears to be biologically 
irrelevant, the non-specific opening with proteins remained unknown. To address this 
unanswered question, epoxyalcohol 79 was reacted with bovine serum albumin in pH 7 buffer 
(Figure 23). This protein was chosen due to its solubility at high concentrations and its reactive 
cysteine residue.169 The consumption of epoxyalcohol 79 gave a half-life of 46 h under the 
experimental conditions, which extrapolates to a biological half-life of 10.5 y. Therefore, non-
specific interactions with proteins fit the previous model, showing no reactivity towards epoxides 
under biological conditions. 
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Consumption of Epoxyalcohol 79
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Figure 23. Consumption of epoxyalcohol 79 by albumin at 37 °C in pH 7 phosphate buffer 
1.9.2 Reactions of α,β-unsaturated enamides with thiols 
The reaction of thiols with acrylamide has generated much interest due to the associated 
neurotoxicity of this small molecule.170-173 At comparable steric environments, amines are 280 
times less nucleophilic towards α,β-unsaturated compounds in buffers.170 Since this discovery, 
acrylamide has been shown to have deleterious effects on enzymes, and undergo reactions with 
endogenous small molecule thiols to generate the carcinogen, glycidamide.171,173 The half-life of 
acrylamide in plasma, assuming 0.6 mM concentration of serum albumin, is approximated to be 
60 h at 37 °C,173 and the half-life intracellularly, assuming 3 mM glutathione concentration, was 
approximated to be 60 h under the same conditions.173  
 While well-defined kinetics for the additions of thiols to acrylamide exist, kinetics of 
additions to Z-enamides remained unknown. As a model system, unsaturated amide Z-206, 
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prepared by the condensation of 2 and isopropylamine, was treated with mercaptoethanol in pH 7 
buffer at 37 °C. After 5 d at this temperature, the mixture consisted of 206 as a 1:2 E/Z mixture, 
E-207, and 208, as a 3:1 unassigned diastereomeric ratio in 36, 10, and 36% yields respectively 
(Scheme 47a). To verify the scrambled geometry in observed in 207, Z-206 was deacetylated 
with basic methanol to give Z-206 in quantitative yield (Scheme 47b). Therefore, it appears that 
non-specific thiol additions should be of no concern to the amide chain of FR901464 considering 
the high concentrations employed in a. 
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Scheme 47. Reactions of Z-206 
 
 The following mechanism could explain the observed products from the reaction of 
mercaptoethanol and Z-206 (Scheme 48). Addition of a mercaptoethanol anion to Z-206 would 
produce enolate 209, presumably as a diastereomeric mixture. This enolate could lose 
mercaptoethanol by β-elimination to give E/Z-206, or could undergo proton exchanges intra- or 
intermolecularly to form alkoxide 210. This alkoxide could be protonated by an equivalent of 
mercaptoethanol or water to give 208, or reversibly attack the pendant acetyl group to form 
tetrahedral intermediate 211. This tetrahedral intermediate could form acetate 212, which then 
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could undergo proton exchange to give enolate 213. This enolate could eject 2-mercaptoethyl 
acetate by β-elimination to give E-207, presumably the thermodynamic geometrical isomer. This 
reaction presumably had not reached equilibrium due to the 1:2 E/Z ratio, the Z-isomer 
presumably being thermodynamically disfavored, in amide E/Z-206. Based on this assumption, 
thiol additions should be negligible to the side chain of FR901464 in biological experiments.  
 
N
H
O
AcO
N
H
O
AcO
S
O
209
H
N
H
O
O
S
O
210
O
N
H
O
O
S
O
212
O
N
H
O
HO
S
O
213
O
N
H
O
OH
E-207
N
H
O
O
S
211
O
O
HO
S
N
H
O
AcO
S
HO
208
N
H
O
AcO
E,Z-206Z-206
 
Scheme 48. Plausible mechanisms for the formation of E/Z-206, E-207, and 207 
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1.10 SUMMARY AND FUTURE DIRECTIONS 
The total synthesis of FR901464 was accomplished in a total of 29 steps, which is the shortest 
synthesis to date. The instability of FR901464 was studied, which led to the rational 
development of meayamycin, an FR901464 analog with enhanced biological properties. 
Additional analogs were synthesized to examine the A-ring, C4’ position, and the C3 position of 
the B-ring. These analogs demonstrated that the A-ring of FR901464 may be optimal, the C4’ 
acetate should remain intact, and the spiroepoxide is required for antiproliferative properties. The 
desepoxy analogs lack of potency strongly suggest that FR901464 covalently modifies its 
target(s) via its epoxide, which led to the synthesis of a non-radioactive iodide-containing analog 
202, which in its 125I form could be used for target identification experiments. Due to the concern 
of non-specific reactions of epoxides with endogenous thiols, a method was developed to study 
the consumption of epoxides with thiols. Experiments of common epoxide motifs showed that 
these reactions were negligible under biologically relevant conditions. Moreover, a model system 
for the amide chain of FR901464 demonstrated that its Z-enamide should not readily react non-
specifically with endogenous thiols. 
 To address the instability of the C4’-acetate group, Dr. Li prepared a C4’ carbamate, 
named meayamycin B (Figure 24). This compound has better stability in serum and is a more 
potent antiproliferative agent in a variety of cell lines. Dr. Li is also preparing fluorescent probes 
to visualize the localization of FR901464 in the cell. 
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Figure 24. Structure of meayamycin B 
 
In the future, target identification experiments will be performed to determine the 
FR901464-binding proteins. Iodides 202 should be suitable probes for these experiments, and the 
synthesis of these compounds have been outlined here. If meayamycin or meayamycin B proceed 
to clinical trials, their syntheses may need to be revised in terms of the number of steps as well as 
the final cross coupling reaction. Electrophilic right fragment analogs, that could containe an 
aldehyde, ketone, or boronic acid at position C3, could serve as the electrophilic moieties that 
will not covalently modify their targets should be synthesized. Finally, a simplified left fragment 
could produce a potent compound when conjugated to the right fragment of meayamycin. 
Towards this end, Sami Osman is nearing completion of TMC-205 (Figure 3), which could serve 
as a left-fragment replacement when conjugated to the right fragment of meayamycin.  
1.11 EXPERIMENTAL SECTION 
General techniques. All reactions were carried out with dry, freshly distilled solvents under 
anhydrous conditions, unless otherwise noted. Tetrahydrofuran (THF) was distilled from 
sodium/benzophenone, and methylene chloride (CH2Cl2) was distilled from calcium hydride. 
Acetonitrile was distilled from CaH2 and stored over 3Å molecular sieves. Yields refer to 
chromatographically and spectroscopically (1H NMR) homogenous materials, unless otherwise 
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stated. All reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25-
mm Merck silica gel plates (60F-254) using UV light (254 nm), 2.4% phosphomolybdic 
acid/1.4% phosphoric acid/5% sulfuric acid in H2O, anisaldehyde in ethanol, or 0.2% ninhydrin 
in ethanol and heat as developing agents. TSI silica gel (230-400 mesh) was used for flash 
column chromatography. NMR spectra were recorded on AM300 or AM500 (Bruker) 
instruments and calibrated using a solvent peak or tetramethylsilane as an internal reference. The 
following abbreviations are used to indicate the multiplicities: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; br, broad. High resolution mass spectra were obtained by using EBE 
geometry. 
 
PhPh
OHC
TMSCHN2
LDA
33  
Preparation of and data for 33. See K. Miwa, T. Aoyama, T. Shiori Synlett 1994, 107. 
 
Ph
Ph
HO
CH3CHO, Zn(OTf)2
(-)-N-methylephedrine
toluene
3033  
General procedure for the preparation of (E)-(2S)-6-phenylhex-5-en-3-yn-2-ol (30). 
To a flask containing Zn(OTf)2 (13.6−16.4 g, 37.5−45.0 mmol) and (−)-N-methylephedrine 
(7.18−8.61 g, 40.0−48.0 mmol) was added the base (see Table 3, 40−48 mmol) followed by 33 
(3.20−3.85 g, 25.0−30.0 mmol) in toluene (15 mL) at 23 °C under a nitrogen atmosphere. After 
1.5 h at the same temperature, the reaction mixture was placed at the desired reaction 
temperature, and acetaldehyde (2.8−3.3 mL, 50−60 mmol) in toluene (70−85 mL) was passed 
through activated 4Å molecular sieves and added dropwise to the reaction mixture. After 17 h at 
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the same temperature, the reaction mixture was diluted with saturated aqueous NH4Cl (70−75 
mL), filtered through a pad of Celite 545®, rinsed with H2O (1 × 15 mL) then EtOAc (3 × 30 
mL), and the layers were separated. The aqueous residue extracted with EtOAc (2 × 50 mL). The 
combined organic layers were washed with aqueous HCl (1 N, 60 mL) then brine (100 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (5 → 15% EtOAc in hexanes) on silica gel 
(125−150 mL) to afford 30 as a pale yellow oil. 
Data for 30: Rf = 0.40 (30% EtOAc in hexanes); [α]D
23 −2.4 (c 4.1, CHCl3);* IR (neat): 
3334 (br, O-H), 3059, 3028, 2980, 2917, 2849, 2207, 1447, 1165, 1074, 1010, 953, 896 cm-1; 1H 
NMR (300 MHz, 293K, CDCl3) δ 7.33–7.20 (m, 5H), 6.89 (d, 1H, J = 16.3 Hz), 6.11 (dd, 1H, J 
= 16.3, 1.7 Hz), 4.65 (br q, 1H, J = 6.4 Hz), 1.91 (br s, 1H), 1.46 (d, 3H, J = 6.6 Hz); 13C NMR 
(75 MHz, 293K, CDCl3) δ 141.7, 136.0, 128.7, 128.4, 126.2, 107.4, 93.1, 83.2, 58.9, 24.3; 
HRMS (EI+) calcd. for C12H12O [M]
+ 172.0888, found 172.0889. 
* [α]D reported is for material in a 86:14 er  
 
Ph
Ph
HO
rac-3033
nBuLi
CH3CHO
93%
 
Procedure for the preparation of rac-30. To a stirred solution of 33 (1.28 g, 9.98 
mmol) in THF (4.5 mL) was added nBuLi (1.6 M in hexanes, 6.25 mL, 10.0 mmol) at −78 °C 
under a nitrogen atmosphere. After 15 min at the same temperature, acetaldehyde (850 µL, 15.1 
mmol) was added. After 10 min at the same temperature, the reaction mixture was warmed to 0 
°C. After 1 h at the same temperature, the reaction mixture was quenched with saturated aqueous 
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NH4Cl (30 mL). The reaction mixture was extracted with EtOAc (3 × 25 mL). The combined 
organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (5 → 15% EtOAc in hexanes) on silica gel (50 mL) to afford a mixture of rac-
30 (1.59 g, 93%) as a pale yellow oil. 
 
Ph
HO
rac-30
SO3 py
Et3N, DMSO
94% Ph
O
61  
Procedure for the preparation of 61. To a stirred solution of 61 (1.13 g, 6.54 mmol) 
and Et3N (3.70 mL, 26.5 mmol) in DMSO (7.0 mL) and CH2Cl2 (14 mL) was added SO3•py 
(2.08 g, 13.0 mmol) at −44 °C under a nitrogen atmosphere. After 20 min at the same 
temperature, the reaction mixture was warmed to 0 °C. After 1 h at the same temperature, the 
reaction mixture was quenched with aqueous HCl (0.1 N, 200 mL). The reaction mixture was 
extracted with Et2O (3 × 100 mL). The combined organic layers were washed with aqueous HCl 
(0.1 N, 200 mL) then brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography (2.5 → 
7.5% EtOAc in hexanes) on silica gel (40 mL) to afford a mixture of 61 (1.04 g, 94%) as a pale 
yellow oil. 
Data for 61: See A. R. Katritzky, J. Yao, M. Qi J. Org. Chem. 1997, 62, 8201−8204 
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Ph
O
61
Ph
HO
30
Noyori cat.
26%, er > 20:1
 
 Procedure for the preparation of 30 by a Noyori reduction. See K. Mataumura, S. 
Hashiguchi, T. Ikariya, R. Noyori J. Am. Chem. Soc. 1997, 119, 8738-8739. Yield: 26% 
 
Ph
AcO
35
CO2H
AcO
63
OsO4, Oxone
 
Preparation of (S)-4-acetoxypent-2-ynoic acid (63) by OsO4-Oxone
®
 procedure. To a 
stirred solution of 35 (196 mg, 0.915 mmol) and Oxone® (2.25 g, 3.66 mmol) in DMF (4.5 mL) 
was added OsO4 (1.7 mg, 6.7 µmol) at 23 °C under an open atmosphere. After 9 h at the same 
temperature, the reaction mixture was quenched with Na2SO3 (692 mg, 5.49 mmol) and stirred 
for 15 min. The reaction mixture was then diluted with H2O (5 mL) and aqueous HCl (1.0 N, 5 
mL).  The resulting mixture was extracted with EtOAc (5 × 10 mL). The combined organic 
layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (20 → 100% EtOAc in hexanes) on silica 
gel (15 mL) to afford a mixture of 63, benzoic acid, and DMF (529 mg). 
 Data for 63: Rf = 0.22 (1.0% AcOH in EtOAc); [α]D
23 −128 (c 1.60, CHCl3); IR (neat): 
3188 (broad, O-H), 2984, 2941, 2248, 1749 (C=O), 1719 (C=O), 1374, 1227, 1049 cm-1; 1H 
NMR (300 MHz, 293K, CDCl3) δ 5.54 (q, 1H, J = 6.8 Hz), 2.11 (s, 3H), 1.57 (d, 3H, J = 6.8 
Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 169.9, 156.8, 87.3, 75.6, 59.4, 20.8, 20.1; HRMS 
(EI+) calcd. for C7H6O3 [M − H2O]
+ 138.0317, found 138.0322. 
 
 113 
N
O
O
OTHP
OTHP
O
(3.0 equiv)
64
nBuLi
78-93%
 
Preparation of 64. To a stirred solution of tetrahydro-2-(prop-2-ynyloxy)-2H-pyran 
(21.01 g, 150 mmol) in THF (90 mL) was added nBuLi (1.6 M in hexanes, 92 mL) dropwise over 
20 min at 0 °C under a nitrogen atmosphere.  After an additional 15 min at the same temperature, 
N-acetylmorpholine (5.8 mL, 50 mmol) in THF (8 mL) was added dropwise to the reaction 
mixture, and then the container that initially contained N-acetylmorpholine was rinsed with THF 
(2 × 1 mL) and added to the reaction mixture at the same temperature.  After an additional 1.4 h 
at 0 °C, the reaction mixture was cannulated into a flask containing AcOH (120 mL) and H2O 
(60 mL) at 0 °C, the reaction container was rinsed with Et2O (50 mL), and then the resulting 
layers were separated.  The organic layer was washed with saturated aqueous NaHCO3 (300 
mL).  The combined aqueous layers were extracted with Et2O (50 mL).  The combined organic 
layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  
The resulting residue was purified by flash chromatography (2.5 → 10% EtOAc in hexanes) on 
silica gel (600 mL) to afford 64 (7.141 g, 78%) as a colorless oil. 
Data for 64: See R. C. Larock, C. L. Liu J. Org. Chem. 1983, 48, 2151−2158. 
 
OTHP
O
64
OTHP
HO
65
CBS
 
Preparation of 65. To a stirred solution of (S)-2-methyl-CBS-oxazaborolidine (554 mg, 
2.00 mmol) and catechol borane (1.7 mL, 16 mmol) in EtNO2 (25 mL) was added 64 (1.83 g, 
10.0 mmol) in EtNO2 (7 mL) via syringe pump over 20 min which was followed by a rinse of the 
container that originally contained 64 with EtNO2 (1 mL) at −78 °C under a nitrogen atmosphere.  
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After an additional 2.7 h at the same temperature, the reaction was quenched with saturated 
aqueous NaHCO3 (35 mL), and the mixture was then diluted with Et2O (100 mL).  The layers 
were separated and the organic layer was washed with aqueous NaOH (1 N, 2 × 20 mL), dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue 
was purified by flash chromatography (10 → 30% EtOAc in hexanes) on silica gel (100 mL) to 
afford 65 and a small amount of catechol (1.979 g) as a pale yellow oil. 
Data for 65: See R. W. Bates, D. Díez-Martín, W. J. Kerr, J. G. Knight, S. V. Ley, A. 
Sakellaridis Tetrahedron 1990, 46, 4063−4082. 
 
OTHP
AcO
66
OTHP
HO
65
Ac2O, py
97%
 
Preparation of 66. To a stirred solution of 65 and catechol (1.59 g, ~8.0 mmol) in 
pyridine (15 mL) was added Ac2O (3.5 mL, 37 mmol) at 23 °C under an open atmosphere. After 
41.5 h at the same temperature, the reaction mixture was diluted with H2O (330 mL) and 
saturated aqueous NaHCO3 (20 mL). The resulting mixture was then extracted with Et2O (3 × 75 
mL). The combined organic layers were washed with saturated aqueous CuSO4 (1 × 50 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (5 → 10% EtOAc in hexanes) on silica gel (75 
mL) to afford 66 (1.79 g, 97% for the two steps) as a colorless oil.  
Data for 66: Rf = 0.54 (30% EtOAc in hexanes); IR (neat): 2941, 1743 (C=O), 1442, 
1372, 1235, 1120, 1053, 1025 cm–1; [α]D
25 −68.0 (c 1.1, CHCl3); 
1H NMR (300 MHz, 293K, 
CDCl3) δ 5.51 (br q, 1H, J = 6.7 Hz),  4.82−4.78 (m, 1H), 4.34 (dd, 1H, J = 15.7, 1.7 Hz), 4.26 
(dd, 1H, J = 15.7, 1.6 Hz), 3.84 (br ddd, 1H, J = 11.9, 9.0, 3.2 Hz), 3.58−3.50 (m, 1H), 2.08 (s, 
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3H), 1.89−1.53 (m, 6H), 1.50 (d, 1H, J = 6 Hz); 13C NMR (75 MHz, 293K, CD2Cl2) δ 169.8, 
96.7, 84.22, 84.19, 80.7, 61.9, 60.3, 54.11, 54.08, 30.1, 25.3, 21.3, 21.0. 
 
OTHP
AcO
66
CO2H
AcO
63
Jones oxid.
74%
 
Preparation of 63 from 66. To a stirred solution of 66 (113 mg, 0.501 mmol) in acetone 
(2 mL) was added cold Na2Cr2O7 (0.5 N in 2 N H2SO4, 3.5 mL) dropwise at 0 °C under an open 
atmosphere.  After 2 h at the same temperature, the reaction was warmed to 23 °C.  After 30 min 
at the same temperature, the reaction was cooled to 0 °C, and to the reaction mixture was added 
Na2SO3 (63.3 mg, 0.502 mmol).  After an additional 15 min at the same temperature, the reaction 
mixture was poured onto aqueous HCl (1 N, 30 mL), and the mixture was extracted with EtOAc 
(5 × 10 mL).  The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (20 → 100% EtOAc in hexanes containing 1% AcOH) on silica gel (5 mL) to 
afford 63 (68.4 mg, 74%) as a colorless oil. 
Data for 63: See B. J. Albert, A. Sivaramakrishnan, T. Naka, K. Koide J. Am. Chem. Soc. 
2006, 128, 2792−2793. 
 
OTHP
AcO
66
CSA, MeOH
82% OH
AcO
214  
Preparation of 214. To a stirred solution of 66 (450 mg, 2.00 mmol) in MeOH (20 mL) 
was added PPTS (101 mg, 0.402 mmol) at 0 °C under an open atmosphere. After 30 min at the 
same temperature, the reaction mixture was warmed to 23 °C. After an additional 17 h at the 
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same temperature, the reaction mixture was quenched with Et3N (70 µL, 0.50 mmol), and 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 40% EtOAc in hexanes) on silica gel (25 mL) to afford 214 (234 mg, 
82%) as a colorless oil. 
Data for 214: Rf = 0.33 (40% EtOAc in hexanes); IR (neat): 3422 (br), 2939, 1736 
(C=O), 1373, 1239, 1025, 849 cm–1; [α]22D –94.6 (c 1.2, CHCl3); 
1H NMR (300 MHz, 293K, 
CDCl3) δ 5.48 (qdd, 1H, J = 6.7, 1.7, 1.7 Hz), 4.33 (dd, 1H, J = 16.1, 1.7 Hz), 4.26 (dd, 1H, 16.1, 
1.7 Hz), 2.08 (s, 3H), 1.78−1.72 (br s, 1H), 1.50 (d, 3H, J = 6.7 Hz); 13C NMR (75 MHz, 293K, 
CDCl3) δ 170.1, 83.6, 83.2, 60.4, 50.5, 21.0, 20.9; HRMS (EI+) calcd. for C7H8O2 [M – H2O]
+ = 
124.0524, found 124.0520. 
 
 
OH
AcO
CO2H
AcO
Dess-Martin;
NaClO2, 84%
63214  
To a stirred solution of 214 (142 mg, 1.00 mmol) in CH2Cl2 (20 mL) was added Dess-
Martin periodinane (638 mg, 1.50 mmol) at 0 °C under an open atmosphere. After 1.5 h at the 
same temperature, the reaction mixture was diluted with hexanes (4 mL), filtered through a pad 
of Florisil (2 mL), rinsed with 40% Et2O in hexanes (2 × 5 mL), and concentrated under reduced 
pressure. Crude 1H NMR showed the clean formation of an aldehyde that was immediately 
subjected to the next reaction without further purification. 
To a stirred solution of this crude aldehyde (~1.00 mmol) and 2-methyl-2-butene (1.0 
mL, 9.3 mmol) in tBuOH (2.5 mL) was added a solution of NaH2PO4 (414 mg, 3.00 mmol) and 
NaClO2 (227 mg, 2.01 mmol) in H2O (2.5 mL) at 23 °C under an open atmosphere. After 30 min 
at the same temperature, aqueous HCl (1 N, 6 mL) was added followed by sodium chloride until 
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the aqueous layer was saturated. The aqueous residue was extracted with EtOAc (4 × 10 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure.  The resulting residue was purified by flash chromatography (20 → 
100% EtOAc in hexanes containing 1% AcOH) on silica gel (15 mL) to afford 66 (133 mg, 84%) 
as a colorless oil. 
Data for 63: See B. J. Albert, A. Sivaramakrishnan, T. Naka, K. Koide J. Am. Chem. Soc. 
2006, 128, 2792−2793. 
 
CO2Me
O
N
Boc
O
N
Boc
DIBALH;
Ph3P=CH2
77%
36 38  
Preparation of 38 by a one-pot procedure. To a stirred solution of Ph3PCH3Br (53.58 
g, 150.0 mmol) in THF (150 mL) at 0 °C was added KOtBu (16.40 g, 146.2 g) in one portion.  
The resulting mixture was stirred for an additional one hour at the same temperature prior to use.   
To a stirred solution of aminoester 36 (20.53 g, 75.11 mmol) in CH2Cl2 (250 mL) was 
added DIBALH (1 M in hexanes, 150 mL) dropwise over 2.5 h at −78 °C under a nitrogen 
atmosphere.  After an additional 1.5 h at the same temperature, the ylide THF solution was added 
dropwise over 1.8 h.  After an additional 15 min, the reaction mixture was warmed to 23 °C, and 
after an additional 2.8 h at the same temperature, the reaction mixture was warmed to 48 °C.  
After an additional 14 h at the same temperature, the reaction mixture was cooled to 23 °C, 
diluted with H2O (100 mL) then aqueous HCl (1 N, 300 mL), and the layers were separated.  The 
aqueous residue was extracted with EtOAc (4 × 200 mL).  The combined organic layers were 
washed with brine (1 × 500 mL), dried over anhydrous Na2SO4, filtered, and concentrated under 
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reduced pressure.  The resulting residue was purified by flash chromatography (1 → 5% EtOAc 
in hexanes) on silica gel (800 mL) to afford 38 (13.91 g, 77%) as a colorless oil. 
Data for 38: Rf = 0.48 (10% EtOAc in hexanes); IR (neat): 2979, 2935, 2880, 1702 
(C=O), 1478, 1456, 1378, 1307, 1135, 1084 cm–1; [α]D
22 +16.6 (c 3.93, CHCl3); 
1H NMR (300 
MHz, 333K, C6D6) δ 5.58 (ddd, 1H, J = 17.2, 10.1, 7.2 Hz), 5.02 (d, 1H, J  = 17.2 Hz), 4.95 (dd, 
1H, J  = 10.4, 1.3 Hz), 3.75−3.64 (m, 2H), 1.73 (s, 3H), 1.57 (s, 3H), 1.41 (s, 9H), 1.10 (d, 3H, J 
= 6.0); 13C NMR (75 MHz, 333K, C6D6) δ 152.2, 138.6, 115., 94.4, 79.3, 75.7, 67.6, 28.5, 27.3, 
26.1, 17.7; HRMS (EI+) calcd. For C12H20NO3 [M − CH3]
+ 226.1443, found 226.1446. 
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Preparation of 43. To a stirred solution of lactone 31 (1.520 g, 6.25 mmol) in THF (30 
mL) at −78 °C was added allylmagnesium chloride (2.0 M solution in THF, 7.0 mL, 12 mmol) 
down the flask side under a nitrogen atmosphere. After 1.5 h at the same temperature, the 
reaction was quenched with saturated aqueous NH4Cl (25 mL) and most of the organic solvent 
was removed under reduced pressure. The aqueous residue was extracted with EtOAc (3 × 25 
mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by 
flash chromatography (10 → 50% EtOAc in hexanes) on silica (100 mL) to afford hemiketal 43 
(1.712 g, 96%) as a colorless oil. 
Data for 43: Rf = 0.26 (40% EtOAc in hexanes); IR (neat): 3437 (N-H), 3391 (br O-H), 
2976, 2933, 1709 (C=O), 1692 (C=O), 1641, 1510, 1366, 1170, 1050 cm–1; 1H NMR (300 MHz, 
293K, CDCl3) δ 6.02–5.81 (m, 1H), 5.20–5.08 (m, 2H), 4.71 (br d, 1H, J = 9.0 Hz), 3.73–3.67 
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(m, 1H), 3.40–3.33 (m, 1H), 3.30–3.27 (m, 2H), 2.78–2.70 (m, 1H), 2.27 (br d, 1H, J = 7.4 Hz), 
2.02–1.93 (m, 2H), 1.45 (s, 9H), 1.16 (d, 3H, J = 6.3 Hz), 1.13 (d, 3H, J = 7.2 Hz); 13C NMR (75 
MHz, 293K, CDCl3) δ 212.6, 156.3, 130.8, 118.5, 79.2, 69.1, 53.7, 46.5, 42.5, 35.7, 28.3, 20.2, 
18.0; HRMS (EI+) calcd. for C12H22NO4 [M − C3H5]
+ 244.1549, found 244.1550. 
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Preparation of 19. To a stirred solution of 43 (3.342 g, 11.71 mmol) in CH2Cl2 (50 mL) 
was added CF3CH2OH (6.8 mL, 93 mmol) and triethylsilane (18.5 mL, 116 mmol) at 23 °C 
under a nitrogen atmosphere.  The reaction was cooled to −78 °C, then BF3•OEt2 (5.9 mL, 47 
mmol) complex was added slowly down the flask side.  After an additional 3 h at the same 
temperature, saturated aqueous NaHCO3 (50 mL) was added at −78 °C, and the layers were 
separated.  The aqueous residue was extracted with EtOAc (3 × 50 mL).  The combined organic 
layers were washed with brine (75 mL), dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure.  The resulting residue was purified by flash chromatography (2 → 
12.5% EtOAc in hexanes) on silica gel (150 mL) to afford 28 (1.242 g, 39%) and 44 (707 mg, 
22%) as colorless oils. 
Data for 28: Rf = 0.30 (10% EtOAc in hexanes); IR (neat): 3460 (N-H), 2977, 2934, 1718 
(C=O), 1642, 1496, 1366, 1171, 1058 cm–1; [α]D
22 −10.1 (c 1.2, CHCl3); 
1H NMR (300 MHz, 
293K, CDCl3) δ 5.80 (dddd, 1H, J = 17.1, 10.2, 7.6, 6.3 Hz), 5.14–5.08 (m, 1H), 5.05 (br d, 1H, 
J = 10.2 Hz), 4.77 (br d, 1H, J = 9.1 Hz), 3.64–3.56 (m, 2H), 3.51 (ddd, J = 7.4, 7.4, 2.9 Hz), 
2.38–2.28 (m, 1H), 2.17–2.06 (m, 1H), 1.93–1.90 (m, 2H), 1.78–1.70 (m, 1H), 1.44 (s, 9H), 1.15 
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(d, 3H, J = 6.3 Hz), 1.04 (d, 3H, J = 7.4 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 155.9, 134.8, 
116.6, 80.6, 78.9, 76.3, 48.3, 37.4, 36.0, 28.8, 28.4, 17.7, 14.9; HRMS (EI+) calcd. for 
C12H22NO3 [M − C3H5]
+ 228.1600, found 228.1593.  
Data for 44: Rf = 0.32 (30% EtOAc in hexanes); IR (neat) 3386 (br O-H), 2974, 2931, 
2868, 1692 (C=O), 1663, 1450, 1397, 1367, 1172, 1233, 1113 cm–1; [α]D
22 +19.9 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.82–5.68 (m, 1H), 5.05 (br s, 1H), 5.02–5.00 (m, 1H), 
3.73 (ddd, J = 7.9, 7.9, 5.9 Hz), 3.62–3.54 (m, 1H), 3.48–3.43 (ddd, J = 7.4, 7.4, 2.9 Hz), 2.28 
(br t, 2H), 2.05–1.97 (m, 1H), 1.75–1.64 (m, 2H), 1.62–1.51 (m, 1H), 1.48 (s, 9H), 1.09 (d, 3H, J 
= 6.1 Hz), 0.95 (d, 3H, J = 6.8 Hz); 13C NMR (75 MHz, 293K, C6D6) δ 158.1, 135.2, 117.2, 
80.1, 72.7, 65.7, 64.8, 39.0, 35.7, 34.9, 28.4, 21.3, 18.9; HRMS (EI+) calcd. for C12H22NO3 [M − 
C3H5]
+ 228.1600, found 228.1598. 
 
HO
THF, 93%
78
HO Br+
Zn
 
Preparation of allyl alcohol 78. See Miwa, K.; Aoyama, T.; Shioiri, T. Synlett 1994, 
107−108. Yield: 93% 
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 Preparation of epoxyalcohol 79. To a stirred suspension of activated 4Å molecular 
sieves (51.39 g) in CH2Cl2 (900 mL) was added (+)–diisopropyl tartrate (4.5 mL, 21 mmol) at 23 
°C under a nitrogen atmosphere. The reaction mixture was cooled to –25 °C then titanium 
isopropoxide (5.2 mL, 18 mmol) was added, followed by tBuOOH (5–6 M in isooctane, 84 mL, 
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420–504 mmol). The mixture was stirred for 45 min at –25 °C to allow for the catalyst to 
generate, then allyl alcohol 78 (25.4 g, 126 mmol) in CH2Cl2 (50 mL) was added over 25 min. 
The reaction was stirred for an additional 3.5 h at −20 to −25 °C, then was quenched with 3 M 
NaOH (25 mL) and vigorously stirred for 1 h at 23 °C. To the resulting reaction mixture was 
added solid NaCl, anhydrous Na2SO4, and Celite 545
®. The mixture was filtered through a pad of 
Celite 545®, eluting with 60% EtOAc in hexanes (1 L), and concentrated under reduced pressure. 
The residue was purified by flash chromatography (10 → 30% EtOAc in hexanes) on silica gel 
(1.0 L) to afford epoxyalcohol 79 (26.21 g, 90% yield) as a colorless liquid. 
Data for 79: Rf = 0.33 (40% EtOAc in hexanes); IR (neat): 3431 (br), 2922, 1650, 1449, 
1045, 896 cm–1; [α]22D –47.8 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 4.88–4.86 (m, 
1H), 4.82–4.81 (m, 1H), 3.77 (dd, 1H, J = 12.4, 4.3 Hz), 3.66 (dd, 1H, J = 12.4, 8.6 Hz), 2.95 (br 
d, 1H, J = 4.8 Hz), 2.71 (br d, 1H, J = 4.8 Hz), 2.53 (br d, 1H, J = 14.4 Hz), 2.22 (br d, 1H, J = 
14.4 Hz), 1.78 (s, 3H), 1.65 (dd, 1H, J = 8.6, 4.5 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 
140.8, 113.8, 62.4, 58.6, 49.7, 40.6, 23.0; HRMS (EI+) calcd. for C7H11O2 [M – H]
+ = 127.0759, 
found 127.0760. 
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Preparation of epoxyaldehyde 32 by Dess-Martin oxidation. To a stirred solution of 
Dess–Martin periodinane (77.5 g, 183 mmol) in CH2Cl2 (350 mL) was added epoxyalcohol 79 
(15.4 g, 122 mmol) in CH2Cl2 (50 mL) dropwise at 0 °C under a nitrogen atmosphere.  The 
reaction was slowly warmed to 23 °C.  After 3.5 h, the reaction was diluted with Et2O (200 mL), 
and poured onto a saturated aqueous solution of NaHCO3 (700 mL) containing NaHSO3 (100 g, 
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961 mmol) and vigorously stirred for 45 min at 23 °C.  After the two layers were separated, the 
aqueous layer was extracted with Et2O (2 × 250 mL).  The combined organic layers were washed 
with a saturated aqueous NaHCO3 (250 mL), then brine (250 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure to afford 32 (13.9 g, ~81 %) as a pale yellow 
crude residue.  The crude residue was not further purified due to the volatility of 32. 
Preparation of epoxyaldehyde 32 by Parikh-Doering oxidation. To a stirred solution 
of 79 (9.62 g, 72.3 mmol) and Et3N (42.0 mL, 300 mmol) in DMSO (65 mL) and CH2Cl2 (185 
mL) was added SO3•py (23.9 g, 153 mmol) at −44 °C under a nitrogen atmosphere. After 15 min 
at the same temperature, the reaction mixture was warmed to 0 °C. After 4 h at the same 
temperature, the reaction mixture was quenched with aqueous HCl (0.3 N, 1.5 L). The reaction 
mixture was extracted with CH2Cl2 (8 × 150 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (5 → 20% Et2O in hexanes) on silica gel (250 mL) to afford a 
mixture of 32 (6.50 g, 69%) as a pale yellow oil. 
Data for 32: Rf = 0.48 (30% EtOAc in hexanes); IR (neat): 2975, 2918, 2826, 1727 
(C=O), 1652, 1449, 898, 871 cm–1; [α]D
22 +24.5 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 
8.96 (s, 1H), 4.88–4.87 (m, 1H), 4.77–4.76 (m, 1H), 3.07 (d, 1H, J  = 4.8 Hz), 3.04 (d, 1H, J  = 
4.8 Hz), 2.66 (d, 1H, J  = 15.3 Hz), 2.54 (d, 1H, J  = 15.3 Hz), 1.76 (br s, 3H); 13C NMR (75 
MHz, 293K, CDCl3) δ 198.5, 139.7, 114.1, 60.3, 49.3, 35.0, 23.5; HRMS (EI+) calcd. for 
C7H9O2 [M – H]
+ 125.0603, found 125.0602. 
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Preparation of alcohols 6 and 7 with divinyl zinc (Table 6, entry 2). Preparation of 
divinyl zinc: Zinc chloride (8.10 g, 59.5 mmmol) was heated to 130 °C under reduced pressure 
for 2 h, then placed under a nitrogen atmosphere, and dissolved in THF (32 mL).  Vinyl 
magnesium bromide (1.0 M in THF, 118 mL) was added dropwise at 23 °C, and then the 
insoluble salts were allowed to settle after addition was complete. 
To a stirred solution of divinyl zinc (130 mL, 51.6 mmol) was added epoxyaldehyde 32 
(3.60 g, 28.5 mmol) in THF (10 mL) over 20 min at –72 °C under a nitrogen atmosphere.  The 
resulting reaction mixture was stirred for an additional 45 min at –78 °C, then warmed to 0 °C. 
After 15 min at the same temperature, the reaction was quenched with saturated aqueous NH4Cl 
(50 mL).  The resulting mixture was then filtered through a pad of Celite 545®, the layers were 
separated, and the aqueous layer was extracted with EtOAc (2 × 50 mL).  The combined organic 
layers were washed with H2O (25 mL), then brine (25 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude residue was purified by flash 
chromatography (10% EtOAc in hexanes) on silica gel (400 mL) to afford 80 (0.831 g, 16% 
yield) and 81 (2.22 g, 55%) as colorless oils.  
Data for alcohol 80: Rf = 0.29 (25% EtOAc in hexanes); IR (neat): 3425 (br), 2929, 1650, 
1437, 1376, 1056, 927, 895 cm–1; [α]D
22 –38.9 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, C6D6) 
δ 5.75 (ddd, 1H, J = 17.2, 10.5, 5.7 Hz), 5.21 (ddd, 1H, J = 17.2, 1.7, 1.7 Hz), 5.01 (ddd, 1H, J = 
10.5, 1.6, 1.6 Hz), 4.76–4.75 (m, 1H), 4.71–4.70 (m, 1H), 3.95 (dddd, 1H, J = 6.9, 5.7, 1.4, 1.3 
Hz), 2.57 (d, 1H, J = 5.1 Hz), 2.35 (d, 1H, J = 14.5 Hz), 2.31 (d, 1H, J = 5.2 Hz), 2.25 (d, 1H, J = 
14.5 Hz), 1.62 (br s, 3H), 1.46 (d, 1H, J = 6.9 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 140.9, 
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136.1, 117.6, 114.3, 73.2, 60.0, 49.5, 39.3, 23.3; HRMS (EI+) calcd. for C9H13O2 [M – H]
+ 
153.0916, found 153.0917. 
Data for alcohol 81: Rf = 0.32 (25% EtOAc in hexanes); IR (neat): 3451 (br), 2920, 1650, 
1435, 1377, 1065, 1029, 928; [α]D
22 +49.8 (c 1.0, CHCl3);  
1H NMR (300 MHz, 293K, CDCl3) δ 
5.81 (ddd, 1H, J = 17.2, 10.3, 6.7 Hz), 5.41 (ddd, 1H, J = 17.2, 1.5, 1.2 Hz), 5.28 (ddd, 1H, J = 
10.3, 1.5, 1.0 Hz), 4.90–4.88 (m, 1H), 4.80–4.79 (m, 1H), 4.27 (br d, 1H, J = 7.7 Hz), 2.89 (d, 
1H, J = 4.8 Hz), 2.63 (d, 1H, J = 4.8 Hz), 2.48 (br d, 1H, J = 14.6 Hz), 2.35 (br d, 1H, J = 14.7 
Hz), 2.19 (br s, 1H), 1.79 (br s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 140.7, 135.8, 118.2, 
114.6, 71.2, 60.0, 48.2, 39.7, 23.2; LRMS (EI+) calcd. for C9H12O [M – H2O]
+ 136.0888, found 
136.0892. 
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Preparation of ester 82. To a stirred solution of Ph3P (1.58 g, 6.01 mmol) and 4-O2N-
PhCO2H (1.00 g, 6.01 g) in THF (8 mL) was added DIAD (1.15 mL, 5.84 mmol) dropwise 
followed by the dropwise addition of 81 (311 mg, 2.02 mmol) in THF (1 mL) and then the 
container that initially contained 81 was rinsed with THF (2 × 0.5 mL) and added to the reaction 
mixture at 0 °C under a nitrogen atmosphere.  After 5 min at the same temperature, the reaction 
mixture was warmed to 23 °C.  After 55 min at the same temperature, most of the solvent was 
removed under reduced pressure.  The residue was purified by flash chromatography (2.5 → 
10% EtOAc in hexanes) on silica gel (150 mL) to afford 82 (522 mg, 85% yield) as colorless oil.  
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Data for alcohol 82: Rf = 0.44 (20% EtOAc in hexanes); IR (neat): 3078, 2920, 1731 
(C=O), 1529, 1348, 1270, 1102, 720 cm–1; [α]D
22 +14.6 (c 1.0, CHCl3); 
1H NMR (300 MHz, 
293K, CDCl3) δ 8.34−8.28 (m, 2H), 8.27−8.21 (m, 2H), 5.95 (ddd, 1H, J = 17.2, 10.5, 6.6 Hz), 
5.60 (br d, 1H, J = 6.6 Hz), 5.43 (br d, 1H, J = 17.2 Hz), 5.40 (br d, 1H, J = 10.5 Hz), 4.91 (br s, 
1H), 4.82 (br s, 1H), 2.89 (br d, 1H, J = 4.6 Hz), 2.77 (br d, 1H, J = 4.6 Hz), 2.60 (br d, 1H, 14.6 
Hz), 2.40 (br d, 1H, J = 14.6 Hz), 1.81 (br s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 163.3, 
150.6, 140.3, 135.2, 131.5, 130.7, 123.6, 119.9, 114.7, 76.7, 58.5, 49.5, 39.9, 23.1; HRMS 
(ESI+) calcd. for C16H17NO2Na [M + Na]
+ 326.1004, found 326.1019. 
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Preparation of 81 from ester 82. To a stirred solution of K2CO3 (1.73 g, 12.5 mmol) in 
MeOH (10 mL) was added nitrobenzoate 82 (1.52 g, 5.03 mmol) in MeOH (10 mL) dropwise 0 
°C under an open atmosphere.  After 30 min at the same temperature, saturated aqueous NH4Cl 
(10 mL) and concentrated under reduced pressure.  The aqueous residue was diluted with H2O 
(10 mL), and extracted with Et2O (3 × 10 mL).  The combined organic layers were washed with 
saturated aqueous NaHCO3 (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure.  The crude residue was purified by flash 
chromatography (2.5 → 15% EtOAc in hexanes) on silica gel (65 mL) to afford 80 (683 mg, 
88%) as colorless oil.  
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Preparation of TES ether 83. To a stirred solution of imidazole (1.18 g, 17.3 mmol) in 
THF (15 mL) was added chlorotriethylsilane (2.4 mL, 14 mmol), followed by the dropwise 
addition of alcohol 80 (1.91 g, 12.4 mmol) in THF (10 mL) at 0 °C under a nitrogen atmosphere.   
After an additional 30 min at the same temperature, saturated aqueous NH4Cl (10 mL) was 
added, the layers were separated, and then the aqueous layer was extracted with Et2O (3 × 25 
mL).  The combined organic layers were washed with H2O (30 mL) then brine (30 mL), dried 
over anhydrous Na2SO4, filtered, and reduced under pressure.  The resulting residue was purified 
by flash chromatography (1 → 5% EtOAc in hexanes) on silica gel (100 mL) to afford 83 (3.32 
g, quant. yield) as a colorless oil. 
Data for 83: Rf = 0.67 (20% EtOAc in hexanes); IR (neat): 2955, 2913, 2877, 1650, 1459, 
1416, 1089, 1007, 831, 743 cm–1; [α]D
22 –7.2 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) 
δ 5.86 (ddd, 1 H, J = 17.2, 10.4, 6.2 Hz), 5.30 (ddd, 1 H, J = 17.2, 1.6, 1.6 Hz), 5.19 (ddd, 1H, J 
= 10.5, 1.5, 1.5 Hz), 4.84–4.83 (m, 1H), 4.74–4.73 (m, 1H), 4.02 (ddd, 1H, J = 6.2, 1.3, 1.3 Hz), 
2.80 (d, 1H, J = 5.0 Hz), 2.66 (d, 1H, J = 5.0 Hz), 2.55 (d, 1H, J = 14.6 Hz), 2.28 (br d, 1H, J = 
14.6 Hz), 1.74 (br s, 3H), 1.00–0.93 (m, 9H), 0.66–0.58 (m, 6H); 13C NMR (75 MHz, 293K, 
CDCl3) δ 141.2, 137.3, 116.3, 114.1, 75.9, 60.7, 49.2, 37.7, 23.5, 6.7, 6.5, 5.8, 4.8; HRMS (EI+) 
calcd. for C15H28O2Si [M]
+ 268.1859, found 268.1851. 
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Preparation of diol 84. To a stirred solution of TES ether 83 (225 mg, 0.839 mmol) in 
THF (4 mL) and H2O (0.5 mL) was added OsO4 (10 mg, 0.038 mmol), and then NMO•H2O (114 
mg, 0.842 mmol) at 23 °C under an open atmosphere.  The resulting brown solution was stirred 
for 1.5 h at the same temperature, then diluted with Et2O (10 mL).  To the reaction mixture was 
added solid NaHCO3 and Na2SO3, then anhydrous Na2SO4.  The mixture was filtered through 
cotton, and concentrated under reduced pressure.  The residue was purified by flash 
chromatography (30% EtOAc in hexanes) on silica gel (8 mL) to afford 84 (146 mg, 58% yield) 
as a mixture of diastereomers (dr ~1.5:1 at C1). 
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Preparation of 85. To a stirred solution of diol 84 (22.1 mg, 0.073 mmol) in THF (0.20 
mL), and H2O (0.2 mL), was added NaIO4 (15.8 mg, 0.074 mmol) at 23 °C under an open 
atmosphere.  After 1 h at the same temperature, the resulting reaction mixture was diluted with 
Et2O (5 mL) and H2O (5 mL).  The layers were separated, and the aqueous layer was extracted 
with Et2O (3 × 10 mL).  The combined organic layers were washed with H2O (5 mL) then brine 
(10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The 
residue was purified by flash chromatography (5 → 15% EtOAc in hexanes) on silica gel (4 mL) 
to afford 85 (19.6 mg, quant.) as a colorless oil. 
Data for 85: Rf = 0.45 (30% Et2O in hexanes); IR (neat): 2956, 1717 (C=O), 1415, 1239, 
1086, 1007, 930, 743 cm-1; [α]22D –3.9 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.80 
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(ddd, 1H, J = 17.1, 10.4, 5.4 Hz), 5.32 (ddd, 1H, J = 17.1, 1.7, 1.7 Hz), 5.18 (ddd, 1H, J = 10.4, 
1.6, 1.6 Hz), 3.90 (ddd, 1H, J = 5.4, 1.5, 1.5 Hz), 2.82 (d, 1H, J = 4.4 Hz), 2.78 (d, 1H, J = 15.4 
Hz), 2.76 (d, 1H, J = 4.4 Hz), 2.71 (d, 1H, J = 15.4 Hz), 2.17 (s, 3H), 0.97 (t, 3H, J = 7.9 Hz), 
1.00–0.94 (m, 9H), 0.67–0.58 (m, 6H); 13C NMR (75 MHz, 293K, C6D6) δ 203.9, 137.4, 115.7, 
77.8, 58.8, 49.6, 42.9, 30.8, 7.0, 5.1; HRMS (EI+) calcd. for C14H24O2Si [M – H2O]
+ 252.1547, 
found 252.1546. 
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Preparation of enone 86. To a solution of 85 (70 mg, 0.26 mmol) in methanol (0.65 mL) 
and CH2Cl2 (0.65 mL) was bubbled O3 until a blue color persisted at −78 °C, then O2 was 
bubbled through the reaction mixture to remove the excess O3 as indicated by the disappearance 
of the blue color. At the same temperature was added Me2S (350 µL, 4.77 mmol), then allowed 
to slowly warm to 23 °C over 3.25 h, then most of the solvent was removed under reduced 
pressure. The reaction mixture was diluted with Et2O (15 mL), then washed with H2O (5 mL) 
and brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated. The crude residue 
was purified by flash chromatography (5 → 30% EtOAc in hexanes) on silica gel (2 mL) to 
afford 86 (15 mg, 15%) as a colorless oil. 
Data for 86: Rf = 0.43 (30% EtOAc in hexanes);
 IR (neat): 3431 (br, O-H), 2956, 1697 
(C=O), 1639, 1363, 1041, 972, 746 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 6.47 (app q, 1H, 
J = 2.5 Hz), 5.35 (d, 1H, J = 4.5 Hz), 4.88 (app dt, 1H, J = 18.0, 2.5 Hz), 4.80−4.72 (m, 1H), 
4.56−4.51 (m, 1H), 2.28 (s, 3H), 0.96 (t, 9H, J = 7.9 Hz), 0.67 (q, 6H, J = 7.9 Hz); 13C NMR (75 
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MHz, 293K, C6D6) δ 197.6, 160.2, 120.1, 94.8, 75.0, 69.3, 31.0, 6.5, 4.7; HRMS (ESI+) calcd. 
for C13H24O4NaSi [M + Na]
+ 295.1342, found 295.1368. 
 
OO
OTES
H
O
26
O
OTES
85
O
O3; Me2S
55-82%
 
Preparation of ketoaldehyde 26 from enone 85. To a solution of 85 (80 mg, 0.30 
mmol) in methanol (0.8 mL) and CH2Cl2 (0.8 mL) was bubbled O3 until a blue color persisted at 
−78 °C, then O2 was bubbled through the reaction mixture to remove the excess O3 as indicated 
by the disappearance of the blue color. At the same temperature was added Me2S (350 µL, 4.77 
mmol), then allowed to slowly warm to 23 °C over 2.5 h, then most of the solvent was removed 
under reduced pressure. The reaction mixture was diluted with Et2O (20 mL), then washed with 
H2O (5 mL) and brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated. The 
crude residue was purified by flash chromatography (5 → 30% EtOAc in hexanes) on silica gel 
(5 mL) to afford 26 (60 mg, 75%) as a colorless oil. 
Data for 26:† Rf = 0.24−0.34 (30% EtOAc in hexanes);
 1H NMR (300 MHz, 293K, 
CDCl3) δ 9.53 (d, 1H, J = 1.1 Hz), 3.80 (d, 1H, J = 1.1 Hz), 3.28 (br d, 1H, J = 17.3 Hz), 3.13 
(dd, 1H, J = 4.1, 1.4 Hz), 2.75 (d, 1H, J = 4.1 Hz), 2.42 (d, 1H, J = 17.3 Hz), 2.18 (s, 3H), 0.98 
(t, 9H, J = 7.7 Hz), 0.66 (q, 6H, J = 7.7 Hz). 
† No further characterization was performed due to the instability of this compound. 
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H
O
O
+ R
R = TMS,
C(OH)Me232
OH
N
Ph
Zn(OTf)2, Et3N
toluene, 23 to 32 oC
decomposition
 
 Procedure for the unsuccessful asymmetric alkynyl addition reactions to aldehyde 
32. See D. E. Frantz, R. Fassler, E. M. Carreira, J. Am. Chem. Soc. 2000, 122, 1806–1807. 
 
H
O
O
32
O
OH
80
O
OH
87
MgBr
34%
dr = 2:1
91%
dr = 1.7:1
H2
 
Preparation of alcohols 80 and 81 with ethynylmagnesium bromide, then partial 
hydrogenation. To a stirred solution of ethynylmagnesium bromide (0.5 M in THF, 2.0 mL) was 
added 32 (125 mg, 1.0 mmol) in THF (0.6 mL), and then the container that initially contained 32 
was rinsed with THF (2 × 0.2 mL) and added to the reaction mixture at −78 °C under a nitrogen 
atmosphere. After 50 min at the same temperature, additional ethynylmagnesium bromide (0.5 M 
in THF, 1.5 mL) was added to the reaction mixture. After an additional 90 min at −78 °C, the 
reaction was quenched with saturated aqueous NH4Cl (3 mL) and most of the solvent was 
removed under reduced pressure. The aqueous residue was extracted with Et2O (3 × 10 mL). The 
combined organic layers were washed with H2O (10 mL) and brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was 
purified by flash chromatography (5 → 15% EtOAc in hexanes) on silica gel (6 mL) to afford 
approximately a 2:1 mixture of diastereomers of 87 (52 mg, 34%) as colorless oils.  
To a stirred solution of 87 (33 mg, 0.22 mmol) in EtOH (2 mL) was added quinoline (25 
µL) and Lindlar’s catalyst (5% wt/wt, 4.7 mg, 2.2 µmol) in one portion at 23 °C under an open 
atmosphere. After 25 min at the same temperature, the reaction mixture was placed under an 
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atmosphere of H2, and vigorously stirred. After an additional 12 h, thre reaction mixture was 
filtered through filter paper, rinsed with 15% EtOAc in hexanes, and concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (5 → 15% EtOAc in 
hexanes) on silica gel (2 mL) to afford approximately a 1.7:1 mixture of diastereomers of 80:81 
(31 mg, 91% yield) as colorless oil.  
 
H
O
O
32
Cp2ZrCl, AgOTf
84%, dr = 6:1
MeO2C Ag
O
OH
MeO2C
89  
Preparation of and data for 89. See S. P. Shahi, K. Koide Angew. Chem., Int. Ed. 2004, 
43, 2525.  
 
O
OH
MeO2C
89
TESCl
imid.
quant. O
OTES
MeO2C
90  
Preparation of and data for 90. To a stirred solution of imidazole (14 mg, 0.20 mmol) 
in THF (200 µL) was added chlorotriethylsilane (40 µL, 0.24 mmol) followed by the dropwise 
addition of alcohol 89 (28 mg, 0.13 mmol) in THF (200 µL) at 0 °C under a nitrogen 
atmosphere. After an additional 30 min at the same temperature, saturated aqueous NH4Cl (3 
mL) was added, and the mixture extracted with Et2O (3 × 10 mL). The combined organic layers 
were washed with H2O (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (2 → 5% EtOAc in hexanes) on silica gel (4 mL) to afford 90 (32 mg, 74%) as a 
colorless oil.  
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Data for 90: Rf = 0.60 (30% EtOAc in hexanes); IR (neat): 2956, 2239, 1720 (C=O), 
1265, 1108, 741 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 4.89−4.88 (m, 1H), 4.82 (br s, 1H), 
4.46 (s, 1H), 3.79 (s, 3H), 2.89 (d, 1H, J = 4.8 Hz), 2.71 (d, 1H, J = 4.8 Hz), 2.65 (d, 1H, J = 14.5 
Hz), 2.46 (d, 1H, J = 14.5 Hz), 1.77 (br s, 3H), 0.99 (t, 9H, J = 7.9 Hz), 0.68 (q, 6H, J = 7.9 Hz); 
13C NMR (75 MHz, 293K, C6D6) δ 153.4, 140.8, 114.9, 85.2, 77.6, 66.8, 66.0, 52.1, 48.7, 37.7, 
23.5, 6.8, 5.0; HRMS (ESI+) calcd. for C17H28O4SiNa [M + Na]
+ 347.1655, found 347.1664. 
 
O
OH
MeO2C
89
Red-Al
81% O
OH
MeO2C
93  
Preparation and data for 93. See C. T. Meta, K. Koide Org. Lett. 2004, 6, 1785. 
 
O
OH
MeO2C
O
OTES
MeO2C
93 94
TESCl
imid.
quant.
 
Preparation of 94. To a stirred solution of imidazole (1.02 g, 15.0 mmol) in THF (20 
mL) was added chlorotriethylsilane (2.35 mL, 14.0 mmol), followed by the dropwise addition of 
alcohol 93 (2.11 g, 9.96 mmol) in THF (3 mL), and then the container that initially contained 93 
was rinsed with THF (2 × 1 mL) and added to the reaction mixture at 0 °C under a nitrogen 
atmosphere. After an additional 45 min at the same temperature, H2O (50 mL) was added, and 
most of the THF was removed under reduced pressure. The aqueous residue was extracted with 
Et2O (2 × 40 mL). The combined organic layers were washed with brine (50 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (1.5 → 3% EtOAc in hexanes) on silica gel (150 mL) to afford 
94 (3.27 g, quantitative yield) as a colorless oil.  
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Data for 94: Rf = 0.30 (10% EtOAc in hexanes); IR (neat): 2954, 1728 (C=O), 1281, 
1167, 978, 744 cm-1; [α]D
22 +9.9 (c 1.1, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 6.94 (dd, 
1H, J = 15.5, 4.6 Hz), 6.10 (dd, 1H, J = 15.5, 1.8 Hz), 4.85−4.84 (m, 1H), 4.73−4.71 (m, 1H), 
4.13 (dd, 1H, J = 4.6, 1.8 Hz), 3.77 (s, 3H), 2.75 (br d, 1H, J = 4.8 Hz), 2.71 (d, 1H, J = 4.8 Hz), 
2.46 (br d, 1H, J = 14.5 Hz), 2.35 (br d, 1H, J = 14.5 Hz), 1.72 (br s, 3H), 0.97 (q, 9H, J = 7.9 
Hz), 0.64 (q, 6H, J = 7.9 Hz); 13C NMR (75 MHz, 293K, C6D6) 166.3, 147.2, 141.0, 121.8, 
114.7, 76.8, 60.1, 51.2, 48.4, 36.2, 23.7, 7.0, 5.0; HRMS (ESI+) calcd. for C17H30O4SiNa [M + 
Na]+  349.1811, found 349.1794.   
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O
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MeO2C
94
O3; Me2S
quant.
 
Preparation of ketoaldehyde 26 from enoate 94. A solution of enoate 94 (2.6 mg, 8.0 
µmol) in methanol (30 µL) and CH2Cl2 (30 µL) was bubbled O3 until a blue color persisted at 
−78 °C, then O2 was bubbled through the reaction mixture to remove the blue color. At the same 
temperature was added Me2S (10 µL, 0.014 mmol), then allowed to slowly warm to 23 °C over 3 
h, then most of the solvent was removed under reduced pressure. The reaction mixture was 
diluted with Et2O (10 mL), then washed with H2O (1 mL) and brine (2 mL), dried over 
anhydrous Na2SO4, filtered and concentrated. The 
1H NMR of the resultant crude residue 
revealed clean formation of ketoaldehyde 26. 
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O
BocHN
I +
25
O
BocHN
58
O
TESO
OO
26
nBuLi
 
Preparation of 58 from 25. To a stirred solution of 25 (14 mg, 0.033 mmol) and 
ketoaldehyde 26 (9.1 mg, 0.033 mmol) in THF (200 µL) was added nBuLi (1.6 M in hexanes, 25 
µL, 0.040 mmol) down the flask side at -98 °C under a nitrogen atmosphere. The reaction 
mixture was slowly warmed to −72 °C over 10 min, and then quenched by the addition of 
saturated aqueous NH4Cl (2 mL) at the same temperature. The aqueous residue was extracted 
with Et2O (3 × 5 mL). The combined organic layers were washed with brine (15 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (5 → 25% EtOAc in hexanes) on silica gel (2 mL) to afford 58 
(7.1 mg, 70%) as a colorless oil.  
Data for 58: Rf = 0.59 (30% EtOAc in hexanes); IR (neat): 3454 (N-H), 2877, 1717 
(C=O), 1496, 1365, 1170, 1077, 902 cm-1; [α]D
22 -34.4 (c 1.0, CHCl3); 
1H NMR (300 MHz, 
293K, CDCl3) δ 6.42 (dd, 1H, J = 17.4, 10.7 Hz), 5.65 (br app t, 1H, J = 6.9 Hz), 5.11 (d, 1H, J = 
17.4 Hz), 4.98−4.90 (m, 2H), 3.65−3.61 (m, 1H), 3.55 (qd, 1H, J = 6.4, 1.6 Hz), 3.05 (ddd, 1H, J 
= 9.7, 7.9, 3.2 Hz), 2.51 (ddd, 1H, J = 15.7, 6.8, 2.6 Hz), 2.30−2.18 (m, 1H), 1.89 (app dt, 1H, J 
= 13.1, 3.1 Hz), 1.75 (br s, 3H), 1.54−1.50 (m, 1H), 1.46 (s, 9H), 1.13 (d, 3H, J = 6.4 Hz), 0.85 
(d, 3H, J = 6.4 Hz); 13C NMR (75 MHz, 293K, C6D6) 166.3, 147.2, 141.0, 121.8, 114.7, 76.8, 
60.1, 51.2, 48.4, 36.2, 23.7, 7.0, 5.0; HRMS (EI+) calcd. for C18H31NO3 [M]
+ 309.2304, found 
309.2305.   
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I
Cp2Zr(H)Cl;
I2  
 Preparation of (E)-1-iodo-3-methylbuta-1,3-diene. To a light-protected stirred solution 
of Cp2Zr(H)Cl (856 mg, 3.32 mmol) in benzene (7 mL) and THF (7 mL) was added 2-methyl-1-
buten-3-yne (300 µL, 3.15 mmol) at 23 °C under a nitrogen atmosphere. After 30 min at the 
same temperature, iodine (862 mg, 3.40 mmol) was added in one portion. After 15 min at the 
same temperature, the reaction was quenched by the addition of aqueous Na2S2O3 (10% wt/wt, 7 
mL), and the mixture was concentrated under reduced pressure. The aqueous residue was 
extracted with pentane (20 mL). The organic layer was washed with H2O (15 mL) then brine (15 
mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by filtration through a plug of silica gel (5 mL), rinsing with 1:1 
pentane/CH2Cl2 (25 mL), and concentrated under reduced pressure to afford (E)-1-iodo-3-
methylbuta-1,3-diene (358 mg, 57%) as a pale yellow oil.  
 Data for (E)-1-iodo-3-methylbuta-1,3-diene: 1H NMR (300 MHz, 293K, CDCl3) δ 7.15 
(br d, 1H, J = 14.7 Hz), 6.33 (ddd, 1H, J = 14.7, 0.5, 0.5 Hz), 5.00−4.97 (m, 2H), 1.83 (dd, 3H, J 
= 1.3, 0.9 Hz). 
 
I
+
O
TESO
5
OO
26
nBuLi
decomposition of 26
 
Decompostion of 26. To a stirred solution of 26 (33.2 mg, 0.122 mmol) and (E)-1-iodo-
3-methylbuta-1,3-diene (24.3 mg, 0.126 mmol) in THF (600 µL) was added nBuLi (1.6 M in 
hexanes, 90 µL, 0.14 mmol) down the flask side at -98 °C under a nitrogen atmosphere. The 
reaction mixture was slowly warmed to −72 °C over 10 min, and then quenched by the addition 
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of saturated aqueous NH4Cl (2 mL) at the same temperature. The aqueous residue was extracted 
with Et2O (3 × 5 mL). The combined organic layers were washed with H2O (5 mL) and brine (10 
mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (5 → 30% EtOAc in hexanes) on silica 
gel (2 mL) to afford only decomposition products.  
 
O
OTES
85
O
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Preparation of lactol 106. To a light–protected stirred solution of 85 (162 mg, 0.598 
mmol) in THF (2.4 mL) and H2O (0.30 mL) was added recrystallized NBS (113 mg, 0.633 
mmol) in one portion under an open atmosphere at 0 °C. The reaction mixture was slowly 
warmed to 23 °C over 2 h. After 2.5 h, 2–methyl–2–butene (0.1 mL) was added to the resulting 
reaction mixture, then H2O (5 mL) at 23 °C. The layers were separated, and the aqueous layer 
was extracted with Et2O (3 × 10 mL). The combined organic layers were washed with brine (1 × 
15 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (10 → 20% EtOAc in hexanes) on silica 
gel (7.5 mL) to afford 106 (164 mg, 75%) as a colorless oil.  
Data for 106: Rf = 0.21 (20% EtOAc in hexanes); IR (neat): 3453 (br), 2956, 2877, 1716 
(w), 1413, 1235, 1149, 1074, 1053, 976, 879, 744 cm–1; [α]22D –32.1 (c 1.0, CHCl3); 
1H NMR* 
(300 MHz, 293K, CDCl3) δ 4.18 (ddd, 1H, J = 8.1, 5.7, 1.3 Hz), 3.51 (dd, 1H, J = 9.7, 8.1 Hz), 
3.45 (br s, 1H), 3.37 (dd, 1H, J = 9.7, 5.7 Hz), 2.83 (d, 1H, J = 4.6 Hz), 2.78 (dd, 1H, J = 4.6, 1.6 
Hz), 2.45 (br d, 1H, J = 12.6 Hz), 1.53 (s, 3H), 1.27 (dd, 1H, J = 12.7, 1.0 Hz), 0.98 (t, 9H, J = 
7.8 Hz), 0.76–0.64 (m, 6H); 13C NMR* (75 MHz, 293K, CDCl3) δ 97.9, 73.4, 70.9, 57.9, 53.3, 
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36.7, 30.4, 30.0, 6.9, 4.9; HRMS (EI+) calcd. for C12H22BrO4Si [M – Et]
+ 337.0471, found 
337.0478.   
*The presence of anomers precluded a comprehensive assignment of all resonances. 
 
PPTS
MeOH, 40%
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TESO
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Preparation of methyl glycoside 107 by PPTS catalyzed ketalization. To a stirred 
solution of lactol 106 (98.8 mg, 0.270 mmol) in CH2Cl2 (0.70 mL) and MeOH (0.30 mL) was 
added PPTS (6.6 mg, 0.026 mmol) at 23 °C under a nitrogen atmosphere. After 15 h at the same 
temperature, saturated aqueous NaHCO3 (5 mL) was added to the resulting reaction mixture at 
23 °C. The layers were separated, and the aqueous layer was extracted with Et2O (3 × 10 mL). 
The combined organic layers were washed with brine (15 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (2.5 → 30% EtOAc in hexanes) on silica gel (6 mL) to afford methyl glycoside 
107 (40.5 mg, 40% yield) as a colorless oil. 
 
O
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Preparation of methyl glycoside 15 by NBS cyclization. To a light–protected, stirred 
mixture of powdered 3Å MS (132 mg), recrystallized NBS (125.1 mg, 0.703 mmol), MeCN (1.0 
mL), and MeOH (0.20 mL) was added ketone 85 (128 mg, 0.474 mmol) in MeCN (0.80 mL) 
dropwise at 0 °C under a nitrogen atmosphere. The reaction mixture was allowed to warm to 23 
°C over 75 min. After 2 h at the same temperature, 2–methyl–2–butene (10 drops), then Et3N (5 
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drops) was added to the reaction mixture. The resulting reaction mixture was then filtered 
through a plug of silica gel (5 mL), and rinsed with 20% EtOAc in hexanes (20 mL), then Et2O 
(20 mL). The eluent was then concentrated under reduced pressure, and the residue was purified 
by flash chromatography (1 → 7.5% EtOAc in hexanes) to afford methyl glycoside 107 (105.8 
mg, 59%) as a colorless oil. 
Data for 107: Rf = 0.36 (20% EtOAc in hexanes); IR (neat): 2956, 1231, 1147, 1086, 
1071, 1040, 744 cm–1; [α]22D –70.6 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, C6D6) δ 3.80 
(ddd, 1H, J = 6.7, 6.7, 1.4 Hz), 3.51 (dd, 1H, J = 9.9, 6.7 Hz), 3.44 (dd, 1H, J = 9.9, 6.7 Hz), 3.23 
(br s, 1H), 3.00 (s, 3H), 2.56 (d, 1H, J = 4.8 Hz), 2.50 (dd, 1H, J = 12.7, 1.6 Hz), 2.30 (dd, 1H, J 
= 4.8, 1.7 Hz), 1.17 (d, 1H, J = 12.8 Hz), 1.14 (s, 3H), 1.03 (t, 9H, J = 7.9 Hz), 0.85–0.63 (m, 
6H); 13C NMR (126 MHz, 293K, C6D6) δ 100.4, 73.9, 72.1, 57.7, 53.3, 48.0, 38.3, 31.5, 23.1, 
7.1, 5.3; HRMS (EI+) calcd. for C14H27BrO3Si [M – CH4O]
+ 350.0913, found 350.0903. 
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Preparation of TES ether 108. To a stirred solution of imidazole (2.18 g, 32.1 mmol) in 
THF (30 mL) was added chlorotriethylsilane (4.3 mL, 26 mmol), followed by the dropwise 
addition of alcohol 81 (3.49 g, 22.6 mmol) in THF (20 mL) at 0 °C under a nitrogen atmosphere. 
After an additional 30 min at the same temperature, saturated aqueous NH4Cl (15 mL) was 
added, the layers were separated, and then the aqueous layer was extracted with Et2O (3 × 25 
mL). The combined organic layers were washed with H2O (30 mL) then brine (30 mL), dried 
over anhydrous Na2SO4, filtered, and reduced under pressure. The resulting residue was purified 
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by flash chromatography (1 → 5% EtOAc in hexanes) on silica gel (225 mL) to afford 108 (6.08 
g, quant. yield) as a colorless oil. 
Data for 108: Rf = 0.68 (20% EtOAc in hexanes); IR (neat): 2955, 2913, 2877, 1650, 
1459, 1417, 1144, 1093, 1006, 893, 743 cm–1; [α]D
22 –13.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 
293K, CDCl3) δ 5.89 (ddd, 1H, J = 17.2, 10.4, 6.0 Hz), 5.31 (ddd, 1H, J = 17.2, 1.9, 1.4 Hz), 
5.19 (ddd, 1H, J = 10.4, 1.9, 1.2 Hz), 4.85–4.82 (m, 1H), 4.74–4.72 (m, 1H), 4.04 (app dt, 1H, J 
= 6.0, 1.3, 1.3 Hz), 2.71 (d, 1H, J = 5.2 Hz), 2.59 (d, 1H, J = 5.3 Hz), 2.49 (br d, 1H, J = 14.5 
Hz), 2.34 (br d, 1H, J = 14.5 Hz), 1.75 (dd, 3H, J = 1.4, 0.9 Hz), 0.96 (t, 9H, J = 7.9 Hz), 0.60 (q, 
6H, J = 7.9 Hz): 13C NMR (75 MHz, 293K, CDCl3) δ 141.3, 137.5, 116.4, 113.9, 74.8, 59.8, 
49.7, 37.9, 23.5, 6.7, 6.5, 5.8, 4.9; HRMS (EI+) calcd. for C15H27O2Si [M
 – H]+ 267.1780, found 
267.1776. 
 
O
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Preparation of diol 109. To a stirred solution of TES-ether 108 (728 mg, 2.71 mmol) in 
THF (14 mL) and H2O (1.4 mL) was added OsO4 (31.2 mg, 0.123 mmol), then NMO•H2O (367 
mg, 2.71 mmol) at 23 °C under an open atmosphere. The resulting brown solution was stirred for 
11 h at the same temperature, then saturated aqueous Na2SO3 was added (15 mL) and 
vigourously stirred for 30 min. The layers were separated, and the aqueous layer was extracted 
with Et2O (3 × 25 mL). The combined organic layers were washed with brine (2 × 30 mL), dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (10 → 40% EtOAc in hexanes) on silica gel (25 mL) to 
afford 109 (498 mg, 60% yield, 69% BORSM) as a mixture of diastereomers (dr ~ 1.5:1 at C1).  
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Preparation of 110. To a stirred solution of diol 109 (187 mg, 0.619 mmol) in THF (2 
mL) and H2O (2 mL) was added NaIO4 (135 mg, 0.630 mmol) at 23 °C under an open 
atmosphere. After 1.5 h at the same temperature, the resulting reaction mixture was diluted with 
Et2O (5 mL) and H2O (5 mL). The layers were separated, and the aqueous layer was extracted 
with Et2O (3 × 15 mL). The combined organic layers were washed with brine (2 × 20 mL), dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography (5 → 15% EtOAc in hexanes) on silica gel (12 mL) to afford 
110 (171 mg, quant. yield) as a colorless oil.  
Data for 110: Rf = 0.50 (30% Et2O in hexanes); IR (neat): 2956, 1717 (C=O), 1416, 1139, 
1007, 849, 742 cm–1; [α]D
22 –48.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.85 
(ddd, 1H, J = 17.2, 10.4, 6.0 Hz), 5.32 (ddd, 1H, J = 17.2, 1.7, 1.4 Hz), 5.24 (ddd, 1H, J = 10.4, 
1.7, 1.3 Hz), 4.06 (br d, 1H, J = 6.0 Hz), 3.01 (br d, 1H, J = 15.4 Hz), 2.80 (d, 1H, J = 4.8 Hz), 
2.77 (d, 1H, J = 4.8 Hz), 2.42 (d, 1H, J = 15.4 Hz), 2.18 (s, 3H), 0.97 (t, 3H, J = 7.9 Hz), 0.94 (t, 
6 H, J  = 7.9 Hz, 7.9 Hz), 0.60 (q, 2H, J = 7.8 Hz) 0.58 (q, 4H, J = 7.9 Hz); 13C NMR (75 MHz, 
293K, CDCl3) δ 205.7, 136.7, 117.2, 75.4, 58.4, 51.0, 44.6, 31.3, 6.7, 6.6, 5.8, 4.6; HRMS (EI+) 
calcd. for C14H25O3Si [M – H]
+ 269.1573, found 269.1575. 
 
 141 
O
OTES
110
O
NBS
H2O, 95%
O
O
OH
TESO
Br
111  
Preparation of lactol 14. To a light–protected stirred solution of 110 (19.2 mg, 0.710 
mmol) in acetone (0.40 mL) and H2O (0.050 mL) was added of recrystallized NBS (16.0 mg, 
0.144 mmol) in one portion at 23 °C under an open atmosphere. The reaction mixture was stirred 
for 40 min at the same temperature, then 2–methyl–2–butene (10 drops) was added, then H2O (5 
mL) at 23 °C. The layers were separated, and the aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic layers were washed with brine (2 × 10 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was purified by 
flash chromatography (5 → 20% EtOAc in hexanes) on silica gel (3 mL), to afford 111 (24.8 mg, 
95% yield) as a colorless oil. 
Data for 111: Rf = 0.37 (30% EtOAc in hexanes); IR (neat): 3451 (br), 2957, 2877, 1716, 
1413, 1316, 1235, 1149, 1053, 1011, 842, 744; [α]D
22 +21.0 (c 1.0, CHCl3);
 1H NMR* (300 
MHz, 293K, CDCl3) δ 4.27 (ddd, 1H, J = 8.7, 5.4, 1.3 Hz), 3.47 (dd, 1H, J = 9.6, 8.8 Hz), 3.38 
(dd, 1H, J = 9.7, 5.4 Hz), 3.35 (br s, 1H), 2.82 (d, 1H, J = 4.2 Hz), 2.75 (d, 1H, J = 4.2 Hz), 2.54 
(d, 1H, J = 13.9 Hz), 1.48 (s, 3H), 1.25 (dd, 1H, J = 13.9, 0.8 Hz), 1.00–0.95 (m, 9H), 0.70–0.57 
(m, 6H); 13C NMR* (75 MHz, 293K, CDCl3) δ 97.3, 71.5, 69.2, 57.7, 52.1, 36.4, 29.7, 28.9, 6.9, 
5.2; HRMS (EI+) calcd. for C14H26BrO3Si [M – H2O]
+ 349.0835, found 349.0823. 
*The presence of anomers precluded a comprehensive assignment of all resonances. 
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Preparation of methyl glycoside 112 by PPTS catalyzed ketalization. To a stirred 
mixture of lactol 111 (1.14 g, 3.11 mmol) in anhydrous methanol (3 mL) and methylene chloride 
(9 mL), was added PPTS (75.9 mg, 0.302 mmol) in one portion under a nitrogen atmosphere at 
23 °C. After 12 h, the resulting reaction mixture was diluted with Et2O (5 mL) then H2O (5 mL) 
at 23 °C. The layers were separated, and the aqueous layer was extracted with diethyl ether (3 × 
25 mL). The combined organics were washed with brine (2 × 25 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography (2.5 → 10% EtOAc in hexanes) on silica gel (60 mL) to afford methyl 
glycoside 112 (894 mg, 75% yield) as a white crystalline solid.   
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Preparation of methyl glycoside 112 by NBS cyclization. To a light–protected stirred 
mixture of powdered 3Å MS (138 mg), recrystallized NBS (90.8 mg, 0.510 mmol), MeOH (0.15 
mL), and MeCN (1.0 mL) was added ketone 110 in MeCN (0.5 mL) dropwise at 0 °C under a 
nitrogen atmosphere. The resulting reaction mixture was slowly warmed to 23 °C over 1 h. After 
3.3 h at the same temperature, 2–methyl–2–butene was added (0.25 mL), saturated aqueous 
NaHCO3 (3 mL), and then Et2O (4 mL). The reaction mixture was filtered through a pad of 
Celite 545®, and rinsed with H2O (5 mL) and Et2O (10 mL). The layers were separated, and the 
aqueous layer was extracted with Et2O (3 × 20 mL). The combined organic layers were washed 
with brine (25 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
 143 
pressure. The resulting residue was purified by flash chromatography (1 → 10% EtOAc in 
hexanes) on silica gel (9 mL) to afford methyl glycoside 112 (65.3 mg, 47%) as a white 
crystalline solid. 
Data for 112: Rf = 0.35 (20% EtOAc in hexanes); m.p. = 44–46 °C; IR (neat): 2955, 
1186, 1152, 1086, 1069, 1042, 848, 743 cm–1; [α]D
22 +75.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 
293K, C6D6) δ 4.29 (app t d, 1H, J = 6.8, 1.3 Hz), 3.47 (dd, 1H, J = 9.9, 7.0 Hz), 3.36 (dd, 1H, J 
= 9.9, 6.6 Hz), 3.16 (br s, 1H), 3.13 (s, 3H), 2.33 (d, 1H, J = 4.7 Hz), 2.26 (d, 1H, J = 13.9 Hz), 
2.19 (d, 1H, J = 4.7 Hz), 1.21 (dd, 1H, J = 13.9, 0.9 Hz), 1.20 (s, 3H), 0.86 (t, 9H, J = 7.9 Hz), 
0.46–0.38 (m, 6H); 13C NMR (125 MHz, 293K, CDCl3) δ 99.2, 71.6, 70.7, 56.6, 51.0, 48.5, 37.0, 
30.9, 23.3, 6.8, 5.2; HRMS (EI+) calcd. for C12H22BrO4Si [M − C4H10]
+ 337.0471, found 
337.0480. 
See Appendix A for X-ray crystal. 
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Preparation of 125. To a stirred solution of methyl glycoside 112 (51 mg, 0.13 mmol) in 
MeCN (250 µL) was added 4-phenyl-tetrazolethiol (27 mg, 0.15 mmol) in one portion followed 
by Et3N (35 µL, 0.25 mmol) at 23 °C under a nitrogen atmosphere. After 30 min at the same 
temperature, the reaction mixture was warmed to reflux. After 3 h at reflux, the reaction mixture 
was cooled, filtered through a pad of Florisil (1 mL), rinsed with 20% EtOAc in hexanes, and 
concentrated. The resulting residue was purified by flash chromatography (2.5 → 15% EtOAc in 
hexanes) on silica gel (4 mL) to afford 125 (45 mg, 60%) as a colorless oil. 
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Data for 125: Rf = 0.13 (10% EtOAc in hexanes); IR (neat): 3446 (br, O-H), 2954, 1500, 
1412, 1383, 1237, 1100, 1016, 741 cm–1; [α]D
22 +57.4 (c 0.7, CHCl3); 
1H NMR (300 MHz, 
293K, CDCl3) δ 7.61−7.53 (m, 5H), 4.96 (br d, 1H, J = 1.2 Hz); 4.09 (ddd, 1H, J = 7.6, 5.6, 1.1 
Hz), 3.84 (dd, 1H, J = 12.5, 1.6 Hz), 3.67 (br s, 1H), 3.50 (br d, 1H, J = 12.5 Hz), 3.45 (dd, 1H, J 
= 10.1, 7.6 Hz), 3.38 (dd, 1H, J = 10.1, 5.6 Hz), 3.29 (s, 3H), 1.98 (d, 1H, J = 14.0 Hz), 1.91 (d, 
1H, J = 14.0 Hz), 1.36 (s, 3H), 1.00 (t, 9H, J = 7.9 Hz), 0.76−0.67 (m, 6H); 13C NMR (75 MHz, 
293K, CDCl3) δ 154.8, 133.9, 130.1, 129.8, 123.9, 100.6, 72.6, 72.3, 70.1, 48.3, 43.4, 37.7, 32.0, 
23.3, 7.0, 5.5; HRMS (ESI+) calcd. for C22H35BrO4SiSNa [M + Na]
+ 581.1229, found 581.1234. 
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Preparation of 123. To a stirred solution of methyl glycoside 112 (101 mg, 0.265 mmol) 
in THF (1 mL) was added TBAF (1M in THF, 300 µL) dropwise at 0 °C under a nitrogen 
atmosphere. After 20 min at the same temperature, the reaction mixture was diluted with Et2O (5 
mL), filtered through a plug of silica gel (3 mL), rinsed with Et2O, and concentrated under 
reduced pressure. The resulting residue was purified by flash chromatography (40 → 50% 
EtOAc in hexanes) on silica gel (5 mL) to afford 123 (53.6 mg, 76%) as a colorless oil. 
Data for 123: Rf = 0.27 (60% EtOAc in hexanes); IR (neat): 3432 (br, O-H), 2926, 1265, 
1026, 739 cm–1; [α]D
22 +97.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 4.24 (app td, 
1H, J = 7.2, 1.4 Hz), 3.50 (app d, 2H, 7.2 Hz), 3.34 (s, 3H), 3.22 (d, 1H, J = 7.9 Hz), 2.74 (br d, 
1H, J = 4.4 Hz), 2.63 (d, 1H, J = 4.4 Hz), 2.41 (d, 1H, J = 14.7 Hz), 1.93 (br d, 1H, 7.9 Hz), 1.44 
(s, 3H), 1.43 (dd, 1H, J = 14.7, 1.0 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 99.4, 70.7, 70.3, 
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56.3, 50.2, 48.6, 37.1, 30.2, 23.1; HRMS (ESI+) calcd. for C9H15BrO4Na [M + Na]
+ 289.0051, 
found 289.0087. 
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Preparation of 126. To a stirred solution of methyl glycoside 123 (4.0 mg, 0.02 mmol) 
in MeCN (50 µL) was added 4-phenyl-tetrazolethiol (2.9 mg, 0.02 mmol) in one portion 
followed by Et3N (5 µL, 0.04 mmol) at 0 °C under a nitrogen atmosphere. After 15 min at the 
same temperature, the reaction mixture was warmed to 23 °C. After an additional 2 h at the same 
temperature, the reaction mixture was warmed to 50 °C. After 3 h at reflux, the reaction mixture 
was cooled, filtered through a pad of silica gel (0.5 mL), rinsed with EtOAc (5 mL), and 
concentrated. The resulting residue was purified by flash chromatography (20 → 60% EtOAc in 
hexanes) on silica gel (0.5 mL) to afford 126 (4.8 mg, 72%) as a colorless oil. 
Data for 126: Rf = 0.27 (60% EtOAc in hexanes); IR (neat): 3442 (br, O-H), 2931, 1500, 
1385, 1236, 1016, 762 cm–1; [α]D
22 +12.9 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, C6D6) δ 
7.16−7.12 (m, 2H), 6.93−6.88 (m, 3H), 5.56 (br d, 1H, J = 5.6 Hz), 4.93 (br d, 1H, J = 1.5 Hz), 
4.17 (br dd, 1H, J = 8.0, 4.8 Hz), 3.81 (br d, 1H, J = 5.6 Hz), 3.71 (dd, 1H, J = 10.4, 8.0 Hz), 
3.65 (dd, 1H, J = 14.2, 1.5 Hz), 3.44 (dd, 1H, J = 10.4, 4.8 Hz), 2.93 (d, 1H, J = 14.2 Hz), 2.89 
(s, 3H), 1.95 (br d, 1H, J = 13.9 Hz), 1.34 (dd, 1H, J = 13.9, 1.3 Hz), 1.14 (s, 3H); 13C NMR (75 
MHz, 293K, C6D6) δ 156.5, 133.8, 129.9, 129.6, 124.0, 100.6, 72.2, 70.7, 68.0, 47.8, 43.2, 39.9, 
33.0, 23.3; HRMS (ESI+) calcd. for C16H21BrO4SNa [M + Na]
+ 467.0365, found 467.0345. 
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Preparation of 127. To a stirred solution of 123 (13 mg, 0.035 mmol) and 18-crown-6 
(9.3 mg, 0.13 mmol) in DMSO (225 µL) was added KO2 (19 mg, 0.070 mmol) in one portion at 
23 °C under a nitrogen atmosphere. After 30 min at the same temperature, the reaction mixture 
was diluted with brine (3 mL) and Et2O (5 mL), the layers were separated, and the aqueous 
residue was extracted with Et2O (2 × 10 mL). The combined organic layers were washed with 
brine (15 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  
The resulting residue was purified by flash chromatography (20 → 30% EtOAc in hexanes) on 
silica gel (1 mL) to afford 127 (4.1 mg, 64%) as a colorless oil. 
Data for 127: Rf = 0.24 (30% EtOAc in hexanes); IR (neat): 2947, 1379, 1232, 1190, 
1168, 1093, 1058, 965 cm–1; 1H NMR (300 MHz, 293K, CDCl3) δ 4.83 (dd, 1H, J = 7.1, 4.3 Hz), 
4.60 (ddd, 1H, J = 4.5, 4.3, 2.1 Hz), 4.44 (br d, 1H, J = 4.5 Hz), 4.32 (ddd, 1H, J = 7.1, 2.1, 1.0 
Hz), 3.32 (s, 3H), 2.81 (d, 1H, J = 4.5 Hz), 2.63 (d, 1H, J = 4.5 Hz), 2.55 (d, 1H, J = 14.6 Hz), 
1.61, dd, 1H, J = 14.6 Hz), 1.48 (s, 3H); 13C NMR (75 MHz, 293K, C6D6) δ 156.5, 133.8, 129.9, 
129.6, 124.0, 100.6, 72.2, 70.7, 68.0, 47.8, 43.2, 39.9, 33.0, 23.3; LRMS (ESI+) calcd. for 
C9H14O4Na [M + Na]
+ 209, 4%; C9H14O4Na [M + H]
+ 181, 5%. 
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Procedure for the Mitsunobu reaction of 123. To a stirred solution of 123 (9.8 mg, 
0.037 mmol) in THF (200 µL) was added p-O2NPhCO2H (13 mg, 0.078 mmol), DIAD (20 µL, 
0.10 mmol), and Ph3P (22 mg, 0.083 mmol) at 0 °C under a nitrogen atmosphere. After two h at 
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the same temperature, the reaction mixture was warmed to 23 °C. After 14 additional h at the 
same temperature, the reaction mixture was diluted with EtOAc (15 mL), washed with brine (5 
mL), dried over over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The 
resulting residue was purified by flash chromatography (10 → 30% EtOAc in hexanes) on silica 
gel (2 mL) to afford a mixture (53 mg) as a yellow solid. 
To a stirred solution of the yellow solid (44 mg) in MeOH (0.50 mL) was added K2CO3 
(46 mg, 0.33 mmol) at 23 °C under an open atmosphere. After 45 min at the same temperature, 
the reaction mixture was diluted with saturated aqueous NH4Cl (0.5 mL), and most of the solvent 
was removed under reduced pressure. The aqueous layer was extracted with EtOAc (10 mL), 
dried over over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The 
resulting residue was purified by flash chromatography (10 → 50% EtOAc in hexanes) on silica 
gel (3 mL) to afford 123 (1.4 mg, 17% for the two steps) as a colorless oil. 
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General procedure for the preparation of 128 and 5-epi-128. To a stirred solution of 
26 (42−88 mg, 0.15−0.32) in THF (0.50−0.80 mL) was added additives (1.9−2.5 equiv) followed 
by the addition of vinyl metal solution (2 equiv) down the flask side at −78 °C under a nitrogen 
atmosphere. After 15−60 min at the same temperature, the reaction was quenched with saturated 
aqueous NH4Cl (3−5 mL). The resulting mixture was then extracted with Et2O (3 × 5−10 mL). 
The combined organic layers were washed with pH 4 phosphate buffer (5 mL) then brine (10 
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mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The 
resulting residue was purified by flash chromatography (5 → 30% EtOAc in hexanes) on silica 
gel (2−5 mL) to afford 128 and 5-epi-128 as colorless oils. 
Data for 128 and 5-epi-128: Rf = 0.28 (30% EtOAc in hexanes); 
1H NMR* (300 MHz, 
293K, CDCl3) δ 5.98−5.84 (m), 5.44 (ddd, J = 12.2, 1.6, 1.6 Hz), 5.40−5.18 (m), 4.49 (br d, J = 
7.1 Hz), 4.37 (br dd, J = 9.2, 6.7 Hz), 4.14 (s), 3.84 (br d, J = 3.4 Hz), 3.82−3.75 (m), 3.71 (d, J = 
9.2 Hz), 3.47 (d, 18.0 Hz), 3.28 (s), 3.22 (br d, J = 17.1 Hz), 3.13 (dd, J = 4.1, 1.4 Hz), 3.05 (d, J 
= 4.8 Hz), 3.01 (d, J = 8.4 Hz), 2.98 (dd, J = 4.2, 1.2 Hz), 2.97−2.95 (m), 2.82 (d, J = 4.2 Hz), 
2.78 (dd, J = 4.6, 1.6 Hz), 2.75 (d, J = 4.6 Hz), 2.59 (d, J = 4.7 Hz), 2.54 (d, J = 18.0 Hz), 2.42 
(d, J = 17.3 Hz), 2.31 (d, J = 14.0 Hz), 2.23 (s), 2.18 (s), 1.64 (d, J = 14.0 Hz), 1.55 (s), 1.47 (s), 
0.99−0.92 (m), 0.72−0.58 (m). 
*The presence of anomers precluded a comprehensive assignment of all resonances. 
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Preparation of 129. To a stirred solution of diene 47 (7.0 mg, 0.020 mmol) and 128-
mixture (6.1 mg, 0.020 mmol) in THF (200 µL) was added Grubbs’ 2nd generation catalyst (1.7 
mg, 0.002 mmol) in one portion at 23 °C under a nitrogen atmosphere. After 5 min at the same 
temperature, the reaction vessel was then placed in a pre-heated oil bath (40 °C). After 2.5 h at 
the same temperature, additional Grubbs’ 2nd generation catalyst (1.7 mg, 0.002 mmol) in THF 
(100 µL) was added. After an additional 1.5 at the same temperature, the reaction mixture was 
cooled, filtered through silica gel (1 mL), and eluted with 60% EtOAc in hexanes (20 mL). To 
the eluent was added activated charcoal (200 mg), and the mixture was stirred. After 14 h of 
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stirring, the mixture was filtered though a pad of Celite 545® (5 mL), rinsed with Et2O (25 mL), 
and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (5 → 50% EtOAc in hexanes) on silica gel (1.8 mL) to afford 129 (2.8 mg, 
22%) as a colorless oil. 
Data for 129: Rf = 0.28 (50% EtOAc in hexanes); 
1H NMR − 129 anti-hemiketal† (300 
MHz, 293K, CDCl3) δ 6.35 (br d, J = 15.1 Hz), 6.30−6.24 (m), 6.00 (br d, J = 9.8 Hz), 5.90 (dd, 
J = 11.5, 7.8 Hz), 5.71 (br d, J = 10.7 Hz), 5.61 (br dd, J = 15.3, 6.3 Hz), 5.50−5.45 (m), 4.42 (br 
app t, J = 8.6 Hz), 3.99−3.92 (m), 3.74 (d, J = 9.3 Hz), 3.70−3.65 (m), 3.54−3.48 (m), 3.04 (d, J 
= 4.7 Hz), 2.59 (d, J = 4.7 Hz), 2.44−2.40 (m), 2.39−2.35 (m), 2.32 (d, J = 13.9 Hz), 2.05 (s), 
1.98−1.93 (m), 1.77 (br s), 1.76−1.74 (m), 1.63 (d, J = 14.0 Hz), 1.47 (s), 1.40 (d, J = 6.5 Hz), 
1.16 (d, J = 6.0 Hz), 1.01 (d, J = 7.3 Hz), 0.98−0.90 (m), 0.72−0.56 (m). 
†The complex spectra of the small quantity inseparable mixture of compounds prohibited 
further characterization. 
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Preparation of FR901464 from 129. To a stirred solution of 129 (0.3 mg, 0.5 µmol) in 
THF (50 µL) was added HF•pyridine (neat, 2 drops) at 0 °C under an open atmosphere. After 45 
min at the same temperature, the reaction mixture was diluted with Et2O (20 mL).  The mixture 
was washed with H2O (10 × 1 mL) and saturated aqueous CuSO4 (1 mL), dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. TLC and HPLC
* analysis of the 
resulting crude residue and an authentic sample of FR901464, including a coinjection of the 
authentic and synthetic materials, strongly suggested that FR901464 was produced. 
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* HPLC analysis was performed on a Varian Microsorb 100 C18 column, 250 × 4.6 
mm, 1.0 mL/min, 5% MeCN/H2O→100% MeCN linear gradient elution from 0 to 31.67 
min, retention time = 17.4 min. 
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Preparation of 130. To a stirred solution of imidazole (421 mg, 6.19 mmol) in DMF (3 
mL) was added tbutyldimethylsilyl chloride (809 mg, 5.37 mmol) then 80 (636 mg, 4.12 mmol) 
in DMF (1 mL), and then the container that initially contained 80 was rinsed with DMF (2 × 0.5 
mL) and added to the reaction mixture at 23 °C under a nitrogen atmosphere.  After 4 h at the 
same temperature, the reaction mixture was diluted with H2O (100 mL), and extracted with Et2O 
(3 × 30 mL).  The combined organic extracts were dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure.  The crude residue was purified by flash chromatography 
(5 → 20% EtOAc in hexanes) on silica gel (8 mL) to afford the 130 (968 mg, 88%) as a colorless 
oil. 
Data for 130: Rf = 0.63 (20% EtOAc in hexanes); IR (neat): 2930, 1254, 837, 778 cm
–1; 
[α]D
22 −2.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.85 (ddd, 1H, J = 17.2, 10.4, 
5.7 Hz), 5.29 (ddd, 1H, J = 17.2, 1.6, 1.6 Hz), 5.18 (ddd, 1H, J = 10.4, 1.3, 1.3 Hz), 4.83 (br s, 
1H), 4.72 (br s, 1H), 3.99 (br d, 1H, J = 5.7 Hz), 2.76 (d, 1H, J = 5.0 Hz), 2.55 (d, 1H, J = 14.5 
Hz), 2.29 (d, 1H, J = 14.5 Hz), 1.73 (br s, 3H), 0.93 (s, 9H), 0.10 (s, 3H), 0.05 (s, 3H); 13C NMR 
(75 MHz, 293K, C6D6) δ 141.6, 137.9, 115.6, 114.3, 78.1, 60.5, 48.6, 36.6, 26.0, 23.8, −4.5, 
−4.7; HRMS (EI+) calcd. for C15H28O2SiNa [M + Na]
+ 291.1756, found 291.1754. 
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Preparation of 131. To a stirred solution of 130 (800 mg, 3.0 mmol) in THF (14 mL) 
and H2O (1.4 mL) was added OsO4 (7.5 mg, 0.03 mmol) then NMO•H2O (410 mg, 3.0 mmol) at 
23 °C under an open atmosphere.  The resulting solution was stirred at 16 h at the same 
temperature, then saturated aqueous Na2SO3 (15 mL) was added, and the mixture was vigorously 
stirred for 30 min.  The layers were then separated, and the aqueous layer was extracted with 
EtOAc (3 × 20 mL).  The combined organic layers washed with saturated aqueous Na2SO3 (20 
mL) and brine (30 mL), were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure.  The crude residue was purified by flash chromatography (10 → 40% EtOAc 
in hexanes) on silica (35 mL) to afford the 131 (480 mg, 53%, 62% based on recovered 130) as a 
colorless oil.  The diastereomeric mixture was used directly without further purification. 
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Preparation of 132. To a stirred solution of 131 (377 mg, 1.25 mmol) in THF (3 mL) 
and H2O (3 mL) was added NaIO4 (279 mg, 1.30 mmol) at 23 °C under an open atmosphere.  
After 1.5 h at the same temperature, the resulting mixture was diluted with Et2O (7 mL) and H2O 
(2 mL).  The layers were separated, and the aqueous layer was extracted with Et2O (3 × 15 mL).  
The combined organic layers were washed with H2O (10 mL) and brine (10 mL), dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure.  The crude residue was 
purified by flash chromatography (5 → 15% EtOAc in hexanes) on silica (15 mL) to afford the 
132 (286 mg, 85%) as a colorless oil. 
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Data for 132: Rf = 0.50 (30% Et2O in hexanes); IR (neat): 2956, 1717 (C=O), 1254, 1033, 
838, 778 cm–1; [α]D
22 −2.3 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.72 (ddd, 1H, J 
= 17.1, 10.4, 4.8 Hz), 5.30 (ddd, 1H, 17.1, 1.6, 1.6 Hz), 5.04 (ddd, 1H, J = 10.4, 1.6, 1.6 Hz), 
3.79 (br d, 1H, J = 4.8 Hz), 2.66 (br d, 1H, J =15.0 Hz), 2.63 (d, 1H, J = 4.6 Hz), 2.54 (br d, 1H, 
J = 15.0 Hz), 2.48 (br d, 1H, J = 4.6 Hz), 1.88 (br s, 3H), 1.05 (s, 9H), 0.21 (s, 3H), 0.12 (s, 3H); 
13C NMR (75 MHz, 293K, C6D6) δ 203.7, 137.4, 115.8, 78.0, 58.7, 49.6, 42.6, 30.9, 26.0, 18.5, 
−4.6, −4.9; HRMS (EI+) calcd. for C14H26O3SiNa [M + Na]
+ 293.1549, found 293.1532. 
 
OO
OTBS
H
O
133
O
OTBS
132
O
O3; Me2S
89%
 
Preparation of ketoaldehyde 133. To a solution of enone 132 (131 mg, 0.484 mmol) in 
MeOH (1.25 mL) and CH2Cl2 (1.25 mL) was bubbled O3 until a blue color persisted at −78 °C, 
then O2 was bubbled through the reaction mixture to remove the blue color.  At the same 
temperature was added Me2S (350 µL, 4.77 mmol), then allowed to slowly warm to 23 °C over 
2.5 h, then most of the solvent was removed under reduced pressure.  The reaction mixture was 
diluted with Et2O (20 mL), then washed with H2O (5 mL) and brine (10 mL), dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure.  The crude residue was 
purified by flash chromatography (5 → 30% EtOAc in hexanes) on silica gel (5 mL) to afford 
the 133 (118 mg, 89%) as a colorless oil. 
Data for 133:† Rf = 0.24−0.34 (30% EtOAc in hexanes); 
1H NMR (300 MHz, 293K, 
CDCl3) δ 9.53 (br s, 1H), 3.80 (br s, 1H), 3.37 (dd, 1H, J = 14.9, 0.9 Hz), 3.12 (br d, 1H, J = 4.1 
Hz), 2.75 (d, 1H, J = 4.1 Hz), 2.42 (d, 1H, J = 14.9 Hz), 2.18 (s, 3H), 0.95 (s, 9H), 0.14 (s, 3H), 
0.11 (s, 3H).   
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† No further characterization was performed due to the instability of this compound. 
 
H
O
O
32
HO
O
142
OHC OTES
OTES
H
O
141
+4 4
L-proline
<5%
 
Preparation of 142. To a stirred solution of 32 (34 mg, 0.27 mmol) and L-proline (6.5 
mg, 0.056 mmol) in DMSO (0.40 mL) was added 141 (77 mg, 0.44 mmol) in DMSO (0.20 mL) 
at 23 °C under a nitrogen atmosphere. After 30 h at the same temperature, the reaction mixture 
was diluted with H2O (25 mL), and the aqueous residue was extracted with Et2O (3 × 25 mL). 
The combined organic layers were washed with brine (25 mL), dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure.  The crude residue was purified by flash 
chromatography (5 → 30% EtOAc in hexanes) on silica gel (6 mL) to afford the 142 (4.3 mg, 
5%) as a colorless oil. 
Data for 133: Rf = 0.18 (30% EtOAc in hexanes); 
1H NMR‡ (300 MHz, 293K, CDCl3) δ 
9.64 (d, 1H, J = 1.1 Hz), 4.02 (d, 1H, J = 4.3 Hz), 2.95 (br d, 1H, J = 4.9 Hz), 2.72 (d, 1H, J = 
4.9 Hz), 2.53 (d, 1H, J = 14.5 Hz), 2.22 (d, 1H, J = 14.5 Hz), 1.79 (br s, 3H), 1.04−0.91 (m, 9H), 
0.75−0.57 (m, 6H).   
‡ Data given for the major diastereomer. 
 
O
TMS
MeO
H
O
O
32 143
+
HO
O
O
OMe
TMS
4
4
144  
Preparation of 144 using Ti(O
i
Pr)4. To a stirred solution of 143 (680 mg, 3.4 mmol) in 
THF (8 mL) was added tBuLi (1.7 M in pentane, 2.0 mL, 3.4 mmol) then Ti(OiPr)4 (1.0 mL, 3.4 
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mmol) at −78 °C under a nitrogen atmosphere. After 35 min at the same temperature, 32 (290 
mg, 2.3 mmol) was added in THF (1.0 mL) dropwise, and then the vessel that originally 
contained 32 was rinsed with THF (2 × 0.5 mL) and added to the reaction mixture at −78 °C. 
After 1 h at the same temperature, the reaction mixture was quenched by the addition of 
saturated aqueous NH4Cl (5 mL), most of the solvent was removed under reduced pressure, and 
the aqueous residue was extracted with Et2O (3 × 10 mL). The combined organic layers were 
washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure.  The crude residue was purified by flash chromatography (5 → 30% EtOAc in 
hexanes) on silica gel (35 mL) to afford the 144 (463 mg, 66%) as a colorless oil. 
Data for 133: Rf = 0.46 (40% EtOAc in hexanes); 
1H NMR* (300 MHz, 293K, CDCl3) δ 
4.90 (br s, 1H), 4.87 (br s, 1H), 4.62, (d, 1H, J = 3.7 Hz), 3.78 (dd, 1H, J = 8.5, 3.7 Hz), 3.25 (s, 
3H), 2.98 (br d, 1H, J = 4.9 Hz), 2.68 (br d, 1H, J = 14.7 Hz), 2.60 (d, 1H, 4.9 Hz), 2.40 (br d, 
1H, J = 14.7 Hz), 1.80 (br s, 3H), 1.47 (s, 3H), 1.40 (s, 3H), 0.18 (s, 9H).   
* Data given for the major, unassigned diastereomer. Diastereomeric ratios were 
determined by comparison of the –OMe and –TMS groups. 
 
O
OTES
MeO2C
94
DIBALH
95% O
OTES
HO
145  
Preparation of 145. To a stirred solution of enoate 94 (968 mg, 2.96 mmol) in THF (10 
mL) was added DIBALH (1 M in hexanes, 8.9 mL) slowly down the flask side at −78 °C under a 
nitrogen atmosphere.  After an additional 1 h at the same temperature, saturated aqueous NH4Cl 
(5 mL) was added at −78 °C, and the reaction mixture was allowed to warm to 23 °C.  After an 
additional 1.5 h at the same temperature, the reaction mixture was diluted with Et2O (15 mL), 
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dried over anhydrous Na2SO4, filtered through a pad of Celite 545
®, rinsed with Et2O (3 × 25 
mL), and concentrated under reduced pressure.  The resulting residue was purified by flash 
chromatography (5 → 20% EtOAc in hexanes) on silica gel (40 mL) to afford 145 (838 mg, 
95%) as a colorless oil. 
Data for 145: Rf = 0.23 (20% EtOAc in hexanes); IR (neat): 3421 (br, O-H), 2955, 1458, 
1124, 1096, 1005, 972, 743; [α]D
22 -13.4 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 
5.89 (dddd, 1H, J = 15.5, 5.2, 5.2, 1.1 Hz), 5.74 (dddd, 1H J = 15.5, 5.9, 1.3, 1.3 Hz), 4.84−4.83 
(m, 1H), 4.74−4.73 (m, 1H), 4.19 (br app t, 2H, J = 5.0 Hz), 4.07 (dd, 1H, J = 5.9, 1.1 Hz), 2.80 
(br d, 1H, J = 5.0 Hz), 2.67 (br d, 1H, J = 5.0 Hz), 2.55 (br d, 1H, J = 14.5 Hz), 2.27 (br d, 1H, J 
= 14.5 Hz), 1.75 (br s, 3H), 0.96 (t, 9H, J = 7.9Hz), 0.62 (q, 6H, J = 7.9 Hz); 13C NMR (75 MHz, 
293K, C6D6) δ 141.7, 131.6, 129.8, 114.3, 76.5, 62.6, 60.9, 48.8, 37.3, 23.8, 7.1, 5.3; HRMS 
(ESI+) calcd. for C16H30O3SiNa [M + Na]
+ 321.1862, found 321.1850. 
 
O
OTES
HO
145
O
OTES
Se
NO2
146
ArSeCN
n-Bu3P
quant.
 
Preparation of 146. To a stirred solution of 2-nitrophenyl selenocyanate (1.10 g, 4.82 
mmol) in THF (7 mL) was added 145 (1.20 g, 4.02 mmol) in THF (4 mL), and then the container 
that initially contained 27 was rinsed with THF (2 × 1 mL) and added to the reaction mixture 
followed by the dropwise addition of freshly distilled nBu3P (1.4 mL, 5.6 mmol) at 0 °C under a 
nitrogen atmosphere.  After 30 min at the same temperature, the reaction mixture was poured 
onto saturated aqueous NaHCO3 (125 mL).  The layers were separated, and the aqueous residue 
was extracted with Et2O (3 × 65 mL).  The combined organic layers were washed with brine (75 
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mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The 
resulting residue was purified by flash chromatography (1 → 5% EtOAc in hexanes) on silica gel 
(100 mL) to afford 146 (2.06 g, quantitative yield) as a pale yellow oil. 
Data for 146: Rf = 0.20 (10% EtOAc in hexanes); IR (neat): 2954, 1516, 1332, 1304, 
1100, 970, 730; [α]D
22 -24.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 8.29 (dd, 1H, 
J = 7.9, 1.2 Hz), 7.56−7.50 (m, 2H), 7.33 (ddd, 1H, J = 8.4, 5.3, 3.2 Hz), 5.92−5.74 (m, 2H), 4.82 
(br s, 1H), 4.67 (br s, 1H), 4.05 (br d, 1H, J = 5.8 Hz), 3.69−3.59 (m, 2H), 2.79 (br d, 1H, J = 5.1 
Hz), 2.63 (d, 1H, J = 5.1 Hz), 2.43 (d, 1H, J = 14.5 Hz), 2.16 (d, 1H, J = 14.5 Hz), 1.70 (br s, 
3H), 0.92 (t, 9H, J = 7.9 Hz), 0.57 (q, 6H, J = 7.9 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 
146.9, 141.0, 133.9, 133.5, 133.2, 129.3, 126.3, 126.1, 125.5, 114.1, 74.3, 60.6, 49.1, 38.1, 27.7, 
23.4, 6.7, 4.8; HRMS (ESI+) calcd. for C22H33NO4SeSiNa [M + Na]
+ 506.1242, found 506.1229. 
 
O
OTES
HO
145
O
OTES
Se
147
PhSeCN
n-Bu3P
quant.
 
Preparation of 147. To a stirred solution of phenyl selenocyanate (175 µL, 1.43 mmol) 
and 145 (2.99 mg, 1.00 mmol) in THF (3.5 mL) was added freshly distilled nBu3P (1.4 mL, 5.6 
mmol) dropwise at 0 °C under a nitrogen atmosphere. After 20 min at the same temperature, the 
reaction mixture was poured onto saturated aqueous NaHCO3 (35 mL). The layers were 
separated, and the aqueous residue was extracted with Et2O (3 × 10 mL). The combined organic 
layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography (1 → 4% 
EtOAc in hexanes) on silica gel (25 mL) to afford 147 (493 mg, quantitative yield) as a pale 
yellow oil.  
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Data for 147.* Rf = 0.20 (10% EtOAc in hexanes); 
1H NMR (300 MHz, 293K, CDCl3) δ 
7.51−7.46 (m, 2H), 7.32−7.23 (m, 3H), 5.82 (dddd, 1H, J = 15.2, 7.4, 7.3, 1.1 Hz), 5.49 (dddd, 
1H, J = 15.2, 6.6, 1.1, 1.1 Hz), 4.80 (br s, 1H), 4.66 (br s, 1H), 3.96 (br d, 1H, J = 6.6Hz), 2.70 
(d, 1H, J = 5.1 Hz), 2.57 (d, 1H, J = 5.1 Hz), 2.34 (d, 1H, J = 14.5 Hz), 2.13 (d, 1H, J = 14.5 Hz), 
1.69 (br s, 3H), 0.93 (t, 9H, J = 7.9 Hz), 0.57 (q, 6H, J = 7.9 Hz). 
* This compound was not further characterized due to its rapid oxidation. 
 
O
OTES
ArSe
146 or 147
O
OTES
OH
5
148
O
OTES
OH
5
5-epi-148
+
 
General procedure for the preparation of 148 and 5-epi-148. To a stirred solution of 
146 or 147 (0.05−4.0 mmol) in solvent (0.25−20 mL) was added base (5−20 mmol) followed by 
the dropwise addition of aqueous H2O2 (30% v/v, 2.5−40 mmol) at −44 °C under an open 
atmosphere. After 15 min at the same temperature, the reaction was warmed to the temperature 
indicated in Table 3. After an additional 12 h at the same temperature, the reaction mixture was 
diluted with Et2O (10−40 mL) and hexanes (0−10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (2 → 8% EtOAc in hexanes) on silica gel to afford 148 and 5-epi-148 as 
colorless oils. 
Data for 148: Rf = 0.24 (10% EtOAc in hexanes); IR (neat): 3471 (br, O-H), 2955, 1648, 
1459, 1239, 1112, 1007, 917, 895, 743; [α]D
25 +6.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, 
C6D6) δ 5.89 (ddd, 1H, J = 17.2, 10.5, 5.6 Hz), 5.27 (ddd, 1H, J = 17.2, 1.6, 1.6 Hz), 5.04 (ddd, 
1H, J = 10.5, 1.6, 1.6 Hz), 4.86−4.83 (m, 1H), 4.81−4.78 (m, 1H), 4.04 (ddddd, 1H, J = 7.1, 5.6, 
3.6, 1.6, 1.6 Hz), 3.22 (d, 1H, J = 7.1 Hz), 2.70 (d, 1H, J = 14.2 Hz), 2.64 (d, 1H, J = 4.9 Hz), 
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2.62 (d, 1H, J = 14.2 Hz), 2.47 (d, 1H, J = 4.9 Hz), 1.79 (br s, 3H), 1.58 (d, 1H, J = 3.6 Hz), 1.02 
(t, 9H, J = 7.9 Hz), 0.75−0.65 (m, 6H); 13C NMR (75 MHz, 293K, C6D6) δ 141.8, 138.6, 115.7, 
114.6, 80.8, 74.5, 59.3, 50.2, 36.7, 24.2, 7.1, 5.3; HRMS (EI+) calcd. for C13H25O2Si [M − 
C3H5O]
+ 241.1624, found 241.1624. 
Data for epi-148: Rf = 0.31 (10% EtOAc in hexanes); IR (neat): 3502 (br, O-H), 2955, 
1649, 1458, 1240, 1092, 1053, 1006, 927, 744; [α]D
25 −7.5 (c 1.0, CHCl3); 
1H NMR (300 MHz, 
293K, C6D6) δ 5.69 (ddd, 1H, J = 17.1, 10.5, 5.6 Hz), 5.37 (ddd, 1H, J = 17.1, 1.6, 1.6 Hz), 5.02 
(ddd, 1H, J = 10.5, 1.9, 1.5 Hz), 4.83−4.80 (m, 1H), 4.69−4.67 (m, 1H), 4.12−4.06 (m, 1H), 3.18 
(d, 1H, J = 6.4 Hz), 2.62 (d, 1H, J = 14.4 Hz), 2.51 (d, 1H, J = 14.4 Hz), 2.50 (d, 1H. J = 4.7 Hz), 
2.44 (d, 1H. J = 4.2 Hz). 2.24 (d, 1H, J = 4.7 Hz), 1.73 (br s, 3H), 1.01 (t, 9H, J = 7.9 Hz), 
0.75−0.65 (m, 6H); 13C NMR (75 MHz, 293K, C6D6) δ 141.2, 137.9, 116.1, 115.0, 81.8, 73.9, 
59.3, 49.5, 36.2, 24.2, 7.1, 5.3; HRMS (ESI+) calcd. for C13H25O2SiNa [M + Na]
+  321.1862, 
found 321.1838. 
 
OO
OTES
OH
5
O
O
OH
TESO
5
128
O
OTES
OH
5
148
OsO4, NaIO4
27%
 
Preparation of enone 128 from 148. To a stirred solution of 148 (5.6 mg, 0.019 mmol) 
and 2,6-lutidine (3.5 µL, 0.030 mmol) in dioxane (150 µL) and H2O (50 µL) was added OsO4 
(2.5 wt% in tBuOH, 5.0 µL, 4.0 µmol) and NaIO4 (10.1 mg, 0.047 mmol) in one portion at 0 °C 
under an open atmosphere. After an additional 0.7 h at the same temperature, the reaction was 
warmed to 23 °C. After an additional 8.3 h at the same temperature, the reaction mixture was 
diluted with Et2O (5 mL) and H2O (5 mL). The layers were separated, and the aqueous residue 
was extracted with Et2O (3 × 5 mL). The combined organic layers were washed with H2O (5 mL) 
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and brine (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (5 → 30% EtOAc in 
hexanes) on silica gel (0.8 mL) to afford 128 (1.5 mg, 27%, 36% based on recovered 148) as a 
pale yellow oil. 
Data for 128: Rf = 0.28 (30% EtOAc in hexanes); 
1H NMR* (300 MHz, 293K, CDCl3) δ 
5.98−5.84 (m), 5.44 (ddd, J = 12.2, 1.6, 1.6 Hz), 5.37 (ddd, J = 17.3, 1.8, 1.8 Hz), 5.28 (br d, J = 
11.1 Hz), 5.21 (ddd, J = 10.5, 1.6, 1.6 Hz), 4.37 (br dd, J = 9.2, 6.7 Hz), 4.14 (s), 3.84 (br d, J = 
3.4 Hz), 3.82−3.75 (m), 3.71 (d, J = 9.2 Hz), 3.47 (d, 18.0 Hz), 3.05 (d, J = 4.8 Hz), 3.01 (d, J = 
8.4 Hz), 2.98 (dd, J = 4.2, 1.2 Hz), 2.82 (d, J = 4.2 Hz), 2.59 (d, J = 4.7 Hz), 2.54 (d, J = 18.0 
Hz), 2.31 (d, J = 14.0 Hz), 2.23 (s), 1.64 (d, J = 14.0 Hz), 1.47 (s), 0.99−0.92 (m), 0.72−0.58 
(m); HRMS (ESI+) calcd. for C15H28O4Si [M + Na]
+ 323.1655, found 323.1664. 
* The presence of anomers precluded a comprehensive assignment of all magnetic 
resonances. 
 
O
OTES
TESO
149
O
OTES
OH
148
TESCl
imid.
95%
 
Preparation of 149. To a stirred solution of imidazole (218 mg, 3.20 mmol) in THF (3 
mL) was added chlorotriethylsilane (470 µL, 2.80 mmol), followed by the dropwise addition of 
alcohol 148 (596 mg, 2.00 mmol) in THF (1 mL), and then the container that initially contained 
148 was rinsed with THF (2 × 0.5 mL) and added to the reaction mixture, at 0 °C under a 
nitrogen atmosphere.  After an additional 1.5 h at the same temperature, H2O (14 mL) was 
added, and most of the THF was removed under reduced pressure.  The aqueous residue was 
extracted with Et2O (2 × 20 mL).  The combined organic layers were washed with brine (20 mL), 
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dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The resulting 
residue was purified by flash chromatography (1.5 → 3% EtOAc in hexanes) on silica gel (40 
mL) to afford 149 (786 mg, 95%) as a colorless oil. 
Data for 149: Rf = 0.65 (5% EtOAc in hexanes); IR (neat): 2955, 1648, 1458, 1239, 1100, 
1006, 788, 744; [α]D
22 -10.0 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 5.80 (ddd, 1H, 
J = 17.3, 10.2, 7.2 Hz), 5.23 (br ddd, 1H, J = 17.3, 1.0, 1.0 Hz), 5.16 (br dd, J = 10.2, 1.0 Hz), 
4.85−4.83 (m, 1H), 4.69 (br s, 1H), 4.09 (br dd, 1H, J = 7.2, 7.2 Hz), 3.21 (d, 1H, J = 7.2 Hz), 
2.72 (d, 1H, J = 5.0 Hz), 2.69 (d, 1H, J = 5.0 Hz), 2.58 (app s, 2H), 1.75 (br s, 3H), 0.96 (t, 9H, J 
= 7.8 Hz), 0.95 (t, 9H, J = 7.9 Hz), 0.67−0.55 (m, 12H); 13C NMR (75 MHz, 293K, CDCl3) δ 
141.3, 139.4, 116.9, 114.3, 80.6, 76.2, 59.4, 49.9, 35.6, 24.1, 6.9, 6.8, 5.2, 5.0; HRMS (EI+) 
calcd. for C22H44O3Si2 [M]
+  412.2829, found 412.2841. 
 
O
OTES
TESO OO
OTES
TESO
150149
OsO4;
Pb(OAc)4
71%
 
Preparation of 150. To a stirred solution of 149 (412 mg, 0.998 mmol) in THF/H2O 
(10:1, 4.4 mL) was added NMO•H2O (129 mg, 0.954 mmol) in one portion, followed by the 
addition of OsO4 (2.5 mg, 9.8 µmol) at 0 °C under an open atmosphere. After 5 min at the same 
temperature, the reaction was warmed to 23 °C.  After an additional 18 h at the same 
temperature, the reaction mixture was diluted with Et2O (2 mL), saturated aqueous Na2SO3 (10 
mL), and saturated aqueous NaHCO3 (1 mL).  After 30 min of vigorous stirring, the mixture was 
extracted with Et2O (3 × 15 mL).  The combined organic layers were washed with saturated 
aqueous Na2SO3 (10 mL), then aqueous HCl (0.1 N, 12 mL), dried over anhydrous Na2SO4, 
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filtered, and concentrated under reduced pressure. The resulting crude material (477 mg) was 
taken to the next step without further purification: Rf = 0.24 (20% EtOAc in hexanes). 
To a solution of the crude tan oil (471 mg) in benzene (5 mL) was added Pb(OAc)4 (534 
mg, 1.20 mmol) in one portion at 0 °C under an open atmosphere.  After 3 min at the same 
temperature, the reaction was warmed to 23 °C.  After an additional 17 min at the same 
temperature, the reaction mixture was diluted with Et2O (5 mL), filtered through a pad of Celite 
545®, rinsed with Et2O (4 × 10 mL), and concentrated under reduced pressure.  The resulting 
residue was purified by flash chromatography (1.25 → 5% EtOAc in hexanes) on silica gel (25 
mL) to return diene 149 (74 mg) and afford 150 (293 mg, 71%; 86% BORSM) as a colorless oil.  
Data for 150: Rf = 0.23 (5% EtOAc in hexanes); IR (neat): 2913, 1717 (C=O), 1415, 
1239, 1100, 1006, 742; [α]D
22 -19.2 (c 1.0, CHCl3); 
1H NMR (300 MHz, 293K, C6D6) δ 5.81 
(ddd, 1H, J = 17.4, 10.3, 7.3 Hz), 5.14 (ddd, 1H, J = 17.2, 1.7, 1.0 Hz), 4.98 (ddd, 1H, J = 10.3, 
1.8, 0.8 Hz), 4.06 (br dd, 1H, J = 7.2, 6.5 Hz), 3.20 (d, 1H, J = 6.5 Hz), 2.93 (d, 1H, J = 14.2 
Hz), 2.83 (d, 1H, J = 4.5 Hz), 2.77 (d, 1H, J = 14.2 Hz), 2.66 (d, 1H, J = 4.5 Hz), 1.93 (s, 3H), 
1.06 (t, 9H, J = 7.9 Hz), 0.99 (t, 9H, J = 8.0 Hz), 0.78−0.70 (m, 6H), 0.66−0.58 (m, 6H); 13C 
NMR (75 MHz, 293K, C6D6) δ 204.1, 139.5, 117.0, 81.5, 76.9, 57.6, 51.0, 42.5, 31.5, 7.2, 7.1, 
5.4, 5.4; HRMS (ESI+) calcd. for C21H42O4Si2Na [M + Na]
+  437.2519, found 437.2533. 
 
O
O
OH
HO
50
OO
OTES
TESO
150
AcOH/THF/H2O
(3:3:1 v/v/v)
91%
 
Preparation of 50. To a flask containing 150 (104 mg, 0.251 mmol) was added 
AcOH/THF/H2O (3:3:1 v/v/v, 2.8 mL) at 0 °C under an open atmosphere.  After 10 min at the 
same temperature, the reaction was warmed to 23 °C.  After an additional 30 h at the same 
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temperature the reaction was diluted with toluene (5 mL), and then concentrated under reduced 
pressure.  The resulting residue was purified by flash chromatography (20 → 50% EtOAc in 
hexanes) on silica gel (6 mL) to afford 50 (42.5 mg, 91%) as a colorless oil. 
Data for 50: Rf = 0.15 (60% EtOAc in hexanes); IR (neat): 3384, 2923, 1701 (C=O, 
weak), 1647, 1412, 1212, 1182, 1085, 1021, 907, 819, 730; [α]D
22 +54.4 (c 0.5, CH2Cl2); 
1H 
NMR (300 MHz, 293K, CD2Cl2) δ 5.97 (ddd, 1H, J = 17.3, 10.5, 6.1 Hz), 5.38 (ddd, 1H, J = 
17.3, 1.8, 1.4 Hz), 5.25 (ddd, 1H, J = 10.5, 1.8, 1.4 Hz), 4.19 (dddd, 1H, J = 9.8, 6.1, 1.4, 1.2 
Hz), 3.54 (app t, 1H, J = 10.1 Hz), 3.31 (br s, 1H), 3.06 (d, 1H, J = 4.4 Hz), 2.55 (d, 1H, J = 4.4 
Hz), 2.33 (d, 1H, J = 14.4 Hz), 1.64 (d, 1H, J = 14.4 Hz), 1.43 (s, 3H); 13C NMR (75 MHz, 
293K, CD2Cl2) δ 136.4, 117.6, 96.7, 73.7, 67.9, 58.1, 48.0, 41.9, 29.1; HRMS (EI+) calcd. for 
C9H12O3 [M − H2O]
+  168.0786, found 168.0790. 
 
O
O
OH
HO
O
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H
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O
O
OH
HO
O
N
H
AcO
O +
50
(1.6−1.8 equiv)
47 FR901464
 
Preparation of FR901464 using the Grela catalyst. A solution of 50 (33.6 mg, 0.180 
mmol) was prepared in ClCH2CH2Cl (200 µL) at 23 °C under an open atmosphere.  To a stirred 
solution of 47 (35.1 mg, 0.100 mmol) in ClCH2CH2Cl (100 µL) was added the solution of 50 (50 
µL), followed by Grela catalyst (1.7 mg, 2.5 µmol) at 23 °C under an open atmosphere.  After 
1.5 h at the same temperature, additional Grela catalyst (1.7 mg, 2.5 µmol) and 50 (50 µL) were 
added.  This addition process was repeated after 3.5 and 6.0 h after the reaction was initiated.  
After 10 total hours, the reaction was concentrated under reduced pressure.  The resulting residue 
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was purified by flash chromatography (10 → 90% EtOAc in hexanes) on silica gel (8 mL) to 
give 47 (24.2 mg, 69%), 50 (11.7 mg, 35%), and FR901464 (14.4 mg, 28%) as pale tan oils. 
To a stirred solution of recovered 47 (24.2 mg, 0.0690 mmol) and recovered 50 (11.7 mg, 
0.0628 mmol) in ClCH2CH2Cl (200 µL) was added Grela catalyst (4.3 mg, 6.3 µmol) at 23 °C 
under an open atmosphere.  After an additional 11 h at the same temperature, the reaction was 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 90% EtOAc in hexanes) on silica gel (5 mL) to give 47 (7.8 mg, 32%) 
and FR901464 (5.7 mg, 18%) as pale tan oils.  The combined yield of FR901464 after one cycle 
is 20.1 mg (40%). 
Data for FR901464 were consistent with the literature (Nakajima, H.; Takase, S.; Terano, 
H.; Tanaka, H. J. Antibiot. 1997, 50, 96 and Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. J. 
Am. Chem. Soc. 2001, 123, 9974). See Appendix 2 for comparison of spectral data. 
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General procedure for the half-life determination for the decomposition of 50. To a 
vial was added 50 (0.8−0.9 mg, 4−5 µmol) under an open atmosphere at 23 °C. The reaction 
mixture was then sealed and warmed to 37 °C. The decomposition was then estimated by TLC 
analysis (80% EtOAc/hexanes) after 2, 5, 9, and 25 h.  
1
H NMR and HPLC studies of the decomposition of 50. Deuterated pH 7.4 buffer was 
prepared by evaporating 4 mL of 50 mM pH 7.4 phosphate buffer, dissolving the remaining salts 
in 0.5 mL of D2O and subsequent evaporation of most of the solvent, and finally diluting the 
resulting mixture to 4 mL with D2O. To an NMR tube was added 50 (8.1 mg, 0.044 mmol) in the 
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pH 7.4 D2O/phospate buffer (0.8 mL) at 23 °C under an open atmosphere. The NMR tube was 
then submerged in a 37 °C incubator. The NMR tube was removed after 30 min, 2.5 h, 18 h, and 
24 h for 1H NMR experiments to be run. Additionally, aliquots were taken out after 3.5 h, 18.5 
and 24.5 h, and subsequently analyzed by HPLC. Neither the 1H NMR experiments nor the 
HPLC traces showed the formation of acrolein.  
Preparation of 151, 152, and 157 by the decomposition of 50. To a flask was added 50 
(17.5 mg, 0.0940 mmol) and then pH 7.4 phosphate buffer (50 mM, 1.0 mL) under an open 
atmosphere at 23 °C. The reaction mixture was then sealed and warmed to 37 °C. After 25 h at 
the same temperature the reaction was cooled to ambient temperature, diluted with MeCN (3 
mL), and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (20 → 70% EtOAc in hexanes) on silica gel (7 mL) to afford A (90) (1.1 mg, 
7%), B‡ (3.6 mg, 21%), and C‡ (3.3 mg, 19%) as a colorless oils. 
‡
 We interpret B and C to be compounds 151 and 152, but are unable to assign them. 
Data for 157 (A): Rf = 0.47 (80% EtOAc in hexanes); 
1H NMR (300 MHz, 293K,  
CD2Cl2) δ 7.27 (br s, 1H), 6.02 (br s, 1H), 5.86 (ddd, 1H, J = 17.3, 10.6, 6.0 Hz), 5.32 (ddd, 1H, 
J = 17.3, 1.6, 1.5 Hz), 5.22 (ddd, 1H, J = 10.5, 1.6, 1.5 Hz), 4.58 (br app t, 1H, J = 4.1 Hz), 
4.28−4.21 (m, 1H), 2.26 (d, 3H, J = 0.8 Hz), 2.18 (br d, 1H, J = 4.3 Hz), 2.05 (br d, 1H, J = 4.4 
Hz); 13C NMR (75 MHz, 293K, CD2Cl2 + CD3OD) δ 137.7, 137.1, 125.2, 117.2, 105.6, 76.1, 
70.5, 13.6; HRMS (EI+) calcd. for C9H12O3 (M)
+ 168.0786, found 168.0789. 
Data for Compound B:* Rf = 0.38, 0.27;
† (80% EtOAc in hexanes); HRMS (EI+) calcd. 
for C8H11O3 [M − CH3O]
+ 155.0708, found 155.0704; LRMS (EI+) C8H11O3 [M − CH3O]
+ 155 
(22%), C6H10O3 [M − C3H4O]
+ 130 (48%), C6H8O2 [M − C3H8O2]
+ 112 (84%). 
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* Compound B exists as hemiketal and linear ketoalcohol conformers. As a result the 
NMR spectral data for B can not easily be reported. 
† This compound gave two spots on TLC, however only one peak by HPLC analysis 
(HPLC analysis was performed on a Varian Microsorb 100 C18 column, 250 × 4.6 mm, 1.0 
mL/min, 5% MeCN/H2O→95% MeCN linear gradient elution from 0 to 30 min, retention time = 
8.0 min, monitored at 220 nM). 
Data for Compound C:§ Rf = 0.30 (80% EtOAc in hexanes); HRMS (EI+) calcd. for 
C9H12O3 [M − H2O]
+ 168.0786, found 168.0795; LRMS (EI+) C9H12O3 [M − H2O]
+ 168 (15%), 
C6H10O3 [M − CH5O]
+ 153 (60%), [M − H4O2]
+ 150 (32%), C6H10O3 [M − C3H4O]
+ 130 (48%), 
C6H8O2 [M − C3H8O2]
+ 112 [M − C3H6O2].
+  
§ Compound C exists as hemiketal and linear ketoalcohol conformers. As a result the 
NMR spectral data for C can not easily be reported. 
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Preparation of 162 on a preparative scale. To a stirred solution of 148 (299 mg, 1.00 
mmol) in 1,2-dimethoxyethane (10 mL) was added NaI (301 mg, 2.01 mmol) in one portion 
followed by Pb(OAc)4 (799 mg, 1.80 mmol) in one portion at −44 °C under a nitrogen 
atmosphere.  After an additional 15 min at the same temperature, the reaction mixture was 
warmed to 0 °C.  After an additional 2.3 h at the same temperature, the reaction mixture was 
poured onto aqueous 0.9 N HCl (100 mL) and Et2O (40 mL), and the layers were separated.  The 
aqueous residue was extracted with Et2O (2 × 40 mL).  The combined organic layers were 
washed with saturated aqueous Na2SO3 (50 mL) then brine (50 mL), dried over anhydrous 
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Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue was purified by 
flash chromatography (2 → 8% EtOAc in hexanes) on silica gel (30 mL) to recover diene 148 
(50.8 mg) and afford 162 (325 mg, 77%; 92% BORSM; dr = 1.2:1) as a pale yellow oil.  
Preparation of 162 on microscale. To a flask was added NaI (0.10 M in H2O, 50 µL, 5 
µmol) then MeCN (1 mL) and the mixture was concentrated under reduced pressure, and 
subsequently then placed under an atmosphere of nitrogen. To this flask was added diene 148 
(6.3 mg, 21 µmol) in 1,2-dimethoxyethane (200 µL) followed by Pb(OAc)4 (4.4 mg, 10 µmol) in 
one portion at 0 °C. After 4 h at the same temperature, the reaction mixture was filtered through 
a pad of Celite 545®, rinsed with Et2O (10 mL) and concentrated under reduced pressure. Crude 
1H NMR shows ~quantitative yield of 162 (based on NaI). 
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Preparation of 161 from 162. To a stirred solution of 162 (106 mg, 0.250 mmol) and 
tributyltin hydride (330 µL, 1.23 mmol) in toluene (5 mL) was added AIBN (20.6 mg, 0.125 
mmol) in one portion at 23 °C under an open atmosphere.  The reaction mixture was then 
warmed to 90 °C.  After 5 h at the same temperature, the reaction was cooled to 23 °C and 
concentrated under reduced pressure.  The resulting residue was purified by flash 
chromatography (2 → 8% EtOAc in hexanes) on silica gel (20 mL) to afford 161 (47.2 mg, 63%) 
as a colorless oil.  
Data for 161: Rf = 0.48 (15% EtOAc in hexanes); IR (neat): 2956, 1460, 1227, 1133, 
1008, 841, 742; [α]D
26 +71.2 (c 1.0, CHCl3);
 1H NMR (300 MHz, 293K, CDCl3) δ 5.89 (ddd 1H, 
J = 17.2, 10.3, 6.8 Hz), 5.41 (ddd, 1H, J = 17.2, 1.8, 1.1 Hz), 5.25 (ddd, 1H, J = 10.3, 1.8, 0.8 
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Hz), 4.16 (br dd, 1H, J = 9.3, 6.8 Hz), 3.65 (d, 1H, J = 9.3 Hz), 2.92 (d, 1H, J = 5.1 Hz), 2.45 (d, 
1H, J = 5.1 Hz), 2.12 (d, 1H, J = 13.9 Hz), 1.43 (s, 3H), 1.39 (d, 1H, 13.9 Hz), 1.27 (s, 3 H), 0.95 
(t, 9H, J = 7.9 Hz), 0.61 (q, 6H, J = 7.9 Hz); 13C NMR (75 MHz, 293K, C6D6) δ 137.6, 116.8, 
74.5, 73.1, 71.4, 57.9, 47.3, 43.7, 31.3, 24.1, 7.2, 7.1, 5.6, 5.4; HRMS (EI+) calcd. for 
C16H30O3Si [M]
+  298.1964, found 298.1972. 
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Preparation of 161 from 148. To a stirred solution of 148 (448 mg, 1.50 mmol) in THF 
(7.5 mL) was added Hg(OAc)2 (526 mg, 1.65 mmol) in one portion at 0 °C under a nitrogen 
atmosphere.  After an additional 0.5 h at the same temperature, the reaction was warmed to 23 
°C.  After an additional 1 h at the same temperature, the reaction mixture was cooled to −78 °C, 
and NaBH4 (113 mg, 2.99 mmol) was added in one portion followed by the addition of Et3B (1.0 
M in hexanes, 1.5 mL) down the flask side.  After an additional 2.8 h at −78 °C, the reaction 
mixture was warmed to −44 °C.  After an additional 0.5 h at the same temperature, the reaction 
mixture was quenched with saturated aqueous NH4Cl (25 mL).  The reaction mixture was then 
extracted with Et2O (3 × 20 mL).  The combined organic layers were washed with H2O (25 mL) 
then brine (25 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure.  The resulting residue was purified by flash chromatography (2 → 10% EtOAc in 
hexanes) on silica gel (40 mL) to afford 161 (325 mg, 76%) as a pale yellow oil.  
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Preparation of and data for aldehyde 163. To a stirred solution of 161 (9.2 mg, 0.050 
mmol) in THF (400 µL) was added HF•pyridine (~70% HF, 15 drops) at 0 °C under an open 
atmosphere. After 3 h at the same temperature, the reaction mixture was purified by flash 
chromatography (10 → 40% EtOAc in hexanes) on silica gel (6 mL) to afford 96 (6.7 mg, 73%) 
as a colorless oil.  
Data for 96: Rf = 0.22 (30% EtOAc in hexanes); IR (neat): 3430 (br, O-H), 2972, 1721 
(C=O), 1370, 1170, 1077, 999, 930; [α]D
23 +60.5 (c 0.60, CHCl3); 
1H NMR (300 MHz, 293K, 
CDCl3) δ 9.62 (s, 1H), 5.91 (ddd, 1H, J = 17.1, 10.5, 6.2 Hz), 5.45 (ddd, 1H, J = 17.1, 1.5, 1.5 
Hz), 5.28 (ddd, 1H, J = 10.5, 1.5, 1.5 Hz), 4.48 (br ddd, 1H, J = 6.2, 1.5, 1.5 Hz), 3.88 (br d, 1H, 
J = 11.1 Hz), 3.81 (br d, 1H, J = 11.1 Hz), 2.17 (d, 1H, J = 13.7 Hz), 2.13 (br s, 1H), 1.94 (d, 1H, 
J = 13.7 Hz), 1.45 (s, 3H), 1.37 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 204.2, 133.4, 
118.1, 82.8, 80.9, 64.4, 63.1, 43.6, 29.6, 28.1; HRMS (EI+) calcd. for C10H16O3 (M)+ 184.1099, 
found 184.1094. 
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Preparation of 164. To a stirred solution of 161 (299 mg, 1.00 mmol) in THF (4 mL) 
was added TBAF (1 M in THF, 1.2 mL) at 0 °C under an open atmosphere. After 20 min at the 
same temperature, the reaction mixture was diluted with Et2O (15 mL), filtered through a pad of 
Florisil, rinsed with Et2O (4 × 10 mL), and concentrated under reduced pressure. The resulting 
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residue was purified by flash chromatography (10 → 40% EtOAc in hexanes) on silica gel (10 
mL) to afford 164 (179 mg, 97%) as a white solid. 
Data for 164: m.p. = 60−62 °C; Rf = 0.39 (30% EtOAc in hexanes); IR (neat): 3403 (br, 
O-H), 2973, 1371, 1223, 1062, 895; [α]D
23 +72.3 (c 1.0, CH2Cl2); 
1H NMR (300 MHz, 293K, 
CD2Cl2) δ 5.95 (ddd, 1H, J = 17.2, 10.5, 5.9 Hz), 5.34 (ddd, 1H, J = 17.2, 1.6, 1.6 Hz), 5.22 
(ddd, 1H, J = 10.5, 1.5, 1.1 Hz), 3.91 (br dd, 1H, J = 9.7, 5.9 Hz), 3.44 (br app t, 1H, J = 10.1 
Hz), 2.96 (d, 1H, J = 4.7 Hz), 2.46 (d, 1H, J = 4.7 Hz), 2.16 (d, 1H, J = 14.3 Hz), 1.65 (br d, 1H, 
J = 10.6 Hz), 1.39 (d, 1H, J = 14.3 Hz), 1.35 (s, 3H), 1.24 (s, 3H); 13C NMR (75 MHz, 293K, 
CD2Cl2) δ 137.5, 117.0, 74.8, 73.0, 68.4, 57.8, 47.8, 43.1, 31.1, 23.7; HRMS (EI+) calcd. for 
C9H13O3 (M − CH3)
+ 169.0865, found 169.0869. 
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General Procedure for the half-life determination for the decomposition of 164. To a 
vial was added 164 (0.2 mg, 1 µmol) and buffer (20 µL) under an open atmosphere at 23 °C. The 
reaction mixture was then sealed and warmed to 37 °C. The decomposition was then estimated 
by TLC analysis (50% EtOAc/hexanes) after 3, 5.5, 20, 25 31, 45, 50, and 56 h. 
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Preparation of 165. A solution of 164 (27.7 mg, 0.150 mmol) was prepared in 
ClCH2CH2Cl (300 µL) at 23 °C under an open atmosphere. To a stirred solution of 47 (34.8 mg, 
0.100 mmol) in ClCH2CH2Cl (200 µL) was added the solution of 164 (100 µL), benzoquinone 
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(2.1 mg, 0.019 mmol), followed by Grela catalyst (3.4 mg, 5.0 µmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 40 °C. After 2 h at the same temperature, 
additional Grela catalyst (3.4 mg, 5.0 µmol) and 164 (100 µL) were added. After an additional 2 
h at the same temperature, 164 (100 µL) was added. After 9 total hours, the reaction was 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 80% EtOAc in hexanes) on silica gel (7 mL) to give 165 (22.8 mg, 45%), 
and an inseparable mixture of 47 and 164 (35.3 mg).  
To a stirred solution of recovered 47 and 164 (35.3 mg) in ClCH2CH2Cl (300 µL) was 
added benzoquinone (1.0 mg, 0.010 mmol) Grela catalyst (3.4 mg, 5.0 µmol) at 23 °C under an 
open atmosphere. The reaction mixture was then heated to 40 °C. After an additional 14 h at the 
same temperature, the reaction was concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (10 → 80% EtOAc in hexanes) on silica gel (5 mL) to 
give 165 (6.9 mg, 14%) as a pale tan solid. The combined yield of 165 after one cycle is 29.7 mg 
(59%). Some of the tan 165 was purified by semi-preparative HPLC† to afford meayamycin as a 
white solid that was subsequently used for biological experiments. 
Data for 165: Rf = 0.23 (60% EtOAc in hexanes); IR (neat): 3441 (br, N-H), 3372 (br, O-
H), 2923, 1736 (C=O), 1668 (C=O), 1637, 1521, 1370, 1243, 1057, 734; [α]D
25 −8.1 (c 0.30, 
CH2Cl2); 
1H NMR (300 MHz, 293K, CD2Cl2) δ 6.36 (d, 1H, J = 15.9 Hz), 6.32−6.24 (m, 1H), 
5.98 (br d, 1H, J = 9.0 Hz), 5.91 (dd, 1H, J = 11.4, 7.5 Hz), 5.72 (dd, 1H, J = 11.7, 1.2 Hz), 5.65 
(dd, 1H, J = 15.9, 6.6 Hz), 5.53 (br app t, 1H, J = 7.1 Hz), 3.97 (br dd, 1H, J = 9.5, 6.6 Hz), 
3.95−3.98 (m, 1H), 3.67 (qd, 1H, J = 6.3, 2.1 Hz), 3.58−3.50 (m, 1H), 3.49 (app t, 1H, J = 10.2 
Hz), 2.97 (d, 1H, J = 4.8 Hz), 2.47 (d, 1H, J = 4.8 Hz), 2.42−2.30 (m, 1H), 2.28−2.16 (m, 1H), 
2.18 (d, 1H, J = 14.4 Hz), 2.01 (s, 3H), 1.96−1.91 (m, 2H), 1.81−1.79 (m, 1H), 1.79 (br s, 3H), 
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1.63 (d, 1H, J = 10.5 Hz), 1.41 (d, 1H, J = 14.4 Hz), 1.36 (s, 3H), 1.35 (d, 3H, J = 6.3 Hz), 1.23 
(s, 3H), 1.12 (d, 3H, J = 6.3 Hz), 1.02 (d, 3H, J = 7.2 Hz); 
13
C NMR (75 MHz, 293K, CD2Cl2) δ 
170.6, 165.0, 143.9, 137.7, 135.0, 129.5, 125.9, 122.9, 81.2, 76.3, 74.9, 73.0, 68.9, 68.6, 57.8, 
47.8, 47.4, 43.1, 36.3, 32.4, 31.1, 29.6, 23.7, 21.4, 20.2, 18.0, 15.3, 12.8; HRMS (EI+) calcd. for 
C28H43NO7 (M)
+
 505.3040, found 505.3057. 
†
 HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 4.3 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 19.6 min. 
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General Procedure for the half-life determination for the decomposition of 165 in 
buffers. To a corning tube (15 mL) was added phosphate buffer (10 mL), benzoic acid (10 mM 
in DMSO, 20 µL), and DMSO (70 µL) under an open atmosphere and warmed to 37 °C. To the 
reaction mixture was added meayamycin A (10 mM in DMSO, 10 µL) and the resulting mixture 
was sealed with a cap, vortexed for 15 s, and then placed in a 37 °C incubator. The 
decomposition was monitored by HPLC* at the indicated times. The resulting data were 
normalized by dividing the ratios of meayamycin A/benzoic acid by the ratio of the first data 
point. 
* HPLC purification was performed on a Varian Pursuit XDR C18 column, 75 × 4.6 cm, 
1.0 mL/min, 10% MeCN/H2O (containing 1% HCO2H) → 100% MeCN linear gradient elution 
from 0.5 to 9.5 min, retention time = 6.7 min (retention time for benzoic acid = 4.3 min), 
monitored at 230 nm.  
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Procedure for the half-life determination for the decomposition of 165 in sera. To a 1 
dram glass vial was added mouse serum (1.0 mL), rhodamine B (10 mM in DMSO, 2.0 µL), and 
DMSO (7.0 µL) under an open atmosphere and warmed to 37 °C. To the mixture was added 
meayamycin A or B (10 mM in DMSO, 1.0 µL) and the resulting solution was sealed with a cap, 
vortexed for 15 s, and then placed in a 37 °C incubator. The decomposition was monitored by 
HPLC* at the indicated times. The resulting data were normalized by dividing the ratios of 
meayamycin A or B/rhodamine B by the ratio of the first data point. 
* HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 2.5 mL/min, 30% MeOH/H2O (containing 1% HCO2H) → 100% MeOH linear gradient 
elution from 0.5 to 22 min, monitored at 230 (for 165) and 550 nM (for rhodamine B).  
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Preparation of 173. To a stirred solution of 47 (26.5 mg, 0.0758 mmol) in MeOH (380 
µL) was added K2CO3 (26.3 mg, 0.190 mmol) at 0 ° C under an open atmosphere. After 2 h at 
the same temperature the reaction was diluted with saturated aqueous NH4Cl (60 µL), and the 
resulting mixture was stirred for 5 min. The resulting reaction mixture was dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was purified by 
flash chromatography (20 → 50% EtOAc in hexanes) on silica gel (3 mL) to give 173 (19.2 mg, 
82%) as a colorless oil. 
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Data for 173: Rf = 0.21 (50% EtOAc in hexanes); IR (neat): 3325, 2975, 1655 (C=O), 
1621, 1522, 1456, 1116, 1062, 894 cm-1; [α]D
26 +10.0 (c 0.95, CHCl3); 
1H NMR (300 MHz, 
293K, 1% CD3OD in CDCl3) δ 6.36 (dd, 1H, J = 17.4, 10.8 Hz), 6.16 (dd, 1H, J = 11.9, 5.6 Hz), 
5.74 (dd, 1H, J = 11.9, 1.3 Hz), 5.44 (br app t, 1H, J = 8.1 Hz), 5.11 (d, 1H, J = 17.4 Hz), 4.96 
(d, 1H, J = 10.8 Hz), 4.83−4.73 (m, 1H), 3.97−3.93 (m, 1H), 3.68 (qd, 1H, J = 6.6, 2.1 Hz), 3.55 
(qd, 1H, J = 7.1, 2.5 Hz), 2.48−2.31 (m, 1H), 2.31−2.13 (m, 1H), 1.95−1.92 (m, 2H), 1.76 (br s, 
3H), 1.34 (d, 3H, J = 6.6 Hz), 1.14 (d, 3H, J = 6.6 Hz), 1.01 (d, 3H, J = 7.1 Hz); 13C NMR (125 
MHz, 293K, CDCl3) δ 166.1, 150.8, 141.2, 135.7, 127.9, 122.5, 111.2, 80.8, 75.8, 64.6, 47.5, 
35.7, 31.8, 28.8, 22.7, 17.9, 15.2, 11.9; HRMS (EI+) calcd. for C18H29NO3 [M]
+  307.2147, found 
307.2148. 
 
O
N
H
OHO
O
O
HO
170
O
N
H
HO
O
173
O
O
HO
+
164
(1.6 equiv)
Grela cat.
55% after
one recycle
 
Preparation of 170. A solution of 164 (16.8 mg, 0.0912 mmol) was prepared in 
ClCH2CH2Cl (100 µL) at 23 °C under an open atmosphere. To a stirred solution of 173 (17.2 mg, 
0.0559 mmol) in ClCH2CH2Cl (200 µL) was added the solution of 164 (50 µL), benzoquinone 
(1.0 mg, 9.3 µmol), followed by Grela catalyst (2.0 mg, 3.0 µmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 32 °C. After 3 h at the same temperature, 
additional Grela catalyst (1.8 mg, 2.7 µmol) and 164 (50 µL) were added. After 8 total hours, the 
reaction was concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 100% EtOAc in hexanes) on silica gel (5 mL) to give 170 (16.1 mg, 
62%), and an inseparable mixture of 173 and 164 (34.1 mg). 
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To a stirred solution of recovered 173 and 164 (12.4 mg) in ClCH2CH2Cl (300 µL) was 
added Grela catalyst (1.4 mg, 2.1 µmol) at 23 °C under an open atmosphere. The reaction 
mixture was then heated to 32 °C. After an additional 14 h at the same temperature, the reaction 
was concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 80% EtOAc in hexanes) on silica gel (3 mL) to give 170 (5.0 mg, 19%) 
as a pale tan solid. The combined yield of 170 after one cycle is 21.1 mg (81%). Some of the tan 
170 was purified by semi-preparative HPLC† to afford 170 as a white solid that was 
subsequently used for biological experiments.  
Data for 170: Rf = 0.21 (80% EtOAc in hexanes); 
1H NMR (300 MHz, 293K, CD2Cl2) δ 
6.34 (br d, 1H, J = 15.8 Hz), 6.16 (dd, 1H, J = 11.7, 5.4 Hz), 5.96 (br d, 1H, J = 9.3 Hz), 5.74 
(dd, 1H, J = 11.7, 1.8 Hz), 5.65 (dd, 1H, J = 15.8, 6.5 Hz), 5.55−5.48 (m, 2H), 4.72−4.64 (m, 
1H), 3.96 (dd, 1H, J = 10.2, 7.0 Hz), 3.94−3.87 (m, 1H), 3.66 (qd, 1H, J = 6.6, 2.1 Hz), 
3.58−3.51 (m, 1H), 3.48 (app t, 1H, J = 10.1 Hz), 2.96 (d, 1H, J = 4.7 Hz), 2.46 (d, 1H, J = 4.7 
Hz), 2.43−2.31 (m, 1H), 2.29−2.21 (m, 1H), 2.17 (d, 1H, J = 14.4 Hz), 1.98−1.91 (m, 2H), 1.78 
(br s, 3H), 1.61 (d, 1H, J = 10.2 Hz), 1.40 (d, 1H, J = 14.4 Hz), 1.36 (s, 3H), 1.28 (d, 3H, J = 6.6 
Hz), 1.23 (s, 3H), 1.11 (d, 3H, J = 6.6 Hz), 1.02 (d, 3H, J = 7.2 Hz); 13C NMR (75 MHz, 293K, 
CD2Cl2) δ 166.5, 150.9, 143.0, 137.7, 135.1, 129.3, 126.0, 123.0, 102.3, 81.3, 76.1, 74.9, 68.6, 
64.9, 57.8, 47.9, 47.8, 36.1, 32.4, 31.2, 29.6, 23.8, 23.0, 18.0, 15.4, 12.8; HRMS (EI+) calcd. for 
C26H41NO6 [M]
+  463.2934, found 463.2937. 
† HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 4.3 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 14.1 min. 
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Preparation of 166. A solution of 164 (24.2 mg, 0.131 mmol) was prepared in 
ClCH2CH2Cl (200 µL) at 23 °C under an open atmosphere. To a stirred solution of 174 (26.8 mg, 
0.0799 mmol) in ClCH2CH2Cl (200 µL) was added the solution of 164 (100 µL), benzoquinone 
(1.8 mg, 0.017 mmol), followed by Grela catalyst (2.7 mg, 4.0 µmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 35 °C. After 3 h at the same temperature, 
additional Grela catalyst (2.7 mg, 4.0 µmol) and 164 (100 µL) were added. After 9 total hours, 
the reaction was concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 80% EtOAc in hexanes) on silica gel (5 mL) to give 166 (12.9 mg, 33%), 
and an inseparable mixture of 174 and 164 (34.1 mg). 
To a stirred solution of recovered 174 and 164 (34.1 mg) in ClCH2CH2Cl (300 µL) was 
added benzoquinone (1.0 mg, 0.010 mmol) and Grela catalyst (3.8 mg, 5.7 µmol) at 23 °C under 
an open atmosphere. The reaction mixture was then heated to 37 °C. After an additional 14 h at 
the same temperature, the reaction was concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (10 → 80% EtOAc in hexanes) on silica gel (3 
mL) to give 166 (6.8 mg, 17%) as a pale tan solid. The combined yield of 166 after one cycle is 
29.7 mg (50%). Some of the tan 166 was purified by semi-preparative HPLC* to afford 166 as a 
white solid that was subsequently used for biological experiments.  
Data for 166: Rf = 0.35 (70% EtOAc in hexanes); IR (neat): 3350 (br), 2925, 1738 
(C=O), 1699 (C=O) 1522, 1370, 1243, 1051, 972 cm-1; [α]D
25 −2.6 (c 0.65, CH2Cl2); 
1H NMR 
(300 MHz, 293K, CD2Cl2) δ 6.50 (br d, 1H, J = 9.0 Hz), 6.35 (br d, 1H, J = 15.6 Hz), 6.10 (app 
quintet, 1H, J = 6.6 Hz), 5.88−5.77 (m, 2H), 5.64 (dd, 1H, J = 15.6, 6.6 Hz), 5.56 (br app t, 1H, J 
 176 
= 7.4 Hz), 4.00−3.91 (m, 2H), 3.63 (qd, 1H, J = 6.5, 1.6 Hz), 3.48 (app t, 1H, J = 10.1 Hz), 
3.47−3.38 (m, 1H), 2.96 (d, 1H, J = 4.8 Hz), 2.46 (d, 1H, J = 4.7 Hz), 2.40−2.31 (m, 2H), 2.17 
(d, 1H, J = 14.2 Hz), 2.03 (s, 3H), 1.96−1.89 (m, 1H), 1.76 (br s, 3H), 1.76−1.67 (m, 1H), 1.61 
(d, 1H, J = 10.2 Hz), 1.52−1.48 (m, 1H), 1.40 (d, 1H, J = 14.3 Hz), 1.36 (s, 3H), 1.34 (d, 3H, J = 
6.6 Hz), 1.23 (s, 3H), 1.09 (d, 3H, J = 6.3 Hz); 13C NMR (75 MHz, 293K, CD2Cl2) δ 170.9, 
165.2, 142.0, 137.8, 135.1, 129.3, 125.9, 123.8, 78.5, 75.4, 74.9, 73.0, 69.1, 68.6, 57.8, 47.8, 
47.2, 43.1, 35.6, 31.2, 29.4, 26.4, 23.7, 21.4, 20.3, 18.3, 12.7; HRMS (EI+) calcd. for 
C27H41NO7Na [M]
+  514.2781, found 514.2782. 
* HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 4.3 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 17.9 min. 
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Preparation of 176. A solution of 164 (24.3 mg, 0.132 mmol) was prepared in 
ClCH2CH2Cl (200 µL) at 23 °C under an open atmosphere. To a stirred solution of 175 (27.2 mg, 
0.0806 mmol) in ClCH2CH2Cl (200 µL) was added the solution of 164 (100 µL), benzoquinone 
(1.9 mg, 0.018 mmol), followed by Grela catalyst (2.8 mg, 4.2 µmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 35 °C. After 3 h at the same temperature, 
additional Grela catalyst (2.7 mg, 4.0 µmol) and 164 (100 µL) were added. After 9 total hours, 
the reaction was concentrated under reduced pressure. The resulting residue was purified by flash 
 177 
chromatography (10 → 80% EtOAc in hexanes) on silica gel (5 mL) to give 176 (14.1 mg, 35%), 
and an inseparable mixture of 175 and 164 (29.9 mg). 
To a stirred solution of recovered 175 and 164 (29.9 mg) in ClCH2CH2Cl (300 µL) was 
added benzoquinone (1.0 mg, 0.010 mmol) and Grela catalyst (3.6 mg, 5.4 µmol) at 23 °C under 
an open atmosphere. The reaction mixture was then heated to 36 °C. After an additional 22 h at 
the same temperature, the reaction was concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (10 → 80% EtOAc in hexanes) on silica gel (3 
mL) to give 176 (6.9 mg, 14%) as a pale tan solid. The combined yield of 176 after one cycle is 
21.0 mg (53%, 89% based on recovered 175). Some of the tan 176 was purified by semi-
preparative HPLC‡ to afford 176 as a white solid that was subsequently used for biological 
experiments.  
Data for 176: Rf = 0.26 (70% EtOAc in hexanes); IR (neat): 3347 (br), 2977, 1735 
(C=O), 1700 (C=O) 1520, 1370, 1245, 1126, 1050 cm-1; [α]D
24 +3.5 (c 0.45, CH2Cl2); 
1H NMR 
(500 MHz, 293K, CD2Cl2) δ 6.75 (br d, 1H, J = 9.0 Hz), 6.35 (br d, 1H, J = 15.5 Hz), 6.20−6.13 
(m, 1H), 5.89 (dd, 1H, J = 11.5, 8.0 Hz), 5.82 (dd, 1H, J = 11.5, 1.0 Hz), 5.66 (dd, 1H, J = 15.5, 
6.5 Hz), 5.53 (br app t, 1H, J = 7.0 Hz), 4.64 (app t, 1H, J = 5.3 Hz), 3.98−3.92 (m, 3H), 
3.90−3.86 (m, 2H), 3.48 (app t, 1H, J = 10.0 Hz), 2.96 (d, 1H, J = 4.7 Hz), 2.53−2.42 (m, 2H), 
2.46 (d, 1H, J = 4.7 Hz), 2.17 (d, 1H, J = 14.3 Hz), 2.02 (s, 3H), 1.77 (br s, 3H), 1.61 (d, 1H, J = 
10.5 Hz), 1.40 (d, 1H, J = 14.3 Hz), 1.36 (s, 3H), 1.34 (d, 3H, J = 6.5 Hz), 1.23 (s, 3H), 1.13 (d, 
3H, J = 6.5 Hz); 13C NMR (125 MHz, 293K, CD2Cl2) δ 170.8, 165.3, 143.0, 137.5, 135.8, 126.6, 
126.3, 123.2, 102.3, 74.92, 74.89, 73.0, 71.4, 68.9, 68.6, 57.7, 47.8, 47.0, 43.0, 34.5, 31.1, 23.7, 
21.4, 20.2, 17.7, 12.7; HRMS (ESI+) calcd. for C26H39NO8Na [M + Na]
+  516.2573, found 
516.2565. 
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‡ HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 4.3 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 16.3 min. 
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Preparation of 177. To a stirred solution of 161 (299 mg, 1.00 mmol) in Et2O (5 mL) 
was added lithium aluminum hydride (1.0 M in Et2O, 5 mL) at 0 °C under a nitrogen 
atmosphere. After 15 min at the same temperature, the reaction was warmed to reflux. After 1.0 
h at the same temperature, the reaction was diluted with wet Et2O (5 mL), followed by the 
dropwise addition of saturated aqueous NH4Cl (5 mL). The layers were separated, and the 
aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic layers were washed 
with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. Purification of the residue by flash chromatography (10 → 30% EtOAc in hexanes) on 
silica gel (40 mL) afforded 177 (149 mg, 80%) as a viscous pale yellow oil. 
Data for 177: Rf = 0.26 (30% EtOAc in hexanes); IR (neat): 3421 (br, O-H), 2973, 1644, 
1369, 1204, 1058, 923 cm-1; [α]D
25 +52.8 (c 1.4, CH2Cl2); 
1H NMR (300 MHz, 293K, CD2Cl2) δ 
5.85 (ddd, 1H, J = 17.3, 10.2, 6.9 Hz), 5.35 (ddd, 1H, J = 17.3, 1.8, 0.9 Hz), 5.26 (ddd, 1H, J = 
10.2, 1.8, 0.6 Hz), 4.03 (br dd, 1H, J = 9.5, 6.9 Hz), 3.06 (dd, 1H, J = 9.5, 4.6 Hz), 2.10 (br d, 
1H, J = 1.5 Hz), 1.92 (br d, 1H, J = 4.6 Hz), 1.79 (d, 1H, J = 14.4 Hz), 1.54 (br d, 1H, J = 14.4 
Hz), 1.40 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H); 13C NMR (75 MHz, 293K, CD2Cl2) δ  137.8, 118.3, 
74.8, 72.7, 72.2, 70.5, 47.4, 32.4, 28.8, 24.4; HRMS (EI+) calcd. for C10H18O3 [M]
+  186.1256, 
found 186.1257. 
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Preparation of 178. To a stirred solution of 177 (28.2 mg, 0.151 mmol) and 
anisaldehyde dimethyl acetal (75 µL, 0.44 mmol) was added CSA (3.5 mg, 0.015 mmol) in 
CH2Cl2 (0.75 mL) at 23 °C. After 15 min at the same temperature, the reaction mixture was 
quenched by the addition of saturated aqueous NaHCO3 (1 mL), and vigorously stirred for 30 
min. The mixture was diluted with Et2O (5 mL), washed with H2O (5 mL) then brine (5 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification of 
the residue by preparatory thin-layer chromatography (25% EtOAc in hexanes containing 1% 
Et3N) afforded 178 (38.8 mg, 84%) as a pale yellow oil. 
Data for 178: Rf = 0.60 (30% EtOAc in hexanes); IR (neat): 2925, 1613, 1367, 1248, 
1170, 1077, 1032, 826; 1H NMR (300 MHz, 293K, CDCl3) δ 7.44 (br d, J = 8.9 Hz), 6.94−6.88 
(m), 6.10 (s), 6.05−5.90 (m), 5.96 (s), 5.47−5.21 (m), 4.17 (dddd, J = 9.3, 5.8, 1.5, 1.5 Hz), 3.96 
(dddd, J = 8.9, 5.4, 1.5, 1.5 Hz), 3.824 (s), 3.817 (s), 3.78 (d, J = 9.3 Hz), 3.65 (d, J = 8.9 Hz), 
2.17 (d, J = 14.7 Hz), 2.13 (d, J = 14.7 Hz), 1.83 (d, J = 14.7 Hz), 1.76 (d, J = 14.7 Hz), 1.46 (s), 
1.43 (s), 1.42 (s), 1.32 (s), 1.31 (s), 1.29 (s); 13C NMR (75 MHz, 293K, CDCl3) δ 160.2 (two 
overlapping carbons), 137.1, 136.8, 130.8, 130.3, 127.74, 127.70, 116.6, 113.7, 102.1, 101.5, 
81.6, 80.7, 79.7, 72.5, 71.5, 69.7, 52.3 (two overlapping carbons), 44.8, 43.6, 31.0, 30.9, 29.1, 
26.1, 25.84, 25.76; HRMS (EI+) calcd. for C18H24O4 [M]
+  304.1675, found 304.1668. 
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 Preparation of 179. To a light-protected, stirred solution of 164 (92.6 mg, 0.503 mmol) 
and PMBCl (200 µL, 1.47 mmol) in DMF (1.0 mL) was added Ag2O (174 mg, 0.751 mmol) at 
23 °C under a nitrogen atmosphere. The resulting mixture was heated to 60 °C. After 43 h at the 
same temperature, the reaction mixture was poured onto H2O (25 mL), and the resulting mixture 
was extracted with Et2O (3 × 15 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (10 → 30% EtOAc in hexanes) on silica gel (8 mL) afforded 179 (113 mg, 
74%) as a colorless oil. 
Data for 179: Rf = 0.26 (30% EtOAc in hexanes); IR (neat): 2973, 1612, 1514, 1466, 
1249, 1115, 1033, 822 cm-1; [α]D
25 +40.2 (c 0.75, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 
7.21 (br d, 2H, J = 8.4 Hz), 6.86 (br d, 2H, J = 8.4 Hz), 5.95 (ddd, 1H, J = 17.3, 10.4, 6.8 Hz), 
5.47 (br d, 1H, J = 17.3 Hz), 5.29 (br d, 1H, J = 10.4 Hz), 4.57 (d, 1H, J = 11.1 Hz), 4.36 (d, 1H, 
J = 11.1 Hz), 4.26 (dd, 1H, J = 9.6, 6.8 Hz), 3.81 (s, 3H), 3.40 (d, 1H, J = 9.6 Hz), 2.85 (d, 1H, J 
= 4.9 Hz), 2.41 (d, 1H, J = 4.9 Hz), 2.10 (d, 1H, J = 14.1 Hz), 1.43 (s, 3H), 1.36 (d, 1H, J = 14.1 
Hz), 1.27 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 159.4, 136.5, 130.0, 129.6, 118.1, 113.8, 
75.8, 74.3, 73.5, 73.2, 57.0, 55.2, 47.5, 43.4, 31.0, 23.7; HRMS (EI+) calcd. for C18H24O4Na [M 
+ Na]+  327.1572, found 327.1556. 
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Preparation of 180. To a stirred solution of 179 (239 mg, 0.785 mmol) in DMSO (1.8 
mL) and H2O (1.2 mL) was added potassium hydroxide (221 mg, 3.94 mmol) at 23 °C under an 
open atmosphere. After 2 min at the same temperature, the reaction was submerged in a 55 °C oil 
bath. After 14 h at the same temperature, the reaction was cooled to 23 °C, diluted with H2O (30 
mL), and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification of the residue 
by flash chromatography (10 → 30% EtOAc in hexanes) on silica gel (10 mL) afforded 180 (195 
mg, 77%) as a colorless oil. 
Data for 180: Rf = 0.22 (40% EtOAc in hexanes); IR (neat): 3446 (br O-H), 2914, 1613, 
1514, 1302, 1249, 1178, 1076, 1034, 830 cm-1; [α]D
24 +11.6 (c 0.98, CHCl3); 
1H NMR (300 
MHz, 293K, CDCl3) δ 7.25 (br d, 2H, J = 8.5 Hz), 6.89 (br d, 2H, J = 8.5 Hz), 5.99 (ddd, 1H, J = 
17.1, 10.2, 7.2 Hz), 5.49 (ddd, 1H, J = 17.1, 1.5, 0.6 Hz), 5.33 (br d, 1H, J = 10.2 Hz), 4.66 (d, 
1H, J = 10.5 Hz), 4.42 (d, 1H, J = 10.5 Hz), 4.26 (dd, 1H, J = 9.5, 7.2 Hz), 3.82 (s, 3H), 3.40 (d, 
1H, J = 10.8 Hz), 3.29 (br d, 1H, J = 10.8 Hz), 3.22 (d, 1H, J = 9.5 Hz), 2.85 (d, 1H, J = 4.9 Hz), 
2.58−2.44 (br s, 1H), 1.76 (d, 1H, J = 14.4 Hz), 1.60 (d, 1H, J = 14.4 Hz), 1.45 (s, 3H), 1.24 (s, 
3H); 13C NMR (75 MHz, 293K, CD2Cl2) δ 159.6, 137.1, 130.0, 129.6, 128.6, 118.3, 114.0, 78.6, 
74.3, 72.9, 71.8, 70.9, 68.7, 55.3, 42.1, 32.2, 24.5; HRMS (EI+) calcd. for C18H26O5Na [M]
+  
322.1780, found 322.1782. 
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Preparation of 181. To a stirred solution of diol 180 (193 mg, 0.599 mmol) in THF (1.5 
mL) and H2O (3.0 mL) was NaIO4 (155 mg, 0.725 mmol) at 23 °C under an open atmosphere. 
After 1.75 h at the same temperature, the reaction was diluted with H2O (20 mL), and extracted 
with Et2O (3 × 10 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure to afford a ketone (161 mg) as a colorless oil. 
This material was used in the next reaction without further purification. 
To a stirred solution of this crude ketone (156 mg, ~0.58 mmol) in THF (2.5 mL) was 
added Li
s
Bu3BH (1.0 M in THF, 1.8 mL) at −78 °C under a nitrogen atmosphere. After 1 h at the 
same temperature, the reaction was diluted by the dropwise addition of aqueous potassium 
hydroxide (5% wt/wt, 1 mL), was then warmed to 0 °C, and then was added aqueous hydrogen 
peroxide (30%, 1 mL). After 1 h at the same temperature, the mixture was further diluted with 
H2O (10 mL), and extracted with Et2O (3 × 5 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification of the residue 
by flash chromatography (5 → 15% EtOAc in hexanes) on silica gel (8 mL) afforded 181 (118 
mg, 69% from 180) as a colorless oil. 
Data for 181: Rf = 0.25 (20% EtOAc in hexanes); IR (neat): 3482 (br, O-H), 2913, 1613, 
1514, 1365, 1249, 1082, 1033, 927, 822 cm
-1
; [α]D
24
 +59.7 (c 0.99, CHCl3); 
1
H NMR (300 MHz, 
293K, CDCl3) δ 7.26 (br d, 1H, J = 8.6 Hz), 6.89 (br d, 1H, J = 8.6 Hz), 5.95 (ddd, 1H, J = 17.0, 
10.5, 6.2 Hz), 5.41 (br d, 1H, J = 17.0 Hz), 5.29 (br d, 1H, J = 10.5 Hz), 4.53 (app s, 2H), 4.25 
(dd, 1H, J = 9.6, 6.2 Hz), 4.25 (ddd, 1H, J = 3.4, 3.3, 3.2 Hz), 3.82 (s, 3H), 3.17 (dd, 1H, J = 9.6, 
 183 
3.2 Hz), 2.48 (br s, 1H), 1.96 (dd, 1H, J = 14.6, 3.3 Hz), 1.61 (dd, 1H, J = 14.6, 3.4 Hz), 1.46 (s, 
3H), 1.21 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 159.5, 137.1, 129.9, 129.5, 117.3, 113.9, 
78.7, 71.5, 71.4, 68.9, 65.3, 55.3, 40.6, 32.0, 25.1; HRMS (EI+) calcd. for C17H24O4 [M]
+  
292.1675, found 292.1673. 
 
O
PMBO
181
OH
O
HO
182
OH
DDQ; CSA;
KOH
79%
 
Preparation of 182. To a stirred solution of 181 (58.4 mg, 0.200 mmol) in CH2Cl2 (1.8 
mL) and saturated aqueous NaHCO3 (0.20 mL) was added DDQ (137 mg, 0.604 mmol) at 0 °C 
under an air atmosphere. After 10 min the reaction mixture was warmed to 23 °C. After 1 h at 
the same temperature, the reaction mixture was poured onto H2O (15 mL), and the resulting 
mixture was extracted with Et2O (4 × 10 mL). The combined organic layers were dried over over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give 69.7 mg of a 
mixture of compounds. 
To a stirred solution of this mixture (69 mg) in MeOH (1.0 mL) was added CSA (2.3 mg, 
9.9 µmol) at 23 °C under an air atmosphere. After 12.5 h at the same temperature, the reaction 
was diluted with aqueous KOH (5% wt/wt, 1.0 mL). After an additional 2 h at 23 °C, the 
reaction mixture was quenched by the addition of saturated aqueous NH4Cl (15 mL), and the 
resulting mixture was extracted with CH2Cl2 (8 × 5 mL). The combined organic layers were 
dried over over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. 
Purification of the residue by flash chromatography (10 → 50% EtOAc in hexanes) on silica gel 
(5 mL) afforded 182 (27 mg, 79%) as a colorless oil. 
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Data for 182: Rf = 0.26 (40% EtOAc in hexanes); IR (neat): 3417 (br O-H), 2918, 1366, 
1229, 1164, 1060, 996, 930 cm-1; [α]D
25 +74.2 (c 0.89, CHCl3); 
1H NMR (300 MHz, 293K, 
CD2Cl2) δ 5.88 (ddd, 1H, J = 17.4, 10.5, 7.2 Hz), 5.38 (ddd, 1H, J = 17.4, 1.8, 1.2 Hz), 5.29 
(ddd, 1H, J = 10.5, 1.8, 0.6 Hz), 4.18−4.10 (m, 2H), 3.29 (dd, 1H, J = 9.5, 3.2 Hz), 2.48 (br s, 
1H), 2.18 (br s, 1H), 1.93 (dd, 1H, J = 14.7, 3.2 Hz), 1.69 (dd, 1H, J = 14.7, 3.3 Hz), 1.44 (s, 
3H), 1.20 (s, 3H); 13C NMR (75 MHz, 293K, CD2Cl2) δ 137.7, 118.3, 71.7, 71.6, 71.2, 67.8, 
41.5, 32.1, 25.3; HRMS (EI+) calcd. for C9H16O3 [M]
+  172.1099, found 172.1101. 
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Preparation of 183. To a stirred solution of 182 (24.3 mg, 0.141 mmol) and 
anisaldehyde dimethyl acetal (70 µL, 0.41 mmol) was added CSA (3.2 mg, 0.014 mmol) in 
CH2Cl2 (0.7 mL) at 23 °C. After 15 min at the same temperature, the reaction mixture was 
quenched by the addition of Et3N (0.10 mL) then saturated aqueous NaHCO3 (1 mL), and 
vigorously stirred for 10 min. The mixture was diluted with Et2O (5 mL), washed with H2O (5 
mL) then brine (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. Purification of the residue by preparatory thin-layer chromatography (25% EtOAc in 
hexanes containing 1% Et3N) afforded 183 and anisaldehyde dimethyl acetal (69.1 mg, quant.) as 
a mixture. 
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Preparation of 184. To a stirred solution of NaH (60% wt/wt in mineral oil, 40.0 mg, 
1.00 mmol) in THF (0.1 mL) was added iodomethane (62 µL, 1.00 mmol) followed by 181 (58.7 
mg, 0.201 mmol) in THF (0.1 mL), and the container that originally contained 181 was rinsed 
with additional THF (2 × 0.1 mL) and added to the reaction mixture at 23 °C under a nitrogen 
atmosphere. After 9.5 h at the same temperature, the reaction was quenched with saturated 
aqueous NH4Cl (5 mL), and extracted with Et2O (3 × 5 mL). The combined organic layers were 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure. Purification of the residue by flash chromatography (2.5 → 10% EtOAc in 
hexanes) on silica gel (4 mL) afforded 184 (57.6 mg, 94%) as a colorless oil. 
Data for 184: Rf = 0.37 (20% EtOAc in hexanes); IR (neat): 2972, 1613, 1513, 1364, 
1248, 1032, 821 cm-1; [α]D
25 +61.6 (c 0.90, CHCl3); 
1H NMR (300 MHz, 293K, CDCl3) δ 7.27 
(br d, 1H, J = 8.4 Hz), 6.87 (br d, 1H, J = 8.4 Hz), 5.95 (ddd, 1H, J = 17.4, 10.5, 6.3 Hz), 5.41 
(ddd, 1H, J = 17.4, 1.8, 1.2 Hz), 5.24 (br ddd, 1H, J = 10.5, 1.8, 0.9 Hz), 4.55 (d, 1H, J = 11.9 
Hz), 4.50 (d, 1H, J = 11.9 Hz), 4.34 (dd, 1H, J = 9.5, 6.3 Hz), 3.81 (s, 3H), 3.65 (ddd, 1H, J = 
3.6, 3.3, 2.9 Hz), 3.42 (s, 3H), 3.13 (dd, 1H, J = 9.5, 3.3 Hz), 2.02 (dd, 1H, J = 14.5, 3.6 Hz), 
1.41 (s, 3H), 1.40 (dd, 1H, J = 14.5, 2.9 Hz), 1.20 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 
159.1, 137.3, 130.4, 129.4, 117.0, 113.6, 78.6, 74.7, 71.6, 70.9, 69.9, 57.0, 55.2, 37.4, 32.0, 24.4; 
HRMS (EI+) calcd. for C18H26O4 [M]
+  306.1831, found 306.1829. 
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Preparation of 185. To a stirred solution of 184 (62 mg, 0.19 mmol) in CH2Cl2 (1.8 mL) 
and saturated aqueous NaHCO3 (0.20 mL) was added DDQ (84 mg, 0.37 mmol) at 23 °C under 
an air atmosphere. After 1.5 h at the same temperature, the reaction mixture was poured onto 
H2O (15 mL), and the resulting mixture was extracted with Et2O (3 × 10 mL). The combined 
organic layers were washed with saturated aqueous NaHCO3 (10 mL) then brine (10 mL), dried 
over over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification of 
the residue by flash chromatography (5 → 25% Et2O in hexanes) on silica gel (5 mL) afforded 
185 (31 mg, 89%) as a pale yellow oil. 
 
O
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OMe
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OMe
quant.
dr = 1:1
 
Preparation of 186. To a stirred solution of 185 (26.8 mg, 0.144 mmol) and 3,4-dihydro-2H-
pyran (20 µL, 0.22 mmol) in CH2Cl2 (0.5 mL) was added CSA (1.7 mg, 7.3 µmol) at 23 °C 
under a nitrogen atmosphere. After 1 h at the same temperature, the reaction mixture was 
quenched with saturated aqueous NaHCO3 (1 mL). The resulting mixture was diluted with Et2O 
(5 mL), washed with brine (5 mL), dried over over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure. Purification of the residue by flash chromatography (2.5 → 10% EtOAc 
in hexanes) on silica gel (5 mL) afforded 186 (41.2 mg, quant. yield) as a colorless oil. 
Data for 186: Rf = 0.24 (60% EtOAc in hexanes); IR (neat): 2940, 1442, 1365, 1126, 
1101, 1073, 1035, 974 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 6.36 (d, 1H, J = 16.0 Hz), 
6.30−6.23 (m, 1H), 5.98 (br d, 1H, J = 11.5, 7.5 Hz), 5.90 (ddd, 1H, J = 11.5, 1.5, 1.0 Hz), 5.71 
 187 
(dd, 1H, J = 11.5, 1.0 Hz), 5.57−5.51 (m, 2H), 4.07 (br app t, 1H, J = 8.5 Hz), 3.92−3.89 (m, 
1H), 3.66 (qd, 1H, 9.5, 8.5, 2.3 Hz), 3.09 (d, 1H, J = 9.5 Hz), 2.40−2.33 (m, 1H), 2.25−2.19 (m, 
1H), 2.14 (br s, 1H), 2.01 (s, 3H), 1.98−1.92 (m, 2H), 1.91−1.88 (m, 1H), 1.79 (d, 1H, J = 14.5 
Hz), 1.78 (br s, 3H), 1.54 (d, 1H, J = 14.5 Hz), 1.41 (s, 3H), 1.34 (d, 1H, J = 6.3 Hz), 1.23 (s, 
3H), 1.16 (s, 3H), 1.11 (d, 3H, J = 7.0 Hz), 1.01 (d, 3H, J = 7.5 Hz); 13C NMR (75 MHz, 293K, 
CDCl3) δ 137.6, 137.0, 117.4, 117.0, 100.8, 94.7, 92.6, 78.9, 77.7, 73.3, 72.9, 71.7, 71.6, 70.3, 
69.7, 63.0, 62.4, 57.0, 56.6, 37.7. 36.8, 32.2, 32.1, 30.7, 30.3, 25.5, 25.4, 24.5, 24.4, 19.8, 19.5, 
18.4; HRMS (ESI+) calcd. for C15H26O4Na [M + Na]
+  293.1729, found 293.1722. 
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Preparation of 187. To a stirred solution of 47 (27.4 mg, 0.0784 mmol) and 178 (31.5 
mg, 0.103 mmol) in ClCH2CH2Cl (300 µL) was added benzoquinone (1.8 mg, 0.017 mmol), 
followed by Grela catalyst (5.5 mg, 8.2 µmol) at 23 °C under an open atmosphere. The reaction 
mixture was then heated to 42 °C. After 9 h, the reaction was concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (10 → 40% EtOAc in 
hexanes) on silica gel (5 mL) to give 187 (13.1 mg, 27%), and an inseparable mixture of 47 and 
178 (45.6 mg). 
To a stirred solution of recovered 47 and 178 (45.3 mg) in ClCH2CH2Cl (300 µL) was 
added benzoquinone (1.4 mg, 0.013 mmol) and Grela catalyst (4.2 mg, 6.3 µmol) at 23 °C under 
an open atmosphere. The reaction mixture was then heated to 40 °C. After 16.5 h at the same 
temperature, the reaction was concentrated under reduced pressure. The resulting residue was 
 188 
purified by flash chromatography (10 → 40% EtOAc in hexanes) on silica gel (4 mL) to give 
187 (7.1 mg, 14%) as a pale tan solid. The combined yield of 187 after two cycles is 20.2 mg 
(41%).  
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Preparation of 167 from 187. Acetal 187 (20.0 mg, 0.0320 mmol) was dissolved in 
AcOH/THF/H2O (3:1:1 v/v/v, 400 µL) at 23 °C under an open atmosphere. After 20 h at the 
same temperature, the reaction mixture was concentrated under reduced pressure. Purification of 
the residue by flash chromatography (20 → 80% EtOAc in hexanes) on silica gel (2 mL) 
afforded 167 (10.7 mg, 66%) as a white solid. Some of this material was purified by HPLC and 
used for biological experiments.* 
Data for 167: Rf = 0.24 (60% EtOAc in hexanes); IR (neat): 3423 (br), 2973, 1734 
(C=O), 1665 (C=O), 1636, 1523, 1369, 1244, 1053, 970 cm-1; [α]D
25 −19.5 (c 0.65, CH2Cl2); 
1H 
NMR (500 MHz, 293K, CD2Cl2) δ 6.36 (d, 1H, J = 16.0 Hz), 6.30−6.23 (m, 1H), 5.98 (br d, 1H, 
J = 11.5, 7.5 Hz), 5.90 (ddd, 1H, J = 11.5, 1.5, 1.0 Hz), 5.71 (dd, 1H, J = 11.5, 1.0 Hz), 
5.57−5.51 (m, 2H), 4.07 (br app t, 1H, J = 8.5 Hz), 3.92−3.89 (m, 1H), 3.66 (qd, 1H, 9.5, 8.5, 2.3 
Hz), 3.53 (ddd, 1H, J = 7.0, 7.0, 2.3 Hz), 3.09 (d, 1H, J = 9.5 Hz), 2.40−2.33 (m, 1H), 2.25−2.19 
(m, 1H), 2.14 (br s, 1H), 2.01 (s, 3H), 1.98−1.92 (m, 2H), 1.91−1.88 (m, 1H), 1.79 (d, 1H, J = 
14.5 Hz), 1.78 (br s, 3H), 1.54 (d, 1H, J = 14.5 Hz), 1.41 (s, 3H), 1.34 (d, 1H, J = 6.3 Hz), 1.23 
(s, 3H), 1.16 (s, 3H), 1.11 (d, 3H, J = 7.0 Hz), 1.01 (d, 3H, J = 7.5 Hz); 13C NMR (125 MHz, 
293K, CD2Cl2) δ 170.6, 165.0, 143.9, 139.1, 134.8, 129.9, 125.7, 122.8, 81.2, 76.3, 75.3, 72.7, 
 189 
72.3, 70.5, 68.9, 47.4, 47.2, 36.2, 32.5, 32.4, 32.0, 29.6, 28.8, 24.4, 20.2, 18.0, 15.2, 12.8; HRMS 
(ESI+) calcd. for C28H45NO7Na [M + Na]
+  530.3094, found 530.3091. 
 * HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 3.6 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 14.0 min. 
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Preparation of 188. To a stirred solution of 47 (27.4 mg, 0.0784 mmol) and 183 (31.5 
mg, 0.103 mmol) in ClCH2CH2Cl (300 µL) was added benzoquinone (1.8 mg, 0.017 mmol), 
followed by Grela catalyst (5.5 mg, 8.2 µmol) at 23 °C under an open atmosphere. The reaction 
mixture was then heated to 40 °C. After 11 h, the reaction was concentrated under reduced 
pressure. The resulting residue was purified by flash chromatography (10 → 40% EtOAc in 
hexanes) on silica gel (5 mL) to give 188 (13.9 mg, 30%), and an inseparable mixture of 47 and 
183 (39.0 mg). 
To a stirred solution of recovered 47 and 183 (38.7 mg) in ClCH2CH2Cl (300 µL) was 
added benzoquinone (1.4 mg, 0.013 mmol) and Grela catalyst (4.2 mg, 6.3 µmol) at 23 °C under 
an open atmosphere. The reaction mixture was then heated to 40 °C. After 13 h at the same 
temperature, the reaction was concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (10 → 40% EtOAc in hexanes) on silica gel (4 mL) to give 
188 (7.1 mg, 14%) as a pale tan solid. The combined yield of 188 after two cycles is 22.0 mg 
(48%).  
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Preparation of 169 from 188. THP-ether 188 (21.6 mg, 0.0353 mmol) was dissolved in 
AcOH/THF/H2O (3:1:1 v/v/v, 500 µL) at 23 °C under an open atmosphere. After 3 h at the same 
temperature, the reaction mixture was concentrated under reduced pressure. Purification of the 
residue by flash chromatography (20 → 80% EtOAc in hexanes) on silica gel (2 mL) afforded 
168 (11.8 mg, 68%) as a white solid. Some of this material was purified by HPLC and used for 
biological experiments.† 
Data for 168: Rf = 0.22 (60% EtOAc in hexanes); IR (neat): 3439 (br), 2973, 1725 
(C=O), 1664 (C=O), 1635, 1523, 1367, 1244, 1050 cm-1; [α]D
25 −8.6 (c 0.28, CH2Cl2); 
1H NMR 
(500 MHz, 293K, CD2Cl2) δ 6.37 (d, 1H, J = 15.5 Hz), 6.29−6.23 (m, 1H), 5.96 (br d, 1H, J = 
9.0 Hz), 5.90 (dd, 1H, J = 11.5, 7.5 Hz), 5.71 (dd, 1H, J = 11.5, 1.5 Hz), 5.55−5.52 (m, 1H), 5.53 
(dd, 1H, J = 15.5, 7.5 Hz), 4.15 (dd, 1H, J = 9.5, 7.5 Hz), 4.13−4.09 (m, 1H), 3.93−3.88 (m, 1H), 
3.66 (qd, 1H, J = 6.3, 2.3 Hz), 3.55−3.51 (m, 1H), 3.29 (ddd, 1H, J = 9.5, 3.5, 2.8 Hz), 2.40−2.33 
(m, 2H), 2.26−2.18 (m, 1H), 2.02−2.00 (m, 1H), 2.01 (s, 3H), 1.96−1.92 (m, 3H), 1.89 (d, 1H, J 
= 3.5 Hz), 1.78 (br s, 3H), 1.80−1.74 (m, 1H), 1.66 (dd, 1H, J = 14.5, 2.5 Hz), 1.42 (s, 3H), 1.34 
(d, 3H, J = 6.5 Hz), 1.17 (s, 3H), 1.11 (d, 3H, J = 6.3 Hz), 1.01 (d, 3H, J = 7.0 Hz); 13C NMR 
(125 MHz, 293K, CD2Cl2) δ 170.6, 164.9, 143.9, 139.1, 134.8, 130.0, 125.5, 122.8, 81.1, 76.3, 
71.73, 71.68, 71.4, 68.9, 67.8, 47.4, 41.4, 36.2, 32.4, 32.2, 29.6, 25.4, 21.4, 20.2, 17.9, 15.3, 
12.8; HRMS (ESI+) calcd. for C27H43NO7Na [M + Na]
+  516.2937, found 516.2937. 
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† HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 3.2 mL/min, 40% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 12.2 min. 
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Preparation of 189. A solution of 47 (42.4 mg, 0.121 mmol) was prepared in 
ClCH2CH2Cl (200 µL) at 23 °C under an open atmosphere. To a stirred solution of 186 (27.2 mg, 
0.101 mmol) in ClCH2CH2Cl (300 µL) was added the solution of 47 (100 µL), benzoquinone 
(2.2 mg, 0.020 mmol), followed by Grela catalyst (3.4 mg, 5.0 µmol) at 23 °C under an open 
atmosphere. The reaction mixture was then heated to 45 °C. After 1.5 h at the same temperature, 
additional Grela catalyst (3.4 mg, 5.0 µmol) and 47 (100 µL) were added. After 8.5 total hours, 
the reaction was concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 40% EtOAc in hexanes) on silica gel (5 mL) to give 189 (16.5 mg, 28%), 
and an inseparable mixture of 47 and 186 (45.9 mg). 
To a stirred solution of recovered 47 and 186 (45.5 mg) in ClCH2CH2Cl (400 µL) was 
added benzoquinone (2.0 mg, 0.019 mmol) and Grela catalyst (6.1 mg, 9.0 µmol) at 23 °C under 
an open atmosphere. The reaction mixture was then heated to 40 °C. After 13 h at the same 
temperature, the reaction was concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (10 → 40% EtOAc in hexanes) on silica gel (4 mL) to give 
189 (5.4 mg, 9%) as a pale tan solid. This recycling procedure was repeated one more time to 
give 189 (1.8 mg, 3%). The combined yield of 189 after two cycles is 23.7 mg (40%).  
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Preparation of 169 from 189. THP-ether 189 (23.5 mg, 0.0397 mmol) was dissolved in 
AcOH/THF/H2O (3:1:1 v/v/v, 500 µL) at 23 °C under an open atmosphere. After 15 h at the 
same temperature, the reaction mixture was concentrated under reduced pressure. Purification of 
the residue by flash chromatography (20 → 80% EtOAc in hexanes) on silica gel (2 mL) 
afforded 169 (12.7 mg, 63%) as a white solid. Some of this material was purified by HPLC and 
used for biological experiments.‡ 
Data for 169: Rf = 0.31 (60% EtOAc in hexanes); IR (neat): 3444 (br), 3364 (br), 2933, 
1737 (C=O), 1668 (C=O), 1637, 1521, 1368, 1244, 1051 cm-1; [α]D
25 +4.5 (c 0.53, CH2Cl2); 
1H 
NMR (500 MHz, 293K, CD2Cl2) δ 6.21 (br d, 1H, J = 16.0 Hz), 6.30−6.23 (m 1H), 5.96 (br d, 
1H, J = 9.0 Hz), 5.90 (dd, 1H, J = 11.5, 8.0 Hz), 5.71 (dd, 1H, J = 11.5, 1.3 Hz), 5.61 (dd, 1H, J 
= 16.0, 6.7 Hz), 5.50 (br app t, J = 7.0 Hz), 4.06 (br dd, 1H, J = 9.5, 6.7 Hz), 3.92−3.88 (m, 1H), 
3.65 (qd, 1H, J = 6.3, 3.0 Hz), 3.61 (ddd, 1H, J = 3.5, 3.3, 3.0 Hz), 3.39 (s, 3H), 3.23 (ddd, 1H, J 
= 9.8, 9.5, 3.5 Hz), 2.39−2.32 (m, 1H), 2.38 (d, 1H, J = 9.8 Hz), 2.24−2.18 (m, 1H), 2.08 (dd, 
1H, J = 14.8, 3.3 Hz), 2.01 (s, 3H), 1.98−1.91 (m, 2H), 1.80−1.74 (m, 1H), 1.77 (br s, 3H), 1.47 
(dd, 1H, 14.8, 3.0 Hz), 1.35 (s, 3H), 1.34 (d, 3H, J = 6.5 Hz), 1.17 (s, 3H), 1.11 (d, 3H, J = 6.3 
Hz), 1.01 (d, 3H, J = 7.5 Hz); 13C NMR (125 MHz, 293K, CD2Cl2) δ 170.6, 164.9, 143.9, 137.3, 
135.1, 128.9, 126.6, 122.8, 81.2, 77.6, 76.2, 72.0, 71.6, 71.5, 68.9, 56.8, 47.4, 37.2, 36.2, 32.3, 
32.1, 29.5, 24.4, 21.4, 20.2, 18.0, 15.3, 12.7; HRMS (ESI+) calcd. for C28H45NO7Na [M + Na]
+  
530.3094, found 530.3094. 
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‡ HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 3.2 mL/min, 50% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 14.0 min. 
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Preparation and data for (Z)-4-acetoxy-2-buten-1-ol. See Bauman, H.; Duthaler, R. O.  
Helv. Chim. Acta 1988, 71, 1025−1034. 
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Preparation of 190. To a stirred solution of (Z)-4-acetoxy-2-buten-1-ol (521 mg, 4.00 
mmol) in CH2Cl2 (20 mL) was added Dess-Martin periodinane (3.39 g, 7.99 mmol) at 23 °C 
under a nitrogen atmosphere. After an additional 1.5 h at the same temperature, the reaction was 
quenched by the addition of EtOH (250 µL).  After an additional 3 min, the reaction mixture was 
concentrated under reduced pressure, filtered through a pad of Florisil (15 mL), and rinsed with 
40% Et2O in pentane (75 mL). The filtrate was concentrated under reduced pressure and afforded 
a mixture of aldehyde 190 and AcOH (718 mg) as a colorless oil. This material was used in the 
next reaction without further purification. 
Data for 190: Rf = 0.44 (40% EtOAc in hexanes); 
1H NMR (300 MHz, 293K, CDCl3) δ 
10.04 (d, 1H, J = 6.3 Hz), 6.55 (td, 1H, J = 11.5, 6.1 Hz), 6.13 (ddt, 1H, J = 11.5, 6.3, 1.9 Hz), 
5.11 (dd, 1H, J = 6.1, 1.9 Hz), 2.13 (s, 3H). 
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Preparation of 191. To a stirred solution of 190 (714 mg, ~4.0 mmol) and 2-methyl-2-
butene (6.5 mL, 60 mmol) in tBuOH (10 mL) was added the mixture of NaClO2 (257 mg, 2.84 
mmol) and NaH2PO4 (393 mg, 2.84 mmol) in H2O (10 mL) at 23 °C under an open atmosphere. 
After an additional 0.5 h at the same temperature, the reaction was quenched by the addition of 
EtOH (250 µL).  After an additional 3 min, the reaction mixture was poured onto aqueous HCl 
(1N, 18 mL), and the resulting mixture was extracted with EtOAc (4 × 20 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. Purification of the residue by flash chromatography (5 → 30% EtOAc in hexanes 
containing 1% AcOH) on silica gel (75 mL) afforded acid 191 (485 mg, 80% from XX) 
as a colorless oil. 
Data for 191: Rf = 0.26 (40% EtOAc in hexanes containing 1% AcOH); IR (neat): 3057 
(br, O-H), 1744 (C=O), 1700 (C=O), 1437, 1374, 1233, 1042 cm-1; 1H NMR (300 MHz, 293K, 
CDCl3) δ 6.41 (dt, 1H, J = 11.7, 5.0 Hz), 5.91 (dt, 1H, J = 2.4 Hz), 5.18 (dd, 1H, J = 5.0, 2.4 Hz), 
2.12 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 171.0, 170.8, 147.5, 120.0, 62.7, 20.7; HRMS 
(EI+) calcd. for C6H9O4 [M + H]
+  145.0501, found 145.0497. 
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Preparation of 192. To a stirred solution of 2-methyl-3-butyn-2-ol (390 µL, 4.02 mmol) 
in THF (28 mL) at −78 °C was added nBuLi (5.3 mL, 8.5 mmol) under a nitrogen atmosphere. 
After 1 h at the same temperature, the reaction mixture was warmed to 0 °C, and dry CO2 was 
 195 
bubbled through the reaction mixture. After 2 h at 23 °C, the reaction was diluted with aqueous 
NaOH (1N, 75 mL), and washed with CH2Cl2 (30 mL).  The resulting aqueous layer was 
acidified with aqueous HCl (12 N, 9 mL) until the pH was approximately 1, and then extracted 
with EtOAc (8 × 40 mL).  The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure to afford acid 192 (524 mg, quant. yield) as a 
white solid.  This material was used in the next reaction without further purification. 
Data for 192: Rf = 0.13 (1% AcOH in EtOAc); 
1H NMR (300 MHz, 293K, CD3OD) δ 
1.50 (s, 6H). 
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Preparation of 193. To crude 192 (509 mg, 3.97 mmol) in CH2Cl2 (1 mL) was added 
added acetyl chloride (4.0 mL, 56 mmol) slowly over 5 min at 0 °C under a nitrogen atmosphere. 
After 10 min at the same temperature, the reaction mixture was warmed to 23 °C. After 30 min at 
the same temperature, the solvents were evaporated under a stream of dry nitrogen. The resulting 
residue was dissolved in pH 9.5 H2O (Na2CO3) at 23 °C. After 5 min at the same temperature, 
the mixture was diluted with aqueous HCl (3N, 0.5 mL) until the pH was approximately 2. The 
aqueous mixture was then extracted with EtOAc (5 × 10 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified by flash chromatography (20 → 100% EtOAc in hexanes containing 1% 
AcOH) on silica (25 mL) to afford acid 193 (671 mg, 99%). 
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Preparation of 194. To a mixture of Lindlar catalyst (85.1 mg, 0.040 mmol) in EtOH (45 
mL) was added quinoline (55 µL, 0.47 mmol), and was stirred for 30 min at 23 °C. To the 
mixture was added a solution of 193 (665 mg, 3.95 mmol) in EtOH (5 mL) and the container that 
originally contained 193 was rinsed with additional EtOH (2 × 5 mL), and the resulting mixture 
was stirred vigorously under a hydrogen atmosphere (1 atm) for 16 h at 23 °C. The mixture was 
filtered through paper filter and washed with EtOAc. The filtrate was concentrated under reduced 
pressure. Purification of the residue by flash chromatography (10 → 40% EtOAc in hexanes 
containing 1% AcOH) afforded acid 194 (212 mg, 31%) as a colorless oil. 
Data for 194: Rf = 0.46 (30% EtOAc in hexanes containing 1% AcOH); IR (neat): 3197 
(br, O-H), 2984, 1734 (C=O), 1705 (C=O), 1368, 1252, 1127 cm-1; 1H NMR (300 MHz, 293K, 
CDCl3) δ 6.36 (d, 1H, J = 13.1 Hz), 5.74 (d, 1H, J = 13.1 Hz), 2.01 (s, 3H), 1.68 (s, 6H); 
13C 
NMR (75 MHz, 293K, CDCl3) δ 170.9, 170.2, 152.0, 117.3, 80.5, 26.0, 21.7; HRMS (EI+) 
calcd. for C8H12O4 [M]
+  172.0736, found 172.0734. 
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Preparation of 195. To a stirred solution of 28 (135 mg, 0.501 mmol) was added 
TFA/CH2Cl2 (1:9, 5 mL) at 0 °C under an open atmosphere. After 1.5 h at the same temperature, 
the reaction was concentrated under reduced pressure to give a lavender oil. This material was 
used in the next reaction without further purification. 
 197 
 To a stirred solution of acid 191 (86.4 mg, 0.599 mmol) in CH3CN (3 mL) at 23 °C was 
added O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethylronium hexafluorophoshate (246 mg, 
0.647 mmol), followed by N,N-diisopropylethylamine (350 µL, 2.00 mmol) under a nitrogen 
atmosphere. The resulting mixture was then transferred by cannula to a stirred solution of the 
ammonium trifluororacetate in CH3CN (2 mL) at the same temperature and rinsed with 
additional CH3CN (1 mL). After 5 h at 23 °C, the reaction was quenched with saturated aqueous 
NH4Cl (5 mL) and most of the organic solvent was removed under reduced pressure. The 
aqueous residue was extracted with EtOAc (4 × 5 mL). The combined organic layers were 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The crude residue was purified by flash chromatography (10 → 40% EtOAc in 
hexanes) on silica (10 mL) to afford amide 195 (90.6 mg, 61%) as a colorless oil.  
Data for 195: Rf = 0.45 (40% EtOAc in hexanes); IR (neat): 3367 (br, N-H), 2937, 1742 
(C=O), 1670 (C=O), 1635, 1521, 1372, 1063, 1036 cm-1; [α]D
26 −41.5 (c 0.94, CHCl3); 
1H NMR 
(300 MHz, 293K, CDCl3) δ 6.04 (ddd, 1H, 11.5, 5.3, 5.3 Hz), 5.87−5.72 (m, 3H), 5.28−5.23 (m, 
2H), 5.12 (dddd, 1H, J = 17.2, 1.6, 1.6, 1.6 Hz), 5.09−5.04 (m, 1H), 3.96 (qd, 1H, J = 6.5, 3.0 
Hz), 3.67 (qd, 1H, J = 6.5 2.2 Hz), 3.56 (ddd, 1H, J = 7.3, 7.3, 2.8 Hz), 2.41−2.29 (m, 1H), 
2.20−2.09 (m, 1H), 2.09 (s, 3H), 1.97−1.92 (m, 2H), 1.84−1.76 (m, 1H), 1.15 (d, 3H, J = 6.5 Hz), 
1.03 (d, 3H, J = 7.3 Hz); 13C NMR (75 MHz, 293K, C6D6) δ 169.9, 164.7, 140.5, 135.3, 123.5, 
116.6, 80.6, 75.9, 63.0, 47.1, 37.9, 35.9, 29.1, 20.4, 17.9, 15.0; HRMS (EI+) calcd. for 
C16H25NO4 [M]
+  295.1784, found 295.1779. 
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Preparation of 196. To a stirred solution of alkene 195 (73.8 mg, 0.250 mmol) and 
methacrolein (400 µL, 4.85 mmol) in benzene (1.25 mL) was added and benzoquinone (5.9 mg, 
0.055 mmol), followed by Grela’s catalyst (13.5 mg, 0.0201 mmol) at 23 °C under a nitrogen 
atmosphere. After 17 h at the same temperature, the solvent was removed under reduced pressure 
and the crude residue was purified by flash chromatography (10 → 50% EtOAc in hexanes) on 
silica (8 mL) to afford aldehyde 196 (19.6 mg, 23%, 46% based on recovered 195) as a pale 
yellow oil. 
Data for 196: Rf = 0.45 (40% EtOAc in hexanes); IR (neat): 3367 (br, N-H), 2934, 1740 
(C=O), 1671 (C=O), 1521, 1372, 1233, 1068, 1035 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 
9.43 (br s, 1H), 6.54 (dd, 1H, J = 6.4, 6.4 Hz, 6.05 (ddd, 1H, 11.5, 5.2, 5.2 Hz), 5.88−5.80 (m, 
1H), 5.79 (ddd, 1H, J = 11.5, 2.0, 2.0 Hz), 5.25 (app dd,* 2H, J = 5.2, 2.0 Hz), 4.01−3.95 (m, 
1H), 3.75−3.63 (m, 2H), 2.64−2.52 (m, 1H), 2.47−2.36 (m, 1H), 2.09 (s, 3H), 2.01−1.95 (m, 2H), 
1.88−1.80 (m, 1H), 1.77 (br s, 3H), 1.16 (d, 1H, J = 6.4 Hz), 1.07 (d, 3H, J = 7.4 Hz); 13C NMR 
(75 MHz, 293K, CDCl3) δ 190.0, 170.8, 164.9, 150.3, 140.7, 140.6, 123.0, 79.7, 76.1, 62.7, 46.8, 
35.7, 32.7, 29.5, 20.9, 17.8, 15.2, 9.5; HRMS (EI+) calcd. for C18H27NO5 [M]
+  337.1889, found 
337.1903. 
* unable to see geminal coupling 
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Preparation of 197. To a stirred suspension of methyltriphenylphosphonium bromide 
(33.3 mg, 0.0932 mmol) in THF (0.2 mL) at 0 °C was added KOtBu (9.4 mg, 0.0838 mmol) 
under a nitrogen atmosphere. After 30 min, aldehyde 196 (14.3 mg, 0.0424 mmol) was added in 
THF (0.1 mL) at the same temperature and the container that originally contained 196 was rinsed 
with additional THF (2 × 0.1 mL) and added to the ylide solution. After 2 h at 23 °C, the reaction 
was quenched with saturated aqueous NH4Cl (3 mL), then most of the solvent was removed 
under reduced pressure, and the aqueous residue was extracted with EtOAc (3 × 3 mL). The 
combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered 
and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (10 → 40% EtOAc in hexanes) on silica (2 mL) to afford diene 197 (8.2 mg, 
58%) as a colorless oil. 
Data for 197: Rf = 0.47 (50% EtOAc in hexanes); IR (neat): 3366 (br, N-H), 2926, 1739 
(C=O), 1667 (C=O), 1634, 1522, 1373, 1234, 1064 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 
6.38 (dd, 1H, J = 17.4, 10.7 Hz), 6.05 (ddd, 1H, 11.5, 5.3, 5.3 Hz) 5.77 (ddd, 1H, J = 11.5, 2.1, 
2.1 Hz), 5.46 (br app t, J = 7.1 Hz), 5.25 (app dd,§ 2H, J = 5.3, 2.1 Hz), 5.12 (d, 1H, J = 17.4 
Hz), 4.97 (d, 1H, J = 10.7 Hz), 4.00−3.92 (m, 1H), 3.68 (qd, 1H, J = 6.5, 2.8, 2.2 Hz), 3.55 (ddd, 
1H, 7.3, 7.3, 2.8 Hz), 2.45−2.35 (m, 1H), 2.32−2.22 (m, 1H), 2.09 (s, 3H), 1.96−1.92 (m, 1H), 
1.85−1.77 (m, 1H), 1.77 (br s, 3H), 1.15 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.3 Hz); 13C NMR 
(75 MHz, 293K, CDCl3) δ 170.7, 164.9, 141.3, 140.5, 135.7, 128.0, 123.3, 111.1, 80.9, 76.0, 
62.7, 47.2, 35.9, 31.9, 29.0, 20.9, 17.9, 15.2, 11.9; HRMS (EI+) calcd. for C19H29NO4 [M]
+  
335.2100, found 335.2105. 
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Preparation of 198. To a stirred solution of 28 (135 mg, 0.501 mmol) was added 
TFA/CH2Cl2 (1:9, 5 mL) at 0 °C under an open atmosphere. After 1.5 h at the same temperature, 
the reaction was concentrated under reduced pressure to give a lavender oil. This material was 
used in the next reaction without further purification. 
 To a stirred solution of acid 194 (104 mg, 0.604 mmol) in CH3CN (3 mL) at 23 °C was 
added O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethylronium hexafluorophoshate (246 mg, 
0.647 mmol), followed by N,N-diisopropylethylamine (350 µL, 2.00 mmol) under a nitrogen 
atmosphere. The resulting mixture was then transferred by cannula to a stirred solution of the 
ammonium trifluororacetate in CH3CN (1.5 mL) at the same temperature and rinsed with 
additional CH3CN (2 × 0.5 mL). After 4 h at 23 °C, the reaction was quenched with saturated 
aqueous NH4Cl (6 mL) and most of the organic solvent was removed under reduced pressure. 
The aqueous residue was extracted with EtOAc (3 × 7 mL). The combined organic layers were 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The crude residue was purified by flash chromatography (10 → 40% EtOAc in 
hexanes) on silica (10 mL) to afford amide 198 (110 mg, 68%) as a colorless oil.  
Data for 198: Rf = 0.44 (40% EtOAc in hexanes); IR (neat): 3359 (br, N-H), 2936, 1733 
(C=O), 1669 (C=O), 1508, 1368, 1254, 1127, 1063 cm-1; [α]D
26 −23.8 (c 0.97, CHCl3); 
1H NMR 
(300 MHz, 293K, C6D6) δ 6.00 (d, 1H, J = 13.0 Hz), 5.74 (dddd, 1H, J = 17.4, 10.6, 7.8, 6.2 Hz), 
5.56 (br d, 1H, J = 8.3 Hz), 5.26 (d, 1H, J = 13.0 Hz), 5.09−4.97 (m, 2H), 3.94−3.87 (m, 1H), 
 201 
3.22−3.12 (m, 2H), 2.34−2.21 (m, 1H), 2.00−1.86 (m, 1H), 1.89 (s, 3H), 1.88 (s, 3H), 1.84−1.76 
(m, 2H), 1.73 (s, 3H), 1.52−1.42 (m, 1H), 1.04 (d, 3H, J = 6.4 Hz), 0.81 (d, 3H, J = 7.3 Hz); 
13
C 
NMR (75 MHz, 293K, C6D6) δ 169.5, 165.0, 146.2, 135.4, 121.5, 116.5, 81.5, 80.6, 76.0, 47.1, 
37.9, 35.9, 29.2, 26.6, 26.3, 21.8, 18.0, 15.0; HRMS (EI+) calcd. for C18H29NO4 [M]
+ 
 323.2097, 
found 323.2082. 
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Preparation of 199. To a stirred solution of alkene 198 (81.1 mg, 0.251 mmol) and 
methacrolein (400 µL, 4.85 mmol) in benzene (1.25 mL) was added benzoquinone (5.9 mg, 
0.055 mmol), followed by Grela’s catalyst (13.4 mg, 0.0200 mmol), at 23 °C under a nitrogen 
atmosphere. After 17 h at 23 °C, the solvent was removed under reduced pressure and the crude 
residue was purified by flash chromatography (10 → 50% EtOAc in hexanes) on silica (8 mL) to 
afford aldehyde 199 (52.3 mg, 57%, 79% based on recovered 198) as a pale yellow oil. 
Data for 199: Rf = 0.30 (50% EtOAc in hexanes); IR (neat): 3360 (br, N-H), 2936, 1732 
(C=O), 1685 (C=O), 1671 (C=O), 1513, 1367, 1255, 1127, 1068 cm
-1
; [α]D
26
 −23.8 (c 0.97, 
CHCl3); 
1
H NMR (300 MHz, 293K, C6D6) δ 9.31 (s, 1H), 6.07 (ddd, 1H, J = 6.3, 6.3, 0.9 Hz), 
6.00 (d, 1H, J = 13.0 Hz), 5.54 (br d, 1H, J = 8.5 Hz), 5.39 (d, 1H, J = 13.0 Hz), 3.91 (dddd, 1H, 
J = 8.5, 4.4, 2.2, 2.2 Hz), 3.14 qd, 1H, J = 6.4, 2.2 Hz), 3.02 (ddd, 1H, J = 8.4, 5.5, 2.9 Hz), 
2.26−2.15 (m, 1H), 1.89 (s, 3H), 1.88 (s, 3H), 1.84−1.81 (m, 1H), 1.80−1.77 (m, 1H), 1.72 (s, 
3H), 1.66 (br s, 3H), 1.50−1.40 (m, 1H), 1.18−1.10 (m, 1H), 1.01 (d, 3H, J = 6.4 Hz), 0.73 (d, 
3H, J = 7.4 Hz); 
13
C NMR (75 MHz, 293K, C6D6) δ 193.9, 169.6, 165.2, 149.5, 146.1, 140.6, 
 202 
121.4, 81.4, 79.6, 76.2, 46.9, 35.7, 32.8, 29.6, 26.6, 26.3, 21.8, 17.9, 15.0, 9.4; HRMS (EI+) 
calcd. for C18H29NO4 [M − OAc]
+ 
 306.2069, found 306.2069. 
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Preparation of 200. To a stirred suspension of methyltriphenylphosphonium bromide 
(85.8 mg, 0.240 mmol) in THF (0.5 mL) at 0 °C was added KO
t
Bu (22.3 mg, 0.199 mmol) under 
a nitrogen atmosphere. After 30 min, aldehyde 199 (36.8 mg, 0.101 mmol) was added in THF 
(0.3 mL) at the same temperature and the container that originally contained 199 was rinsed with 
additional THF (2 × 0.1 mL) and added to the reaction mixture. After 2 h at the same 
temperature, the reaction was quenched with saturated aqueous NH4Cl (4 mL), then most of the 
solvent was removed under reduced pressure, and the aqueous residue was extracted with EtOAc 
(3 × 5 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by 
flash chromatography (10 → 30% EtOAc in hexanes) on silica (4 mL) to afford diene 200 (25.5 
mg, 69%) as a colorless oil. 
 Data for 200: 
1
H NMR (300 MHz, 293K, C6D6) δ 6.44 (dd, J = 17.4, 10.7 Hz), 6.00 (d, J 
= 13.0 Hz), 5.62 (br d, J = 8.7 Hz), 5.46 (br app t, J = 7.2 Hz), 5.29 (d, J = 13.0 Hz), 5.11 (d, J = 
17.4 Hz), 4.98 (d, J = 12.5 Hz), 4.96 (d, J = 11.0 Hz), 4.49 (br d, 1H, J = 7.7 Hz), 3.95−3.89 (m), 
3.42 (br d, J = 7.8 Hz), 3.24−3.14 (m), 2.43−2.31 (m), 2.14−2.02 (m), 1.89 (s), 1.88 (s), 
1.87−1.77 (m), 1.73 (s), 1.68 (br s), 1.52−1.44 (m), 1.36−1.26 (m), 1.05 (d, J = 6.5 Hz), 0.99 (d, 
J = 6.3 Hz), 0.92 (d, J = 6.3 Hz), 0.82 (d, J = 7.3 Hz). 
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Preparation of 201 on a preparative scale. To a stirred solution of 162 (42.8 mg, 0.101 
mmol) in THF (0.40 mL) was added TBAF (1.0 M in THF, 120 µL, 0.120 mmol) at 0 °C under 
an open atmosphere. After 30 min at the same temperature, the reaction mixture was diluted with 
Et2O (5 mL), filtered through a pad of Florisil, rinsed with Et2O (3 × 5 mL), and concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography (10 → 30% 
EtOAc in hexanes) on silica gel (2 mL) to afford 201 (31.1 mg, 99%) as a colorless oil.  
Preparation of 201 on microscale. To a solution containing iodoether 162 and alcohol 
148 (500 µL, ~10.5 µmol combined) in THF (75 µL) was added TBAF (1.0 M, 25 µL) at 0 °C 
under an open atmosphere.  After 1.0 h at the same temperature, the reaction mixture was filtered 
through a pad of Florisil (0.5 mL), rinsed with Et2O (3 × 2 mL), and concentrated under reduced 
pressure. 
Data for 201: Rf = 0.25 (30% EtOAc in hexanes); IR (neat): 3434 (br, O-H), 2923, 1458, 
1377, 1267, 1065, 929, 730 cm
-1
; 
1
H NMR (300 MHz, 293K, CD2Cl2) δ 6.01 (ddd, 0.5H, J = 
17.1, 10.8, 5.4 Hz), 5.98 (ddd, 0.5H, J = 16.8, 10.8, 5.9 Hz), 5.48 (dddd, 1H, J = 17.2, 7.4, 1.7, 
1.7 Hz), 5.36−5.25 (m, 1H), 4.00−3.93 (m, 0.5H), 3.94 (d, 0.5H, J = 11.4 Hz), 3.80 (br dd, 0.5H, 
J = 9.8, 5.9 Hz), 3.60−3.44 (m, 1H), 3.37 (d, 0.5H, J = 11.4 Hz), 3.35 (d, 0.5H, J = 10.2 Hz), 
3.30 (d, 0.5H, J = 10.2 Hz), 3.04 (d, 0.5H, J = 4.7 Hz), 3.03 (d, 0.5H, J = 4.8 Hz), 2.56 (d, 0.5H, 
J = 4.8 Hz), 2.54 (d, 0.5H, J = 4.7 Hz), 2.46 (d, 0.5H, J = 15.0 Hz), 2.38 (dd, 0.5H, J = 14.1, 0.6 
Hz), 1.75 (d, 0.5H, J = 15.0 Hz), 1.53 (d, 0.5H, J = 14.1 Hz), 1.53 (s, 1.5H), 1.34 (s, 1.5H); 
13
C 
NMR (75 MHz, 293K, CD2Cl2) δ 136.2, 135.9, 117.8, 116.9, 74.7, 74.4, 72.5, 72.2, 67.8, 67.3, 
57.2, 57.1, 47.7, 47.4, 40.5, 39.1, 29.0, 21.3, 19.3, 14.2. 
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Preparation of 202 on a preparative scale. A solution of 201 (14.8 mg, 0.0477 mmol) 
was prepared in ClCH2CH2Cl (100 µL) at 23 °C under an open atmosphere. To a stirred solution 
of 47 (14.0 mg, 0.0401 mmol) in ClCH2CH2Cl (100 µL) was added the solution of 201 (50 µL), 
benzoquinone (0.9 mg, 8 µmol), followed by Grela catalyst (1.3 mg, 1.9 µmol) at 23 °C under an 
open atmosphere. The reaction mixture was then heated to 38 °C. After 2.5 h at the same 
temperature, additional Grela catalyst (1.4 mg, 2.1 µmol) and 201 (50 µL) were added. After 9 
total hours, the reaction was concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (20 → 60% EtOAc in hexanes) on silica gel (2 mL) to give 
202 (9.4 mg, 37%), and an inseparable mixture of 47 and 201 (34.1 mg). 
To a stirred solution of recovered 47 and 201 (12.4 mg) in ClCH2CH2Cl (150 µL) was 
added Grela catalyst (1.4 mg, 2.1 µmol) and benzoquinone (0.7 mg, 6 µmol) at 23 °C under an 
open atmosphere. The reaction mixture was then heated to 38 °C. After an additional 8 h at the 
same temperature, the reaction was concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (20 → 60% EtOAc in hexanes) on silica gel (2 mL) to 
give 202 (3.7 mg, 15%) as a pale tan solid. The combined yield of 202 after one cycle is 13.1 mg 
(52%). Some of the tan 202 was purified by semi-preparative HPLC
†
 to afford this compound as 
a white solid that was subsequently used for biological experiments.  
Preparation of 202 on microscale. To a stirred solution of 47 (10.4 mg, 30 µmol) was 
added purified 201 (0.93 mg, 3.0 µmol) in ClCH2CH2Cl (65 µL) at 23 °C under an open 
atmosphere. To the mixture was added Grela catalyst (1.0 mg, 1.5 µmol) and the mixture was 
 205 
allowed to stir for an additional 20 h. After 20 h, the reaction mixture was filtered through a pad 
of Florisil (0.5 mL), rinsed with 80% EtOAc/hexanes (3 × 2 mL), and concentrated under 
reduced pressure to afford 202 and 47 as a mixture. 
Data for 202: Rf = 0.29 (60% EtOAc in hexanes); 
1
H NMR (500 MHz, 293K, CD2Cl2) δ 
6.46 (dd, J = 15.5 Hz), 6.43 (d, J = 16.0 Hz), 6.35−6.27 (m), 6.01 (br d, J = 9.0 Hz), 5.94 (dd, J = 
11.5, 7.5 Hz), 5.75 (dd, J = 11.5, 1.5 Hz), 5.70 (dd, J = 16.0, 6.5 Hz), 5.68 (dd, J = 16.0, 6.8 Hz), 
5.62−5.56 (m), 4.03 (br dd, J = 9.5, 6.8 Hz), 3.98 (d, J = 11.5 Hz), 3.98−3.92 (m), 3.86 (br dd, J 
= 9.0, 6.5 Hz), 3.72−3.68 (m), 3.59 (app t, J = 10.0 Hz) 3.62−3.56 (m), 3.53 (app t, J = 10.5 Hz), 
3.38 (d, J = 11.5 Hz), 3.35 (d, J = 10.5 Hz), 3.31 (d, J = 10.5 Hz), 3.05 (d, J = 4.8 Hz), 3.04 (d, J 
= 5.0 Hz), 2.58 (d, J = 4.8 Hz), 2.56 (d, J = 5.0 Hz), 2.48 (d, J = 14.8 Hz), 2.44−2.39 (m), 2.39 
(d, J = 15.2 Hz), 2.30−2.23 (m), 2.05 (s), 1.99−1.95 (m), 1.83 (br s), 1.83−1.80 (m), 1.75 (d, J = 
15.2 Hz), 1.66 (d, J = 10.5 Hz), 1.63 (d, J = 10.5 Hz), 1.54 (s), 1.54 (d, J = 14.8 Hz), 1.38 (d, J = 
6.5 Hz), 1.35 (s), 1.15 (d, J = 6.5 Hz), 1.05 (d, J = 7.5 Hz); 
13
C NMR (125 MHz, 293K, CD2Cl2) 
δ 170.8, 164.9, 143.9, 138.0, 129.8, 125.0, 122.8, 81.1, 76.2, 75.4, 74.9, 73.0, 72.7, 68.9, 68.4, 
68.0, 57.6, 48.1, 47.8, 47.4, 41.0, 36.2, 32.4, 32.3, 30.1, 29.5, 29.3, 21.7, 21.4, 20.2, 19.7, 17.9, 
15.3, 12.7; HRMS (ESI+) calcd. for C28H42INO7Na [M + Na]
+ 
 654.1904, found 654.1919. 
 
†
 HPLC purification was performed on a Varian Pursuit XRs 5 C18 column, 250 × 10.0 
cm, 4.0 mL/min, 40% MeCN/H2O → 100% MeCN linear gradient elution from 0.5 to 22 min, 
retention time = 24.7 and 25.1 min. 
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Preparation of 204 in organic solvent. To a stirred solution of Et3N (140 µL, 1.0 mmol) 
and N-acetylcysteamine (65 µL, 0.61 mmol) was added epoxide 79 (65 mg, 0.51 mmol) in 
MeCN (1.0 mL) at 23 °C under an open atmosphere. The reaction mixture was then warmed to 
61 °C and capped to prevent solvent evaporation. After 2 d at the same temperature, the reaction 
mixture was concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (1 → 5% MeOH in CH2Cl2) on silica gel (5 mL) to afford 204 (42 mg, 34%) as 
a pale yellow oil.  
Data for 204: TLC (5% MeOH in CH2Cl2): Rf = 0.24; [α]D
25
 −4.2 (c 0.45 in CHCl3); 
1
H-
NMR (300 MHz, 293K, D2O): δ 4.97 (br s, 1H), 4.82 (br s, 1H), 3.54 (br app s, 2H), 3.38 (br app 
t, 2H, J = 6.5 Hz); 2.78 (br app s, 2H), 2.72 (br app t, 2H, J = 6.5 Hz), 2.33 (d, 1H, J = 14.1 Hz), 
2.28 (d, 1H, J = 14.1 Hz), 1.98 (s, 3H), 1.80 (br s, 3H); 
13
C-NMR (75 MHz, 293K, D2O): δ 
176.1, 143.8, 117.3, 77.0, 67.4, 44.8, 40.8, 40.2, 34.2, 25.9, 23.8; IR (neat): 3308 (br), 3076, 
2924, 1653 (C=O), 1555, 1437, 1294, 1044, 894 cm
-1
; HRMS (ESI+) calcd. for C11H21NO3NaS 
[M + Na]
+ 
270.1140, found 270.1124. 
 
O O
205
CH2Br2
n-BuLi
43%
 
Procedure and data for the preparation of 1-oxaspiro[2.5]octane (205): T. J. 
Michnik, D. S. Matteson Synlett 1991, 631–632. 
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A representative procedure for the epoxide opening experiments with N-
acetylcysteamine. To phosphate buffer (4.9 mL, 50 mM phosphate) was added benzyl alcohol 
(2.0 M in DMSO-d6, 50 µL) followed by epoxide 79 (1.0 M in DMSO-d6, 100 µL) under an 
open atmosphere. An aliquot (0.4 mL) of the mixture was removed and extracted with CDCl3 
(0.5 mL). The extract was then dried over Na2SO4, filtered into an NMR tube, rinsed with CDCl3 
(0.2 mL), and an NMR spectrum was obtained. The remaining reaction mixture was transferred 
to a vessel containing the thiol, vortexed, and maintained at 37 °C by immersion in a water-filled 
incubator. Aliquots (0.4 mL) of the reaction mixture was removed and extracted with CDCl3 (0.5 
mL). The extract was then dried over Na2SO4, filtered into an NMR tube, rinsed with CDCl3 (0.2 
mL), and an NMR spectra were obtained. The consumption of epoxide was determined by 
comparison of the integrations of epoxide signals to the benzylic signal of benzyl alcohol. Data 
analyses were performed on Microsoft Excel. The volumes of epoxide solutions, benzyl alcohol, 
and buffer were varied depending on the reaction rate. No more than 5% DMSO-d6 total volume 
was employed during these reactions.   
The consumption of 79, when monitored in an NMR tube (method A), was only shown to 
give 204 as a product. This result also confirms that the thioetherification proceeds by a SN2 
mechanism. 
 
Procedure for the conversion of the half-lives for 2-cyclohexen-1-one oxide in Table 
14. To convert the experimentally obtained data for 2-cyclohexen-1-one oxide in Figure  21 to 
the data shown in Table 14, the half-lives from Figure  21 were divided by 20 (1 µM used in 
experiment vs. 20 µM used in other experiments shown in Table 2) and then divided by 50 (2 
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µM used in experiment vs. 100 µM used in other experiments in Table 14). The resulting number 
(in hours) was converted to seconds. 
 
General Procedure for the Determination of t1/2
biol
 in Table 14. The derivative of the 
rate equation generated by Microsoft Excel was taken at time = 0.0 h to obtain the initial rate. 
The resulting linear equation, [epoxide] = (derivative at t = 0) × time, was used to determine the 
epoxide’s pseudo-first order half-life. The resulting half-life was adjusted to biologically relevant 
conditions (1 µM = [epoxide] and 12 mM = [thiolintracellular] as discussed above. 
 
N
H
O
AcO
Z-206
OH
O
AcO
2  
Preparation of Z-206. To a stirred solution of acid 2 (63.4 mg, 0.401 mmol) and 
i
Pr2NEt 
(275 µL, 1.58 mmol) in MeCN (2 mL) was added HATU (183 mg, 0.481 mmol) and isopropyl 
amine (70 µL, 0.82 mmol) at 0 °C under a nitrogen atmosphere. After 5 min at the same 
temperature, the reaction mixture was warmed to 23°C. After 1 h at the same temperature, the 
reaction mixture was diluted with saturated aqueous NH4Cl (12 mL). The aqueous residue was 
extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with aqueous HCl 
(0.3 N, 10 mL) then saturated aqueous NaHCO3 (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10 → 50% EtOAc in hexanes) on silica gel (5 mL) to afford Z-206 (80.7 mg, 
quant.) as a pale yellow oil. 
Data for Z-206: Rf = 0.31 (80% EtOAc in hexanes); IR (neat): 3410 (br, N-H), 2977, 
1725 (C=O), 1669 (C=O), 1637, 1536, 1372, 1260, 1048, 851 cm
-1
; [α]D
25
 −16.7 (c 0.85, 
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CH3CN); 
1
H NMR (300 MHz, 293K, CD3OD) δ 6.32 (app quint d, 1H, J = 6.5, 1.1 Hz),  5.91 
(dd, 1H, J = 11.6, 7.6 Hz), 5.79 (dd, 1H, J = 11.6, 1.1 Hz), 3.96 (hept, 1H, J = 6.6 Hz), 2.01 (s, 
3H), 1.34 (d, 3H, J = 6.5 Hz), 1.14 (d, 6H, J = 6.6 Hz);
 13
C NMR (75 MHz, 293K, CD3OD) δ  
171.4, 165.3, 143.5, 123.7, 68.9, 41.7, 22.5, 21.3, 20.3; HRMS (EI+) calcd. for C8H14NO [M − 
OAc]
+ 
 140.1085, found 140.1074. 
 
N
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O
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Z-206 Z-207
K2CO3, MeOH
quant.
 
Preparation of Z-207. To a stirred solution of Z-206 (19.8 mg, 0.0994 mmol) in MeOH 
(0.4 mL) was added K2CO3 (34.3 mg, 0.248 mmol) at 0 °C under an open atmosphere. After 1 h 
at the same temperature, the reaction was quenched with saturated aqueous NH4Cl (60 µL), 
warmed to 23°C, diluted with EtOAc (10 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure to afford, Z-207 (16.8 mg, quant.) as a colorless oil. This 
material was not further purified. 
Data for Z-207: Rf = 0.31 (80% EtOAc in hexanes); IR (neat): 3408 (br, N-H), 3284 (br, 
O-H), 2973, 1654 (C=O), 1621, 1539, 1458, 1255, 1115, 1057, 843 cm
-1
; [α]D
25
 −16.7 (c 0.85, 
CH3CN); 
1
H NMR (300 MHz, 293K, CD3OD) δ 5.99 (dd, 1H, J = 11.8, 7.1 Hz),  5.75 (dd, 1H, J 
= 11.8, 1.2 Hz), 5.15 (app quint d, 1H, J = 6.6, 1.2 Hz), 3.97 (hept, 1H, J = 6.6 Hz), 2.01 (s, 3H), 
1.25 (d, 3H, J = 6.5 Hz), 1.14 (d, 6H, J = 6.6 Hz);
 13
C NMR (75 MHz, 293K, CD3OD) δ  167.5, 
149.5, 122.7, 65.4, 42.3, 23.1, 22.6, 22.5; HRMS (EI+) calcd. for C8H15NO2 [M]
+ 
 157.1103, 
found 157.1105. 
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HO
SH
(3.3 equiv)
pH 7 buffer
37 oC, 5 dZ-206
(0.5 M)
N
H
O
AcO
S
HO
N
H
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AcO
E,Z-206
33% (E/Z = 1:2)
N
H
O
OH
E-207
10%
208
36%
+ +
 
Reactions of Z-206 in the presence of mercaptoethanol. To a stirred solution of Z-206 
(6.0 mg, 0.030 mmol) in MeCN (5 µL) pH 7 phosphate buffer (55 µL) was added 2-
mercaptoethanol (7 µL, 0.1 mmol) at 37 °C under an open atmosphere. After 5 d at the same 
temperature, the reaction was concentrated under reduced pressure. Purification of the residue by 
flash chromatography (3 → 80% EtOAc in hexanes) on silica gel (1 mL) returned 206 (2.0 mg, 
33%, E/Z = 1:2), afforded a mixture of mercaptoethanol and 207 (3.7 mg, 10% for 207, E only), 
and gave 208 (3.0 mg, 33%, dr = 3:1) as a pale yellow oil. 
Data for 208: Rf = 0.14 (60% EtOAc in hexanes); 
1
H NMR (300 MHz, 293K, CD3OD) δ 
5.08−5.02 (m), 4.02−3.90 (m), 3.78 (t, J = 6.5 Hz), 3.72−3.64 (m), 2.82 (t, J = 6.5 Hz), 
2.78−2.63 (m), 2.55−2.45 (m), 2.34−2.22 (m), 2.03 (s), 2.02 (s), 1.30 (d, J = 6.3 Hz), 1.28 (d, J = 
6.4 Hz), 1.14 (d, J = 6.6 Hz), 1.13 (d, J = 6.6 Hz); HRMS (EI+) calcd. for C12H23NO4S [M]
+ 
 
277.1348, found 277.1360. 
 
Materials and Methods for the Growth Inhibition Assays 
Materials: FR901464 and its dimethyl analog were produced by total chemical synthesis 
in our laboratory. The compounds were dissolved in dimethyl sulfoxide (DMSO) as 10 mM 
stocks and stored at −20 °C. For the experiments, aliquots were thawed at room temperature and 
dilutions were prepared in RPMI 1640 medium containing 2 % DMSO at 2× the desired 
concentration prior to addition to the cells. 
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Cell Culture: MCF-7 and HeLa cells were grown at 37 °C in an atmosphere containing 
5% carbon dioxide in corning cell culture dishes (150 mm) in RPMI 1640 cell culture medium 
containing 10% fetal bovine serum, glutamine (5 mL), and pen-strep solution (Invitrogen, 5 mL) 
per 500 mL of medium. 
Growth Inhibition Assay: Cells were plated in 96 well plates at an initial density of 2,000 
cells per well in 100 µL of medium and were incubated for 48 hours prior to compound addition. 
Serial two-fold dilutions were used in this experiment for the indicated ranges. The compounds 
were added to the cells at 2× the desired concentration in 100 µL cell culture medium 
(containting 2% DMSO). The cells were then incubated for an additional 5 to 10 days. Cell 
proliferation was measured using a commercial MTS solution (20 µL per well). The absorbance 
(at 490 nm and 630 nm) was measured by a Spectromax M5 plate reader (Molecular Devices). 
Each concentration was done in quadruplicate and the final numbers were averaged. 
Meayamycin Reversibility Assay: Cells were plated in 96 well plates at an initial density 
of 5,000 cells per well in 100 µL of medium and were incubated for 48 hours prior to addition of 
meayamycin. Meayamycin was added to the cells at 2× the desired concentration in 100 µL cell 
culture medium (containting 2% DMSO). The cells were then incubated for a total additional 3 
to 7 days. Meayamycin-containing cell culture media was removed after the 4, 8, 12, 24, 48, and 
72 h by suction, the wells were washed with fresh cell culture media (3 × 100 µL), and finally 
fresh, meayamycin-free cell culture media was added to the wells (200 µL). Cell proliferation 
was measured using a commercial MTS solution (20 µL per well). The absorbance (at 490 nm 
and 630 nm) was measured by a Spectromax M5 plate reader (Molecular Devices). Each 
concentration was done in quadruplicate and the final numbers were averaged. 
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1H NMR of 214: 1% CD3OD in CDCl3, 293 K, 300 MHz 
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1H NMR of 79: CDCl3, 293 K, 300 MHz 
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NOESY of 86: CDCl3, 293 K, 500 MHz 
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1H NMR of 112: C6D6, 293 K, 300 MHz 
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1H NMR of 125: CDCl3, 293 K, 300 MHz 
 
 
13C NMR of 125: CDCl3, 293 K, 75 MHz 
 240 
1H NMR of 123: CDCl3, 293 K, 300 MHz 
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1H NMR of 126: C6D6, 293 K, 300 MHz 
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1H NMR of 127: CDCl3, 293 K, 300 MHz 
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1H NMR of 128-mixture: CDCl3, 293 K, 300 MHz 
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HPLC comparison of crude and authentic FR901464 
HPLC conditions: Varian Chrompack Microsorb 100 C18 column (5 μm packing; 
2 mm × 250 mm); 5 → 95% MeCN in H2O (containing 0.05% HCO2H); 0.8 mL/min; 
237 nm. 
 A: crude (reaction mixture after a small silica plug) synthetic FR901464 
 B: co-injection of A and C 
 C: authentic FR901464 obtained from Fujisawa Pharmaceutical Co. 
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1H NMR of 132: CDCl3, 293 K, 300 MHz 
 
 
13C NMR of 132: C6D6, 293 K, 75 MHz 
O
OTBS
O
132
O
OTBS
O
132
 248 
1H NMR of 133: CDCl3, 293 K, 300 MHz 
 
O
OTBS
O
133
H
O
 249 
1H NMR of 145: CDCl3, 293 K, 300 MHz 
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1H NMR of 146: CDCl3, 293 K, 300 MHz 
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1H NMR of 148: C6D6, 293 K, 300 MHz 
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1H NMR of 128: CDCl3, 293 K, 300 MHz 
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1H NMR of 149: CDCl3, 293 K, 300 MHz 
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1H NMR of 150: C6D6, 293 K, 300 MHz 
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1H NMR of 50: CD2Cl2, 293 K, 300 MHz 
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1H NMR of FR901464: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 163: CDCl3, 293 K, 300 MHz 
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1H NMR of 164: CD2Cl2, 293 K, 300 MHz 
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1H NMR of 170: CD2Cl2, 293 K, 300 MHz 
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1H NMR of 166: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 176: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 177: CD2Cl2, 293 K, 300 MHz 
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1H NMR of 179: CDCl3, 293 K, 300 MHz 
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1H NMR of 181: CDCl3, 293 K, 300 MHz 
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1H NMR of 186: CDCl3, 293 K, 300 MHz 
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1H NMR of 167: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 168: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 169: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 201: CD2Cl2, 293 K, 300 MHz 
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1H NMR of 202: CD2Cl2, 293 K, 500 MHz 
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1H NMR of 204: D2O, 293 K, 300 MHz 
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1H NMR of 208: CD3OD, 293 K, 300 MHz 
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2.0  SILVER AND ZIRCONIUM PROMOTED ALKYNYL ADDITIONS TO 
ALDEHYDES AND EPOXIDES 
2.1 METHODS FOR ALKYNYL ADDITIONS TO ALDEHYDES 
Methods to give addition of alkynes to aldehydes have tremendously impacted synthetic organic 
chemistry because the products are highly versatile propargylic alcohols 215 (Scheme 49).
174
 
When the R’ group of the alkyne is an aliphatic or aromatic group, the terminus of the alkyne 
may be deprotonated and substituted with a variety of metals (Scheme 49a). These metals may 
be Li, Mg, B, Ce, Ti, Sn, and Cs. When propiolate esters are used as the nucleophiles the 
products are γ-hydroxy-α,β-unsaturated ynoates 216, which are highly versatile compounds that 
have been exploited in complex molecule synthesis (Scheme 49b).
175-184
 To prepare the lithium 
acetylides from propiolate esters, the most common metal used is Li (although B, Sn, and Si can 
be used).
185
 To generate these lithium acetylides, typically a strong base such as 
n
BuLi is 
employed, and therefore base-stable substrates must be employed to tolerate the highly basic 
conditions. Morever, 
n
BuLi is also nucleophilic towards aldehydes and ketones, and thus the 
stoichiometry of reagents must be carefully controlled. 
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R H
O
R
OH
R'
R'M
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R H
O
R
OH
CO2R'
CO2R'M
M = Li, B, Sn, Si
a.
b.
215
216
 
Scheme 49. (a) Preparation of propargylic alcohols from aldehydes; (b) Preparation of γ-hydroxy-α,β-unsaturated 
ynoates from aldehydes. 
 
 In 2002, the Koide group became interested in the preparation of γ-hydroxy-α,β-
unsaturated ynoates from aldehydes under milder conditions. In 2000, a new alkynyl addition 
method was developed in the Carreira laboratories involving the in situ preparation of zinc 
acetylides, from terminal alkynes, Zn(OTf)2, and tertiary amines, and their subsequent additions 
to aldehydes.
83,186-189
 However, these reaction conditions proved to be incompatible with methyl 
propiolate and acetaldehyde giving 217 in 10−30% yields with no formation of the desired 
ynoate (Scheme 50).
190
 This called for the development of a more robust, general, and mild 
method to form γ-hydroxy-α,β-unsaturated ynoates from aldehydes and ynoates.  
 
H
O
CO2MeH+
Zn(OTf)2 (1.0 equiv)
(−)-N-methylephedrine (1.1 equiv)
iPr2NEt (1.1 equiv)
CH2Cl2, 0 to 23
oC
CO2Me
N
217  
Scheme 50. Unexpected formation of 217 
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2.2 DEVELOPMENT OF THE SILVER AND ZIRCONIUM PROMOTED ALKYNYL 
ADDITION TO ALDEHYDES 
Due to the difficulty in preparing γ-hydroxy-α,β-unsaturated ynoates using lithium and zinc 
acetylides, a different strategy was envisioned. The preparation of other terminally-protected 
alkynes (B, Sn, Si) also requires the use of strong bases which is undesirable (Scheme 49b). In 
contrast, silver acetylide 88 is readily prepared in excellent yields employing a known protocol 
using AgNO3 and aqueous ammonia (Scheme 51).
191
 Moreover, this method was shown to be an 
effective method to prepare several other silver acetylides. These reagents are H2O stable, of low 
basicity and nucleophilicity.
191-193
 
 
Ag CO2MeCO2Me
AgNO3 (2.1 equiv)
NH4OH
MeOH/H2O, 23
oC
quant.
88
 
Scheme 51. Preparation of silver acetylide 88 
 
 The condensation of silver acetylide 88 and m-O2NPhCHO was chosen for the model 
system (Table 15). No condensation occurs between 88 and m-O2NPhCHO (entry 1), and 
therefore Lewis acid additives were screened. Addition of BF3•OEt2 or Cu(OTf)2 to the reaction 
mixture did promote the generation of ynoate 218 (entries 2 and 3). Addition of ZnBr2 and 
Cp2TiCl2 to the reaction mixture afforded this ynoate in 4% and 30% yields, respectively (entries 
4 and 5). However, the use of ZrCl4 and Cp2ZrCl2 gave 218 in 51% and 73% yields, respectively 
(entries 6 and 7). Therefore, zirconium appeared to be the metal of choice, and the reaction was 
optimized using Cp2ZrCl2. The Jordan, Suzuki, and Wipf groups observed that silver salts can 
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promote the couplings of organozirconium species and aldehydes.
194-197
 Addition of a 
substoichiometric amount of AgOTf gave 218 in 95% yield, in only 5 h (entry 8). As a control 
reaction, this reaction was attempted using Cp2HfCl2 which gave no formation of this ynoate 
(entry 9). Moreover, the use of methylpropiolate in combination with Cp2ZrCl2 led to no 
formation of 218 (entry 10).
121
 Therefore, the use of Cp2ZrCl2 in combination with a 
substoichiometric amount of AgOTf was optimal to form 218. The role of the Cp2ZrCl2 appeared  
 
Table 15. Development of the Cp2ZrCl2-promoted alkynlation reaction 
O2N H
O
(1.6 equiv)
reagents (see below)
CH2Cl2, 23
oC
M CO2Me
O2N
OH
CO2Me
218
entry
1
2
3
M reagents time (h) yield (%)
Ag
Ag
Ag
Ag
H
4
5
30
30
5
18
30
0
73
95
0
0
none
Cp2ZrCl2 (1.2 equiv)
Cp2ZrCl2 (1.2 equiv) +
AgOTf (0.2 equiv)
Cp2HfCl2 (1.2 equiv) +
AgOTf (0.2 equiv)
Cp2ZrCl2 (1.2 equiv)
6
7
8
9
Ag
Ag
Ag
Ag
BF3 OEt2 (1.2 equiv)
ZnCl2 (1.2 equiv)
Cu(OTf)2 (1.2 equiv)
Cp2TiCl2 (1.2 equiv)
ZrCl4 (1.2 equiv)
10
0
0
4
30
51
30
7
24
27
15
Ag
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to be more than that of a simple Lewis acid as demonstrated in entry 2, presumably generating a 
zirconium acetylide in situ by transmetallation and precipitation of AgCl.
198
   
 This potentially valuable methodology was then further explored, and 13 successful 
reactions were described yielding ynoates in 59−95% yields.
121
 The reaction conditions were 
found to be compatible with a variety of functional groups including variously substituted 
aromatic aldehydes, enolizable aliphatic aldehydes, acid labile 
t
butyl carbamates bearing an 
acidic N-H bond, base labile Fmoc carbamates, epoxides, and acid labile ketals. Moreover, this 
method proved to be higher yielding and gave higher diastereoselectivities for two chiral 
aldehydes than the method described by Midland.
121,185
  
 Later, a catalytic version of this Ag/Zr-promoted reaction of aldehydes and silver 
acetylides 219 was desired to eliminate the need for a stoichiometric amount of Cp2ZrCl2 
(Scheme 52). This catalytic cycle would require an electrophile, E−Cl, to break the Zr−O bond in 
221, to regenerate Cp2ZrCl2 and give 222 as the product. Carreira’s catalytic method involved 
protonolysis of the putative Zn−O bond from a protonated amine using heat to achieve the 
activation barrier for this reaction. However, HCl would be required for protonolysis of Koide’s 
alkynyl addition reaction and thus too harsh of conditions. Alternatively, chlorotriethylsilane 
could serve the role as regenerating Cp2ZrCl2 and promoting the formation of 222.
199
 This would 
require that the sum of the bond enthalpy of the Zr−Cl and O−Si bonds be greater than that of 
Zr−O and Cl−Si bonds to drive this reaction, and that the activation barrier is low. Although 
some of these bond enthalpies are unknown, this reaction was still deemed reasonable. Towards 
this end, treatment of m-O2NPhCHO to a substiochiometric amount of Cp2ZrCl2 and AgOTf, and 
a stoichiometric amount of 88 and TESCl did not afford ynoate 223 (Scheme 53). Furthermore, 
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heating of this reaction mixture to 40 °C did not promote the desired reaction, and therefore this 
strategy was temporarily abandoned.  
 
Cp2ClZr R' R
OZrClCp2
R'
R
OE
R'
R H
O
Ag R'
Cp2ZrCl2
E−Cl
221220
219
222  
Scheme 52. Proposed catalytic cycle for the alkynyl addition 
 
O2N CHO
88 (1.6 equiv)
Cp2ZrCl2 (0.2 equiv)
Ag CO2Me
AgOTf (0.05 equiv)
TESCl (1.2 equiv)
CH2Cl2, 23 to 40
oC
O2N
OTES
CO2Me
223
NOT OBSERVED  
Scheme 53. Unsuccessful catalytic alkynylation 
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2.3 METHODS FOR ALKYNYL ADDITIONS TO EPOXIDES 
A complementary reaction to the alkynyl addition to aldehydes is to epoxides (Scheme 54). 
Alkenes are a common precursor to both aldehydes 224 and epoxides 226 by ozonolysis and 
epoxidation reactions, respectively. The subsequent alkynyl addition to aldehyde 224 with 
metallated alkyne 219 giving 225 as products has been discussed previously. However, alkynyl 
addition to epoxide 226 can proceed by either pathway A to afford homopropargylic alcohols 
227 or by pathway B to afford propargylic alcohols 228. Pathway A is a widely used method to 
add alkynes to enantioenriched epoxides stereospecifically, and therefore has been oft-employed 
in organic synthesis.
200-204
 Typically, pathway A can be accomplished when M = Li and highly 
Lewis-acidic BF3•OEt2 is added to the reaction mixture.
202
 Pathway B is complementary to the 
alkynyl addition of aldehyde 224 because 228 contains one extra carbon not removed by the 
ozonolysis reaction. Although pathway B should be of importance, there remained no general 
method for this transformation, only scarce examples in the literature.
205,206
 Alternatively, 228 
can be obtained by hydroboration of an alkene to give 229, subsequent oxidation to aldehyde 
230, and finally alkynyl addition. However, this strategy requires one more synthetic step than 
the epoxidation/alkynyl addition strategy.  
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Scheme 54. Alkynyl addition reactions 
 
 The utility of pathway B (Scheme 54) has been neglected with respect to alkynyl 
addition, but other nucleophilic addition reactions have been exploited. Rose and coworkers 
developed methods to selectively add phenyl groups to butadienemonoxide to give propargylic 
and homopropargylic alcohols.
207
 More recently, the Wipf group developed a method to add 
alkenyl groups to epoxides to give allylic alcohols (Scheme 55).
196
 It was postulated that addition 
of Schwartz’s reagent [Cp2Zr(H)Cl] across an alkyne to generate alkenylzirconocene 231, and 
subsequent reaction with AgClO4 would give cationic complex 232.
195
 Coordination of an 
epoxide would give 233, which could undergo a 1,2-hydride shift to complex 234, and 
subsequent intramolecular alkenyl addition would give alcohol 235 upon aqueous workup. 
Therefore, it is possible that the aldehyde alkynyl addition method developed in the Koide group 
could function similarly. 
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Scheme 55. Wipf’s alkenyl addition method 
 
With the goal of alkynyl addition to epoxides via pathway B (Scheme 54), initial 
experimentation was undertaken in the Koide laboratories. It was demonstrated that styrene 
oxide smoothly reacts with silver acetylide 88 to give ynoate 236 in 64% yield (Scheme 55). 
However, 1,2-epoxy-3-phenoxypropane under similar reaction conditions gave chlorohydrin 237 
in 88% yield. Due some to initial success with this methodology and the scarcity for this method 
in the literature it warranted further investigation. 
 
88 (1.6 equiv)
Ag CO2Me
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.05 equiv)
CH2Cl2, 23
oC, 64%
88 (1.6 equiv)
Ag CO2Me
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.2 equiv)
CH2Cl2, 23
oC, 88%
Ph
O
O
PhO PhO
OH
Cl
Ph
OH
CO2Me
236
237
 
Scheme 56. Initial alkynylation experiments 
 
 302 
2.4 PREPARATION OF SILVER ACETYLIDE 88 
The reaction of epoxyaldehyde 32 and silver acetylide 88 was crucial in the total synthesis of 
FR901464, but inconsistent yields (20−84%) beset scale-up efforts, and 88 was thought to be the 
cause of the irreproducibility (Scheme 57). Due to these unpredictable yields, the preparation of 
88 was studied thoroughly. The source of methyl propiolate and silver nitrate were found to be 
inconsequential to the yield of 88 or to the alkynyl addition reaction. To determine the quantity 
of NH4OH required for the preparation of 88, a solution of 1.00 N NH4OH was employed, which 
determined that 2.0 molar equivalents of NH4OH (relative to AgNO3) were required to generate 
a clear solution of aqueous AgNO3. The source of NH4OH was also shown to be inconsequential 
for the alkynyl addition reaction. Finally, the purity of methanol and H2O (tap, deionized, and 
Millipore) were examined, but displayed no difference in the subsequent alkynyl addition 
reaction. From these experiments it was determined that the quality of the reagents used for the 
preparation of silver acetylide 88 were not responsible for the poor alkynyl addition results, and 
other variables would have to be investigated. 
 
H
O
O
32
MeO2C Ag
Cp2ZrCl, AgOTf
84%, dr = 6:1
88 (1.6 equiv)
O
OH
MeO2C
89
4
 
Scheme 57. Alkynyl addition to 88 
 
 The first variable that was examined was the exposure to light during the preparation of 
88 (possibly light-sensitive as is AgNO3). Separate preparations of 88, with one being exposed to 
ambient light, and the other protected from light with aluminum foil gave no difference in the 
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physical appearance of this silver acetylide. More importantly, the subsequent alkynyl addition 
reaction gave low yields in forming 218 (~30% yield). The second variable examined was 
residual H2O. Drying for several days under high vacuum while drying over P2O5 gave no 
improvement in yield of 218. Cationic silver coordinates well with phosphines and amines, but 
no phosphines were present in the preparation of 88. However, it was possible that the washing 
process of 88 was inefficiently removing all of the ammonia. Therefore, a sample of 88 that was 
found to afford 218 in 30% yield for the alkynyl addition reaction to m-O2NPhCHO was 
rewashed with H2O thoroughly and dried under high vacuum overnight. The resulting silver 
acetylide was used in the alkynyl addition reaction of m-O2NPhCHO to yield 218 in 64% yield! 
This experiment was validated by using this washing procedure to prepare 88, and consistently 
giving high yields in the subsequent alkynyl addition reaction. It was concluded that residual 
H2O-soluble materials poisons for the Ag/Zr-promoted alkynyl addition reaction, but can be 
easily removed by thorough washing of the silver acetylides with H2O.  
2.5 PREPARATION, APPEARANCE, AND REACTIVITY OF SILVER 
ACETYLIDES 
With a well understood process to prepare 88 from methyl propiolate, the generality of the 
procedure was explored (Table 16). Simple aliphatic and aromatic terminal alkynes are 
compatible with the reaction conditions as demonstrated with the quantitative preparations of 
238 from 1-hexyne and 239 from phenylacetylene (entries 1 and 2). Protected acid-labile 
propargylic substituted alkynes gave 240 and 241 in 45% and quantitative yields, respectively 
(entries 3 and 4). However, the low yield of 240 was attributed to its solubility in CH2Cl2 during 
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the washing process, which is discussed below. Base-labile acetate-protected hydroxy-groups are 
compatible with the reaction conditions, and were used to prepare acetylides 242 and 248 in 
79−97 and 81% yields, respectively (entries 5 and 11). These are remarkable results since the 
pKa of the α-hydrogen of an ester and the acetylenic hydrogen are both ~25, which demonstrates 
the selective activation of the terminal alkynes in the presence of similarly acidic hydrogen 
atoms. Moreover, in the presence of excess ammonia, the deacetylations of 242, 248, and their 
respective hydrocarbon starting materials appear to be minor. The preparation of 243 was 
accomplished in the presence of a selenium atom in 90% (entry 6). Preparations of 244 and 245 
were accomplished in 76 and 86% yields respectively showing the tolerance of amides (entries 7 
and 8). Finally, preparation of 246 and 247 were accomplished in 95 and 52% yields, 
respectively, demonstrating the compatibility of protected amines (entries 9 and 10). Therefore, 
the preparation of silver acetylides is broadly applicable to a variety of aliphatic, conjugated, 
acid-labile, and base-labile terminal alkynes.  
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Table 16. Preparation of silver acetylides 
Ag RR
AgNO3 (2.1 equiv)
NH4OH
MeOH/H2O, 23
oC
entry product yield (%)
Ag
OTHP
OEt
OEt
OAc
SeAr
Ag
Ag
Ag
Ag
243: Ar = o-O2NPh
N
O
O
Ag
N
O
Ag
NHBoc
Ag
NBoc2
Ag
239
240
241
244
245
246
247
242
entry product yield (%)
OAc
Ag
248
1
2
3
4
5 11
10
9
8
7
quant.
45
quant.
79−97
90
81
52
95
86
76
Ag
nBu
quant.
238
6
 
 
 Typically, silver acetylides are off-white powders, as shown with silver acetylide 88 
(Figure 25a). After 10 d of exposure of thoroughly washed 88 to ambient air, the appearance 
slowly changes to a light tan solid (Figure 25b). Moreover, exposure of 88 to ambient air and 
light causes no further change in the appearance of this silver acetylide (Figure 25c). To test the 
efficacy of these samples of 88, they were subjected to the alkynyl addition conditions using m-
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O2NPhCHO as the electrophile to give 218 in 76 and 75% yields respectively (compared to 81% 
for freshly prepared 88 from the same batch). However, insufficient washing of 88 with H2O 
gives a tan material that rapidly decomposes to a dark brown solid that gives adverse effects on 
the subsequent alkynyl addition reaction. Although this silver acetylide is fairly insensitive 
towards air, light, and moisture,191,192 silver acetylides are typically stored in amber vials/bottles 
as a precaution.  
 
a.  b.  c.  
Figure 25. Appearances of 88: (a) freshly prepared; (b) exposed to air for 10 d; (c) exposed to air and ambient light 
for 10 d 
 
 The solubility of these silver acetylides in organic solvents is not always predictable, but 
generally are more soluble in CH2Cl2 with more hydrophobic character. Since silver acetylide 88 
was found to be poorly soluble in CH2Cl2, the final washing would be with 9:1 CH2Cl2/MeOH to 
dry the solid and remove organic impurities. However, this procedure is usually omitted since 
silver acetylides 238, 240, 241, 242, 245, 247, and 248 were found to be soluble in CH2Cl2. 
Silver acetylide 246 was approximately soluble at 0.1 M in CH2Cl2 at 23 °C, while 239, 243, and 
244 were poorly soluble. Therefore, it remains inconclusive what molecular alterations give the 
bulk properties of these silver acetylides. Although a common bulk property of these reagents is 
the insolubility in H2O and MeOH.  
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Koide and Naka demonstrated that 88 slowly decomposed when the neat material was 
heated to 150 °C, without explosion.190 However, the safety of using silver acetylides was further 
examined partially because of two safety concerns in the literature.121,208,209 A falling hammer 
test, an industrial standard for safety, was performed to examine the stability of silver acetylide 
88 towards shock. The off-white powder was placed on aluminum foil (Figure 26a), and 
subsequently struck with a hammer, but neither an explosion of 88 nor physical change in 
appearance was observed (Figure 26b). Moreover, this silver acetylide was prepared for the total 
synthesis of FR901464 in 140 mmol scale, and used for the alkynyl addition of epoxyaldehyde 
88 (90 mmol) in the same scale without precaution or incident. 
 
a.  b.  
Figure 26. Falling hammer test of 88: (a) appearance of 88 before striking with a hammer; (b) appearance of 88 
after being struck with a hammer 
 
To examine why less silver acetylide 88 than Cp2ZrCl2 was detrimental for the alkynyl 
addition of aldehydes and to confirm some trace impurities, the following control reactions were 
performed (Table 17). Treatment of Cp2ZrCl2 with 0.45 equiv of silver acetylide 88 gave only 
6% of exclusively E-249 (entry 1). Increasing the amount of 88 to 1.1 equiv caused a decrease in 
the already low yield of 249 to 3% in a 1:1 E/Z ratio. Further increasing of 88 to 2.1 equiv gave 
enyne 249 in 4% yield in a 1:1 E/Z ratio. The low yields of 249 did not increase by the addition 
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of more 88, and thus are likely intermediates of a polymerization process, since Zr-species are 
excellent polymerization catalysts.210-213 This explains why an excess of 88 is beneficial to the 
alkynyl addition yield, and why it is better to add it to the reaction mixture after the aldehyde and 
Cp2ZrCl2.  
 
Table 17. Formation of enynes 249 
CH2Cl2, 23
oC, 4h
Ag CO2Me CO2Me
MeO2C
Cp2ZrCl2 (1.0 equiv)
88 249
entry equiv of 88 E/Zayield (%)
1
2
3
0.45
1.1
2.1
6
3
4
1:0
1:1
1:1
a Based on isolated yields  
2.6 BROADENING THE SCOPE OF THE EPOXIDE OPENING METHODOLOGY 
With an understanding of the Ag/Zr-promoted alkynyl addition of aldehydes, the successful 
implementation in the addition to styrene oxide, and an arsenal of silver acetylides, the epoxide 
alkynyl addition generality was further explored (Table 18). The model epoxide chosen was 1,2-
epoxydecane, and the model silver acetylide was 88. Reaction of these reagents to the standard 
alkynyl addition reaction conditions gave ynoate 250 in 44% yield (entry 1). Simply increasing 
the temperature of the reaction to 40 °C improved the yield to 57% (entry 2). Alternatively, 
implementation of 0.5 equiv of AgOTf increased the yield of 250 to 58% (entry 3), but 
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increasing the amount of AgOTf to 1.0 equiv had a deleterious effect giving this ynoate in only 
43% yield (entry 4). Therefore, either by heating or adding 0.5 equiv AgOTf to the reaction 
mixture was effective in preparing 250, but heating of the reaction mixture proved not to be a 
general method (see below).  
 
Table 18. Optimization for the alkynyl addition to 1,2-epoxydecane 
O7 7
OH
CO2Me
88 (1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf, CH2Cl2
Ag CO2Me
250
entry AgOTf (equiv) temp (oC) % yield
1
2
3
4
0.2
0.2
0.5
1.0
23
40
23
23
44
57
58
43
 
  
With optimized epoxide alkynyl addition reaction conditions in hand, the epoxide scope 
was explored (Table 19). Reaction of 1-oxaspiro[2.5]octane (205) to the alkynyl addition 
conditions gave 251 in 43% yield. However, lowering the amount of AgOTf to 0.2 equiv in this 
reaction gave 251 in 54% yield (entry 1). Subjection of cyclohexene oxide or cyclopentene oxide 
to the alknylation conditions generated intractable mixtures consisting of the desired products, 
ring-contracted products, and chlorohydrins (entries 2 and 3). Butadienemonoxide gave 252 in 
9% yield under the alkynyl addition conditions (entry 4). Treatment of 1,2-epoxy-5-hexene to the 
alkynyl addition conditions gave 253 in 33% yield, and interestingly only 12% of this ynoate was 
formed when the reaction was conducted with 0.2 equiv AgOTf and at 40 °C (entry 5). Similarly, 
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1,2-epoxy-3-phenylpropane gave 254 in 22% yield, but afforded no product when treated with 
0.2 equiv AgOTf and at 40 °C (entry 6). Finally, epoxide 255 afforded 256 in 35% yield under 
the reaction conditions (entry 7). These results show that monosubstituted and 1,1-  
 
Table 19. Epoxide scope with silver acetylide 88 
88 (1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
Ag CO2Me
OH
CO2Me
R
R'
O
R
R'
entry epoxide product yield (%)
1 43, 54aO
O
O
O
O
O
OH
CO2Me
OH
CO2Me
OH
CO2Me
OH
CO2Me
intractable
mixture
intractable
mixture
2
3
4
5
6
NA
NA
9
33, 12a,b
22, 0a,b
251
252
253
254
time (h)
8
8
8
6, 3a
6
6
O
TBSO
TBSO
OH
CO2Me
35
256
6.57
a 0.2 equiv AgOTf employed; b 40 oC reaction temperature
255
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disubstituted epoxides are compatible for this reaction, and that additional oxygen atoms are 
tolerated on the epoxide. However, cyclic 1,2-disubstituted epoxides suffer from poor selectivity 
in 1,2-alkyl vs. -hydrogen atom shifts, and sensitive allylic epoxides may be challenging 
substrates to add electron deficient alkynyl groups under these reaction conditions. 
Since silver acetylide 88 is electron poor from the inductively electron withdrawing ester 
moiety, a more electron rich alkyne could perform better in this alkynyl addition reaction. The 
results from this hypothesis using silver acetylide 238 are shown in Table 20. Treatment of 1,2-
epoxydecane gave 257 in 69% yield (entry 1). Somewhat surprisingly, 1,2-epoxy-5-hexene gave 
258 in 59% yield (entry 2), a rather large increase in yield (26%) as compared to the yield in 
forming 253. Allylic spiroepoxide 259 generated 260 in 53% yield and a 2:1 unassigned 
diastereomeric ratio under the reaction conditions (entry 3). This was a surprising result due to 
the instability of this epoxide, and because the alkene avoided migration during the reaction 
conditions. When 1,2-epoxy-3-pheoxypropane was subjected to the same reaction conditions 
again chlorohydrin 237 was the major product (entry 4). Carbamate 261 when subjected to the 
alkynyl addition conditions generated an intractable mixture (entry 5). Silyl ethers 255 and 263 
react similarly under the reaction conditions to afforded 262 and 264 in 52 and 55% yields, 
respectively (entries 6 and 7). Finally, tbutylacrylate oxide when subjected to these reaction 
conditions somewhat surprisingly gave no reaction (entry 8). This table verifies our hypothesis 
that more electron rich silver acetylide 238 gives products in higher yields as shown in entries 1, 
2, and 6. Moreover, highly acid-sensitive allylic epoxides are compatible with the reaction 
conditions and avoid isomerization of the putative aldehyde to the thermodynamically favored 
α,β-unsaturated enal. 
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Table 20. Epoxide scope with silver acetylide 238 
238 (1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
Ag nBu
OH
nBu
R
R'
O
R
R'
entry epoxide product yield (%)
1 69
O
OH
nBu
OH
nBu
2
3
4
5
6
59
NA
NA
260
258
O
7
OH
nBu
257
PhO
O
BocHN
O
O
O
OtBu
O
TBSO
O
TBDPSO
O
TBSO
TBDPSO
OH
OH
nBu
nBu
no reaction NA
53a
52
55
264
262
8
7
time (h)
8.5
8
4
8
9
8
10.5
8
7
PhO Cl
OH
237
259
261
255
263
intractable
mixture
a Unassigned dr = 2:1  
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With an understanding of the limitations of the epoxide for the alkynyl addition reaction, 
the scope of the alkynes was then examined (Table 21). Silver acetylide derived from 
phenylacetylene afforded 265 in 82% yield under the reaction conditions (entry 1). Acid labile 
silver acetylides 240 and 241 remarkably gave propargylic alcohols 266 and 267 in 82 and 81% 
respectively despite the Lewis acidic reaction conditions (entries 2 and 3). Moreover, the 
reaction utilizing 241 proved to be mildly sensitive to H2O, giving 267 in 66% yield in non-
distilled CH2Cl2, and in 57% yield in non-distilled CH2Cl2 and under a wet air atmosphere (entry 
3). Base-labile 242 generated propargylic alcohol 268 in 57% yield under the reaction conditions 
(entry 4). This compound is of synthetic importance by simple conversions to give versatile γ-
hydroxy α,β-unsaturated aldehydes as demonstrated by the Carreira group.214 The alkynyl 
addition of epoxydecane with 243 gave 269 in 52% yield, showing that selenium atoms are 
compatible with the reaction conditions (entry 5). Amide-derived silver acetylides 244 and 245 
gave no reaction with 1,2-epoxydecane, even upon heating to 40 °C (entries 6 and 7). Quenching 
of entry 7 with D2O suppressed the acetylenic proton in the crude 
1H NMR, thereby 
demonstrating that transmetallation had indeed occurred, and that ambient H2O was not the 
reason for the failed alkynyl addition. Propargylic amine-derived silver acetylide 246 gave no 
desired alkynyl addition, and when quenched with D2O showed no deuterium incorporation in N-
(tbutoxycarbonyl)propargylamine, implying intermolecular protonation from the acidic N-H 
moiety (entry 8). Therefore acetylide 247 was prepared and under the alkynyl addition conditions 
gave only N-(tbutoxycarbonyl)propargylamine and bis-N-(tbutoxycarbonyl)propargylamine 
(entry 9). From these results, acid and base-labile protected hydroxy groups, conjugated alkynes, 
and selenium atoms are all tolerated, but nitrogen atoms appear to be incompatible with the 
reaction conditions. 
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Table 21. Alkyne scope with 1,2-epoxydecane 
O7 7
OH
R
(1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
Ag R
entry alkyne product yield (%)
1 82
time (h)
7
OH
265
7
OH
267
OEt
OEt
7
OH
266
OTHP
7
OH
268
OAc
7
OH
269
SeAr
2
3
4
5
6.5
828.5
81, 66a, 57a,b7
5710
5210
30
10c
30
6
7
8
9
---
no reaction ---
no reaction ---
246
245
244
243
242
241
240
239
aPerformed in non-distilled CH2Cl2;
bPerformed under an air atm;
cHeated to reflux
30 ---247
NHBoc
NBoc2
NHBoc
+
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 Substrate control is a common method to induce stereoselectivity in condensation 
reactions when one of the components contains a stereocenter. Towards this end, chiral silver 
acetylide 248 was prepared and tested under the alkynyl addition conditions to examine whether 
the propargylic position of this alkyne could direct the forming hydroxy group stereocenter 
(Scheme 58). This silver acetylide was treated with ibutyraldehyde under the alkynyl addition 
conditions and afforded the desired adduct 270 in 38% yield but without diastereoselectivity. 
Therefore, this method to induce stereoelectivity was temporarily abandoned.  
 
OAc
Ag
248
CHO
+
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
38%, dr = 1:1
OAc
270
OH
 
Scheme 58. Examining the stereoinduction of a chiral alkyne 
 
To determine the relationship between cis and trans disubstituted epoxides and their role 
in the formation of products, cis- and trans-stilbene oxide were treated with 238 under the 
alkynyl addition conditions (Scheme 59). Treatment of trans- and cis-stilbene oxide to the 
alkynyl addition conditions with 238 both gave phenyl group migration affording alcohol 271 in 
86 and 88% yields, respectively.  Inspection of Newman projection 272, of the Zr-coordinated 
epoxides, shows that when R = H there will be a clear prefence for the zirconium atom to 
coordinate away from the bulky phenyl rings. However, when R = Ph, there is no preferential 
face since trans-stilbene oxide is symmetrical. These were somewhat surprising results since in 
related systems, there have been precedence for syn migrations where bulky groups shield one 
lone pair of the epoxide oxygen atom.215 However, for cis-stilbene oxide no formation of a 
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ketone via a syn-hydride shift was observed. Therefore, the dominant factor in determining the 
migrating group is the migratory ability of these possible groups. 
 
O
Ph
Ph
or
O
Ph Ph
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
86% for trans
88% for cis
Ag
nBu
238
+
Ph
Ph
OH
nBu
271
O
PhH
R'
R
272
Cp2ClZr
 
Scheme 59. Examining the stereospecificity in 1,2-migration 
 
To determine if a chiral, enantioenriched 1,1-disubstituted epoxide would give 
enantioenriched products, (R)-273 was synthesized (Scheme 60). Cyclohexyl methyl ketone was 
transformed to racemic epoxide 273 in 77% yield. This racemic epoxide was then resolved using 
Jacobsen’s catalyst 275 to give (R)-273 in 84% yield (based on TMSN3).
216 Condensation of this 
enriched epoxide with (R)-(+)-α-methylbenzylamine showed a >40:1 ratio of diastereomers 
when compared to the reaction with racemic 273, showing the high enantiopurity of (R)-273. 
Treatment of 273 with silver acetylide 238 under the reaction conditions gave 274 in 79% yield 
as a 1:1 mixture of diastereomers. Accordingly, exposure of (R)-273 with 238 under the alkynyl 
addition conditions afforded enriched-274 in 63% yield again in a 1:1 diastereomeric ratio. 
Preparation of the Mosher esters revealed that the enantiomeric ratios of syn-274 and anti-274 
were 9:1 as determined by preparation of their Mosher esters and subsequent HPLC analyses. 
The stereochemistry of enriched-274 was tentatively assigned based on the literature.217-219  
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O O
OH
nBu
O
OH
nBu
CH2Br2,
nBuLi
THF, -78−23 oC, 77%
273 274
Ag nBu
238 (1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
79%, dr = 1:1
(R)-273 274
cat. 275 (2 mol %)
TMSN3,
iPrOH, tBuOMe
0 to 23 oC, 84%
Ag nBu
238 (1.6 equiv)
Cp2ZrCl2 (1.2 equiv)
AgOTf (0.5 equiv)
CH2Cl2, 23
oC
63%, dr = 1:1
er = 9:1
NN
O O
Cr
Cl
tBu
tBu
tBu
tBu
cat. 275  
Scheme 60. Examining the enantiospecificity of the 1,2-hydride shift 
 
The stereospecific 1,2-hydride shift observed in (R)-273 could occur via a short- or a 
long-lived carbocation intermediate, but hydride shift via a long-lived carbocation could allow 
for free rotation and significant loss of enantiopurity. A long-lived carbocation was suggested by 
Fujimoto with their results in the epoxide rearrangement of 276 (Scheme 61a).220 Treatment of 
this epoxide with BF3•OEt2 would give putative carbocation 277. Rotation of this carbocation 
60° clockwise would give overlap of HB with the empty p-orbital of 277 to give 279 in 41% 
yield after 1,2-hydride shift. Additional 60° clockwise rotation would give overlap of HA with 
the empty p-orbital to give 278 in 25% yield. Alternatively, 60° counterclockwise rotation of 277 
would give overlap of HA with the empty p-orbital, producing 280 in 16% yield after 1,2-hydride 
shift. Additional 60° counterclockwise rotation of 277 would give overlap of HB with 
carbocation and lead to the formation of 281 observed in 18% yield. The authors suggested that 
clockwise rotations were preferred to avoid the steric repulsion of the –OBF3 group with the 
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bulky –C(CH3)2-(CH2)4Ph group. Lemaire and coworkers found that the rearrangement of 
enriched epoxide 282 with IrCl3•×H2O gave aldehyde 283 in racemic form (Scheme 61b).
221 This 
result may be consistent with Fujimoto’s assuming that the lifetime of the putative carbocation 
allows for 60 and/or 120° rotations in either direction. Since Lemaire’s tertiary benzylic 
carbocation should be more stable than Fujimoto’s teriary carbocation, the requisite 120° rotation 
should be feasible to give a racemic product. Jung found the rearrangement of 284 (96% ee) in 
the presence of BF3•OEt2 and Et3SiH to give 285 in 70% yield and 94% ee (Scheme 61c).
218 The 
authors explained this result by inferring the greater stability of the putative tertiary allylic 
carbocation as compared to the secondary benzylic cation, since the migratory abilities of a 
phenyl and vinyl group are similar. Moreover, this rearrangement would require a 60° rotation 
that would create only a vinyl-hydrogen atom eclipsing interaction, and thus nearly complete 
retention of the stereochemical information. Suda and coworkers found the rearrangement of 
epoxides 286 and 288 to give aldehydes 287 and 289, respectively, in high yields and with 
retentions of enantiopurity (Scheme 61d and e).222 Both of these rearrangements can be 
explained by 60° rotations that would create only a carbon-hydrogen atom eclipsing interactions 
and subsequent aliphatic migration.  
The observed stereospecificity is for the rearrangement of (R)-273 is remarkable because 
no related 1,1-disubstituted epoxides gave any appreciable specificity under these different 
reaction conditions.223,224 Moreover, this result could indicate that the lifetime of the putative 
tertiary carbocation from epoxide (R)-273 is short, and a 60° rotation is strongly preffered 
(presumably generating a H−Me eclipsing interaction, rather than the H−c-Hex eclipsing 
interaction). Thus, the stereochemical information in (R)-273 is highly conserved as seen in 
propargylic alcohol 274.  
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Ph OTBS
O
Ph CHO
OTBS
Ph
O
OSiPh3
Ph
OHC OSiPh3
288
99% ee
289
99% ee
286
99% ee
287
97% ee
Ph
O
Ph CHO
282
60% ee
283
0% ee
Ph(H2C)4
O HB
HA BF3 OEt2
HA
OBF3
HB
MePh(H2C)4
276
Ph(H2C)4
O HA
HB
279
41%
Ph(H2C)4
O HA
HB
281
18%
277
120o cw 120o ccw
Ph(H2C)4
O HB
HA
280
16%
a.
b. c.
d. e.
IrCl3 (1 mol%)
Cr(TPP)OTf
(1 mol%)
Cr(TPP)OTf
(1 mol%)
60o 60o
ccwcw
Ph(H2C)4
O HB
HA
278
25%
Ph
O
Ph
HO
284
96% ee
285
94% ee
BF3 OEt2
Et3SiH
 
Scheme 61. Rearrangements of chiral epoxides 
2.7 MECHANISTIC STUDIES AND PROPOSED MECHANISM 
To understand the processes occurring other than the desired alkynyl addition, the roles of all 
additives were determined (Table 22). Treatment of 1,2-epoxydecane with an excess of Cp2ZrCl2 
gave a mixture of chlorohydrins 290 and 291 in a 5.0:1 ratio, respectively, without formation of 
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decanal. Interestingly, treatment of 1,2-epoxydecane with AgOTf gave no rearrangement to 
decanal. Although, Wipf reported the rearrangement of highly activated styrene oxide under 
similar conditions.196 The combination of Cp2ZrCl2 and AgOTf generated chlorohydrins 290 and 
291 in 87% yield in a 0.8:1 ratio respectively with trace formation of decanal. The combination 
of these reagents presumably generates Cp2ZrCl(OTf) in situ and allows for the 1,2-hydride shift 
to occur, but chlorohydrin formation promoted by Cp2ZrCl2 and/or Cp2ZrCl(OTf) is strongly 
preferred. Finally, treatment of 1,2-epoxydecane with Cp2ZrCl2 and silver acetylide 88 gave 
chlorohydrins 290 and 291 in 22% yield in a 2.5:1 ratio, respectively, with no formation of 
decanal. Presumably this reagent combination generates [Cp2ClZr−C≡C−CO2Me] in situ, and is 
not responsible for the neither the alkynyl addition reaction nor aldehyde formation, but 
suppresses the formation of chlororhydrins to some extent. From these results, the presumed 
electronic nature of the zirconium atom plays a crucial role in formation of chlorohydrins, and 
the propensity for promoting the 1,2-shift. Chlorohydrin formation possibly occurs by different 
mechanisms due to the wide range of ratios observed in the formation of the two regiomeric 
products.  
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Table 22. Control experiments 
O7
7
entry reagents (equiv)
290:291
(% yield) decanal
1 Cp2ZrCl2 (1.6) none
Cl
OH
7
OH
Cl
7
H
O
290 291 decanal
2
3
4 none
trace
none
Cp2ZrCl2 (1.2) +
88 (1.6 equiv)
Cp2ZrCl2 (1.2) +
AgOTf (0.5)
AgOTf (0.5)
5.0:1 (83)
none
0.8:1 (87)
2.5:1 (22)
++
see below
CH2Cl2, 23
oC
 
 
In order to probe the electronic nature of the zirconium atom in this alkynyl addition 
reaction NMR experiments were conducted (Scheme 62). Silver acetylide 241 was chosen as a 
model due to its solubility in CH2Cl2, and was then characterized by 
1H and 13C NMR (selected 
13C data in Table 23, see experimental section for all data). To an NMR tube was added 241 and 
Cp2ZrCl2 which rapidly formed 292 via transmetallation which was again characterized by 
1H 
and 13C NMR. Treatment of this zirconium acetylide with a stoichiometric amount of AgOTf 
rapidly generated a new species showing downfield chemical shifts of the alkyne compared to 
292, which was assigned as 293. Both 292 and 293 were sensitive to H2O, and could not be 
isolated after aqueous workups, only yielding 3,3-diethoxypropyne. To probe the Lewis acidities 
of these zirconium acetylides, benzophenone was employed as a Lewis base for its attenuated 
reactivity to towards these species. Treatment of complex 292 with benzophenone showed slight 
upfield chemical shifts in benzophenone and the alkynyl carbons in the 13C spectra. This was 
interpreted as an equilibrium existing between the starting materials and ate-complex 294. 
However, it is possible that this could imply that the equilibrium is between the starting materials 
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and an α-chlorohydrin. However, no zirconium α-chlorohydrins have been characterized in the 
literature and therefore its formation is unlikely. Treatment of 293 with benzophenone gave 13C 
chemical shifts slightly downfield relative to the starting materials which were interpreted as 
complex 295. These results demonstrate that the zirconium atoms in both 292 and 293 are Lewis-
acidic, and that 295 exists in a higher population than 294. Moreover, this is consistent with the 
observation that AgOTf is required to induce a 1,2-hydride shift in 1,2-epoxydecane.  
 
Ag R
Cp2ZrCl2 (1.1 equiv)
ClCp2Zr R
AgOTf (1.0 equiv)
(TfO)Cp2Zr R
H
OEt
OEt
H2O H2O
ClCp2Zr O
Ph Ph
R
Cp2Zr
O
Ph Ph
R
TfO
Ph2C=O Ph2C=O
CD2Cl2, 23
oC
5 min
CD2Cl2, 23
oC
5 min
241
R = CH(OEt)2
292
294
293
295
α
β
α
β
γ γ
α β α βα β
 
Scheme 62. Spectroscopically characterized species 
 
Table 23. Selected 13C NMR data for 241, 292, 293, 294, and 295 
13C NMR δ (75 MHz, 293K, CD2Cl2) 
compound 
α β γ 
3,3-diethoxypropyne 73.35 79.60 NA 
241
 a 117.93 93.65 NA 
292 114.41 113.77 NA 
293
 b 115.81 114.70 NA 
benzophenone NA NA 198.68 
294 114.42 113.72 198.63 
295 b 115.82 114.70 196.83 
a Determined by an HMBC experiment; b Contaminated by hydrolysis products. 
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Based on the understanding of the mechanistic roles of all components involved in the 
alkynylation methodology, and the spectroscopic characterization of reaction intermediates, the 
following mechanism is proposed (Scheme 62). Treatment of silver acetylide 219 with Cp2ZrCl2 
rapidly generates zirconium acetylide 220 that could reversibly coordinate an epoxide and/or 
lead to chlorohyrin formations. However, in the presence of AgOTf, this compound rapidly 
generates a more Lewis acidic zirconium acetylide, 296. This complex can reversibly coordinate 
epoxide 226 to give 297, which then is electronically tuned for the 1,2-hydride shift giving 
aldehyde-zirconium complex 298. Complex 298 could be responsible for the alkynyl addition to 
give 299, or could undergo triflate-chloride exchange to ate complex 300. This ate complex 
could enhance the alkynyl addition to give 301, which may explain why using a stoichiometric 
amount of AgOTf gave 250 in lower yield due to the lack of chloride ions. Finally, alkoxide-
zirconium complex 299 could undergo triflate-chloride exchange to give 301, explaining why a 
sub-stoichiometric amount of AgOTf is needed for the reaction.   
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Cp2ZrCl2
ClCp2Zr R'
AgOTf
(TfO)Cp2Zr R'
Cp2Zr O
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R
TfO
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R
ClCp2Zr O
R'
R
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exchange
O
R
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R
296
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226
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220219
300
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Scheme 63. Proposed mechanism for the Ag/Zr-promoted alkynyl addition to epoxides 
2.8 SUMMARY  
There was a need for a general method for the alkynyl addition to epoxides to give propargylic 
alcohols as products. Towards this end, the Ag/Zr-promoted alkynyl addition methodology 
discovered in the Koide laboratories was successfully applied. These studies began with the 
preparation of 11 silver acetylides and examining their safety as reagents for organic synthesis. 
Subsequently, these silver acetylides were shown to add to epoxides via 1,2-shifts to give 
propargylic alcohols in the presence of Cp2ZrCl2 and AgOTf. The scope and limitations of both 
the epoxide and alkyne were realized and was demonstrated in over 20 successful reactions. 
Moreover, the 11 new silver acetylides used in the epoxide alkynyl addition methodology should 
 325 
be readily applicable to the aldehyde alkynyl addition methodology. Finally, mechanistic studies 
were undertaken and were crucial in understanding the roles of all additives necessary for this 
alkynyl addition reaction to be successful, culminating in the generating of the proposed 
mechanism seen in Scheme 62.  
2.9 EXPERIMENTAL SECTION 
General techniques. All reactions were carried out with dry, freshly distilled solvents under 
anhydrous conditions, unless otherwise noted. Tetrahydrofuran (THF) was distilled from 
sodium/benzophenone, and methylene chloride (CH2Cl2) was distilled from calcium hydride. 
Acetonitrile was distilled over CaH2 and stored over 3Å molecular sieves. Yields refer to 
chromatographically and spectroscopically (1H NMR) homogenous materials, unless otherwise 
stated. All reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25-
mm Merck silica gel plates (60F-254) using UV-light (254 nm), 2.4% phosphomolybdic 
acid/1.4% phosphoric acid/5% sulfuric acid in H2O, anisaldehyde in ethanol, or 0.2% ninhydrin 
in ethanol and heat as developing agents. TSI silica gel (230-400 mesh) was used for flash 
column chromatography. NMR spectra were recorded on AM300 or AM500 (Bruker) 
instruments and calibrated using a solvent peak or tetramethylsilane as an internal reference. The 
following abbreviations are used to indicate the multiplicities: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; br, broad. High resolution mass spectra were obtained by using EBE 
geometry. 
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O2N CHO Cp2ZrCl2, AgOTf
TESCl, 23 to 40 oC
Ag CO2Me
O2N
OTES
CO2Me
223
NOT OBSERVED  
Procedure used in the failed catalytic alkynylation reaction. To a stirred solution 
silver acetylide 88 (153 mg, 0.801 mmol) and 3-nitrobenzaldehyde (75.8 mg, 0.502 mmol) in 
CH2Cl2 was added Cp2ZrCl2 (29.6 mg, 0.101 mmol), AgOTf (6.6 mg, 0.026 mmol), and 
chlorotriethylsilane (100 µL, 0.600 mmol) at 23 °C under a nitrogen atmosphere. After 5 h at the 
same temperature, the reaction vessel was sealed and heated to 43 °C. After an additional 5 h at 
this temperature the reaction mixture was cooled to 23 °C, and subsequently quenched by the 
addition of saturated aqueous NaHCO3 (5 mL). The resulting mixture was filtered through a pad 
of Celite 545®, rinsed with EtOAc (3 × 5 mL), and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography (2.5 → 20% EtOAc/hexanes) on silica 
gel (8 mL) to no desired adducts. 
 
General procedure for the preparation of the silver acetylides. To a stirred solution of 
AgNO3 (2.1–283 mmol, 2.1 equiv) in deionized H2O (1.0–84 mL) and MeOH
§ (0.4–50 mL) was 
added NH4OH (28–30%, 0.4–54 mL) until the solution became clear again at 23 °C under 
ambient light.  After 30 min at the same temperature, terminal alkynes (1.0–138 mmol, 1 equiv) 
in MeOH (0.3–6 mL) were added dropwise.  After an additional 10–30 min of vigorous stirring 
at the same temperature, the reaction mixture was filtered through a frit, thoroughly rinsed with 
deionized H2O (8 × 5–250 mL), and MeOH (5–250 mL).  The resulting solids were dried under 
high vacuum overnight over P2O5 to give the appropriate silver acetylides (79%–quant. yield) as 
powders. 
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§ EtOH was used instead of MeOH for the preparation of the silver acetylide 20 from 3,3-
diethoxypropyne. 
 
Ag CO2Me CO2Me
MeO2C
88 249
Cp2ZrCl2
 
Representative procedure for the isolation of enynes 249. To a stirred solution of 88 
(211 mg, 1.11 mmol) in CH2Cl2 (4 mL) was added Cp2ZrCl2 (292 mg, 1.00 mmol) in one portion 
at 23 °C. The resulting mixture was vigorously stirred for 4 h at the same temperature, then 
quenched with H2O (5 mL), filtered through a pad of Celite 545
®, rinsed with EtOAc (3 × 5 mL) 
and H2O (5 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 
× 5 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was purified by 
flash chromatography (10 → 40% EtOAc/hexanes) on silica gel (20 mL) to afford E-249 (1.5 
mg, 1.6%) as a white solid and Z-249 (1.2 mg, 1.3%) as a pale yellow oil. 
 Data for E-249: See C. S. Yi, N. Liu Organometallics 1997, 16, 3910–3913. 
 Data for Z-249: Rf = 0.36 (30% EtOAc in hexanes); 
1H NMR (300 MHz, 293K, CDCl3) δ 
6.36 (d, 1H, J = 11.6 Hz), 6.22 (d, 1H, J = 11.6 Hz), 3.83 (s, 3H), 3.81 (s, 3H). 
 
General procedure for the addition of silver acetylides to epoxides. To a stirred 
solution or suspension of silver acetylide (0.8–16 mmol, 1.6 equiv) in CH2Cl2 (1.8–30 mL) was 
added epoxide (0.5–9.9 mmol, 1 equiv) followed by the addition of Cp2ZrCl2 (0.6–12 mmol, 1.2 
equiv) and AgOTf (0.025–5.0 mmol, 0.05–0.5 equiv) in one portion at 23 °C under ambient 
light.  After vigorous stirring at the same temperature for 1–10 h the solution was quenched with 
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saturated aqueous NH4Cl or saturated aqueous NaHCO3 (0.5–6 mL).  After stirring for 15–30 
min at the same temperature, the reaction mixture was filtered through a pad of Celite 545® and 
Na2SO4, rinsed with Et2O (2 × 5–30 mL), and concentrated under reduced pressure.  The 
resulting residues were purified by flash chromatography (EtOAc/hexanes) on silica gel to afford 
the corresponding alcohols. 
 
O7 7
OH
CO2Me
Cp2ZrCl2, AgOTf
Ag CO2Me
250  
Data for 250: colorless oil; Rf = 0.29 (20% EtOAc in hexanes); IR (neat): 3419 (br, O-H), 
2924, 2855, 2237, 1717, 1436, 1251, 1065, 752 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 4.50 
(br app q, 1H, J = 6.4 Hz), 3.80 (s, 3H), 1.91 (d, 1H, J = 5.8 Hz), 1.82−1.73 (m, 2H), 1.53−1.22 
(m, 14H), 0.89 (t, 3H, J = 6.7 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 153.8, 88.4, 76.1, 62.1, 
52.8, 36.8, 31.8, 29.44, 29.39, 29.2, 29.1, 24.9, 22.6, 14.0; HRMS (EI+) calcd. for C14H24O3 
[M]+  240.1725, found 240.1735.  
 
O
OH
CO2Me
251
Cp2ZrCl2, AgOTf
54%
Ag CO2Me
205  
Data for 251: See S. P. Shahi, K. Koide Angew. Chem., Int. Ed. 2004, 43, 2525–2527. 
 
O
OH
CO2Me252
Cp2ZrCl2, AgOTf
9%
Ag CO2Me
 
Data for 252: See C. T. Meta “Stereoselective Preparation of Highly Substituted Olefins 
and Synthetic Studies Toward Stresgenin B,” Univ. of Pittsburgh. 
 329 
 
O
OH
CO2Me253
Cp2ZrCl2, AgOTf
33%
Ag CO2Me
 
Data for 253: colorless oil; Rf = 0.40 (30% EtOAc in hexanes); IR (neat): 3412 (br, O-H), 
2952, 2237, 1718, 1436, 1254, 1068, 914, 752 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 5.79 (dddd, 1H, J = 16.8, 10.2, 6.6, 6.6 Hz), 5.06–4.94 (m, 2H), 4.46 (app t, 1H, J = 
6.6 Hz), 3.78 (s, 3H), 2.13–2.04 (m, 2H), 1.80−1.51 (m, 4H); 13C NMR (75 MHz, 293K, CDCl3) 
δ 153.9, 138.0, 115.0, 88.6, 75.9, 61.6, 52.7, 36.1, 33.1, 24.0; LRMS (EI+) C10H11O2 [M − H3O]
+ 
163 (58%), C9H9O2 [M − CH5O]
+ 149 (14%), C7H11O [M − C2H4O2]
+ 122 (26%). 
 
TBSO
O
255
TBSO
mCPBA
 
Procedure for the preparation of 255. To a stirred solution of 1-tbutyldimethylsiloxy-3-
butene (935 mg, 5.02 mmol) in CH2Cl2 (17 mL) was added mCPBA (70%, 2.47 g, 10.0 mmol) at 
0 °C. After 10 min at the same temperature, the reaction was allowed to warm to 23 °C. After 14 
h at the same temperature, the reaction was quenched by the addition of saturated aqueous 
NaHCO3 (10 mL) and saturated aqueous Na2SO3 (10 mL). The reaction mixture was then 
vigorously stirred for an additional 15 min, then diluted with hexanes (25 mL), and the layers 
were separated. The organic layer was then washed with saturated aqueous NaHCO3 (20 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (1–5% EtOAc in hexanes) on silica gel (50 mL) to 
afford 255 (964 mg, 95%) as a colorless oil. 
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 Data for 255: See E. N. Lawson, J. F. Jamie, W. Kitching J. Org. Chem. 1992, 57, 353–
358. 
 
O
TBSO
TBSO
OH
CO2Me
256255
Cp2ZrCl2, AgOTf
35%
Ag CO2Me
 
Data for 256: pale yellow oil; Rf = 0.30 (20% EtOAc in hexanes); IR (neat): 3411 (br O-
H), 2954, 2858, 2237, 1720 (C=O), 1436, 1255, 1100, 837 cm-1; 1H NMR (300 MHz, 293K, 1% 
CD3OD in CDCl3) δ 4.53 (br app t, 1H, J = 5.3 Hz), 3.77 (s, 3H), 3.76−3.60 (m, 2H), 1.96−1.64 
(m, 4H), 0.90 (s, 9H), 0.083 (s, 3H), 0.079 (s, 3H); 13C NMR (75 MHz, 293K, CDCl3) δ 153.9, 
88.6, 76.0, 63.0, 61.5, 52.6, 34.5, 28.3, 25.8, 18.3, −5.48, −5.53; HRMS (ESI+) calcd. for 
C14H27O4Si [M + H]
+  287.1679, found 287.1675. 
 
Ag nBu
O 7
OH
nBu
257
7 Cp2ZrCl2, AgOTf
69%  
Data for 257: colorless oil; Rf = 0.40 (15% EtOAc in hexanes); IR (neat): 3384 (br, O-H), 
2926, 2855, 2233, 1466, 1379, 1026, 722 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 4.35 (br app t, 1H, J = 6.4 Hz), 2.22 (app td, 2H, J = 6.9, 1.8 Hz), 1.72–1.60 (m, 2H), 
1.55–1.24 (m, 18H), 0.96–0.85 (m, 6H); 13C NMR (75 MHz, 293K, CDCl3) δ 85.4, 81.4, 62.8, 
38.2, 31.9 30.8, 29.52, 29.48, 29.27, 29.26, 25.2, 22.7, 21.9, 18.4, 14.1, 13.5; HRMS (EI+) calcd. 
for C16H30O [M]
+  238.2297, found 238.2288.  
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O
OH
nBu
258
Ag nBu
Cp2ZrCl2, AgOTf
59%  
Data for 258: colorless oil; Rf = 0.27 (15% EtOAc in hexanes); IR (neat): 3345 (br O-H), 
2933, 2863, 2232, 1641, 1459, 996, 911 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in CDCl3) 
δ 5.79 (dddd, 1H, J = 17.2, 10.0, 6.5, 6.5 Hz), 4.99 (dddd, 1H, J = 17.2, 1.5, 1.5, 1.5 Hz), 4.93 
(br d, 1H, J = 10.0 Hz), 4.31 (br app t, 1H, J = 3.9 Hz), 2.18 (app td, 2H, J = 7.0, 2.0 Hz), 2.06 
(br app q, 2H, J = 7.5 Hz), 1.71−1.58 (m, 2H), 1.56−1.33 (m, 6H), 0.88 (t, 3H, J = 7.3 Hz); 13C 
NMR (125 MHz, 293K, CDCl3) δ 138.5, 114.6, 85.3, 81.1, 62.2, 37.4, 33.2, 30.7, 24.4, 21.8, 
18.2, 13.5; LRMS (EI+) C12H19O [M − H]
+  179 (5%), C9H13O [M − C3H7]
+ 137 (75%), C7H11O 
[M − C5H9]
+ 111 (100%). 
 
O O
259
CH2Br2
n-BuLi
43%
 
Procedure for the preparation of 259: See T. J. Michnik, D. S. Matteson Synlett 1991, 
631–632. 
Data for 259: See S. P. Tanis, M. C. McMills, P. M. Herrington J. Org. Chem. 1985, 50, 
5587–5589. 
 
OH
nBu
260
O
259
Ag nBu
Cp2ZrCl2, AgOTf
53%; dr = 2:1  
Data for 260: colorless oil; Rf = 0.28 (15% EtOAc in hexanes); IR (neat): 3360 (br O-H), 
2931, 2862, 2224, 1451, 1379, 1140, 1047, 725 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 5.90−5.66 (m, 2H), 4.19 (br app s, 1H), 2.40−2.28 (m, 1H), 2.21 (app t, 2H, J = 6.5 
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Hz), 2.06−1.94 (m, 2H), 1.92−1.73 (m, 2H), 1.64−1.35 (m, 6H), 0.90 (t, 3H, J = 7.1 Hz); 13C 
NMR (125 MHz, 293K, CD2Cl2) δ 130.1, 129.9, 127.2, 126.5, 86.2, 86.1, 80.2, 80.0, 66.2, 66.0, 
42.4, 30.7, 25.18, 25.16, 24.5, 21.8, 21.4, 21.0, 18.3, 13.5; HRMS (EI+) calcd. for C13H20O [M]
+  
192.1514, found 192.1508. 
 
TBSO
O
TBSO
OH
nBu
262255
Ag nBu
Cp2ZrCl2, AgOTf
52%  
Data for 262: colorless oil; Rf = 0.31 (15% EtOAc in hexanes); IR (neat): 3385 (br O-H), 
2931, 2859, 2235, 1468, 1387, 1254, 1103, 837 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 4.39 (br s, 1H), 3.71−3.63 (m, 2H), 2.24−2.16 (m, 2H), 1.82−1.64 (m, 4H), 1.51−1.23 
(m, 4H), 0.93−0.87 (m, 12H), 0.07 (s, 6H); 13C NMR (125 MHz, 293K, CD2Cl2) δ 85.2, 81.1, 
63.2, 62.2, 35.5, 30.7, 28.5, 25.9, 21.9, 18.34, 18.27, 13.5, −5.4; HRMS (ESI+) calcd. for 
C16H32O2NaSi [M + Na]
+  307.2069, found 307.2070. 
 
TBDPSO
O
263
TBDPSO
mCPBA
 
Procedure for the preparation of 263. To a stirred solution of 1-tbutyldiphenylsiloxy-3-
butene (1.24 g, 3.99 mmol) in CH2Cl2 (14 mL) was added mCPBA (70%, 2.47 g, 6.0 mmol) at 0 
°C. After 10 min at the same temperature, the reaction was allowed to warm to 23 °C. After 14 h 
at the same temperature, the reaction was quenched by the addition of saturated aqueous 
NaHCO3 (10 mL) and saturated aqueous Na2SO3 (10 mL). The reaction mixture was then 
vigorously stirred for an additional 15 min, then diluted with hexanes (20 mL), and the layers 
were separated. The organic layer was then washed with saturated aqueous NaHCO3 (20 mL), 
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dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (2.5–15% EtOAc in hexanes) on silica gel (60 
mL) to afford 263 (1.18 g, 91%) as a colorless oil. 
 Data for 263: See R. Hanessian, A. Tehim, P. Chen J. Org. Chem. 1993, 58, 7768–7781. 
 
TBDPSO
O
TBDPSO
OH
nBu264263
Ag nBu
Cp2ZrCl2, AgOTf
55%  
Data for 264: colorless oil; Rf = 0.27 (15% EtOAc in hexanes); IR (neat): 3383 (br O-H), 
2932, 2856, 2235, 1469, 1428, 1389, 1189, 1110, 702 cm-1; 1H NMR (300 MHz, 293K, 1% 
CD3OD in CDCl3) δ 7.74−7.62 (m, 4H), 7.46−7.33 (m, 6H), 4.40 (br s, 1H), 3.72−3.67 (m, 2H), 
2.21 (app td, 2H, J = 6.9, 1.5 Hz), 1.80−1.35 (m, 8H), 1.05 (s, 9H), 0.92 (t, 3H, J = 7.0 Hz); 13C 
NMR (125 MHz, 293K, CD2Cl2) δ 135.5, 133.6, 129.6, 127.6, 85.3, 81.1, 63.9, 62.3, 35.2, 30.7, 
28.2, 26.7, 21.9, 19.1, 18.3, 13.5; HRMS (ESI+) calcd. for C26H37O2Na [M + H]
+  409.2563, 
found 409.2556. 
 
7
OH
265
Cp2ZrCl2, AgOTf
82%
O7
Ag
 
Data for 265: pale yellow oil; Rf = 0.31 (15% EtOAc in hexanes); IR (neat): 3329 (br, O-
H), 2924, 2855, 2229, 1599, 1490, 1070, 1027, 755 cm-1; 1H NMR (300 MHz, 293K, 1% 
CD3OD in CDCl3) δ 7.45−7.39 (m, 2H), 7.34−7.28 (m, 3H), 4.57 (app t, 1H, J = 6.6 Hz), 
1.83−1.74 (m, 2H), 1.57−1.23 (m, 14H), 0.87 (t, 3H, J = 6.6 Hz); 13C NMR (75 MHz, 293K, 
CDCl3) δ 131.7, 128.3, 128.2, 122.7, 90.3, 84.8, 63.0, 37.9, 31.9, 29.5, 29.3, 25.2, 22.7, 14.1; 
HRMS (EI+) calcd. for C18H26O [M]
+  258.1984, found 258.1975.  
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7
OH
266
OTHPCp2ZrCl2, AgOTf
82%
O7
OTHP
Ag
 
Data for 266: colorless oil; Rf = 0.14 (15% EtOAc in hexanes); IR (neat): 3423 (br, O-H), 
2924, 2854, 1466, 1343, 1201, 1120, 1024, 902 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 4.81 (br s, 1H), 4.40−4.33 (m, 1H), 4.33 (dd, 1H, J = 15.6, 1.5 Hz), 4.25 (dd, 1H, J = 
15.6, 1.2 Hz), 3.88−3.79 (m, 1H), 3.56−3.49 (m, 1H), 1.88−1.20 (m, 22H), 0.87 (t, 3H, J = 5.9 
Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 96.9, 87.4, 80.2, 62.1, 62.0, 54.3, 37.6, 31.8, 30.1, 
29.47, 29.45, 29.22, 29.21, 25.2, 25.1, 22.6, 18.9, 14.0; HRMS (ESI+) calcd. for C18H32O3 [M + 
Na]+  319.2249, found 319.2250.  
 
7
OH
267
OEt
OEt
Cp2ZrCl2, AgOTf
81%
O7
OEt
OEt
Ag
 
Data for 267: colorless oil; Rf = 0.22 (15% EtOAc in hexanes); IR (neat): 3425 (br, O-H), 
2925, 2856, 2241, 1467, 1328, 1145, 1054, 1012 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD 
in CDCl3) δ 5.29 (d, 1H, J = 1.2 Hz), 4.39 (br app t, 1H, J = 6.6 Hz), 3.81−3.68 (m, 2H), 
3.63−3.56 (m, 2H), 1.75−1.66 (m, 2H), 1.52−1.18 (m, 20H), 0.87 (t, 3H, J = 6.8 Hz); 13C NMR 
(75 MHz, 293K, CDCl3) δ 91.2, 86.5, 80.0, 62.2, 60.9, 60.8, 37.4, 31.8, 29.5, 29.3, 29.2, 25.1, 
22.6, 15.0, 14.1; HRMS (EI+) calcd. for C15H27O2 [M – OEt]
+  239.2011, found 239.2007.  
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7
OH
268
OAcCp2ZrCl2, AgOTf
57%
O7
OAc
Ag
 
Data for 268: colorless oil; Rf = 0.24 (20% EtOAc in hexanes); IR (neat): 3424 (br, O-H), 
2925, 2855, 1750, 1457, 1379, 1226, 1028 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in 
CDCl3) δ 4.73 (d, 1H, J = 18.2 Hz), 4.67 (d, 1H, J = 18.2 Hz), 4.37 (br app t, 1H, J = 6.3 Hz), 
2.10 (s, 3H), 1.73−1.64 (m, 2H), 1.48−1.21 (m, 14H), 0.87 (t, 3H, J = 6.6 Hz); 13C NMR (75 
MHz, 293K, CDCl3) δ 170.3, 88.0, 78.6, 62.3, 62.2, 53.3, 37.5, 31.8, 29.5, 29.3, 29.2, 25.1, 22.6, 
20.7, 14.1; HRMS (ESI+) calcd. for C15H26O3 [M + Na]
+  277.1780, found 277.1829.  
 
Se
O2N
NCSe
O2N
OH
 
Procedure for the preparation of 2-nitrophenyl propargyl selenide.  To a stirred 
solution of 2-nitrophenylselenocyanate (2.27 g, 10.0 mmol) and propargyl alcohol (650 µL, 11.2 
mmol) in THF (35 mL) was added nBu3P (3.0 mL, 12 mmol) dropwise at 0 °C.  After 40 min at 
the same temperature, the reaction was poured onto saturated aqueous NaHCO3 (300 mL).  The 
layers were separated, and the aqueous layer was extracted with Et2O (3 × 100 mL).  The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure.  The resulting residue was purified by column chromatography (1 → 5% Et2O 
in hexanes) on silica gel (250 mL) to afford 2-nitrophenyl propargyl selenide (1.90 g, 79%) as 
a yellow solid. 
Data for 2-nitrophenyl propargyl selenide: yellow solid; m.p. = 85−86 °C; Rf = 0.29 
(15% EtOAc in hexanes); IR (KBr pellet): 3272, 3088, 2925, 1589, 1565, 1497, 1352, 1306, 
1100, 1038, 731 cm-1; 1H NMR (300 MHz, 293K, CDCl3) δ 8.37 (dd, 1H, J = 8.4, 1.2 Hz), 7.69 
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(dd, 1H, J = 8.1, 1.2 Hz), 7.62 (ddd, 1H, J = 8.1, 6.9, 1.5 Hz), 7.39 (ddd, 1H, J = 8.4, 6.9, 1.5 
Hz), 3.55 (d, 2H, J = 2.7 Hz), 2.28 (t, 1H, J = 2.7 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 
146.0, 134.0, 132.9, 128.8, 126.4, 125.9, 79.5, 72.1, 11.4; HRMS (EI+) calcd. for C9H7NO2
80Se 
[M]+  240.9642, found 240.9633.  
 
7
OH
Se
SeAr
Ag
Cp2ZrCl2, AgOTf
52%
O7
O2N
269  
Data for 269: pale yellow solid; m.p. = 71−72 °C; Rf = 0.34 (30% EtOAc in hexanes); IR 
(KBr pellet): 3332 (br, O-H), 2923, 2850, 1589, 1567, 1503, 1330, 1306, 1038, 729 cm-1; 1H 
NMR (300 MHz, 293K, 1% CD3OD in CDCl3) δ 8.34 (dd, 1H, J = 8.3, 1.3 Hz), 7.65 (dd, 1H, J 
= 8.1, 1.3 Hz), 7.58 (ddd, 1H, J = 8.1, 7.2, 1.5 Hz), 7.36 (ddd, 1H, J = 8.3, 7.2, 1.5 Hz), 4.33 (br 
app t, 1H, J = 6.6 Hz), 3.62−3.55 (m, 2H), 1.71−1.15 (m, 16H), 0.87 (t, 3H, J = 6.8 Hz); 13C 
NMR (75 MHz, 293K, CDCl3) δ 146.2, 133.9, 133.2, 129.0, 126.4, 125.8, 85.2, 80.2, 62.6, 37.8, 
31.8, 29.5 (two overlapping carbons), 29.25, 29.20, 25.1, 22.6, 14.1, 12.0; HRMS (EI+) calcd. 
for C19H27NO3
80Se [M]+  397.1156, found 397.1141.  
 
OAc
Ag
CHO
Cp2ZrCl2, AgOTf
38%, dr = 1:1 OAc
270
OH
 
Data for 270: See X. Ariza, J. Garcia, Y. Georges, M. Vicente Org. Lett. 2006, 8, 4501–
4504. 
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Cp2ZrCl2, AgOTf
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nBu
271  
Data for 271: Rf = 0.40 (20% EtOAc in hexanes); IR (neat): 3420 (br, O-H), 3028, 2931, 
2228, 1495, 1452, 1032, 746 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in CDCl3) δ 
7.42−7.18 (m, 10H), 5.02 (ddd, 1H, J = 7.2, 1.8, 1.8 Hz), 4.20 (br d, 1H, J = 7.2 Hz), 2.16−1.95 
(m, 3H), 1.40−1.16 (m, 4H), 0.82 (t, 3H, J = 7.2 Hz); 13C NMR (75 MHz, 293K, 1% CD3OD in 
CDCl3) δ 141.2, 140.6, 128.9, 128.8, 128.3, 128.1, 126.7, 126.6, 87.6, 79.9, 65.2, 58.2, 30.4, 
21.6, 18.2, 13.4; HRMS (ESI+) calcd. for C20H22ONa [M + Na]
+  301.1568, found 301.1579. 
 
O OCH2Br2,
nBuLi
77%
273  
Procedure for the preparation of racemic-273.  To a stirred solution of 
cyclohexylmethyl ketone (1.4 mL, 10 mmol) and CH2Br2 in THF (30 mL) was added 
nBuLi (1.6 
M in hexanes, 7.0 mL) down the flask side over 15 min at −78 °C.  After an additional 30 min at 
the same temperature, the reaction was warmed to 23 °C. After 2.75 h at the same temperature, 
the reaction mixture was poured onto saturated aqueous NH4Cl (40 mL) and concentrated under 
reduced pressure to remove most of the THF.  The resulting aqueous residue was extracted with 
Et2O (2 × 25 mL).  The combined organic layers were dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure.  The resulting residue was purified by column 
chromatography (2 → 4% EtOAc in hexanes) on silica gel (50 mL) to afford racemic-273 (1.08 
g, 77%) as a colorless oil. 
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O
OH
nBu
273 274
Ag nBu
Cp2ZrCl2, AgOTf
79%, dr = 1:1
 
Data for 274: Rf = 0.27 (10% EtOAc in hexanes); IR (neat): 3417 (br, O-H), 2924, 1637, 
1490, 1447, 1000, 755 cm-1; 1H NMR (300 MHz, 293K, 1% CD3OD in CDCl3) δ 7.41−7.38 (m), 
7.33−7.28 (m), 4.61 (d, J = 5.7 Hz), 1.82−1.52 (m), 1.36−1.10 (m), 1.06 (t, J = 6.6 Hz), 1.03 (t, J 
= 6.9 Hz); 13C NMR (75 MHz, 293K, CDCl3) δ 131.7, 131.6, 128.3, 122.8, 90.2, 89.2, 85.9, 85.3, 
65.40, 65.35, 45.0, 44.8, 39.5, 35.0, 31.6, 31.4, 29.2, 28.7, 26.71, 26.64, 26.59, 26.47, 11.43, 
11.40; HRMS (EI+) calcd. for C17H22O [M]
+  242.1671, found 242.1676. 
 
O
273
O
(R)-273
NN
O O
Cr
Cl
tBu
tBu
tBu
tBu
TMSN3, i-PrOH
 
Procedure and data for the preparation of (R)-273: See H. Lebel, E. N. Jacobsen 
Tetrahedron Lett. 1999, 40, 7303–7306. 
 
O
(R)-273
Ph
NH2 OH
HN
Ph
302  
General procedure for the determination of the enantiomeric ratio of 273. To a 
stirred solution of 273 (9.2 mg, 0.066 mmol) and (R)-(+)-α-methylbenzylamine (25 µL, 0.19 
mmol) in MeOH (0.3 mL) was added KI (2.2 mg, 0.013 mmol) in one portion at 23 °C. After 5 
min at the same temperature, the reaction mixture was heated to 55 °C. After an additional 2 d at 
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the same temperature, the reaction mixture was cooled and concentrated under reduced pressure. 
The resulting crude residue was analyzed by 1H NMR spectroscopy revealing the diastereomeric 
ratio of 302 to be >40:1 by comparison with 302 prepared from racemic-273. 
 
OH
nBu
274
HO
Ph
O
F3C OMe
O
nBu
O
Ph
OMe
F3C
DCC, DMAP
303  
General procedure for the determination of the enantiomeric ratios of 274 by 
Mosher ester synthesis. To a stirred solution of 274 (9.9 mg, 0.041 mmol) and (R)-(+)-α-
methoxy-(trifluoromethyl)phenylacetic acid (40 mg, 0.17 mmol) in CH2Cl2 was added DCC (34 
mg, 0.17 mmol) followed by DMAP (12 mg, 0.098 mmol) in one portion at 0 °C. After 10 min at 
the same temperature, the reaction was warmed to 23 °C. After an additional 20 min at the same 
temperature, the reaction mixture was filtered through a pad of Florisil (3 mL), rinsed with 15% 
EtOAc in hexanes (3 × 5 mL), and concentrated under reduced pressure. The resulting crude 
residue was analyzed by 1H NMR spectroscopy and reverse phase HPLC revealing the 
diastereomeric ratio of 303 to be 9:9:1:1 by comparison with 303 prepared from racemic-274. 
 
O7
7
Cl
OH
7
OH
Cl
7
H
O
290 291 decanal
++
 
General procedure for the preparation of 290, 291, and decanal from 1,2-
epoxydecane. To a stirred solution of 1,2-epoxydecane (45 µL, 0.24 mmol) in CH2Cl2 (1.0 mL) 
were added the other reaction components (equivalents based on optimized alkynylation reaction 
conditions) at 23 °C.  After 3.5−19 h at the same temperature, the reaction was quenched by the 
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addition of saturated aqueous NaHCO3 (0.3 mL).  After stirring for 15–30 min at the same 
temperature, the reaction mixture was filtered through a pad of Celite 545® and Na2SO4, rinsed 
with Et2O (3 × 5 mL), and concentrated under reduced pressure.  The resulting residues were 
purified by flash chromatography (EtOAc/hexanes) on silica gel to afford the corresponding 
products. 
 Data for 290 and 291: See Barry, C. N.; Evans, S. A., Jr. J. Org. Chem. 1983, 48, 
2825−2828 
 
Ag
Cp2ZrCl2
CD2Cl2
ClCp2Zr
292241
OEt
OEt
OEt
OEt
 
Procedure for the preparation of 292 and 294 from 241. To an NMR tube was added 
241 (35–49 mg, 0.15–0.20 mmol) followed by CD2Cl2 (0.8 mL) under Ar at 23 °C. To the 
homogeneous solution was added Cp2ZrCl2 (1.1 equiv) and the resulting mixture was vortexted 
for 5 min. NMR experiments were then performed on the rapidly generated acetylide 292. To 
this solution was added benzophenone (1.0 equiv) and the mixture was vortexed for 2 min. NMR 
experiments were then performed on equilibrium between 292 and 294.  See Tables 24 and 25 
for complete NMR data. 
 
ClCp2Zr
292
OEt
OEt AgOTf
CD2Cl2
(TfO)Cp2Zr
293
OEt
OEt
 
Procedure for the preparation of 293 and 295 from 292. To an NMR tube containing 
292 (0.15–0.20 mmol) in CD2Cl2 (0.8 mL) was added AgOTf (1.0 equiv) under Ar at 23 °C, and 
the mixture was then vortexed for 5 min. NMR experiments were immediately performed on the 
rapidly generated acetylide 293. To this solution was added benzophenone (1.0 equiv) and the 
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mixture was vortexed for 2 min. NMR experiments were then performed on equilibrium between 
293 and 295 (see Tables 24 and 25 for spectral data). 
 
Table 24. Complete 1H NMR data for 241, 292, 293, 294, and 295 
Compound 1H NMR (300 MHz, 293K, CD2Cl2) 
3,3-diethoxypropyne 5.22 (d, 1H, J = 1.8 Hz), 3.72 (q, 1H, J = 7.1 Hz), 3.69 (q, 1H, J = 7.1 
Hz), 3.56 (q, 1H, J = 7.0 Hz), 3.53 (q, 1H, J = 7.1 Hz), 2.57 (d, 1H, J = 
1.8 Hz), 1.19 (t, 6H, J = 7.1 Hz) 
241 5.32 (br s, 1H), 3.77−3.71 (m, 2H), 3.66−3.55 (m, 2H), 1.23 (t, 6H, J = 
7.1 Hz) 
292 6.48 (br s, 10 H), 5.32 (br s, 1H), 3.79−3.71 (m, 2H), 3.68−3.56 (m, 2H), 
1.22 (t, 6H, J = 7.1 Hz) 
293† 6.67 (br s, 10 H), 5.34 (br s, 1H), 3.84−3.72 (m, 2H), 3.70−3.55 (m, 2H), 
1.27 (t, 6H, J = 7.1 Hz) 
benzophenone 7.83−7.77 (m, 4H), 7.65−7.58 (m, 2H), 7.55−7.47 (m, 4H) 
294 7.82−7.77 (m, 4H), 7.64−7.58 (m, 2H), 7.55−7.47 (m, 4H), 6.64 (br s, 
10H), 5.35 (br s, 1H), 3.84−3.74 (m, 2H), 3.71−3.56 (m, 2H), 1.27 (t, 6H, 
J = 7.1 Hz) 
295† 7.82−7.77 (m, 4H), 7.65−7.58 (m, 2H), 7.55−7.47 (m, 4H), 6.50 (br s, 
10H), 5.36 (br s, 1H), 3.83−3.73 (m, 2H), 3.69−3.58 (m, 2H), 1.25 (t, 6H, 
J = 7.1 Hz) 
 
Table 25. Complete 13C NMR data for 241, 292, 293, 294, and 295 
Compound 13C NMR (75 MHz, 293K, CD2Cl2) 
3,3-
diethoxypropyne 
91.31, 79.60, 73.35, 61.24, 15.18 
241 
117.93 (C≡C−Ag),‡ 93.65(C≡C−CH(OEt)2),
‡ 91.86(−CH(OEt)2),
‡ 61.40, 
15.35 
292 116.44, 114.41, 113.77, 92.00, 61.48, 15.33 
293
†
 119.40 (q), 117.62, 116.46, 115.81, 91.78, 61.93, 15.28  
benzophenone 198.68, 138.00, 132.71, 130.29, 128.62 
294 
198.63, 137.94, 132.69, 130.24, 128.59, 116.44, 113.72, 92.01, 61.52, 
15.35 
295
†
 
196.83, 137.90, 132.76, 130.30, 119.43 (q), 117.60, 116.46, 115.82, 
91.79, 61.94, 15.29 
 
† Contaminated by hydrolysis products; ‡ Determined by an HMBC experiment 
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2.10 1H AND 13C SPECTRA 
1H NMR of 250: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13C NMR of 250: CDCl3, 293 K, 75 MHz 
 
7
OH
CO2Me
250
7
OH
CO2Me
250
 343 
1
H NMR of 253: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 253: CDCl3, 293 K, 75 MHz 
 
OH
CO2Me253
OH
CO2Me253
 344 
1
H NMR of 256: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 256: CDCl3, 293 K, 75 MHz 
 
TBSO
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CO2Me
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 345 
1
H NMR of 257: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 257: CDCl3, 293 K, 75 MHz 
 
7
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7
OH
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1
H NMR of 258: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 258: CDCl3, 293 K, 75 MHz 
 
OH
nBu
258
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1
H NMR of 260: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 260: CDCl3, 293 K, 75 MHz 
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1
H NMR of 262: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 262: CDCl3, 293 K, 75 MHz 
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1
H NMR of 264: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 264: CDCl3, 293 K, 75 MHz 
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 350 
1
H NMR of 265: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 265: CDCl3, 293 K, 75 MHz  
 
7
OH
265
7
OH
265
 351 
1
H NMR of 266: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 266: CDCl3, 293 K, 75 MHz 
7
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 352 
1
H NMR of 267: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 267: CDCl3, 293 K, 75 MHz 
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 353 
1
H NMR of 268: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 268: CDCl3, 293 K, 75 MHz  
 
7
OH
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7
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 354 
1
H NMR of 2-nitrophenyl propargyl selenide: CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 2-nitrophenyl propargyl selenide: CDCl3, 293 K, 75 MHz 
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 355 
1
H NMR of 269: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 269: CDCl3, 293 K, 75 MHz  
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 356 
1
H NMR of 270: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 270: CDCl3, 293 K, 75 MHz 
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 357 
1
H NMR of 271: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
13
C NMR of 271: CDCl3, 293 K, 75 MHz 
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 358 
1
H NMR of 302: 1% CD3OD in CDCl3, 293 K, 300 MHz 
 
 
1
H NMR of 302 – prepared from (R)-273: 1% CD3OD in CDCl3, 293 K, 300 MHz 
  
OH
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OH
HN
Ph
 359 
1
H NMR of 303 – prepared from 274: CDCl3, 293 K, 300 MHz 
 
 
1
H NMR of 303 – prepared from enantioenriched-274: CDCl3, 293 K, 300 MHz 
O
nBu
O
Ph
OMe
F3C
O
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O
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OMe
F3C
 360 
 1H NMR of 241: CD2Cl2, 293 K, 300 MHz 
 
 
13
C NMR of 241: CDCl3, 293 K, 75 MHz 
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 361 
1
H NMR of 292: CD2Cl2, 293 K, 300 MHz 
 
 
13
C NMR of 292: CD2Cl2, 293 K, 75 MHz 
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 362 
1
H NMR of 293: CD2Cl2, 293 K, 300 MHz 
 
 
13
C NMR of 293: CD2Cl2, 293 K, 75 MHz 
(TfO)Cp2Zr
293
OEt
OEt
(TfO)Cp2Zr
293
OEt
OEt
 363 
1
H NMR of 292 + benzophenone: CD2Cl2, 293 K, 300 MHz 
 
 
13
C NMR of 292 + benzophenone: CD2Cl2, 293 K, 75 MHz 
 
 364 
1
H NMR of 293 + benzopehenone: CD2Cl2, 293 K, 300 MHz 
 
 
13
C NMR of 293 + benzophenone: CD2Cl2, 293 K, 75 MHz 
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3.0  APPENDIX  
A.1 SPECTRAL COMPARISON OF FR901464 
Table 26. 1H NMR assignments for FR901464 
Position 
Synthetic FR901464 - our 
material: δH (mult, J (Hz)) 
Natural FR901464:  
δH (mult, J (Hz)) 
Synthetic FR901464 – Jacobsen’s:  
δH (mult, J (Hz)) 
1-OH 3.31 (s) 3.38 (s) 3.40 (s) 
2axial 
2equitorial 
2.34 (d, 14.4) 
1.64 (d, 14.4) 
2.36 (d, 14) 
1.66 (d, 14) 
2.34 (d, 14.5) 
1.64 (d, 14) 
4 3.57 (app t, 10.0) 3.58 (dd, 10, 10) 3.57 (dd, 10, 10) 
4-OH 1.59 (10.3) 1.66 (d, 10) 1.67 (d, 10) 
5 4.24 (dd, 9.3, 7.0) 4.25 (10, 7) 4.24 (dd, 9, 7) 
6 5.65 (dd, 15.7, 7.0) 5.66 (dd, 7, 16) 5.66 (dd, 7, 16) 
7 6.38 (d, 15.7) 6.37 (d, 16) 6.37 (d, 15.5) 
9 5.54 (br app t, 7.0) 5.53 (br t, 7) 5.53 (br t, 7) 
10 2.40−2.30 (m) 
2.28−2.20 (m) 
2.36 (m) 
2.24 (m) 
2.35 (m) 
2.22 (m) 
11 3.57−3.50 (m) 3.53 (m) 3.53 (m) 
12 1.77 (m) 1.77 (m) 1.77 (m) 
13 1.95−1.93 (m) 
1.93−1.91 (m) 
1.94 (m) 
1.91 (m) 
1.93 (m) 
1.92 (m) 
14 3.94−3.88 (m) 3.90 (m) 3.90 (m) 
14-NH 5.96 (br d, 8.9) 5.99 (d, 9) 6.00 (d, 9) 
15 3.66 (qd, 6.5, 2.2) 3.66 (qd, 7, 2) 3.65 (qd, 6.5, 2.5) 
16 1.11 (3H, d, 6.4) 1.11 (3H, d, 7) 1.11 (3H, d, 6.5) 
17 1.43 (3H, s) 1.43 (3H, s) 1.42 (3H, s) 
18 3.06 (d, 4.5) 
2.55 (d, 4.5) 
3.07 (d, 4.5) 
2.55 (d, 4.5) 
3.05 (d, 4.5) 
2.55 (d, 4.5) 
19 1.78 (3H, br s) 1.78 (3, s) 1.78 (3H, s) 
20 1.01 (3H, d, 7.3) 1.01 (3H, d, 7) 1.01 (3H, d, 7.5) 
2’ 5.71 (dd, 11.6, 1.3) 5.71 (dd, 11.5, 1) 5.71 (dd, 12, 1.5) 
3’ 5.90 (dd, 11.6, 7.8) 5.90 (11.5, 8) 5.90 (dd, 11, 8) 
4’ 6.26 (m) 6.26 (m) 6.26 (m) 
5’ 1.34 (3H, d, 6.5) 1.33 (3H, d, 6.5) 1.33 (3H, d, 8.5) 
2” 2.01 (3H, s) 2.02 (3H, s) 2.01 (3H, s) 
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Table 27. 13C NMR assignments for FR901464 
Position Natural FR901464: δC  
Synthetic FR901464 - 
our material: δC  
Synthetic FR901464 - 
Jacobsen’s: δC  
1 96.7 96.7 96.6 
2 41.8 41.8 41.8 
3 58.1 58.1 58.1 
4 68.1 68.1 68.1 
5 73.8 73.9 73.8 
6 124.7 124.6 124.6 
7 138.3 138.3 138.2 
8 134.8 134.8 134.7 
9 129.8 129.9 129.7 
10 32.4 32.4 32.4 
11 81.2 81.2 81.1 
12 29.6 29.6 29.6 
13 36.3 36.2 36.2 
14 47.4 47.4 47.4 
15 76.3 76.3 76.2 
16 17.9 17.9 18.0 
17 29.1 29.1 29.1 
18 48.0 48.1 48.1 
19 12.7 12.7 12.8 
20 15.2 15.2 15.3 
1’ 165.0 165.0 164.8 
2’ 122.8 122.8 122.7 
3’ 143.9 143.9 143.7 
4’ 68.9 68.9 68.9 
5’ 20.2 20.1 20.2 
1” 170.6 170.6 170.4 
2” 21.4 21.4 21.4 
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A.2 X-RAY DATA FOR METHYL GLYCOSIDE 112 
 
Figure 27. X-ray structure of 112 
 368 
Table 28.  Crystal data and structure refinement for 112 
 
Identification code  112 
Empirical formula  C15 H26 Br O4 Si 
Formula weight  378.36 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 8.7770(19) Å = 90°. 
 b = 20.887(5) Å = 101.429(4)°. 
 c = 10.432(2) Å  = 90°. 
Volume 1874.5(7) Å3 
Z 4 
Density (calculated) 1.341 Mg/m3 
Absorption coefficient 2.268 mm-1 
F(000) 788 
Crystal size 0.06 x 0.06 x 0.21 mm3 
Theta range for data collection 1.95 to 33.18°. 
Index ranges -13<=h<=12, -30<=k<=31, -15<=l<=15 
Reflections collected 22623 
Independent reflections 12241 [R(int) = 0.1181] 
Completeness to theta = 33.18° 91.9 %  
Absorption correction Sadabs 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12241 / 1 / 380 
Goodness-of-fit on F2 0.639 
Final R indices [I>2sigma(I)] R1 = 0.0506, wR2 = 0.0994 
R indices (all data) R1 = 0.1382, wR2 = 0.1173 
Absolute structure parameter 0.033(8) 
Largest diff. peak and hole 0.670 and -0.634 e.Å-3 
 369 
Table 29.  Atomic coordinates  (× 104) and equivalent  isotropic displacement parameters (Å2 ×  103) for 112.  
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 
______________________________________________________________________________ 
x y z U(eq) 
______________________________________________________________________________ 
Br 5172(1) 5913(1) 16867(1) 50(1) 
Si 5088(1) 3289(1) 14865(2) 34(1) 
O(1) 7931(3) 5076(1) 16082(3) 34(1) 
C(1) 6445(4) 5050(2) 15220(5) 28(1) 
O(2) 7339(3) 4808(2) 12449(4) 38(1) 
C(2) 6265(5) 4467(2) 14339(5) 31(1) 
O(3) 9117(4) 5647(2) 14612(4) 46(1) 
C(3) 7602(5) 4447(2) 13648(5) 31(1) 
O(4) 6291(3) 3907(1) 15138(4) 35(1) 
C(4) 9168(5) 4531(2) 14526(6) 36(1) 
C(5) 9224(5) 5089(3) 15409(6) 45(2) 
C(6) 5243(5) 5077(2) 16065(6) 38(1) 
C(7) 7412(5) 4132(2) 12394(6) 42(1) 
C(8) 10666(5) 5082(3) 16502(6) 59(2) 
C(9) 9078(8) 6248(3) 15306(8) 76(2) 
C(10) 3050(5) 3572(2) 14333(7) 44(2) 
C(11) 1850(5) 3024(2) 14007(7) 56(2) 
C(12) 5379(6) 2878(3) 16468(6) 48(2) 
C(13) 4619(9) 3195(4) 17439(9) 47(3) 
C(13") 4907(17) 2234(7) 16591(17) 40(5) 
C(14) 5619(5) 2739(2) 13622(6) 41(1) 
C(15) 7326(6) 2496(3) 13959(7) 57(2) 
Br' -1844(1) 4089(1) -1021(1) 47(1) 
Si' -235(2) 6783(1) 575(2) 43(1) 
O(1') 1426(3) 4834(1) -253(3) 35(1) 
C(1') 327(5) 4922(2) 595(6) 35(1) 
C(2') 645(5) 5537(2) 1367(5) 30(1) 
O(2') 2475(4) 5135(1) 3332(4) 43(1) 
C(3') 2292(5) 5503(2) 2151(5) 34(1) 
O(4') 3230(3) 4256(1) 1265(4) 36(1) 
 370 
C(4') 3453(4) 5376(2) 1304(5) 38(1) 
O(4') 510(3) 6062(1) 492(3) 36(1) 
C(5') 3013(5) 4797(2) 436(5) 34(1) 
C(6') -1276(4) 4924(2) -282(5) 33(1) 
C(7') 2699(6) 5816(2) 3416(6) 50(2) 
C(8') 3929(5) 4756(3) -651(6) 53(2) 
C(9') 2835(6) 3655(2) 646(7) 50(2) 
C(10') 649(7) 7274(2) -592(6) 56(2) 
C(11') 2433(7) 7292(3) -291(8) 81(2) 
C(12') 299(6) 7084(2) 2283(7) 56(2) 
C(13') -361(8) 7760(3) 2470(8) 75(2) 
C(14') -2363(6) 6772(3) 32(9) 88(3) 
C(15') -3273(7) 6466(3) 949(13) 161(6) 
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 Table 30.   Bond lengths [Å] and angles [°] for 112 
 
_____________________________________________________ 
Br-C(6)  1.941(4) 
Si-O(4)  1.657(3) 
Si-C(12)  1.851(6) 
Si-C(14)  1.859(5) 
Si-C(10)  1.861(5) 
O(1)-C(1)  1.431(5) 
O(1)-C(5)  1.448(6) 
C(1)-C(6)  1.505(6) 
C(1)-C(2)  1.516(6) 
O(2)-C(7)  1.416(6) 
O(2)-C(3)  1.440(6) 
C(2)-O(4)  1.433(5) 
C(2)-C(3)  1.494(6) 
O(3)-C(5)  1.424(6) 
O(3)-C(9)  1.452(6) 
C(3)-C(7)  1.445(7) 
C(3)-C(4)  1.503(6) 
C(4)-C(5)  1.480(7) 
C(5)-C(8)  1.526(7) 
C(10)-C(11)  1.547(7) 
C(12)-C(13)  1.475(10) 
C(14)-C(15)  1.555(7) 
Br'-C(6')  1.932(4) 
Si'-O(4')  1.652(3) 
Si'-C(14')  1.842(5) 
Si'-C(12')  1.860(7) 
Si'-C(10')  1.874(6) 
O(1')-C(5')  1.437(5) 
O(1')-C(1')  1.444(6) 
C(1')-C(2')  1.512(6) 
C(1')-C(6')  1.519(6) 
C(2')-O(4')  1.416(5) 
C(2')-C(3')  1.515(6) 
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O(2')-C(3')  1.433(6) 
O(2')-C(7')  1.437(5) 
C(3')-C(7')  1.452(7) 
C(3')-C(4')  1.499(7) 
O(4')-C(5')  1.414(5) 
O(4')-C(9')  1.422(6) 
C(4')-C(5')  1.514(7) 
C(5')-C(8')  1.517(7) 
C(10')-C(11')  1.535(8) 
C(12')-C(13')  1.552(7) 
C(14')-C(15')  1.505(11) 
O(4)-Si-C(12) 103.7(2) 
O(4)-Si-C(14) 111.2(2) 
C(12)-Si-C(14) 109.6(3) 
O(4)-Si-C(10) 110.19(18) 
C(12)-Si-C(10) 111.7(3) 
C(14)-Si-C(10) 110.3(3) 
C(1)-O(1)-C(5) 113.6(4) 
O(1)-C(1)-C(6) 106.7(4) 
O(1)-C(1)-C(2) 112.6(3) 
C(6)-C(1)-C(2) 112.6(3) 
C(7)-O(2)-C(3) 60.8(3) 
O(4)-C(2)-C(3) 109.5(3) 
O(4)-C(2)-C(1) 108.4(4) 
C(3)-C(2)-C(1) 108.5(3) 
C(5)-O(3)-C(9) 114.9(5) 
O(2)-C(3)-C(7) 58.8(3) 
O(2)-C(3)-C(2) 113.4(4) 
C(7)-C(3)-C(2) 119.3(4) 
O(2)-C(3)-C(4) 115.9(4) 
C(7)-C(3)-C(4) 122.2(4) 
C(2)-C(3)-C(4) 114.5(5) 
C(2)-O(4)-Si 126.9(3) 
C(5)-C(4)-C(3) 112.7(4) 
O(3)-C(5)-O(1) 109.3(4) 
O(3)-C(5)-C(4) 106.9(5) 
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O(1)-C(5)-C(4) 110.8(4) 
O(3)-C(5)-C(8) 113.2(4) 
O(1)-C(5)-C(8) 104.5(5) 
C(4)-C(5)-C(8) 112.2(4) 
C(1)-C(6)-Br 111.9(3) 
O(2)-C(7)-C(3) 60.4(3) 
C(11)-C(10)-Si 113.8(3) 
C(13)-C(12)-Si 114.3(4) 
C(15)-C(14)-Si 114.0(4) 
O(4')-Si'-C(14') 111.1(2) 
O(4')-Si'-C(12') 109.3(2) 
C(14')-Si'-C(12') 110.3(3) 
O(4')-Si'-C(10') 104.3(2) 
C(14')-Si'-C(10') 109.4(3) 
C(12')-Si'-C(10') 112.3(3) 
C(5')-O(1')-C(1') 113.5(4) 
O(1')-C(1')-C(2') 111.0(3) 
O(1')-C(1')-C(6') 106.5(4) 
C(2')-C(1')-C(6') 111.7(3) 
O(4')-C(2')-C(1') 109.4(4) 
O(4')-C(2')-C(3') 109.5(3) 
C(1')-C(2')-C(3') 107.7(4) 
C(3')-O(2')-C(7') 60.8(3) 
O(2')-C(3')-C(7') 59.7(3) 
O(2')-C(3')-C(4') 116.0(4) 
C(7')-C(3')-C(4') 122.8(4) 
O(2')-C(3')-C(2') 115.0(4) 
C(7')-C(3')-C(2') 120.4(4) 
C(4')-C(3')-C(2') 112.1(4) 
C(5')-O(4')-C(9') 116.0(4) 
C(3')-C(4')-C(5') 111.7(3) 
C(2')-O(4')-Si' 131.0(3) 
O(4')-C(5')-O(1') 110.4(3) 
O(4')-C(5')-C(8') 112.6(4) 
O(1')-C(5')-C(8') 103.5(4) 
O(4')-C(5')-C(4') 106.6(4) 
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O(1')-C(5')-C(4') 111.3(3) 
C(8')-C(5')-C(4') 112.5(4) 
C(1')-C(6')-Br' 111.9(3) 
O(2')-C(7')-C(3') 59.5(3) 
C(11')-C(10')-Si' 114.7(4) 
C(13')-C(12')-Si' 113.5(5) 
C(15')-C(14')-Si' 116.4(6) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms 
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Table 31.   Anisotropic displacement parameters  (Å2 × 103) for 112.  The anisotropic displacement factor exponent 
takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 
______________________________________________________________________________ 
U11 U22  U33 U23 U13 U12 
______________________________________________________________________________ 
Br 53(1)  34(1) 71(1)  -6(1) 27(1)  -2(1) 
Si 23(1)  27(1) 54(1)  7(1) 11(1)  2(1) 
O(1) 15(1)  46(2) 41(2)  -2(2) 8(1)  -5(1) 
C(1) 14(2)  32(2) 37(3)  2(2) 3(2)  1(2) 
O(2) 26(2)  40(2) 48(3)  11(2) 11(2)  -1(1) 
C(2) 17(2)  31(2) 43(4)  9(2) 3(2)  -1(2) 
O(3) 36(2)  39(2) 68(3)  -5(2) 24(2)  -13(1) 
C(3) 20(2)  32(2) 42(4)  2(2) 12(2)  0(2) 
O(4) 21(1)  31(2) 53(3)  9(2) 9(2)  1(1) 
C(4) 14(2)  45(3) 49(4)  8(2) 9(2)  2(2) 
C(5) 13(2)  55(3) 66(5)  5(3) 9(2)  -7(2) 
C(6) 17(2)  25(2) 73(5)  -1(2) 12(2)  -3(2) 
C(7) 27(2)  35(3) 68(4)  9(3) 19(2)  -1(2) 
C(8) 23(2)  101(5) 52(5)  -5(4) 2(3)  -14(3) 
C(9) 76(4)  55(4) 112(7)  -27(4) 53(5)  -30(3) 
C(10) 20(2)  32(3) 78(5)  10(3) 11(2)  0(2) 
C(11) 27(3)  50(3) 90(6)  -1(3) 8(3)  -10(2) 
C(12) 41(3)  48(3) 57(5)  19(3) 13(3)  7(2) 
C(13) 39(4)  52(5) 50(7)  13(4) 9(4)  0(4) 
C(14) 37(3)  29(2) 56(4)  6(2) 11(3)  4(2) 
C(15) 44(3)  56(4) 75(6)  5(3) 22(3)  17(3) 
Br' 31(1)  40(1) 68(1)  -5(1) 6(1)  -6(1) 
Si' 26(1)  29(1) 71(1)  5(1) 1(1)  2(1) 
O(1') 19(2)  39(2) 48(3)  6(2) 10(2)  5(1) 
C(1') 20(2)  27(2) 62(4)  8(2) 16(2)  -1(2) 
C(2') 21(2)  30(2) 39(3)  6(2) 6(2)  3(2) 
O(2') 32(2)  30(2) 65(3)  7(2) 6(2)  4(1) 
C(3') 21(2)  29(2) 49(4)  8(2) 0(2)  -2(2) 
O(4') 24(2)  32(2) 50(3)  4(2) 5(2)  1(1) 
C(4') 15(2)  39(3) 56(4)  13(3) 0(2)  -3(2) 
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C(5') 17(2)  36(3) 51(4)  8(2) 9(2)  3(2) 
C(6') 18(2)  39(3) 40(4)  -2(2) 4(2)  5(2) 
C(7') 35(2)  28(3) 81(5)  -1(3) 0(3)  0(2) 
C(8') 30(3)  71(4) 63(5)  19(3) 19(3)  5(3) 
C(9') 43(3)  39(3) 67(5)  1(3) 8(3)  5(2) 
C(10') 86(4)  31(3) 47(4)  11(3) 8(3)  2(3) 
C(11') 69(4)  76(5) 106(7)  34(4) 40(4)  -13(4) 
C(12') 36(3)  40(3) 99(6)  3(3) 29(3)  2(2) 
C(13') 93(5)  46(4) 90(7)  7(4) 32(5)  22(3) 
C(14') 25(3)  46(4) 180(9)  7(5) -11(4)  -1(3) 
C(15') 37(4)  59(4) 400(19)  66(7) 76(7)  3(3) 
______________________________________________________________________________ 
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 Table 32.   Hydrogen coordinates (× 104) and isotropic  displacement parameters (Å2 × 10 3) for 112 
 
______________________________________________________________________________ 
 x  y  z  U(eq) 
_____________________________________________________________________________ 
 
H(1A) 6330 5441 14655 34 
H(2A) 5262 4490 13689 37 
H(4A) 9429 4139 15057 43 
H(4B) 9962 4586 13980 43 
H(6A) 5484 4748 16759 46 
H(6B) 4209 4978 15526 46 
H(7A) 8345 3938 12151 50 
H(7B) 6431 3897 12076 50 
H(8A) 10654 5457 17064 89 
H(8B) 11600 5093 16120 89 
H(8C) 10670 4691 17022 89 
H(9A) 9006 6605 14687 115 
H(9B) 10029 6291 15975 115 
H(9C) 8172 6253 15725 115 
H(10A) 2772 3839 15036 52 
H(10B) 2988 3846 13550 52 
H(11A) 807 3206 13734 84 
H(11B) 1881 2757 14783 84 
H(11C) 2101 2763 13297 84 
H(12A) 4975 2436 16331 58 
H(12B) 6509 2850 16830 58 
H(13A) 4825 2951 18257 71 
H(13B) 3495 3215 17103 71 
H(13C) 5031 3630 17602 71 
H(14A) 4912 2365 13522 49 
H(14B) 5454 2964 12770 49 
H(15A) 7521 2210 13264 86 
H(15B) 7495 2262 14790 86 
H(15C) 8038 2862 14037 86 
H(1'A) 406 4553 1215 42 
 378 
H(2'A) -106 5585 1966 36 
H(4'A) 4489 5306 1864 45 
H(4'B) 3523 5756 751 45 
H(6'A) -1292 5236 -999 39 
H(6'B) -2052 5062 232 39 
H(7'A) 3775 5977 3692 60 
H(7'B) 1891 6077 3709 60 
H(8'A) 3601 4376 -1186 80 
H(8'B) 5040 4725 -270 80 
H(8'C) 3737 5140 -1199 80 
H(9'A) 3020 3313 1303 75 
H(9'B) 3479 3581 -7 75 
H(9'C) 1736 3656 217 75 
H(10C) 295 7102 -1485 67 
H(10D) 256 7718 -587 67 
H(11D) 2800 7554 -949 121 
H(11E) 2839 6856 -308 121 
H(11F) 2799 7479 578 121 
H(12C) -89 6780 2871 67 
H(12D) 1447 7098 2545 67 
H(13D) -41 7890 3387 112 
H(13E) -1498 7748 2234 112 
H(13F) 39 8067 1909 112 
H(14C) -2726 7219 -126 106 
H(14D) -2612 6544 -816 106 
H(15D) -4385 6485 565 241 
H(15E) -3071 6695 1785 241 
H(15F) -2955 6018 1094 241 
______________________________________________________________________________ 
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